Environmental Health Perspectives
Vol. 100, pp. 65–135, 1993

The Fifth Plot of the Carcinogenic Potency Database: Results of Animal Bioassays Published in the General Literature through 1988 and by the National Toxicology Program through 1989

by Lois Swirsky Gold,[1,2] Neela B. Manley,[2] Thomas H. Slone,[1,2] Georganne Backman Garfinkel,[2] Lars Rohrbach,[1] and Bruce N. Ames[2]

This paper is the fifth plot of the Carcinogenic Potency Database (CPDB) that first appeared in this journal in 1984 (1–5). We report here results of carcinogenesis bioassays published in the general literature between January 1987 and December 1988, and in technical reports of the National Toxicology Program between July 1987 and December 1989. This supplement includes results of 412 long-term, chronic experiments of 147 test compounds and reports the same information about each experiment in the same plot format as the earlier papers: the species and strain of test animal, the route and duration of compound administration, dose level and other aspects of experimental protocol, histopathology and tumor incidence, TD_{50} (carcinogenic potency) and its statistical significance, dose response, author's opinion about carcinogenicity, and literature citation. We refer the reader to the 1984 publications (*1,5,6*) for a guide to the plot of the database, a complete description of the numerical index of carcinogenic potency, and a discussion of the sources of data, the rationale for the inclusion of particular experiments and particular target sites, and the conventions adopted in summarizing the literature. The five plots of the database are to be used together, as results of individual experiments that were published earlier are not repeated. In all, the five plots include results of 4487 experiments on 1136 chemicals.

Several analyses based on the CPDB that were published earlier are described briefly, and updated results based on all five plots are given for the following earlier analyses: the most potent TD_{50} value by species, reproducibility of bioassay results, positivity rates, and prediction between species. A new feature of this supplement is that Appendix 14 now provides a summary compendium of positivity and potency, as well as an index to all chemicals in the five plots of the CPDB. It provides the following summary data for each chemical: (*a*) whether it has been tested in each sex of rats and mice, and positivity results in each group; (*b*) for positive chemicals, a summary of carcinogenic potency for rats and for mice; (*c*) an index to the CPDB sorted by chemical name that reports synonyms, CAS number, and the plot numbers that include experiments on the chemical. For readers using the CPDB more extensively, a combined plot of all results from the five separate plot papers, ordered alphabetically by chemical is available from the first author in printed form or on computer tape or diskette. A SAS database is also available.

Background

The Carcinogenic Potency Database (CPDB) is a widely used, standardized resource of results of chronic, long-term carcinogenesis bioassays. The CPDB has been published in plot format in this and four earlier papers. To facilitate its use by other researchers, we have prepared a printed version of a combined plot that merges results from all five plots organized by chemical, as well as a computer-readable (SAS) database. These are obtainable from the first author.

In this paper we *a*) briefly describe the CPDB and the plot included in this fourth supplement; *b*) refer the reader to our earlier papers; *c*) update some of the earlier published findings using results from all five plots; and *d*) report errata to earlier papers.

Our goal in developing the CPDB over the past 12 years has been to provide a single, standardized and easily accessible resource that includes sufficient information on each experiment to permit investigations in many research areas of carcinogenesis. Therefore, the CPDB provides both qualitative and

[1]Cell and Molecular Biology Division, Lawrence Berkeley Laboratory, Berkeley, CA 94720.

[2]Division of Biochemistry and Molecular Biology, University of California, Berkeley, CA 94720.

Address reprint requests to L. S. Gold, Cell and Molecular Biology Division, Lawrence Berkeley Laboratory, Berkeley, CA 94720.

quantitative information on positive and negative tests (*1–4*), including for each experiment, the species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; histopathology and tumor incidence; carcinogenic potency and its statistical significance; shape of the dose-response curve; author's opinion as to carcinogenicity; and literature citation. All experiments in the CPDB meet a specific set of inclusion criteria that are designed to permit the estimation of carcinogenic potency; therefore, reasonable consistency of experimental protocols is assured. Rodent bioassays are included in the database only if the test agent was administered alone, rather than in combination with other substances; if the bioassay included a control group; if the route of administration was diet, water, gavage, inhalation, IV injection or IP injection; and if the length of experiment was at least 1 year with dosing for at least 6 months. Many cancer tests do not meet these rules and are not included, e.g., if route of administration was skin painting or SC injection, or if dosing was not chronic. We do not evaluate whether the results in each experiment provide evidence for carcinogenicity; rather, we report the published opinions of the investigators and the statistical significance of the dose response. The CPDB includes results of all NCI/NTP technical reports published through 1989, with a few exceptions where the chemicals were particulates or the route of administration was skin painting.

A detailed guide to the plot of the database was included in the first published plot in 1984 (*1*); it described the contents, field by field, and discussed the sources of data, the criteria for the inclusion of particular experiments and particular target sites, and the conventions adopted in summarizing the literature. It is our intention that readers who are not familiar with the CPDB will first read the 1984 paper when using the plot in this paper.

The TD_{50}, our numerical index of carcinogenic potency, has been fully described (*1,5,6*) and may be briefly defined as follows: For a given target site(s), if there are no tumors in control animals, then TD_{50} is the chronic dose rate in mg/kg body weight/day that would induce tumors in half the test animals at the end of a standard lifespan for the species. Because the tumor(s) of interest often does occur in control animals, TD_{50} is more precisely defined as the chronic dose rate that will halve the probability of remaining tumor-free throughout the standard life span. One reason for choosing TD_{50} is that it is easy to understand the concept, particularly because of the analogy to LD_{50}. Importantly, TD_{50} is often within the range of doses tested; thus the experimental results do not have to be extrapolated far to estimate TD_{50}. The TD_{50} does not indicate anything about carcinogenic effects at low doses because carcinogenesis bioassays are generally conducted at doses at or near the maximum tolerated dose (MTD). In the CPDB, the range of statistically significant TD_{50} values for chemicals that are carcinogenic in rodents is more than 10 millionfold (*1*).

A new compendium has been prepared for this paper in Appendix 14, which includes summary evaluations of positivity and carcinogenic potency in rats and mice for each chemical in all five plots of the CPDB. This tabulation can be used to investigate associations between rodent potency and other factors such as mutagenicity, teratogenicity, chemical structure, and human, exposure, as well as to obtain summary information on individual compounds. Methods are described in Appendix 14, and are the same as were used in our earlier publication (*7*). Appendix 14 lists alphabetically the 1136 chemicals that appear in any of the five plots and indicates which plot includes results of experiments on each chemical. It also lists CAS (Chemical Abstracts Service registry) numbers and common synonyms. In this Appendix 14, four columns have been added that summarize for each chemical whether there are tests in the CPDB in male rats, female rats, male mice, and female mice; for each group we report the strongest level of evidence for carcinogenicity as defined by the opinion of the published author. For chemicals that are classified as positive, two columns report the most potent TD_{50} value in each species that has a positive test in the CPDB. Several footnotes in Appendix 14 give additional information about individual chemicals: e.g., that there is more than one positive test in the species (footnote a); that the TD_{50} values from different positive experiments of the chemical vary by more than 10-fold from one another (footnote f); and that the CPDB includes results in a species other than rats or mice and at least one test is positive (footnote g) or that none are positive (footnote h).

In each of the five plot papers, Appendices 1–13 are in the same format and provide information for the data in that publication. In this paper, Appendices 1–13 apply only to the plot presented here. Appendix 1 lists alphabetically the compounds included in the current plot, their common synonyms, and Chemical Abstracts Service (CAS) registry number; Appendix 2 provides a list of those same compounds ordered by CAS number. The next several appendices provide codes and definitions required for using the plot: strains of test animal (Appendix 3); routes of administration (Appendix 4); sites of tumor induction (Appendix 5); histopathology (Appendix 6); notecodes (Appendix 7); dose–response curve symbols (Appendix 8); reference codes (Appendix 9); NCI/NTP bioassays evaluated as inadequate (Appendix 10); and author's opinion codes (Appendix 11). Appendices 12 and 13 give full bibliographic information for all experiments reported in this plot: a bibliography for the general literature (Appendix 12); and a list of the NTP technical reports (Appendix 13).

Plot in this Supplement

This fifth plot of the CPDB includes results of 412 long-term, chronic experiments on 147 chemicals. It reports results for 47 compounds from technical reports of the NTP published between July 1987 and December 1989, and results for 101 compounds published in the general literature between January 1987 and December 1988. Experiments in rats, mice, and hamsters are reported here for compounds representing a variety of chemical classes and a variety of uses. Some are naturally occurring substances (e.g., catechol, 8-methoxypsoralen, and malonaldehyde); food additives (e.g., potassium bromate and geranyl acetate); industrial chemicals (e.g., 1,3 butadiene, styrene, and pentachlorophenol); and drugs (e.g., ciprofibrate, salbutamol, and diphenhydramine • HCl). Sixty-four of the 147 chemicals in this plot were also included in an earlier plot, and we have flagged these names in this plot with a triple asterisk (***). For some substances, only a few experiments are reported here, but several experiments were reported in earlier plots (e.g., benzene and formaldehyde). The TD_{50} values for the compounds in this plot fall within the 10 million-fold range reported earlier.

Overview and Update of Our Papers That Use the CPDB

The CPDB is exhaustive in that it includes all published tests that meet a set of experimental criteria. There is great diversity in the testing of chemicals reported in the database; while most chemicals have been tested in rats or mice, some have been tested in hamsters, dogs, or monkeys. Experiments with 101 different mouse strains and 74 rat strains are included. For a given chemical, the database may contain only a single experiment or several experiments. For example, among the 857 chemicals tested in rats, 29% have only one rat test and 53% have two tests; however, 15 chemicals have more than 10 tests.

Our group has used the CPDB to address many issues relevant to chemical carcinogenesis and interspecies extrapolation. Below we refer the reader to the appropriate papers. Additionally, because the CPDB now includes many more tests and chemicals than were used in the earlier papers, we have updated several of the original tables from our earlier analyses. Specifically, updated results are reported for the proportion of chemicals that are positive for several datasets, the association between mutagenicity and carcinogenicity, prediction of positivity between species, reproducibility of results in "near-replicate" experiments, carcinogen identification on the basis of two versus four sex-species groups. In each case, the updated findings are similar to those reported earlier, and we refer the reader to the earlier papers for methods and discussion.

Carcinogenic Potency (TD_{50})

With respect to the measurement of carcinogenic potency, two methods for estimating TD_{50} from animal bioassays were compared, one based on lifetable data and one based on summary incidence data (*8*). There is substantial agreement between these two methods of analysis. Second, we have shown that the potency calculated from experimental results (given the usual experimental design and the lack of 100% tumor incidence in dosed animals) is restricted to an approximately 30-fold range surrounding the maximum dose tested in a standard bioassay (*9*). Third, correlation studies have been conducted of carcinogenic potency between rats and mice (*9*) and of mutagenic and carcinogenic potencies (*10*). Fourth, we have shown that, with few exceptions, among chemicals that are positive in more than one test in a species, the most potent TD_{50} value from among all positive tests is similar to other measures that average TD_{50} values [harmonic mean, geometric mean, or arithmetic mean] (*7*). Using the most potent TD_{50} in rats and in mice, we presented a concise tabulation of TD_{50}values for positive chemicals, which also includes a summary of positivity in each sex-species group (*7*). These results are updated in Appendix 14 of this paper and include results for all five plots of the CPDB.

In addition to positivity and potency, other bioassay measures of carcinogenic hazard that we have investigated are whether tumors were induced at more than one site, whether tumors may have caused the death of the animal or instead were found at sacrifice, and whether metastases of induced tumors occurred (*11,12*).

Reproducibility

Reproducibility of results in animal bioassays has been investigated in "near-replicate" comparisons consisting of two or more tests of the same chemical administered by the same route and using the same sex and strain of rodent (*13*). The updated results continue to show good reproducibility. Among 132 comparisons 86% (114/132) have concordant authors' opinions about whether tumors were induced in the individual experiments. In all but 3 of the 69 positive comparisons, at least 1 target site is identical. TD_{50} values are within a factor of 2 of each other in 51% of the positive comparisons, within a factor of 4 in 77%, and within a factor of 10 in 91%.

Positivity

In several papers we have shown that approximately half the chemicals tested in rats or mice are positive in at least one test, according to the opinion of the published author. Using all data currently in the CPDB, positivity rates are reported in Table 1 separately for chemicals tested in NCI/NTP bioassays, in the general literature, and in either of these sources. Table 2 reports a similar positivity rate for several additional subsets of the CPDB: naturally occurring chemicals, synthetic chemicals, natural pesticides, mold toxins, and chemicals in roasted coffee. We have discussed why it is unlikely that the 50% positivity rate is due simply to selection of suspicious chemical structures (*14–16*), and show in Table 2 that this rate is similar for chemicals tested before 1979 by NCI and those tested later by NCI/NTP.

Mitogenesis

We have postulated that the high positivity rate is to be expected because the administration of chemicals at the maximum

Table 1. Proportion of CPDB chemicals tested in at least one species that have been evaluated as carcinogenic, by species and reference source.[a]

Refererence source	Proportion carcinogenic in rats or mice (%)	Proportion carcinogenic in rats (%)	Proportion carcinogenic in mice (%)
NCI/NTP or literature[b]	584/1117 (52%)	424/857 (49%)	324/745 (43%)
NCI/NTP	165/315 (52%)	119/303 (39%)	121/308 (39%)
Literature	448/894 (50%)	321/608 (53%)	216/498 (43%)

[a]A chemical is classified as positive if the author of at least one published experiment has evaluated the compound as carcinogenic in that species.
[b]The number of chemicals in the "NCI/NTP or literature" is smaller than the sum of each source separately because some of the chemicals have been reported by both sources.

Table 2. Proportion of chemicals evaluated as carcinogenic for several datasets in the CPDB.[a]

Chemicals tested in both rats and mice	288/479 (60%)
Naturally occurring chemicals tested in both rats and mice	56/101 (55%)
Synthetic chemicals tested in both rats and mice	232/378 (61%)
NCI/NTP chemicals[b]	
NCI/NTP chemicals tested before 1979	60/117 (51%)
NCI/NTP chemicals tested after 1979	105/198 (53%)
Chemicals tested in at least 1 species	
Natural pesticides	29/57 (51%)
Mold toxins	12/20 (60%)
Chemicals in roasted coffee	19/26 (73%)

[a]A chemical is classified as positive if the author of at least one published experiment evaluated results as evidence that the compound is carcinogenic.
[b]94% (296/315) are tested by NCI/NTP in both rats and mice.

tolerated dose (MTD) in standard animal cancer tests increases cell division (mitogenesis), which in turn increases rates of mutagenesis and thus carcinogenesis (*15,17*). The high rate of endogenous DNA damage contributes to the importance of mitogenesis. A variety of studies on mechanisms of carcinogenesis are consistent with this explanation (*17–19*). We conclude that at the low doses of most human exposures where cell killing does not occur, the hazards to humans of rodent carcinogens may be much lower than is commonly assumed. Thus, understanding the role of mitogenesis in mutagenesis is critical for clarifying the mechanisms of carcinogenesis and interpreting the results of animal cancer tests (*15,17–19*).

Mutagenicity

We have also examined mutagenicity rates in the CPDB (*14–16*) and have updated the results in Table 3. Of the 384 chemicals tested in both rats and mice and for which mutagenicity data in Salmonella are available, 72% are either mutagens or carcinogens or both. Overall, mutagens are more often carcinogenic than nonmutagens; however 45% of carcinogens tested in rats and mice are not mutagenic, suggesting the importance of mitogenesis in animal tests at the MTD.

Interspecies Extrapolation

The issue of exrapolating carcinogenesis results from one species to another has been addressed in analyses of prediction between two closely related species, rats and mice (*12,14*). We have examined how well one can predict carcinogenicity from rats to mice and from mice to rats. The updated results in Table 4 indicate that among chemicals tested in both species, 74% of rat carcinogens are positive in mice, and 72% of mouse carcinogens are positive in rats. We earlier discussed three factors that affect the accuracy of prediction: chemical class, mutagenicity, and the dose level at which a chemical is toxic (*14*).

Table 3. Comparison of mutagenicity and carcinogenicity for 384 CPDB chemicals tested for carcinogenicity in both rats and mice and for mutagenicity in Salmonella.[a]

		Carcinogenic		
		+	-	Total
Mutagenic	+	131	38	169[b]
	-	106	109	215
Total		237[c]	147[d]	384[e]

[a] A chemical is classified as positive if the author of at least one published experiment evaluated the results as evidence that the compound is carcinogenic. Mutagens are more likely to be carcinogenic 78% (131/169) than nonmutagens 49% (106/215).

[b] Of 169 mutagens, 22% are not carcinogenic 38/(131 + 38).

[c] Of 237 carcinogens, 45% are not mutagens 106/(131 + 106).

[d] Of 147 noncarcinogens, 26% are mutagens 38/(38 + 109).

[e] Of 384 chemicals, 44% are mutagens, 62% are carcinogens, and 72% are either mutagens or carcinogens or both (131 + 106 + 38)/384.

Table 4. Comparison of carcinogenic response in rats and mice for 479 CPDB chemicals tested in both species.

		Rats		
		+	-	Total
Mice	+	165	64	229[a]
	-	59	191	250
Total		224[b]	255	479[c]

[a] Of 229 mouse carcinogens, 72% are rat carcinogens 165/(165 + 64).

[b] Of 224 rat carcinogens, 74% are mouse carcinogens 165/(165 + 59).

[c] Of 479 chemicals, 60% are positive in at least one test (165 + 59 + 64)/479.

Table 5. Predictive value of two sex-species groups for CPDB carcinogens tested in both sexes of rats and mice.[a]

	NCI/NTP or literature experiments	NCI/NTP experiments
Sex-species groups used to identify carcinogens	Number identified as carcinogenic at least once (N=212)[b,c]	Number identified as carcinogenic at least once (N=149)[c]
MM, MR	194 (92%)	135 (91%)
FM, MR	194 (92%)	136 (91%)
MM, FR	183 (86%)	122 (82%)
FM, FR	184 (87%)	124 (83%)
FM, MM	167 (79%)	112 (75%)
FR, MR	162 (76%)	112 (75%)

Abbreviations: FM, female mice, MM, male mice, FR, female rats, MR, male rats.

[a] For chemicals tested in both sexes of rats and mice that were evaluated as carcinogenic in at least one experiment.

[b] The total number of positive chemicals for "NCI/NTP or literature" in this table is 212, while the number in Table 4 is 288. This difference is due to the fact that 76 positive chemicals were tested in both rats and mice, but not in both sexes of rats and mice.

[c] Percentage indicates the proportion that would be correctly identified as carcinogens using results from experiments only in the two sex-species groups, considering as positive an evaluation of carcinogenic in either sex-species group.

Target Organ

We have presented a compendium of bioassay results organized by target organ for chemicals that are carcinogenic in at least one species. This compendium reports on 35 target sites and can be used to identify chemicals that induce tumors at particular sites and to determine whether target sites are the same for each chemical that is positive in more than one species (*12*). Site-specific prediction between rats and mice is less accurate than overall prediction of positivity. Knowing that a chemical is positive at any site in one species gives about a 50% chance that it will be positive at the same site in the other species. Among chemicals with a target site in common between rats and mice, the liver is the most frequent site in common (*12*). Because the liver is the most common site in both species, we have studied liver carcinogenesis in detail (*11,12,14*).

Carcinogen Identification by Two Versus Four Sex-Species Groups

We have also addressed the question of how many rodent carcinogens currently identified by performing tests in four sex-' species groups would be identified if tests were conducted in only two sex-species groups. The updated results in Table 5 continue to show that few carcinogens would be missed by testing one sex of each species. The greatest number (91–92%) would have been identified by conducting tests only in male rats and male mice/or in male rats and female mice.

Chemicals Selected for Testing

The natural world makes up the vast bulk of chemicals that humans consume each day in both weight and number. Yet, the natural chemicals have never been tested systematically; synthetic chemicals account for 79% (378/479) of the chemicals adequately tested in both rats and mice (Table 2). Because about half

```
    Spe Strain  Site     Xpo+Xpt                                                                                  TD50     2Tailpvl
      Sex   Route   Hist       Notes                                                                                    DR       AuOp
BISPHENOL A                     1_00ng..:..1_ug....:..1_0.....:..1_00....:..1_mg....:..1_0.....:..1_00....:..1_g.....:..1_0
1     M f b6c eat TBA MXB 24m25 t                                                                        :>      no dre   P=1.    -
 a    M f b6c eat liv MXB 24m25 t                                                                                13.1gm * P<.05
 b    M f b6c eat lun MXB 24m25 t                                                                                41.4gm * P<.6


    RefNum  LoConf UpConf   Cntrl   1Dose    1Inc  2Dose    2Inc                           Citation or Pathology
                                                                                                              Brkly Code
BISPHENOL A  (4,4'-isopropylidenediphenol) 80-05-7
1     c50635  2.27gm n.s.s.  21/50   626.mg  17/50  1.25gm  19/50
 a    c50635  4.53gm n.s.s.   0/50   626.mg   1/50  1.25gm   3/50                                   liv:hpa,hpc,nnd.
 b    c50635  6.29gm n.s.s.   1/50   626.mg   1/50  1.25gm   2/50                                       lun:a/a,a/c.
```

FIGURE 1. Corrected plot for bisphenol A.

of natural chemicals and half of natural pesticides are positive in animal tests (Table 2), we conclude that our diet is filled with rodent carcinogens as defined by high-dose tests. We have described the concentrations in common foods of natural pesticides that are rodent carcinogens (*16*). Additionally, we have discussed the toxicological significance of exposures to synthetic chemicals in the context of exposures to naturally occurring chemicals, and we argue that animals have a broad array of inducible general defenses that at low dose are effective against both natural and synthetic toxins (*16,20,21*). The relatively high and widespread exposure to natural chemicals that are rodent carcinogens, and the 50% positivity rate among natural chemicals that have been tested, indicate that cancer-prevention strategies aimed at chemical carcinogens need to take a broad overview of chemicals, whether synthetic or natural.

Ranking Possible Carcinogenic Hazards

We have proposed a rough index of possible carcinogenic hazard to humans, HERP (Human Exposure Rodent Potency). HERP compares for a given chemical the chronic dose rate at which humans are exposed (mg/kg/day) to the TD_{50} (mg/kg/day) in rodents. To put possible carcinogenic hazards in perspective, we have used the HERP index to rank a variety of man-made and naturally occurring chemical exposures to humans (*22*). In a separate analysis a similar index, PERP (Permitted Exposure Rodent Potency) was calculated by using the U.S. Occupational Safety and Health Administration Permitted Exposure Limit (OSHA PEL), and assuming a daily worklife exposure at that limit (*23*). Permitted worker exposure levels for several rodent carcinogens are close to the dose rate that induces tumors in half the test animals. For high occupational exposures, comparatively little extrapolation is required from the doses used in rodent bioassays, and therefore assumptions about extrapolation from high to low dose are less important.

Errata in Earlier Plots

Some errors and additional information about results reported in earlier plots of the CPDB (*1–4*) have come to our attention. For two NCI/NTP bioassays in the second plot (*2*), the route of administration was reported incorrectly: for cytembena the route was reported as diet and should have been IP injection; for vinylidene chloride the reported route was diet and should have been gavage. All other information including dose rates and TD_{50} values was reported correctly for these two chemicals.

Issues related to the purity of test compounds have resulted in some name changes. For two NCI/NTP bioassays, we have added "technical grade" to the chemical name in the CPDB (Appendix 14) because of impurities in the test agent: 1,1,1-trichloroethane and trifluralin. For 2,3,4,5,6-pentachlorophenol two papers reported results for the technical grade (cited in the plot as Innes et al., 1968/1969 and Schwetz et al., 1975) . We now report 2,3,4,5,6-pentachlorophenol (Dowicide EC-7) in Appendix 14 for these papers. The chemical name for the paper of Boberg et al., 1983, remains 2,3,4,5,6-pentachlorophenol.

Two other errors in chemical names have been corrected. Nitro-4-hydroxyphenylarsonic should have been reported as 3-nitro-4-hydroxyphenylarsonic acid (CAS number 121-19-7). Cadmium sulfate should have been reported as cadmium sulfate (1:1) hydrate (3:8).

CAS numbers have been changed for a few chemicals. The CAS number for sodium hypochlorite phosphate has been changed by the American Chemical Society to 11084-85-8. The corrected CAS number for DL-α-tocopheryl acetate is 58-95-7, and the corrected synonym is vitamin E acetate. The corrected CAS number for 1,2-di-*N*-butylhydrazine • 2HCl is 78776-28-0. The corrected CAS number for propanolol •HCl is 525-66-6.

For several NTP chemicals in the third plot listed below, evaluations for some target tissues were reported as "a," and we have re-assigned the evaluation as "p" indicating the NTP category, "some evidence of carcinogenicity," which NTP defines as a positive category. Our earlier assignment of "a" had been made before current descriptions of the evaluation categories were published by NTP. These sites with opinion "p" should be interpreted as positive. For the chemicals in italics, "p" is the highest level of evidence in the NTP evaluation: benzene, HC Blue No. 1, *chlorobenzene, chlorodibromomethane, decabromodiphenyl oxide, dimethyl morpholinophosphoramidate, isophorone,* methylene chloride, 1,2-propylene oxide, Telone II, tetrachloroethylene, *tris(2-ethylhexyl)phosphate.*

For bisphenol A in female mice, the dose used was incorrect. Therefore, other values such as the TD_{50} were also incorrect. The corrected plot for this experiment is shown in Figure 1.

There are many people who have provided us with valuable assistance in the course of our work. We thank Jerrold Ward and Leslie Bernstein for their advice on pathology and statistics and Bonnie Stern for suggestions on the manuscript. We also thank Leah Slyder for technical assistance. This work was supported through the University of California, Berkeley, by National Institute of Environmental Health Sciences Center grant ESO1896, and through the Lawrence Berkeley Laboratory by U.S. Department of Energy, contract DE-AC-03-76SF00098 and U.S. Environmental Protection Agency, agreement R-815619-01-0.

REFERENCES

1. Gold, L. S., Sawyer, C. B., Magaw, R., Backman, G. M., de Veciana, M., Levinson, R., Hooper, N. K., Havender, W. R., Bernstein, L., Peto, R., Pike, M. C., and Ames, B. N. A Carcinogenic Potency Database of the standardized results of animal bioassays. Environ. Health Perspect. 58: 9–319 (1984).
2. Gold, L. S., de Veciana, M., Backman, G. M., Magaw, R., Lopipero, P., Smith, M., Blumenthal, M., Levinson, R., Bernstein, L., and Ames, B. N. Chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1982. Environ. Health Perspect. 67: 161–200 (1986).
3. Gold, L. S., Slone, T. H., Backman, G. M., Magaw, R., Da Costa, M., Lopipero, P., Blumenthal, M., and Ames, B. N. Second chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1984 and by the National Toxicology Program through May 1986. Environ. Health Perspect. 74: 237–329 (1987).
4. Gold, L. S., Slone, T. H., Backman, G. M., Eisenberg, S., Da Costa, M., Wong, M., Manley, N. B., Rohrbach, L., and Ames, B. N. Third chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1986 and by the National Toxicology Program through June 1987. Environ. Health Perspect. 84: 215–286 (1990).
5. Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., and Ames, B. N. The TD_{50}: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. Environ. Health Perspect. 58: 1–8 (1984).
6. Sawyer, C., Peto, R., Bernstein, L., and Pike, M. C. Calculation of carcinogenic potency from long-term animal carcinogenesis experiments. Biometrics 40: 27–40 (1984).
7. Gold, L. S., Slone, T. H., and Bernstein, L. Summary of carcinogenic potency (TD_{50}) and positivity for 492 rodent carcinogens in the Carcinogenic Potency Database. Environ. Health Perspect. 79:259–272 (1989).
8. Gold, L. S., Bernstein, L., Kaldor, J., Backman, G. M., and Hoel, D. An empirical comparison of methods used to estimate carcinogenic potency in long-term animal bioassays: lifetable vs. summary incidence data. Fundam. Appl. Toxicol. 6: 263–269 (1986).
9. Bernstein, L., Gold, L. S., Ames, B. N., Pike, M. C., and Hoel, D. Some tautologous aspects of the comparison of carcinogenic potency in rats and mice. Fundam. Appl. Toxicol. 5: 79–86 (1985).
10. McCann, J., Gold, L. S., Horn, L., McGill, R., Graedel, T. E., and Kaldor, J. Statistical analysis of Salmonella test data and comparison to results of animal cancer tests. Mutat. Res. 205: 183–195 (1988).
11. Gold, L. S., Ward, J., Bernstein, L., and Stern, B. Association between carcinogenic potency and tumor pathology in rodent carcinogenesis bioassays. Fundam. Appl. Toxicol. 6: 677–690 (1986).
12. Gold, L. S., Slone, T. H., Manley, N. B., and Bernstein, L. Target organs in chronic bioassays of 533 chemical carcinogens. Environ. Health Perspect. 93: 233–246 (1991).
13. Gold, L. S., Wright, C., Bernstein, L., and de Veciana, M. Reproducibility of results in 'near-replicate' carcinogenesis bioassays. J. Natl. Cancer Inst. 78: 1149–1158 (1987).
14. Gold, L. S., Bernstein, L., Magaw, R., and Slone, T. H. Interspecies extrapolation in carcinogenesis: prediction between rats and mice. Environ. Health Perspect. 81: 211–219 (1989).
15. Ames, B. N., and Gold, L. S. Perspective: too many rodent carcinogens: mitogenesis increases mutagenesis. Science 249: 970-971 (1990).
16. Ames, B. N., Profet, M., and Gold, L. S. Dietary pesticides (99.99% all natural). Proc. Natl. Acad. Sci. U.S.A. 87: 7777-7781 (1990).
17. Ames, B. N., and Gold, L. S. Chemical carcinogenesis: too many rodent carcinogens. Proc. Natl. Acad. Sci. U.S.A. 87: 7772-7776 (1990).
18. Ames, B. N., and Gold, L. S. Animal cancer tests and the prevention of cancer. J. Natl. Cancer Inst. Monogr. 12: 125–132 (1992).
19. Ames, B. N. Endogenous oxidative DNA damage, aging, and cancer. Free Rad. Res. Commun. 7: 121–128 (1989).
20. Ames, B. N., Profet, M., and Gold, L. S. Nature's chemicals and synthetic chemicals: comparative toxicology. Proc. Natl. Acad. Sci. U.S.A. 87: 7782-7786 (1990).
21. Ames, B. N., and Gold, L. S. Dietary carcinogens, environmental pollution, and cancer: some misconceptions. Med. Oncol. Tumor Pharmacother. 7: 69–85 (1990).
22. Gold, L. S., Slone, T. H., Stern, B. R., Manley, N. B., and Ames, B. N. Rodent carcinogens: setting priorities. Science 258: 261–265 (1992).
23. Gold, L. S., Backman, G. M., Hooper, K., and Peto, R. Ranking the potential carcinogenic hazards to workers from exposures to chemicals that are tumorigenic in rodents. Environ. Health Perspect. 76: 211–219 (1987).

Fifth Plot of the Carcinogenic Potency Database

Fifth Plot of the Carcinogenic Potency Database

```
     Spe Strain  Site     Xpo+Xpt                                                                                   TD50     2Tailpvl
       Sex    Route    Hist       Notes                                                                                   DR      AuOp
ACETALDEHYDE***                   100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
1    R f wsr inh nac mix 12m24 erv                                                             . +  .               148.mg * P<.0005+
 a   R f wsr inh nac adc 12m24 erv                                                                                  201.mg * P<.0005+
 b   R f wsr inh nac sqc 12m24 erv                                                                                  574.mg * P<.01  +
2    R m wsr inh nac mix 12m24 erv                                                           . + .                  88.5mg * P<.0005+
 a   R m wsr inh nac adc 12m24 erv                                                                                  190.mg * P<.002 +
 b   R m wsr inh nac sqc 12m24 erv                                                                                  200.mg Z P<.0005+

ACETALDOXIME                      100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
3    R m f34 wat liv hnd 26m30 e                                                               .>                   445.mg * P<.4
 a   R m f34 wat adr cca 26m30 e                                                                                    no dre   P=1.

2-ACETYLAMINOFLUORENE***          100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
4    M f b6c eat liv hpb 24m24 r                                                                     .   ±          846.mg * P<.06  +
5    M m b6c eat liv hpb 24m24 r                                                             . +      .             92.1mg * P<.004 +
6    M f bcn eat liv hpb 24m24 r                                                                       .>           3.20gm * P<.5   -
7    M m bcn eat liv hpb 24m24 r                                                          .>                        no dre   P=1.    -

ACROLEIN                          100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
8    R f f34 wat adr cca 24m31 e                                                          .    ±                    93.9mg   P<.07
 a   R f f34 wat liv mix 24m31 e                                                                                    188.mg   P<.4
 b   R f f34 wat liv hnd 24m31 e                                                                                    388.mg   P<.7
 c   R f f34 wat liv hpc 24m31 e                                                                                    433.mg   P<.3
9    R m f34 wat for tum 27m31 ae                                                   .  +     .                      14.4mg Z P<.002
 a   R m f34 wat liv hpc 27m31 ae                                                                                   1.32gm * P<.9
 b   R m f34 wat adr cca 27m31 ae                                                                                   no dre   P=1.
 c   R m f34 wat liv hnd 27m31 ae                                                                                   no dre   P=1.
 d   R m f34 wat liv mix 27m31 ae                                                                                   no dre   P=1.

ACROLEIN DIETHYLACETAL            100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
10   R f f34 wat liv mix 24m30 ae                                                           .   ±                   123.mg * P<.06
 a   R f f34 wat liv hnd 24m30 ae                                                                                   131.mg * P<.06
 b   R f f34 wat adr cca 24m30 ae                                                                                   no dre   P=1.
 c   R f f34 wat liv hpc 24m30 ae                                                                                   no dre   P=1.
11   R m f34 wat liv hpc 24m30 ae                                                             .     ±               262.mg * P<.1
 a   R m f34 wat liv mix 24m30 ae                                                                                   124.mg * P<.2
 b   R m f34 wat liv hnd 24m30 ae                                                                                   266.mg * P<.4
 c   R m f34 wat adr cca 24m30 ae                                                                                   no dre   P=1.

ACROLEIN OXIME                    100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
12   R f f34 wat liv hnd  7m29 e                                                      .>                            41.9mg   P<.3
 a   R f f34 wat adr cca  7m29 e                                                                                    no dre   P=1.
13   R f f34 wat liv mix 24m30 e                                                      .   ±                         27.1mg   P<.03
 a   R f f34 wat liv hpc 24m30 e                                                                                    104.mg   P<.1
 b   R f f34 wat liv hnd 24m30 e                                                                                    43.8mg   P<.2
 c   R f f34 wat adr cca 24m30 e                                                                                    no dre   P=1.
14   R m f34 wat liv mix  7m29 e                                                   .    ±                           16.4mg   P<.06
 a   R m f34 wat liv hpc  7m29 e                                                                                    50.7mg   P<.1
 b   R m f34 wat liv hnd  7m29 e                                                                                    29.3mg   P<.3
 c   R m f34 wat adr cca  7m29 e                                                                                    no dre   P=1.
15   R m f34 wat liv hpc 24m30 e                                                        .     ±                     72.6mg   P<.1
 a   R m f34 wat liv mix 24m30 e                                                                                    30.4mg   P<.2
 b   R m f34 wat liv hnd 24m30 e                                                                                    64.9mg   P<.4
 c   R m f34 wat adr cca 24m30 e                                                                                    no dre   P=1.

ACRYLONITRILE***                  100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
16   R m cdr wat zym sqc 24m24 es                                                      .  +   .                     30.1mg * P<.0005+
 a   R m cdr wat for pam 24m24 s                                                                                    97.4mg * P<.003
 b   R m cdr wat pit ade 24m24 es                                                                                   no dre   P=1.
 c   R m cdr wat tba mal 24m24 es                                                                                   31.3mg * P<.02
17   R f sda inh adr phe 12m24                                                .  ±                                  1.49mg Z P<.02
 a   R f sda inh bra gli 12m24                                                                                      41.2mg * P<.2    +
 b   R f sda inh liv hpt 12m24                                                                                      no dre   P=1.
 c   R f sda inh tba mix 12m24                                                                                      2.09mg Z P<.3
 d   R f sda inh tba mal 12m24                                                                                      no dre   P=1.
18   R f sda gav liv hpt 12m24                                                           .>                         no dre   P=1.    -
 a   R f sda gav tba mix 12m24                                                                                      2.97mg   P<.3    -
 b   R f sda gav tba mal 12m24                                                                                      no dre   P=1.    -
19   R f sda inh mam mix 24m24 g                                                       .  +       .                 11.7mg   P<.003
 a   R f sda inh bra gli 24m24 g                                                                                    132.mg   P<.04   +
 b   R f sda inh liv hpt 24m24 g                                                                                    no dre   P=1.
 c   R f sda inh tba mal 24m24 g                                                                                    25.2mg   P<.008  +
 d   R f sda inh tba mix 24m24 g                                                                                    10.6mg   P<.02
20   R m sda inh bra gli 12m24                                                         .    ±                       19.1mg * P<.04   +
 a   R m sda inh liv hpt 12m24                                                                                      no dre   P=1.
 b   R m sda inh tba mix 12m24                                                                                      1.30mg * P<.002
 c   R m sda inh tba mal 12m24                                                                                      1.43mg Z P<.04
```

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc				Citation or Pathology	Brkly Code
ACETALDEHYDE* 75-07-0**												
1 1863	85.3mg	288.mg	0/18	50.1mg	1/20	100.mg	7/18	149.mg	11/17		Woutersen;txcy,47,295-305;1987/1986/pers.comm.	
a 1863	110.mg	439.mg	0/18	50.1mg	0/20	100.mg	7/18	149.mg	8/17			
b 1863	234.mg	38.9gm	0/18	50.1mg	1/20	100.mg	0/18	149.mg	5/17			
2 1863	54.4mg	157.mg	0/19	35.1mg	2/20	70.1mg	8/20	104.mg	15/22			
a 1863	102.mg	710.mg	0/19	35.1mg	2/20	70.1mg	6/20	104.mg	6/22			
b 1863	105.mg	463.mg	0/19	35.1mg	0/20	70.1mg	2/20	104.mg	11/22			
ACETALDOXIME 107-29-9												
3 1853	100.mg	n.s.s.	2/20	19.5mg	3/20	50.3mg	4/20				Lijinsky;txih,3,337-345;1987/pers.comm.	
a 1853	323.mg	n.s.s.	1/20	19.5mg	1/20	50.3mg	0/20					
2-ACETYLAMINOFLUORENE* (N-2-fluorenylacetamide) 53-96-3**												
4 1874	345.mg	n.s.s.	0/96	19.5mg	2/96	26.0mg	1/96	32.5mg	3/96		Nonoyama;pavt,25,286-296;1988/pers.comm.	
5 1874	50.6mg	444.mg	0/96	4.80mg	4/96	7.20mg	5/96	9.60mg	6/96			
6 1874	521.mg	n.s.s.	0/96	13.0mg	0/96	16.2mg	1/96	19.5mg	0/96			
7 1874	25.9mg	n.s.s.	1/96	2.40mg	0/96	4.80mg	0/96	7.20mg	0/96			
ACROLEIN 107-02-8												
8 1853	30.8mg	n.s.s.	1/20	20.1mg	5/20						Lijinsky;txih,3,337-345;1987/pers.comm.	
a 1853	39.2mg	n.s.s.	2/20	20.1mg	4/20							
b 1853	48.5mg	n.s.s.	2/20	20.1mg	3/20							
c 1853	70.4mg	n.s.s.	0/20	20.1mg	1/20							
9 1853	7.36mg	55.4mg	0/20	2.64mg	5/20	6.81mg	7/20	(14.1mg	3/20)			
a 1853	57.7mg	n.s.s.	0/20	2.64mg	2/20	6.81mg	0/20	14.1mg	1/20			
b 1853	128.mg	n.s.s.	1/20	2.64mg	1/20	6.81mg	0/20	14.1mg	0/20			
c 1853	64.1mg	n.s.s.	2/20	2.64mg	6/20	6.81mg	0/20	14.1mg	2/20			
d 1853	52.1mg	n.s.s.	2/20	2.64mg	8/20	6.81mg	0/20	14.1mg	3/20			
ACROLEIN DIETHYLACETAL 3054-95-3												
10 1853	47.6mg	n.s.s.	2/20	15.4mg	5/20	39.5mg	7/20				Lijinsky;txih,3,337-345;1987/pers.comm.	
a 1853	50.7mg	n.s.s.	2/20	15.4mg	4/20	39.5mg	7/20					
b 1853	129.mg	n.s.s.	1/20	15.4mg	3/20	39.5mg	1/20					
c 1853	197.mg	n.s.s.	0/20	15.4mg	1/20	39.5mg	0/20					
11 1853	79.3mg	n.s.s.	0/20	10.8mg	1/20	27.6mg	2/20					
a 1853	42.6mg	n.s.s.	2/20	10.8mg	3/20	27.6mg	6/20					
b 1853	60.9mg	n.s.s.	2/20	10.8mg	2/20	27.6mg	4/20					
c 1853	49.9mg	n.s.s.	1/20	10.8mg	0/20	27.6mg	0/20					
ACROLEIN OXIME 5314-33-0												
12 1853m	11.3mg	n.s.s.	2/20	7.96mg	5/20						Lijinsky;txih,3,337-345;1987/pers.comm.	
a 1853m	45.9mg	n.s.s.	1/20	7.96mg	0/20							
13 1853n	10.4mg	n.s.s.	2/20	10.4mg	8/20							
a 1853n	25.7mg	n.s.s.	0/20	10.4mg	2/20							
b 1853n	13.8mg	n.s.s.	2/20	10.4mg	6/20							
c 1853n	66.2mg	n.s.s.	1/20	10.4mg	0/20							
14 1853m	5.80mg	n.s.s.	2/20	5.57mg	7/20							
a 1853m	12.5mg	n.s.s.	0/20	5.57mg	2/20							
b 1853m	7.88mg	n.s.s.	2/20	5.57mg	5/20							
c 1853m	19.2mg	n.s.s.	1/20	5.57mg	1/20							
15 1853n	17.8mg	n.s.s.	0/20	7.37mg	2/20							
a 1853n	9.61mg	n.s.s.	2/20	7.37mg	6/20							
b 1853n	13.5mg	n.s.s.	2/20	7.37mg	4/20							
c 1853n	46.0mg	n.s.s.	1/20	7.37mg	0/20							
ACRYLONITRILE* 107-13-1**												
16 1881	14.5mg	77.9mg	0/18	1.00mg	0/20	5.00mg	1/19	25.0mg	9/18		Gallagher;jact,7,603-615;1988	
a 1881	33.6mg	591.mg	0/20	1.00mg	0/20	5.00mg	0/20	25.0mg	4/20			
b 1881	15.4mg	n.s.s.	5/18	1.00mg	3/20	5.00mg	1/19	(25.0mg	0/18)			
c 1881	12.6mg	n.s.s.	3/18	1.00mg	1/20	5.00mg	8/20	25.0mg	8/18			
17 bt201	.679mg	n.s.s.	1/30	.271mg	5/30	.542mg	7/30	(1.08mg	2/30	2.17mg 0/30)	Maltoni;anya,534,179-202;1988	
a bt201	10.1mg	n.s.s.	0/30	.271mg	0/30	.542mg	0/30	1.08mg	1/30	2.17mg 1/30		
b bt201	.893mg	n.s.s.	0/30	.271mg	0/30	.542mg	0/30	1.08mg	0/30	2.17mg 0/30		
c bt201	.623mg	n.s.s.	9/30	.271mg	23/30	.542mg	15/30	1.08mg	17/30	(2.17mg 10/30)		
d bt201	4.00mg	n.s.s.	3/30	.271mg	12/30	.542mg	6/30	1.08mg	7/30	2.17mg 6/30		
18 bt203	8.83mg	n.s.s.	0/75	1.07mg	0/40							
a bt203	.782mg	n.s.s.	39/75	1.07mg	25/40							
b bt203	2.33mg	n.s.s.	17/75	1.07mg	9/40							
19 bt4003	5.82mg	75.7mg	24/60	11.1mg	37/54							
a bt4003	40.1mg	n.s.s.	0/60	11.1mg	3/54							
b bt4003	123.mg	n.s.s.	0/60	11.1mg	0/54							
c bt4003	11.7mg	495.mg	9/60	11.1mg	20/54							
d bt4003	4.69mg	n.s.s.	35/60	11.1mg	43/54							
20 bt201	5.77mg	n.s.s.	0/30	.190mg	0/30	.379mg	0/30	.759mg	1/30	1.52mg 2/30		
a bt201	.625mg	n.s.s.	0/30	.190mg	0/30	.379mg	0/30	.759mg	0/30	1.52mg 0/30		
b bt201	.674mg	6.77mg	8/30	.190mg	7/30	.379mg	19/30	.759mg	15/30	1.52mg 19/30		
c bt201	.565mg	n.s.s.	3/30	.190mg	0/30	.379mg	10/30	(.759mg	9/30	1.52mg 10/30)		

```
     Spe Strain  Site    Xpo+Xpt                                                                    TD50     2Tailpvl
       Sex   Route   Hist      Notes                                                                    DR     AuOp

21   R m sda gav liv hpt 12m24                                          .>                          no dre   P=1.   -
 a   R m sda gav tba mix 12m24                                                                     5.59mg   P<.3   -
 b   R m sda gav tba mal 12m24                                                                     33.4mg   P<.8   -

AFLATOXIN B1***                  100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
22   R f f34 eat liv hpc 24m24 er                    .      ±                                     52.7ug * P<.06  -
23   R m f34 eat liv hpc 24m24 er                   .>                                            49.9ug * P<.3   -

ALLYL ALCOHOL                    100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
24   R f f34 wat liv hpc 25m29 e                                          .    ±                   64.2mg   P<.04
 a   R f f34 wat liv mix 25m29 e                                                                   41.5mg   P<.2
 b   R f f34 wat liv hnd 25m29 e                                                                   182.mg   P<.7
 c   R f f34 wat adr cca 25m29 e                                                                   no dre   P=1.
25   R m f34 wat liv mix 25m29 e                                         .>                        128.mg   P<.7
 a   R m f34 wat liv hpc 25m29 e                                                                   142.mg   P<.3
 b   R m f34 wat liv hnd 25m29 e                                                                   no dre   P=1.
 c   R m f34 wat adr cca 25m29 e                                                                   no dre   P=1.

2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE  ....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
26   M f cdf eat liv mix 84w84 e                                        . +  .                      14.2mg   P<.0005+
 a   M f cdf eat liv hpa 84w84 e                                                                   14.2mg   P<.0005
 b   M f cdf eat liv hpc 84w84 e                                                                   27.8mg   P<.0005
 c   M f cdf eat lun mix 84w84 e                                                                   77.2mg   P<.002 +
 d   M f cdf eat lun ade 84w84 e                                                                   143.mg   P<.02
 e   M f cdf eat lun adc 84w84 e                                                                   257.mg   P<.1
 f   M f cdf eat --- mix 84w84 e                                                                   6.82gm   P<1.
27   M m cdf eat liv hpa 84w84 e                                             .   +                 86.9mg   P<.01
 a   M m cdf eat liv hpc 84w84 e                                                                   102.mg   P<.0005
 b   M m cdf eat --- mix 84w84 e                                                                   109.mg   P<.006
 c   M m cdf eat liv mix 84w84 e                                                                   83.8mg   P<.02  +
 d   M m cdf eat lun mix 84w84 e                                                                   134.mg   P<.2
 e   M m cdf eat lun adc 84w84 e                                                                   236.mg   P<.4
 f   M m cdf eat lun ade 84w84 e                                                                   262.mg   P<.2
28   R f f3d eat cli sqc 61w61 e                                  .  +   .                          4.72mg   P<.0005+
 a   R f f3d eat liv nnd 61w61 e                                                                   6.31mg   P<.0005+
 b   R f f3d eat zym sqc 61w61 e                                                                   6.31mg   P<.0005+
 c   R f f3d eat ski sqc 61w61 e                                                                   87.2mg   P<.3
29   R m f3d eat liv mix 61w61 e                                 <+                                noTD50   P<.0005+
 a   R m f3d eat liv hpc 61w61 e                                                                   1.26mg   P<.0005+
 b   R m f3d eat zym mix 61w61 e                                                                   2.72mg   P<.0005+
 c   R m f3d eat zym sqc 61w61 e                                                                   3.59mg   P<.0005+
 d   R m f3d eat ski mix 61w61 e                                                                   8.76mg   P<.002 +
 e   R m f3d eat ski sqc 61w61 e                                                                   13.1mg   P<.008 +
 f   R m f3d eat zym sqp 61w61 e                                                                   35.8mg   P<.1
 g   R m f3d eat ski sqp 61w61 e                                                                   73.5mg   P<.3
 h   R m f3d eat ski bcc 61w61 e                                                                   73.5mg   P<.3
 i   R m f3d eat liv nnd 61w61 e                                                                   73.5mg   P<.3

2-AMINO-4-NITROPHENOL            100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
30   M f b6c gav TBA MXB 24m24                                                    :>                 no dre   P=1.   -
 a   M f b6c gav liv MXB 24m24                                                                     2.16gm * P<.5
 b   M f b6c gav lun MXB 24m24                                                                     2.18gm * P<.5
31   M m b6c gav MXA MXA 24m24                                                       :   +    :    #798.mg * P<.007 -
 a   M m b6c gav TBA MXB 24m24                                                                     582.mg * P<.6
 b   M m b6c gav liv MXB 24m24                                                                     no dre   P=1.
 c   M m b6c gav lun MXB 24m24                                                                     no dre   P=1.
32   R f f34 gav TBA MXB 24m24                                                  :>                 no dre   P=1.   -
 a   R f f34 gav liv MXB 24m24                                                                     no dre   P=1.
33   R m f34 gav tes ict 24m24 s                                          :  +      :               68.2mg * P<.003
 a   R m f34 gav k/c adn 24m24 s                                                                   839.mg * P<.01  p
 b   R m f34 gav sub MXA 24m24 s                                                                   458.mg * P<.05
 c   R m f34 gav sub fib 24m24 s                                                                   584.mg * P<.05
 d   R m f34 gav liv MXA 24m24 s                                                                   1.30gm * P<.02
 e   R m f34 gav TBA MXB 24m24 s                                                                   84.1mg * P<.02
 f   R m f34 gav liv MXB 24m24 s                                                                   1.30gm * P<.02

2-AMINO-5-NITROPHENOL            100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
34   M f b6c gav TBA MXB 24m24 ns                                                    :>               5.76gm * P<.9   -
 a   M f b6c gav liv MXB 24m24 ns                                                                   no dre   P=1.
 b   M f b6c gav lun MXB 24m24 ns                                                                   807.gm * P<1.
35   M m b6c gav TBA MXB 24m24 ns                                                      :>             no dre   P=1.   -
 a   M m b6c gav liv MXB 24m24 ns                                                                   no dre   P=1.
 b   M m b6c gav lun MXB 24m24 ns                                                                   no dre   P=1.
36   R f f34 gav TBA MXB 24m24                                                  :>                 no dre   P=1.   -
 a   R f f34 gav liv MXB 24m24                                                                     no dre   P=1.
37   R m f34 gav tes ict 24m24 s                                          : +   :                   28.6mg * P<.0005
 a   R m f34 gav pan MXA 24m24 s                                                                   107.mg * P<.0005
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc		Citation or Pathology	Brkly Code
21	bt203	8.83mg	n.s.s.	0/75	1.07mg	0/40					
a	bt203	1.55mg	n.s.s.	13/75	1.07mg	11/40					
b	bt203	3.14mg	n.s.s.	6/75	1.07mg	4/40					
AFLATOXIN B1*** 1162-65-8											
22	1824	8.58ug	n.s.s.	0/144	250.ng	0/24	750.ng	0/24	2.25ug 1/24	Elashoff;jnci,79,509-526;1987	
23	1824	6.83ug	n.s.s.	1/144	200.ng	0/23	600.ng	0/24	1.80ug 1/23		
ALLYL ALCOHOL 107-18-6											
24	1853	19.4mg	n.s.s.	0/20	10.4mg	3/20				Lijinsky;txih,3,337-345;1987/pers.comm.	
a	1853	13.1mg	n.s.s.	2/20	10.4mg	6/20					
b	1853	22.8mg	n.s.s.	2/20	10.4mg	3/20					
c	1853	62.7mg	n.s.s.	1/20	10.4mg	0/20					
25	1853	16.0mg	n.s.s.	2/20	7.26mg	3/20					
a	1853	23.2mg	n.s.s.	0/20	7.26mg	1/20					
b	1853	20.8mg	n.s.s.	2/20	7.26mg	2/20					
c	1853	43.9mg	n.s.s.	1/20	7.26mg	0/20					
2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE (MeIQx) 77500-04-0											
26	1820	7.95mg	25.6mg	0/39	78.0mg	32/35				Ohgaki;carc,8,665-668;1987	
a	1820	7.95mg	25.6mg	0/39	78.0mg	32/35					
b	1820	16.6mg	50.3mg	0/39	78.0mg	25/35					
c	1820	37.2mg	370.mg	4/39	78.0mg	15/35					
d	1820	59.2mg	n.s.s.	2/39	78.0mg	9/35					
e	1820	83.2mg	n.s.s.	2/39	78.0mg	6/35					
f	1820	83.2mg	n.s.s.	11/39	78.0mg	10/35					
27	1820	38.8mg	10.9gm	5/36	72.0mg	15/37					
a	1820	49.6mg	273.mg	0/36	72.0mg	10/37					
b	1820	48.9mg	1.23gm	2/36	72.0mg	11/37					
c	1820	37.0mg	n.s.s.	6/36	72.0mg	16/37					
d	1820	42.9mg	n.s.s.	10/36	72.0mg	16/37					
e	1820	60.9mg	n.s.s.	7/36	72.0mg	11/37					
f	1820	77.2mg	n.s.s.	3/36	72.0mg	7/37					
28	1867	2.34mg	11.3mg	0/20	20.0mg	12/19				Kato;carc,9,71-73;1988/pers.comm.	
a	1867	3.00mg	16.4mg	0/20	20.0mg	10/19					
b	1867	3.00mg	16.4mg	0/20	20.0mg	10/19					
c	1867	14.2mg	n.s.s.	0/20	20.0mg	1/19					
29	1867	n.s.s.	2.01mg	0/19	16.0mg	20/20					
a	1867	.518mg	2.88mg	0/19	16.0mg	19/20					
b	1867	1.39mg	6.00mg	0/19	16.0mg	15/20					
c	1867	1.82mg	8.30mg	0/19	16.0mg	13/20					
d	1867	3.75mg	34.5mg	0/19	16.0mg	7/20					
e	1867	4.95mg	197.mg	0/19	16.0mg	5/20					
f	1867	8.79mg	n.s.s.	0/19	16.0mg	2/20					
g	1867	12.0mg	n.s.s.	0/19	16.0mg	1/20					
h	1867	12.0mg	n.s.s.	0/19	16.0mg	1/20					
i	1867	12.0mg	n.s.s.	0/19	16.0mg	1/20					
2-AMINO-4-NITROPHENOL 99-57-0											
30	c55958	181.mg	n.s.s.	32/50	87.6mg	27/50	175.mg	29/50			
a	c55958	449.mg	n.s.s.	2/50	87.6mg	2/50	175.mg	4/50		liv:hpa,hpc,nnd.	
b	c55958	450.mg	n.s.s.	2/50	87.6mg	2/50	175.mg	4/50		lun:a/a,a/c.	
31	c55958	323.mg	2.80gm	0/50	87.6mg	1/50	175.mg	5/50		abc:hem; liv:hes; mln:hes; pan:hem; spl:hes; sub:hem.	S
a	c55958	103.mg	n.s.s.	34/50	87.6mg	39/50	175.mg	35/50			
b	c55958	292.mg	n.s.s.	15/50	87.6mg	18/50	175.mg	10/50		liv:hpa,hpc,nnd.	
c	c55958	363.mg	n.s.s.	9/50	87.6mg	8/50	175.mg	6/50		lun:a/a,a/c.	
32	c55958	146.mg	n.s.s.	42/50	87.6mg	39/50	175.mg	39/50			
a	c55958	n.s.s.	n.s.s.	0/50	87.6mg	1/50	175.mg	0/50		liv:hpa,hpc,nnd.	
33	c55958	35.2mg	387.mg	39/50	87.6mg	39/50	175.mg	36/50			S
a	c55958	286.mg	62.3gm	0/50	87.6mg	1/50	175.mg	3/50			
b	c55958	171.mg	n.s.s.	2/50	87.6mg	6/50	175.mg	4/50		sub:fbs,fib,nfs,srn.	S
c	c55958	213.mg	n.s.s.	1/50	87.6mg	5/50	175.mg	3/50			S
d	c55958	368.mg	n.s.s.	0/50	87.6mg	0/50	175.mg	3/50		liv:hpc,nnd.	S
e	c55958	39.6mg	13.1gm	45/50	87.6mg	43/50	175.mg	37/50			
f	c55958	368.mg	n.s.s.	0/50	87.6mg	0/50	175.mg	3/50		liv:hpa,hpc,nnd.	
2-AMINO-5-NITROPHENOL 121-88-0											
34	c55970	364.mg	n.s.s.	29/50	283.mg	30/50	566.mg	8/50			
a	c55970	1.48gm	n.s.s.	5/50	283.mg	3/50	566.mg	1/50		liv:hpa,hpc,nnd.	
b	c55970	1.14gm	n.s.s.	4/50	283.mg	4/50	566.mg	1/50		lun:a/a,a/c.	
35	c55970	550.mg	n.s.s.	31/50	283.mg	32/50	566.mg	8/50			
a	c55970	497.mg	n.s.s.	17/50	283.mg	16/50	(566.mg	1/50)		liv:hpa,hpc,nnd.	
b	c55970	1.02gm	n.s.s.	7/50	283.mg	8/50	566.mg	2/50		lun:a/a,a/c.	
36	c55970	105.mg	n.s.s.	46/50	70.7mg	45/50	142.mg	38/50			
a	c55970	n.s.s.	n.s.s.	0/50	70.7mg	0/50	142.mg	0/50		liv:hpa,hpc,nnd.	
37	c55970	16.8mg	65.2mg	42/50	70.7mg	40/50	142.mg	39/50			S
a	c55970	52.7mg	328.mg	1/50	70.7mg	11/50	142.mg	3/50		pan:acc,ana.	S

```
     Spe Strain  Site    Xpo+Xpt                                                                                  TD50      2Tailpvl
       Sex    Route   Hist      Notes                                                                                   DR      AuOp

 b   R m f34 gav pan ana 24m24 s                                                                                    111.mg * P<.0005p
 c   R m f34 gav pre can 24m24 s                                                                                    562.mg / P<.004
 d   R m f34 gav amd MXA 24m24 s                                                                                    101.mg * P<.02
 e   R m f34 gav pre MXA 24m24 s                                                                                    392.mg * P<.04
 f   R m f34 gav pni isc 24m24 s                                                                                    393.mg * P<.04
 g   R m f34 gav TBA MXB 24m24 s                                                                                    33.6mg * P<.0005
 h   R m f34 gav liv MXB 24m24 s                                                                                    1.56gm * P<.05

L-ASCORBATE, SODIUM               100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
38   R m f3d eat eso tum 52w52 er                                                  .>                               no dre   P=1.   -
 a   R m f3d eat for tum 52w52 er                                                                                   no dre   P=1.   -
 b   R m f3d eat liv tum 52w52 er                                                                                   no dre   P=1.   -

AURANOFIN                         100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
39   M f cd1 gav liv mix 80w81 erv                                               .>                                 no dre   P=1.   -
40   M m cd1 gav liv mix 80w81 erv                                    .>                                            42.6mg * P<.2   -

5-AZACYTIDINE***                  100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
41   M f bal ipj lmr mix 50w72 e                            . +  .                                                  56.9ug   P<.0005+
 a   M f bal ipj mgl mix 50w72 e                                                                                    .432mg   P<.002
 b   M f bal ipj mgl adb 50w72 e                                                                                    .618mg   P<.008 +
 c   M f bal ipj ski mix 50w72 e                                                                                    .499mg   P<.03  +
 d   M f bal ipj lun ade 50w72 e                                                                                    no dre   P=1.
 e   M f bal ipj liv tum 50w72 e                                                                                    no dre   P=1.
 f   M f bal ipj tba tum 50w72 e                                                                                    36.4ug   P<.0005
42   M m bal ipj lun ade 50w67 e                              .  +       .                                          .121mg   P<.003 +
 a   M m bal ipj lmr mix 50w67 e                                                                                    .285mg   P<.01  +
 b   M m bal ipj ski mix 50w67 e                                                                                    .980mg   P<.04  +
 c   M m bal ipj liv hpa 50w67 e                                                                                    1.49mg   P<.1
 d   M m bal ipj tba tum 50w67 e                                                                                    53.9ug   P<.0005
43   R m f34 ipj tes tum 52w52 e                                   . +  .                                           .222mg * P<.0005+
 a   R m f34 ipj liv tum 52w52 e                                                                                    no dre   P=1.
 b   R m f34 ipj tba tum 52w52 e                                                                                    .170mg * P<.0005+

6-AZACYTIDINE                     100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
44   R m f34 ipj liv tum 52w52 e                                          .>                                        no dre   P=1.
 a   R m f34 ipj tba tum 52w52 e                                                                                    no dre   P=1.   -

AZOXYMETHANE***                   100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
45   R m f34 gav col tum 30w65 e                              .   +  .                                              .102mg   P<.0005+
 a   R m f34 gav col mal 30w65 e                                                                                    .171mg   P<.0005
 b   R m f34 gav zym car 30w65 e                                                                                    .204mg   P<.0005+
 c   R m f34 gav kid mnp 30w65 e                                                                                    .300mg   P<.002 +
 d   R m f34 gav liv tum 30w65 e                                                                                    no dre   P=1.   -

1-AZOXYPROPANE                    100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
46   R m sda gav ski mix 26w77 ev     <+                                                                            noTD50   P<.0005+
 a   R m sda gav ski ker 26w77 ev                                                                                   380.ng   P<.0005+
 b   R m sda gav nas mix 26w77 ev                                                                                   596.ng   P<.0005+
 c   R m sda gav nas ene 26w77 ev                                                                                   723.ng   P<.0005+
 d   R m sda gav nas pam 26w77 ev                                                                                   7.36ug   P<.1   +
 e   R m sda gav liv hpc 26w77 ev                                                                                   7.36ug   P<.1
 f   R m sda gav liv hpa 26w77 ev                                                                                   no dre   P=1.

2-AZOXYPROPANE                    100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
47   R m sda gav ski ker 26w77 ev            .    ±                                                                 2.68ug   P<.04  +
 a   R m sda gav liv hpc 26w77 ev                                                                                   7.36ug   P<.1
 b   R m sda gav liv hpa 26w77 ev                                                                                   no dre   P=1.

BENZENE***                        100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
48   M f swi gav mam car 18m24                                                   .  +   .                           279.mg   P<.0005+
 a   M f swi gav lun mix 18m24                                                                                      453.mg   P<.004 +
 b   M f swi gav lun ata 18m24                                                                                      1.02gm   P<.004
 c   M f swi gav lun ade 18m24                                                                                      1.10gm   P<.2
 d   M f swi gav zym car 18m24                                                                                      6.52gm   P<.3   +
 e   M f swi gav liv hpt 18m24                                                                                      no dre   P=1.
 f   M f swi gav tba mix 18m24                                                                                      150.mg   P<.0005
 g   M f swi gav tba mal 18m24                                                                                      187.mg   P<.0005+
49   M m swi gav lun mix 18m24                                                    .  +     .                        382.mg   P<.0005+
 a   M m swi gav lun ade 18m24                                                                                      811.mg   P<.02
 b   M m swi gav lun ata 18m24                                                                                      1.20gm   P<.04
 c   M m swi gav zym car 18m24                                                                                      1.57gm   P<.02  +
 d   M m swi gav liv hpt 18m24                                                                                      6.19gm   P<.7
 e   M m swi gav lun adc 18m24                                                                                      6.52gm   P<.3
 f   M m swi gav tba mix 18m24                                                                                      370.mg   P<.05
 g   M m swi gav tba mal 18m24                                                                                      939.mg   P<.3   +
50   R f wis gav zym sqc 24m24                                                         .   +                       .1.36gm   P<.004
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	c55970	53.8mg	359.mg	1/50	70.7mg	10/50	142.mg	3/50		
c	c55970	163.mg	5.02gm	0/50	70.7mg	0/50	142.mg	4/50		S
d	c55970	43.3mg	n.s.s.	20/50	70.7mg	16/50	142.mg	12/50	amd:phe,phm.	S
e	c55970	126.mg	n.s.s.	3/50	70.7mg	2/50	142.mg	5/50	pre:adn,can.	S
f	c55970	118.mg	n.s.s.	0/50	70.7mg	3/50	142.mg	0/50		S
g	c55970	19.0mg	88.7mg	42/50	70.7mg	44/50	142.mg	34/50		
h	c55970	332.mg	n.s.s.	0/50	70.7mg	0/50	142.mg	2/50	liv:hpa,hpc,nnd.	
L-ASCORBATE, SODIUM (vitamin C, sodium) 134-03-2										
38	1900	206.mg	n.s.s.	0/10	400.mg	0/10			Hirose;carc,8,1731-1735;1987/pers.comm.	
a	1900	206.mg	n.s.s.	0/10	400.mg	0/10				
b	1900	206.mg	n.s.s.	0/10	400.mg	0/10				
AURANOFIN ((2,3,4,6-tetra-O-acetyl-1-thio-1-beta-D-glucopyranosato-S) (triethylphosphine) gold) 34031-32-8										
39	1870	130.mg	n.s.s.	4/220	1.00mg	3/110	3.00mg	0/110	7.45mg 0/110 Markiewicz;faat,11,277-284;1988	
40	1870	13.8mg	n.s.s.	24/220	1.00mg	21/110	3.00mg	17/110	7.45mg 20/110	
5-AZACYTIDINE*** 320-67-2										
41	1819	35.2ug	.104mg	6/50	.198mg	36/50			Cavaliere;clet,37,51-58;1987	
a	1819	.186mg	1.82mg	0/50	.198mg	7/50				
b	1819	.235mg	12.0mg	0/50	.198mg	5/50				
c	1819	.196mg	n.s.s.	1/50	.198mg	7/50				
d	1819	.329mg	n.s.s.	9/50	.198mg	7/50				
e	1819	.980mg	n.s.s.	0/50	.198mg	0/50				
f	1819	21.5ug	69.4ug	14/50	.198mg	44/50				
42	1819	60.4ug	.719mg	12/50	.213mg	27/50				
a	1819	.126mg	41.7mg	3/50	.213mg	12/50				
b	1819	.297mg	n.s.s.	0/50	.213mg	3/50				
c	1819	.365mg	n.s.s.	0/50	.213mg	2/50				
d	1819	31.5ug	.116mg	13/50	.213mg	38/50				
43	1906	.144mg	.404mg	10/49	10.7ug	1/10	.107mg	2/10	1.07mg 56/87 Carr;bjca,57,395-402;1988	
a	1906	5.01ug	n.s.s.	0/49	10.7ug	0/10	.107mg	0/10	1.07mg 0/87	
b	1906	.114mg	.282mg	10/49	10.7ug	1/10	.107mg	2/10	1.07mg 63/87	
6-AZACYTIDINE 3131-60-0										
44	1906	.662mg	n.s.s.	0/49	1.07mg	0/12			Carr;bjca,57,395-402;1988	
a	1906	.340mg	n.s.s.	10/49	1.07mg	2/12				
AZOXYMETHANE*** (Z-methyl-O,N,N-azoxymethane) 25843-45-2										
45	1864	48.5ug	.249mg	0/19	.527mg	12/16			Lijinsky;canr,47,3968-3972;1987/pers.comm.	
a	1864	77.9ug	.474mg	0/19	.527mg	9/16				
b	1864	90.0ug	.610mg	0/19	.527mg	8/16				
c	1864	.121mg	1.26mg	0/19	.527mg	6/16				
d	1864	.679mg	n.s.s.	0/19	.527mg	0/16				
1-AZOXYPROPANE 17697-55-1										
46	1837	n.s.s.	241.ng	1/29	1.40ug	29/29			Fiala;carc,8,1947-1949;1987/pers.comm.	
a	1837	214.ng	751.ng	1/29	1.40ug	22/29				
b	1837	330.ng	1.22ug	0/29	1.40ug	17/29				
c	1837	390.ng	1.55ug	0/29	1.40ug	15/29				
d	1837	1.81ug	n.s.s.	0/29	1.40ug	2/29				
e	1837	1.81ug	n.s.s.	0/29	1.40ug	2/29				
f	1837	2.77ug	n.s.s.	1/29	1.40ug	1/29				
2-AZOXYPROPANE 17697-53-9										
47	1837	971.ng	n.s.s.	1/29	1.40ug	6/29			Fiala;carc,8,1947-1949;1987/pers.comm.	
a	1837	1.81ug	n.s.s.	0/29	1.40ug	2/29				
b	1837	2.77ug	n.s.s.	1/29	1.40ug	1/29				
BENZENE*** 71-43-2										
48	bt908	154.mg	655.mg	2/40	241.mg	19/40			Maltoni;anya,534,412-426;1988	
a	bt908	214.mg	3.43gm	4/40	241.mg	15/40				
b	bt908	414.mg	6.13gm	0/40	241.mg	6/40				
c	bt908	362.mg	n.s.s.	4/40	241.mg	9/40				
d	bt908	1.06gm	n.s.s.	0/40	241.mg	1/40				
e	bt908	1.99gm	n.s.s.	0/40	241.mg	0/40				
f	bt908	77.1mg	523.mg	16/40	241.mg	32/40				
g	bt908	99.1mg	589.mg	11/40	241.mg	28/40				
49	bt908	193.mg	1.39gm	3/40	241.mg	16/40				
a	bt908	330.mg	n.s.s.	2/40	241.mg	9/40				
b	bt908	436.mg	n.s.s.	1/40	241.mg	6/40				
c	bt908	541.mg	n.s.s.	0/40	241.mg	4/40				
d	bt908	756.mg	n.s.s.	2/40	241.mg	3/40				
e	bt908	1.06gm	n.s.s.	0/40	241.mg	1/40				
f	bt908	149.mg	n.s.s.	15/40	241.mg	24/40				
g	bt908	279.mg	n.s.s.	9/40	241.mg	14/40				
50	bt907	552.mg	8.18gm	0/40	321.mg	6/40				

	Spe	Sex	Strain	Route	Site	Hist	Xpo+Xpt	Notes		TD50	DR	2Tailpvl	AuOp
a	R	f	wis	gav	orc	sqc	24m24			2.09gm		P<.02	
b	R	f	wis	gav	nas	ulc	24m24			8.70gm		P<.3	
c	R	f	wis	gav	tba	mal	24m24			482.mg		P<.02	
d	R	f	wis	gav	tba	mix	24m24			no dre		P=1.	
51	R	m	wis	gav	zym	sqc	24m24		. + .	1.14gm		P<.002	
a	R	m	wis	gav	nas	ulc	24m24			4.29gm		P<.1	
b	R	m	wis	gav	orc	sqc	24m24			8.48gm		P<.6	
c	R	m	wis	gav	tba	mal	24m24			523.mg		P<.01	
d	R	m	wis	gav	tba	mix	24m24			no dre		P=1.	
BENZOFURAN									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
52	M	f	b6c	gav	MXB	MXB	24m24		: + :	33.4mg		P<.0005	
a	M	f	b6c	gav	liv	hpa	24m24			34.4mg		P<.0005	c
b	M	f	b6c	gav	liv	MXA	24m24			36.4mg		P<.0005	
c	M	f	b6c	gav	for	MXA	24m24			145.mg		P<.003	c
d	M	f	b6c	gav	for	sqp	24m24			172.mg		P<.005	
e	M	f	b6c	gav	lun	MXA	24m24			174.mg	*	P<.0005	c
f	M	f	b6c	gav	lun	a/a	24m24			224.mg	*	P<.0005	
g	M	f	b6c	gav	MXA	MXA	24m24			322.mg		P<.04	
h	M	f	b6c	gav	TBA	MXB	24m24			45.9mg		P<.002	
i	M	f	b6c	gav	liv	MXB	24m24			36.4mg		P<.0005	
j	M	f	b6c	gav	lun	MXB	24m24			174.mg	*	P<.0005	
53	M	m	b6c	gav	liv	MXA	24m24		: + :	19.8mg		P<.0005	c
a	M	m	b6c	gav	liv	hpa	24m24			20.5mg		P<.0005	c
b	M	m	b6c	gav	liv	MXA	24m24			21.3mg		P<.0005	
c	M	m	b6c	gav	MXB	MXB	24m24			23.9mg		P<.002	
d	M	m	b6c	gav	liv	hpb	24m24			102.mg	*	P<.0005	c
e	M	m	b6c	gav	for	MXA	24m24			108.mg	*	P<.002	c
f	M	m	b6c	gav	liv	MXA	24m24			114.mg	*	P<.006	
g	M	m	b6c	gav	lun	a/a	24m24			136.mg	*	P<.004	
h	M	m	b6c	gav	for	sqp	24m24			154.mg	*	P<.007	
i	M	m	b6c	gav	lun	MXA	24m24			160.mg	*	P<.04	c
j	M	m	b6c	gav	for	sqc	24m24			383.mg	*	P<.03	
k	M	m	b6c	gav	mul	mlp	24m24			919.mg	*	P<.04	
l	M	m	b6c	gav	TBA	MXB	24m24			54.3mg	*	P<.02	
m	M	m	b6c	gav	liv	MXB	24m24			21.3mg		P<.0005	
n	M	m	b6c	gav	lun	MXB	24m24			160.mg	*	P<.04	
54	R	f	f34	gav	sub	nlm	24m24		: + :	98.8mg		P<.005	
a	R	f	f34	gav	lun	MXA	24m24			418.mg	*	P<.04	
b	R	f	f34	gav	kid	uac	24m24			424.mg	*	P<.02	p
c	R	f	f34	gav	lun	a/a	24m24			530.mg	*	P<.04	
d	R	f	f34	gav	ton	sqp	24m24			574.mg	*	P<.04	
e	R	f	f34	gav	TBA	MXB	24m24			577.mg	*	P<.9	
f	R	f	f34	gav	liv	MXB	24m24			2.09gm	*	P<.3	
55	R	m	f34	gav	tes	ict	24m24		: + :	#8.03mg		P<.004	-
a	R	m	f34	gav	pit	adn	24m24			45.8mg	*	P<.03	
b	R	m	f34	gav	MXA	MXA	24m24			55.3mg	*	P<.02	
c	R	m	f34	gav	lun	a/c	24m24			166.mg	*	P<.03	
d	R	m	f34	gav	mgl	fba	24m24			271.mg	*	P<.03	
e	R	m	f34	gav	thy	fcc	24m24			389.mg	*	P<.03	
f	R	m	f34	gav	TBA	MXB	24m24			22.5mg	*	P<.02	
g	R	m	f34	gav	liv	MXB	24m24			no dre		P=1.	
BENZYL ALCOHOL									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
56	M	f	b6c	gav	TBA	MXB	24m24		:>	57.5gm	*	P<1.	-
a	M	f	b6c	gav	liv	MXB	24m24			1.04gm	*	P<.4	
b	M	f	b6c	gav	lun	MXB	24m24			no dre		P=1.	
57	M	m	b6c	gav	adr	coa	24m24		: ±	#1.62gm	*	P<.05	-
a	M	m	b6c	gav	TBA	MXB	24m24			no dre		P=1.	
b	M	m	b6c	gav	liv	MXB	24m24			588.mg	*	P<.4	
c	M	m	b6c	gav	lun	MXB	24m24			546.mg	*	P<.3	
58	R	f	f34	gav	TBA	MXB	24m24	s	:>	885.mg	*	P<.7	-
a	R	f	f34	gav	liv	MXB	24m24	s		no dre		P=1.	
59	R	m	f34	gav	mgl	MXA	24m24		: ±	#1.14gm	*	P<.03	-
a	R	m	f34	gav	mgl	fba	24m24			1.38gm	*	P<.04	
b	R	m	f34	gav	TBA	MXB	24m24			no dre		P=1.	
c	R	m	f34	gav	liv	MXB	24m24			no dre		P=1.	
HC BLUE NO. 1*									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
60	M	f	b6c	eat	liv	mix	9m23	er	. + .	41.3mg		P<.0005	+
a	M	f	b6c	eat	liv	hpc	9m23	er		114.mg		P<.0005	+
b	M	f	b6c	eat	liv	hpa	9m23	er		165.mg		P<.0005	
61	M	f	b6c	eat	liv	mix	15m23	er	. + .	81.5mg		P<.0005	+
a	M	f	b6c	eat	liv	hpc	15m23	er		94.0mg		P<.0005	+
b	M	f	b6c	eat	liv	hpa	15m23	er		969.mg		P<.05	
62	M	f	b6c	eat	liv	mix	91w91	ekr	. + .	85.0mg		P<.0005	+
a	M	f	b6c	eat	liv	hpc	91w91	ekr		148.mg		P<.004	+

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	bt907	722.mg	n.s.s.	0/40	321.mg	4/40				
b	bt907	1.42gm	n.s.s.	0/40	321.mg	1/40				
c	bt907	217.mg	n.s.s.	10/40	321.mg	21/40				
d	bt907	408.mg	n.s.s.	34/40	321.mg	27/40				
51	bt907	494.mg	4.73gm	0/40	321.mg	7/40				
a	bt907	1.06gm	n.s.s.	0/40	321.mg	2/40				
b	bt907	1.16gm	n.s.s.	1/40	321.mg	2/40				
c	bt907	238.mg	26.9gm	8/40	321.mg	19/40				
d	bt907	490.mg	n.s.s.	30/40	321.mg	23/40				
BENZOFURAN	271-89-6									
52	c56166	18.8mg	73.8mg	5/50	84.9mg	27/50	(170.mg	29/50)	for:sqc,sqp; liv:hpa; lun:a/a,a/c.	C
a	c56166	19.7mg	71.5mg	1/50	84.9mg	22/50	(170.mg	21/50)		
b	c56166	20.4mg	80.8mg	4/50	84.9mg	25/50	(170.mg	22/50)	liv:hpa,hpc.	S
c	c56166	61.8mg	890.mg	2/50	84.9mg	9/50	(170.mg	5/50)	for:sqc,sqp.	
d	c56166	69.8mg	1.88gm	2/50	84.9mg	8/50	(170.mg	5/50)		S
e	c56166	98.1mg	449.mg	2/50	84.9mg	9/50	170.mg	14/50	lun:a/a,a/c.	
f	c56166	122.mg	565.mg	1/50	84.9mg	5/50	170.mg	13/50		S
g	c56166	101.mg	n.s.s.	1/50	84.9mg	4/50	(170.mg	1/50)	mul:mlu; spl:mlu.	S
h	c56166	22.3mg	255.mg	27/50	84.9mg	35/50	(170.mg	35/50)		
i	c56166	20.4mg	80.8mg	4/50	84.9mg	25/50	(170.mg	22/50)	liv:hpa,hpc,nnd.	
j	c56166	98.1mg	449.mg	2/50	84.9mg	9/50	170.mg	14/50	lun:a/a,a/c.	
53	c56166	10.7mg	52.5mg	12/50	42.4mg	31/50	(84.9mg	40/50)	liv:hpa,hpb,hpc.	
a	c56166	11.5mg	46.9mg	4/50	42.4mg	24/50	(84.9mg	34/50)		
b	c56166	11.4mg	58.6mg	12/50	42.4mg	30/50	(84.9mg	37/50)	liv:hpa,hpc.	S
c	c56166	11.7mg	108.mg	20/50	42.4mg	32/50	(84.9mg	45/50)	for:sqc,sqp; liv:hpa,hpb,hpc; lun:a/a,a/c.	C
d	c56166	60.1mg	191.mg	0/50	42.4mg	3/50	84.9mg	18/50		
e	c56166	58.7mg	438.mg	2/50	42.4mg	11/50	84.9mg	13/50	for:sqc,sqp.	
f	c56166	55.7mg	1.46gm	9/50	42.4mg	10/50	84.9mg	22/50	liv:hpb,hpc.	S
g	c56166	67.8mg	1.08gm	4/50	42.4mg	7/50	84.9mg	15/50		S
h	c56166	74.8mg	2.64gm	2/50	42.4mg	7/50	84.9mg	10/50		S
i	c56166	67.6mg	n.s.s.	10/50	42.4mg	9/50	84.9mg	19/50	lun:a/a,a/c.	
j	c56166	163.mg	n.s.s.	0/50	42.4mg	4/50	84.9mg	3/50		S
k	c56166	272.mg	n.s.s.	0/50	42.4mg	0/50	84.9mg	3/50		S
l	c56166	25.8mg	n.s.s.	29/50	42.4mg	32/50	84.9mg	45/50		
m	c56166	11.4mg	58.6mg	12/50	42.4mg	30/50	(84.9mg	37/50)	liv:hpa,hpc,nnd.	
n	c56166	67.6mg	n.s.s.	10/50	42.4mg	9/50	84.9mg	19/50	lun:a/a,a/c.	
54	c56166	42.7mg	939.mg	1/50	42.4mg	9/50	(84.9mg	3/50)		S
a	c56166	159.mg	n.s.s.	0/50	42.4mg	2/50	84.9mg	3/50	lun:a/a,a/c.	S
b	c56166	161.mg	n.s.s.	0/50	42.4mg	1/50	84.9mg	4/50		
c	c56166	183.mg	n.s.s.	0/50	42.4mg	1/50	84.9mg	3/50		S
d	c56166	194.mg	n.s.s.	0/50	42.4mg	1/50	84.9mg	3/50		S
e	c56166	40.0mg	n.s.s.	46/50	42.4mg	48/50	84.9mg	42/50		
f	c56166	341.mg	n.s.s.	0/50	42.4mg	0/50	84.9mg	1/50	liv:hpa,hpc,nnd.	
55	c56166	3.77mg	68.2mg	42/50	21.2mg	40/50	(42.4mg	41/50)		S
a	c56166	19.5mg	n.s.s.	18/50	21.2mg	16/50	42.4mg	22/50		S
b	c56166	25.4mg	n.s.s.	10/50	21.2mg	13/50	42.4mg	17/50	liv:mnl; mul:mnl.	S
c	c56166	60.0mg	n.s.s.	0/50	21.2mg	3/50	42.4mg	2/50		S
d	c56166	77.8mg	n.s.s.	0/50	21.2mg	0/50	42.4mg	3/50		S
e	c56166	103.mg	n.s.s.	0/50	21.2mg	0/50	42.4mg	3/50		S
f	c56166	10.4mg	n.s.s.	45/50	21.2mg	42/50	42.4mg	46/50		
g	c56166	147.mg	n.s.s.	1/50	21.2mg	1/50	42.4mg	0/50	liv:hpa,hpc,nnd.	
BENZYL ALCOHOL	100-51-6									
56	c06111	120.mg	n.s.s.	27/50	70.7mg	24/50	142.mg	36/50		
a	c06111	279.mg	n.s.s.	1/50	70.7mg	6/50	142.mg	4/50	liv:hpa,hpc,nnd.	
b	c06111	588.mg	n.s.s.	4/50	70.7mg	1/50	142.mg	4/50	lun:a/a,a/c.	
57	c06111	489.mg	n.s.s.	0/50	70.7mg	0/50	142.mg	3/50		S
a	c06111	134.mg	n.s.s.	34/50	70.7mg	27/50	142.mg	34/50		
b	c06111	148.mg	n.s.s.	11/50	70.7mg	16/50	142.mg	16/50	liv:hpa,hpc,nnd.	
c	c06111	174.mg	n.s.s.	10/50	70.7mg	6/50	142.mg	17/50	lun:a/a,a/c.	
58	c06111	133.mg	n.s.s.	46/50	142.mg	29/50	283.mg	26/50		
a	c06111	n.s.s.	n.s.s.	0/50	142.mg	0/50	283.mg	0/50	liv:hpa,hpc,nnd.	
59	c06111	465.mg	n.s.s.	0/50	142.mg	3/50	283.mg	3/50	mgl:adn,fba.	S
a	c06111	523.mg	n.s.s.	0/50	142.mg	2/50	283.mg	3/50		S
b	c06111	171.mg	n.s.s.	44/50	142.mg	32/50	283.mg	38/50		
c	c06111	1.47gm	n.s.s.	2/50	142.mg	0/50	283.mg	1/50	liv:hpa,hpc,nnd.	
HC BLUE NO. 1***	2784-94-3									
60	1860m	19.7mg	91.7mg	3/38	151.mg	20/22			Burnett;fctx,25,703-707;1987/pers.comm.	
a	1860m	56.4mg	302.mg	2/38	151.mg	13/22				
b	1860m	77.2mg	499.mg	1/38	151.mg	10/22				
61	1860n	41.2mg	177.mg	3/38	252.mg	20/23				
a	1860n	48.9mg	201.mg	2/38	252.mg	19/23				
b	1860n	300.mg	n.s.s.	1/38	252.mg	4/23				
62	1860o	33.8mg	291.mg	0/10	195.mg	7/10				
a	1860o	54.2mg	1.03gm	0/10	195.mg	5/10				

	Spe Sex	Strain	Route	Site	Hist	Xpo+Xpt	Notes	TD50	DR	2Tailpvl	AuOp
b	M	f b6c	eat	liv	hpa	91w91	ekr	287.mg		P<.04	
63	M	f b6c	eat	liv	mix	23m23	er	51.4mg		P<.0005	+
a	M	f b6c	eat	liv	hpc	23m23	er	163.mg		P<.0005	+
b	M	f b6c	eat	liv	hpa	23m23	er	185.mg		P<.0005	
64	M	f b6c	eat	liv	hpc	91w91	ekr	noTD50		P<.0005	+
a	M	f b6c	eat	liv	mix	91w91	ekr	noTD50		P<.0005	+
b	M	f b6c	eat	liv	hpa	91w91	ekr	574.mg		P<.04	
65	M	f b6c	eat	liv	mix	23m23	er	noTD50		P<.0005	+
a	M	f b6c	eat	liv	hpc	23m23	er	87.1mg		P<.0005	+
b	M	f b6c	eat	liv	hpa	23m23	er	1.30gm		P<.02	
HC BLUE NO. 1 (PURIFIED)							100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
66	M	f b6c	eat	liv	mix	91w91	ekr	noTD50		P<.0005	+
a	M	f b6c	eat	liv	hpc	91w91	ekr	88.9mg		P<.0005	+
b	M	f b6c	eat	liv	hpa	91w91	ekr	917.mg		P<.09	
67	M	f b6c	eat	liv	mix	23m23	er	70.6mg		P<.0005	+
a	M	f b6c	eat	liv	hpc	23m23	er	115.mg		P<.0005	+
b	M	f b6c	eat	liv	hpa	23m23	er	530.mg		P<.0005	
BORIC ACID							100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
68	M	f b6c	eat	TBA	MXB	24m24		no dre		P=1.	-
a	M	f b6c	eat	liv	MXB	24m24		31.0gm	*	P<.9	
b	M	f b6c	eat	lun	MXB	24m24		4.19gm	*	P<.3	
69	M	m b6c	eat	liv	MXA	24m24	s	#638.mg	*	P<.009	-
a	M	m b6c	eat	sub	MXA	24m24	s	706.mg		P<.004	
b	M	m b6c	eat	sub	MXA	24m24	s	1.07gm		P<.009	
c	M	m b6c	eat	liv	hpc	24m24	s	1.12gm	*	P<.02	
d	M	m b6c	eat	TBA	MXB	24m24	s	500.mg	*	P<.03	
e	M	m b6c	eat	liv	MXB	24m24	s	638.mg	*	P<.009	
f	M	m b6c	eat	lun	MXB	24m24	s	38.6gm	*	P<1.	
BROMATE, POTASSIUM***							100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
70	R	m f3d	wat	kid	mix	6m24	e	6.67mg		P<.0005	+
a	R	m f3d	wat	kid	ade	6m24	e	6.67mg		P<.0005	
b	R	m f3d	wat	per	mso	6m24	e	7.84mg		P<.0005	
c	R	m f3d	wat	thy	fct	6m24	e	11.3mg		P<.003	
d	R	m f3d	wat	kid	adc	6m24	e	79.2mg		P<.3	
71	R	m f3d	wat	kid	mix	9m24	e	4.81mg		P<.0005	+
a	R	m f3d	wat	kid	ade	9m24	e	5.57mg		P<.0005	
b	R	m f3d	wat	per	mso	9m24	e	14.0mg		P<.002	
c	R	m f3d	wat	kid	adc	9m24	e	16.9mg		P<.003	
72	R	m f3d	wat	kid	mix	12m24	e	8.32mg		P<.0005	+
a	R	m f3d	wat	kid	ade	12m24	e	10.1mg		P<.0005	
b	R	m f3d	wat	per	mso	12m24	e	19.4mg		P<.003	
c	R	m f3d	wat	thy	fct	12m24	e	19.4mg		P<.003	
d	R	m f3d	wat	kid	adc	12m24	e	35.5mg		P<.02	
73	R	m f3d	wat	kid	ade	52w52	e	4.98mg		P<.002	
a	R	m f3d	wat	per	mso	52w52	e	25.6mg		P<.2	
74	R	m f3d	wat	per	mso	24m24	e	12.4mg		P<.0005	
a	R	m f3d	wat	kid	mix	24m24	e	28.7mg		P<.0005	+
b	R	m f3d	wat	thy	fct	24m24	e	39.8mg		P<.002	
c	R	m f3d	wat	kid	ade	24m24	e	48.0mg		P<.004	
d	R	m f3d	wat	thy	fca	24m24	e	59.5mg		P<.008	
e	R	m f3d	wat	kid	adc	24m24	e	105.mg		P<.04	
75	R	m f3d	wat	per	mso	24m24		29.1mg	*	P<.0005	
a	R	m f3d	wat	kid	rct	24m24		41.6mg	*	P<.0005	+
b	R	m f3d	wat	kid	ade	24m24		52.0mg	*	P<.0005	+
c	R	m f3d	wat	thy	fct	24m24	e	78.6mg	*	P<.0005	
d	R	m f3d	wat	kid	adc	24m24		326.mg	*	P<.004	
e	R	m f3d	wat	liv	nnd	24m24		68.2mg	Z	P<.2	
BROMODICHLOROMETHANE***							100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
76	M	f b6c	gav	liv	MXA	24m24		28.9mg	*	P<.0005	c
a	M	f b6c	gav	liv	hpa	24m24		36.0mg	*	P<.0005	c
b	M	f b6c	gav	liv	hpc	24m24		144.mg	*	P<.002	c
c	M	f b6c	gav	MXA	MXA	24m24		132.mg		P<.02	
d	M	f b6c	gav	TBA	MXB	24m24		62.9mg	*	P<.04	
e	M	f b6c	gav	liv	MXB	24m24		28.9mg	*	P<.0005	
f	M	f b6c	gav	lun	MXB	24m24		644.mg	*	P<.2	
77	M	m b6c	gav	mul	mlp	24m24		74.2mg		P<.008	
a	M	m b6c	gav	kid	MXA	24m24		137.mg	*	P<.02	c

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	1860o	85.8mg	n.s.s.	0/10	195.mg	3/10				
63	1860r	28.5mg	95.5mg	3/38	195.mg	33/36				
a	1860r	91.4mg	358.mg	2/38	195.mg	20/36				
b	1860r	103.mg	402.mg	1/38	195.mg	18/36				
64	1860s	n.s.s.	162.mg	0/10	390.mg	10/10				
a	1860s	n.s.s.	162.mg	0/10	390.mg	10/10				
b	1860s	172.mg	n.s.s.	0/10	390.mg	3/10				
65	1860u	n.s.s.	106.mg	3/38	390.mg	36/36				
a	1860u	45.8mg	163.mg	2/38	390.mg	34/36				
b	1860u	515.mg	n.s.s.	1/38	390.mg	7/36				
HC BLUE NO. 1 (PURIFIED) 2784-94-3										
66	1860m	n.s.s.	162.mg	0/10	390.mg	10/10			Burnett;fctx,25,703-707;1987/pers.comm.	
a	1860m	31.2mg	277.mg	0/10	390.mg	9/10				
b	1860m	224.mg	n.s.s.	0/10	390.mg	2/10				
67	1860n	31.7mg	141.mg	3/38	390.mg	35/36				
a	1860n	66.1mg	210.mg	2/38	390.mg	32/36				
b	1860n	275.mg	1.41gm	1/38	390.mg	14/36				
BORIC ACID 10043-35-3										
68	c56417	777.mg	n.s.s.	25/50	319.mg	27/50	638.mg	26/50		
a	c56417	1.77gm	n.s.s.	5/50	319.mg	4/50	638.mg	6/50	liv:hpa,hpc,nnd.	
b	c56417	1.38gm	n.s.s.	1/50	319.mg	5/50	638.mg	4/50	lun:a/a,a/c.	
69	c56417	296.mg	27.8gm	14/50	296.mg	19/50	591.mg	15/50	liv:hpa,hpc.	S
a	c56417	308.mg	5.24gm	2/50	296.mg	10/50	(591.mg	2/50)	sub:fbs,fib,nfs,srn.	S
b	c56417	425.mg	45.2gm	1/50	296.mg	7/50	(591.mg	2/50)	sub:fbs,nfs,srn.	S
c	c56417	500.mg	n.s.s.	5/50	296.mg	12/50	591.mg	8/50		S
d	c56417	218.mg	n.s.s.	31/50	296.mg	37/50	591.mg	23/50		
e	c56417	296.mg	27.8gm	14/50	296.mg	19/50	591.mg	15/50	liv:hpa,hpc,nnd.	
f	c56417	799.mg	n.s.s.	11/50	296.mg	11/50	591.mg	4/50	lun:a/a,a/c.	
BROMATE, POTASSIUM*** 7758-01-2										
70	1814m	3.08mg	18.8mg	0/19	6.25mg	9/19			Kurokawa;gann,78,358-364;1987	
a	1814m	3.08mg	18.8mg	0/19	6.25mg	9/19				
b	1814m	3.50mg	24.7mg	0/19	6.25mg	8/19				
c	1814m	4.57mg	58.1mg	0/19	6.25mg	6/19				
d	1814m	12.9mg	n.s.s.	0/19	6.25mg	1/19				
71	1814n	2.42mg	10.9mg	0/19	9.38mg	14/19				
a	1814n	2.79mg	12.9mg	0/19	9.38mg	13/19				
b	1814n	5.97mg	52.5mg	0/19	9.38mg	7/19				
c	1814n	6.85mg	87.2mg	0/19	9.38mg	6/19				
72	1814o	3.72mg	23.3mg	0/19	12.5mg	9/14				
a	1814o	4.41mg	30.2mg	0/19	12.5mg	8/14				
b	1814o	7.26mg	103.mg	0/19	12.5mg	5/14				
c	1814o	7.26mg	103.mg	0/19	12.5mg	5/14				
d	1814o	10.7mg	n.s.s.	0/19	12.5mg	3/14				
73	1814r	2.66mg	14.9mg	0/8	25.0mg	15/26				
a	1814r	8.84mg	n.s.s.	0/8	25.0mg	4/26				
74	1814s	6.33mg	27.2mg	0/19	25.0mg	15/20				
a	1814s	13.3mg	81.8mg	0/19	25.0mg	9/20				
b	1814s	17.0mg	156.mg	0/19	25.0mg	7/20				
c	1814s	19.4mg	271.mg	0/19	25.0mg	6/20				
d	1814s	22.5mg	895.mg	0/19	25.0mg	5/20				
e	1814s	31.8mg	n.s.s.	0/19	25.0mg	3/20				
75	1851	17.0mg	64.2mg	0/20	.900mg	0/20	1.70mg	3/20	3.30mg 4/24 7.30mg 2/24 16.0mg 3/20	
					43.4mg	15/20			Kurokawa;jnci,77,977-982;1986	
a	1851	24.4mg	82.5mg	0/20	.900mg	0/20	1.70mg	0/20	3.30mg 1/24 7.30mg 5/24 16.0mg 5/20	
					43.4mg	9/20				
b	1851	29.4mg	133.mg	0/20	.900mg	0/20	1.70mg	0/20	3.30mg 1/24 7.30mg 5/24 16.0mg 5/20	
					43.4mg	6/20				
c	1851	39.3mg	199.mg	0/16	.900mg	0/19	1.70mg	0/20	3.30mg 1/24 7.30mg 0/24 16.0mg 3/20	
					43.4mg	7/19				
d	1851	98.7mg	2.93gm	0/20	.900mg	0/20	1.70mg	0/20	3.30mg 0/24 7.30mg 0/24 16.0mg 0/20	
					43.4mg	3/20				
e	1851	19.1mg	n.s.s.	2/20	.900mg	0/20	1.70mg	4/20	3.30mg 7/24 7.30mg 0/24 16.0mg 6/20	
				(43.4mg	5/20)					
BROMODICHLOROMETHANE*** (dichlorobromomethane) 75-27-4										
76	c55243	18.6mg	52.2mg	3/50	52.0mg	18/50	104.mg	29/50	liv:hpa,hpc.	
a	c55243	22.8mg	65.0mg	1/50	52.0mg	13/50	104.mg	23/50		
b	c55243	69.9mg	734.mg	2/50	52.0mg	5/50	104.mg	10/50		
c	c55243	47.5mg	n.s.s.	2/50	52.0mg	7/50	(104.mg	1/50)	mul:mlh; spl:mlh.	S
d	c55243	26.3mg	n.s.s.	34/50	52.0mg	31/50	104.mg	35/50		
e	c55243	18.6mg	52.2mg	3/50	52.0mg	18/50	104.mg	29/50	liv:hpa,hpc,nnd.	
f	c55243	176.mg	n.s.s.	1/50	52.0mg	2/50	104.mg	3/50	lun:a/a,a/c.	
77	c55243	28.1mg	1.51gm	0/50	17.5mg	5/50	(35.0mg	3/50)		S
a	c55243	61.8mg	n.s.s.	1/50	17.5mg	2/50	35.0mg	9/50	kid:tla,uac.	

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes		TD50 DR	2Tailpvl AuOp
b	M m b6c gav kid tla 24m24		215.mg *	P<.09 c
c	M m b6c gav kid uac 24m24		336.mg *	P<.03 c
d	M m b6c gav TBA MXB 24m24		no dre	P=1.
e	M m b6c gav liv MXB 24m24		no dre	P=1.
f	M m b6c gav lun MXB 24m24		no dre	P=1.
78	R f f34 gav MXB MXB 24m24	: + :	84.8mg /	P<.0005
a	R f f34 gav kid MXA 24m24		143.mg *	P<.0005c
b	R f f34 gav col MXA 24m24		200.mg /	P<.0005c
c	R f f34 gav kid uac 24m24		272.mg *	P<.002 c
d	R f f34 gav kid tla 24m24		351.mg *	P<.008 c
e	R f f34 gav col apn 24m24		364.mg *	P<.004 c
f	R f f34 gav col acn 24m24		411.mg *	P<.007 c
g	R f f34 gav TBA MXB 24m24		no dre	P=1.
h	R f f34 gav liv MXB 24m24		no dre	P=1.
79	R m f34 gav MXB MXB 24m24	:+ :	30.3mg /	P<.0005
a	R m f34 gav MXA MXA 24m24		30.7mg /	P<.0005c
b	R m f34 gav MXA MXA 24m24		35.6mg /	P<.0005c
c	R m f34 gav MXA MXA 24m24		55.6mg /	P<.0005c
d	R m f34 gav kid MXA 24m24		152.mg /	P<.0005c
e	R m f34 gav kid uac 24m24		213.mg /	P<.0005c
f	R m f34 gav tnv men 24m24		350.mg *	P<.05
g	R m f34 gav lun MXA 24m24		366.mg *	P<.02
h	R m f34 gav lun a/a 24m24		447.mg *	P<.05
i	R m f34 gav kid tla 24m24		583.mg *	P<.05 c
j	R m f34 gav TBA MXB 24m24		267.mg *	P<.7
k	R m f34 gav liv MXB 24m24		747.mg *	P<.2
BROMOETHANE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
80	M f b6c inh ute MXA 24m24	: + :	535.mg Z	P<.0005c
a	M f b6c inh ute MXA 24m24		596.mg Z	P<.0005
b	M f b6c inh ute MXA 24m24		681.mg Z	P<.0005
c	M f b6c inh ute acn 24m24		822.mg Z	P<.0005
d	M f b6c inh ute adn 24m24		2.61gm *	P<.002
e	M f b6c inh ute sqc 24m24		4.44gm *	P<.03
f	M f b6c inh TBA MXB 24m24		571.mg *	P<.009
g	M f b6c inh liv MXB 24m24		no dre	P=1.
h	M f b6c inh lun MXB 24m24		5.81gm *	P<.5
81	M m b6c inh lun MXA 24m24	: ±	1.10gm *	P<.03 e
a	M m b6c inh lun a/c 24m24		2.39gm *	P<.04
b	M m b6c inh TBA MXB 24m24		1.63gm *	P<.5
c	M m b6c inh liv MXB 24m24		3.67gm *	P<.7
d	M m b6c inh lun MXB 24m24		1.10gm *	P<.03
82	R f f34 inh bra gln 24m25	: ±	1.02gm *	P<.05 e
a	R f f34 inh lun a/a 24m25		1.28gm *	P<.03 e
b	R f f34 inh TBA MXB 24m25		no dre	P=1.
c	R f f34 inh liv MXB 24m25		670.mg Z	P<.3
83	R m f34 inh liv nnd 24m25	: ±	1.14gm *	P<.03
a	R m f34 inh amd MXA 24m25		149.mg *	P<.2 p
b	R m f34 inh MXB MXB 24m25		151.mg Z	P<.2
c	R m f34 inh lun MXA 24m25	+hist	582.mg *	P<.2 p
d	R m f34 inh bra gcl 24m25	+hist	80.7gm *	P<1. p
e	R m f34 inh bra MXA 24m25	+hist	no dre	P=1. p
f	R m f34 inh TBA MXB 24m25		no dre	P=1.
g	R m f34 inh liv MXB 24m25		2.28gm Z	P<.6
1,3-BUTADIENE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
84	R f cdr inh mgl mix 24m24 e	. + .	133.mg	P<.0005+
a	R f cdr inh mgl ben 24m24 e		182.mg	P<.0005
b	R f cdr inh thy fca 24m24 e		8.27gm *	P<.0005
c	R f cdr inh mgl mal 24m24 e		7.72gm *	P<.07
d	R f cdr inh tba tum 24m24 e		no dre	P=1.
85	R m cdr inh tes ldc 26m26 e	. +	7.55gm *	P<.003 +
a	R m cdr inh pan exa 26m26 e		9.31gm *	P<.006
b	R m cdr inh tba tum 26m26 e		1.47gm *	P<.08
BUTYLATED HYDROXYANISOLE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
86	R m f34 eat for car 6m24 e	.>	no dre	P=1.
a	R m f34 eat for pam 6m24 e		no dre	P=1.
b	R m f34 eat liv tum 6m24 e		no dre	P=1.
87	R m f34 eat for sqc 12m24 e	. ±	4.06gm	P<.04 +
a	R m f34 eat fls pam 12m24 e		4.06gm	P<.04
b	R m f34 eat fgr pam 12m24 e		12.5gm	P<.3
c	R m f34 eat liv tum 12m24 e		no dre	P=1.
88	R m f34 eat fgr pam 24m24 e	. + .	298.mg	P<.0005
a	R m f34 eat fls pam 24m24 e		298.mg	P<.0005
b	R m f34 eat for sqc 24m24 e		7.76gm	P<.04 +
c	R m f34 eat liv tum 24m24 e		no dre	P=1.

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
b	c55243	80.4mg	n.s.s.	1/50	17.5mg	2/50	35.0mg	6/50				
c	c55243	116.mg	n.s.s.	0/50	17.5mg	0/50	35.0mg	4/50				
d	c55243	42.5mg	n.s.s.	38/50	17.5mg	36/50	35.0mg	35/50				
e	c55243	51.4mg	n.s.s.	17/50	17.5mg	16/50	35.0mg	20/50			liv:hpa,hpc,nnd.	
f	c55243	158.mg	n.s.s.	12/50	17.5mg	3/50	35.0mg	7/50			lun:a/a,a/c.	
78	c55243	52.7mg	150.mg	0/50	34.7mg	1/50	70.1mg	24/50			col:acn,apn; kid:tla,uac.	C
a	c55243	79.8mg	294.mg	0/50	34.7mg	1/50	70.1mg	15/50			kid:tla,uac.	
b	c55243	103.mg	505.mg	0/50	34.7mg	0/50	70.1mg	12/50			col:acn,apn.	
c	c55243	128.mg	934.mg	0/50	34.7mg	0/50	70.1mg	9/50				
d	c55243	152.mg	5.11gm	0/50	34.7mg	1/50	70.1mg	6/50				
e	c55243	157.mg	2.04gm	0/50	34.7mg	0/50	70.1mg	7/50				
f	c55243	168.mg	4.92gm	0/50	34.7mg	0/50	70.1mg	6/50				
g	c55243	73.5mg	n.s.s.	48/50	34.7mg	43/50	70.1mg	43/50				
h	c55243	303.mg	n.s.s.	1/50	34.7mg	3/50	70.1mg	1/50			liv:hpa,hpc,nnd.	
79	c55243	21.7mg	43.8mg	0/50	35.0mg	13/50	70.1mg	46/50			col:acn,apn; kid:tla,uac; rec:acn,apn.	C
a	c55243	22.0mg	44.5mg	0/50	35.0mg	13/50	70.1mg	45/50			col:acn,apn; rec:acn,apn.	
b	c55243	24.9mg	53.3mg	0/50	35.0mg	11/50	70.1mg	38/50			col:acn; rec:acn.	
c	c55243	36.8mg	89.2mg	0/50	35.0mg	3/50	70.1mg	33/50			col:apn; rec:apn.	
d	c55243	81.6mg	345.mg	0/50	35.0mg	1/50	70.1mg	13/50			kid:tla,uac.	
e	c55243	103.mg	603.mg	0/50	35.0mg	0/50	70.1mg	10/50				
f	c55243	143.mg	n.s.s.	0/50	35.0mg	3/50	70.1mg	3/50				S
g	c55243	149.mg	n.s.s.	0/50	35.0mg	2/50	70.1mg	4/50			lun:a/a,a/c.	S
h	c55243	169.mg	n.s.s.	0/50	35.0mg	2/50	70.1mg	3/50				S
i	c55243	201.mg	n.s.s.	0/50	35.0mg	1/50	70.1mg	3/50				
j	c55243	37.0mg	n.s.s.	43/50	35.0mg	41/50	70.1mg	47/50				
k	c55243	207.mg	n.s.s.	1/50	35.0mg	0/50	70.1mg	4/50			liv:hpa,hpc,nnd.	
BROMOETHANE (ethyl bromide) 74-96-4												
80	c55481	356.mg	855.mg	0/50	137.mg	4/50	275.mg	5/50	550.mg	27/50	ute:acn,adn,sqc.	
a	c55481	387.mg	981.mg	0/50	137.mg	3/50	275.mg	4/50	550.mg	25/50	ute:acn,adn.	S
b	c55481	434.mg	1.15gm	0/50	137.mg	3/50	275.mg	4/50	550.mg	22/50	ute:acn,sqc.	S
c	c55481	503.mg	1.47gm	0/50	137.mg	2/50	275.mg	3/50	550.mg	19/50		S
d	c55481	1.17gm	11.3gm	0/50	137.mg	1/50	275.mg	1/50	550.mg	6/50		S
e	c55481	1.67gm	n.s.s.	0/50	137.mg	1/50	275.mg	1/50	550.mg	3/50		S
f	c55481	275.mg	16.5gm	27/50	137.mg	24/50	275.mg	29/50	550.mg	37/50		
g	c55481	1.47gm	n.s.s.	5/50	137.mg	6/50	275.mg	6/50	550.mg	3/50	liv:hpa,hpc,nnd.	
h	c55481	1.19gm	n.s.s.	6/50	137.mg	3/50	275.mg	5/50	550.mg	6/50	lun:a/a,a/c.	
81	c55481	481.mg	n.s.s.	7/50	115.mg	6/50	229.mg	12/50	458.mg	15/50	lun:a/a,a/c.	
a	c55481	965.mg	n.s.s.	2/50	115.mg	0/50	229.mg	5/50	458.mg	6/50		S
b	c55481	328.mg	n.s.s.	30/50	115.mg	30/50	229.mg	34/50	458.mg	33/50		
c	c55481	537.mg	n.s.s.	21/50	115.mg	18/50	229.mg	20/50	458.mg	22/50	liv:hpa,hpc,nnd.	
d	c55481	481.mg	n.s.s.	7/50	115.mg	6/50	229.mg	12/50	458.mg	15/50	lun:a/a,a/c.	
82	c55481	373.mg	n.s.s.	0/50	32.7mg	1/50	65.5mg	1/50	131.mg	3/50		
a	c55481	388.mg	n.s.s.	0/50	32.7mg	0/50	65.5mg	0/50	131.mg	3/50		
b	c55481	99.5mg	n.s.s.	49/50	32.7mg	46/50	65.5mg	40/50	131.mg	44/50		
c	c55481	178.mg	n.s.s.	1/50	32.7mg	0/50	65.5mg	4/50	(131.mg	0/50)	liv:hpa,hpc,nnd.	
83	c55481	339.mg	n.s.s.	0/50	22.9mg	0/50	45.8mg	0/50	91.7mg	3/50		S
a	c55481	49.7mg	n.s.s.	8/50	22.9mg	23/50	45.8mg	18/50	91.7mg	21/50	amd:phe,phm.	
b	c55481	47.4mg	n.s.s.	8/50	22.9mg	28/50	45.8mg	21/50	91.7mg	22/50	amd:phe,phm; bra:ast,gcl,gln,oli; lun:a/a,a/c.	P
c	c55481	219.mg	n.s.s.	0/50	22.9mg	0/50	45.8mg	4/50	91.7mg	1/50	lun:a/a,a/c.	
d	c55481	259.mg	n.s.s.	0/50	22.9mg	3/50	45.8mg	1/50	91.7mg	1/50		
e	c55481	557.mg	n.s.s.	0/50	22.9mg	3/50	45.8mg	0/50	91.7mg	0/50	bra:ast,gln,oli.	
f	c55481	63.2mg	n.s.s.	43/50	22.9mg	47/50	45.8mg	47/50	91.7mg	43/50		
g	c55481	358.mg	n.s.s.	2/50	22.9mg	0/50	45.8mg	0/50	91.7mg	3/50	liv:hpa,hpc,nnd.	
1,3-BUTADIENE*** 106-99-0												
84	1829	78.0mg	341.mg	50/100	166.mg	79/100(1.32gm		81/100)			Owen;amih,48,407-413;1987	
a	1829	110.mg	428.mg	32/100	166.mg	64/100(1.32gm		55/100)				
b	1829	4.26gm	24.8gm	0/100	166.mg	2/100	1.32gm	10/100				
c	1829	2.91gm	n.s.s.	18/100	166.mg	15/100	1.32gm	26/100				
d	1829	893.mg	n.s.s.	97/100	166.mg	98/100	1.32gm	94/100				
85	1829	3.58gm	52.9gm	0/100	116.mg	3/100	927.mg	8/100				
a	1829	3.98gm	136.gm	3/100	116.mg	1/100	927.mg	10/100				
b	1829	550.mg	n.s.s.	84/100	116.mg	70/100	927.mg	87/100				
BUTYLATED HYDROXYANISOLE*** (BHA, 2(3)-tert-butyl-4-hydroxyanisole) 25013-16-5												
86	1902m	2.06gm	n.s.s.	0/50	200.mg	0/50					Nera;txcy,53,251-268;1988	
a	1902m	2.06gm	n.s.s.	0/50	200.mg	0/50						
b	1902m	2.06gm	n.s.s.	0/50	200.mg	0/50						
87	1902n	1.23gm	n.s.s.	0/50	400.mg	3/46						
a	1902n	1.23gm	n.s.s.	0/50	400.mg	3/46						
b	1902n	2.03gm	n.s.s.	0/50	400.mg	1/46						
c	1902n	3.79gm	n.s.s.	0/50	400.mg	0/46						
88	1902o	186.mg	495.mg	0/50	800.mg	37/44						
a	1902o	186.mg	495.mg	0/50	800.mg	37/44						
b	1902o	2.35gm	n.s.s.	0/50	800.mg	3/44						
c	1902o	7.25gm	n.s.s.	0/50	800.mg	0/44						

	Spe	Sex	Strain	Route	Site	Hist	Xpo+Xpt	Notes		TD50	DR	2Tailpvl	AuOp
89	R	m	f3d	eat	for	mix	52w52		. ±	1.30gm	*	P<.08	
a	R	m	f3d	eat	for	pam	52w52			1.99gm	*	P<.2	-
b	R	m	f3d	eat	for	sqc	52w52			4.04gm	*	P<.4	-
c	R	m	f3d	eat	liv	tum	52w52			no dre		P=1.	-
90	R	m	f3d	eat	eso	tum	52w52	er	.>	no dre		P=1.	-
a	R	m	f3d	eat	for	tum	52w52	er		no dre		P=1.	-
b	R	m	f3d	eat	liv	tum	52w52	er		no dre		P=1.	-
BUTYLATED HYDROXYTOLUENE***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
91	M	f	b6c	eat	lun	a/c	24m28	e		71.3gm	*	P<.6	
a	M	f	b6c	eat	liv	hem	24m28	e		126.gm	*	P<.3	
b	M	f	b6c	eat	liv	hpc	24m28	e		no dre		P=1.	
c	M	f	b6c	eat	liv	hpa	24m28	e		no dre		P=1.	
d	M	f	b6c	eat	lun	a/a	24m28	e		no dre		P=1.	
e	M	f	b6c	eat	liv	hct	24m28	e		no dre		P=1.	-
f	M	f	b6c	eat	tba	tum	24m28	e		no dre		P=1.	
92	M	m	b6c	eat	liv	hpa	24m28	e	. +	3.45gm	*	P<.003	
a	M	m	b6c	eat	liv	hct	24m28	e		2.90gm	*	P<.02	+
b	M	m	b6c	eat	lun	a/a	24m28	e		18.5gm	*	P<.3	
c	M	m	b6c	eat	liv	ang	24m28	e		128.gm	*	P<.3	
d	M	m	b6c	eat	liv	hpc	24m28	e		no dre		P=1.	
e	M	m	b6c	eat	liv	hem	24m28	e		no dre		P=1.	
f	M	m	b6c	eat	lun	a/c	24m28	e		no dre		P=1.	
g	M	m	b6c	eat	tba	tum	24m28	e		no dre		P=1.	
93	R	m	f3d	eat	eso	tum	52w52	er	.>	no dre		P=1.	-
a	R	m	f3d	eat	for	tum	52w52	er		no dre		P=1.	-
b	R	m	f3d	eat	liv	tum	52w52	er		no dre		P=1.	-
CADMIUM CHLORIDE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
94	R	m	wis	inh	lun	car	18m31	eo	. +.	12.7ug	*	P<.0005	+
a	R	m	wis	inh	lun	adc	18m31	eo		22.0ug	*	P<.0005	
b	R	m	wis	inh	lun	epc	18m31	eo		58.8ug	*	P<.0005	
c	R	m	wis	inh	lun	mec	18m31	eo		.315mg	*	P<.03	
d	R	m	wis	inh	lun	ade	18m31	eo		.563mg	*	P<.5	
e	R	m	wis	inh	adr	pbm	18m31	eo		.591mg	*	P<.8	
CATECHOL***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
95	R	m	f3d	eat	stg	ade	51w52	rv	<+	noTD50		P<.0005	
a	R	m	f3d	eat	stg	adc	51w52	rv		257.mg		P<.07	+
b	R	m	f3d	eat	for	pam	51w52	rv		833.mg		P<.4	
p-CHLOROANILINE.HCl									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
96	M	f	b6c	gav	TBA	MXB	24m24		:>	no dre		P=1.	-
a	M	f	b6c	gav	liv	MXB	24m24			176.mg	*	P<.5	
b	M	f	b6c	gav	lun	MXB	24m24			no dre		P=1.	
97	M	m	b6c	gav	liv	hpc	24m24		: + :	33.8mg	*	P<.002	
a	M	m	b6c	gav	---	hes	24m24			89.5mg	*	P<.04	p
b	M	m	b6c	gav	liv	MXA	24m24			49.3mg	*	P<.2	p
c	M	m	b6c	gav	MXB	MXB	24m24			56.0mg	*	P<.2	
d	M	m	b6c	gav	TBA	MXB	24m24			83.7mg	*	P<.6	
e	M	m	b6c	gav	liv	MXB	24m24			49.3mg	*	P<.2	
f	M	m	b6c	gav	lun	MXB	24m24			2.78gm	*	P<1.	
98	R	f	f34	gav	amd	pob	24m24		:>	105.mg	*	P<.2	e
a	R	f	f34	gav	spl	MXA	24m24			232.mg	*	P<.3	e
b	R	f	f34	gav	TBA	MXB	24m24			145.mg	Z	P<.9	
c	R	f	f34	gav	liv	MXB	24m24			no dre		P=1.	
99	R	m	f34	gav	spl	MXA	24m24		:+ :	7.62mg	Z	P<.0005	c
a	R	m	f34	gav	spl	MXA	24m24			7.90mg	Z	P<.0005	
b	R	m	f34	gav	amd	MXA	24m24			13.3mg	Z	P<.009	e
c	R	m	f34	gav	spl	ost	24m24			15.5mg	Z	P<.0005	
d	R	m	f34	gav	spl	MXA	24m24			16.9mg	*	P<.0005	
e	R	m	f34	gav	spl	fbs	24m24			19.0mg	*	P<.0005	
f	R	m	f34	gav	spl	hes	24m24			107.mg	*	P<.005	
g	R	m	f34	gav	amd	MXA	24m24			14.8mg	Z	P<.02	
h	R	m	f34	gav	TBA	MXB	24m24			20.8mg	Z	P<.4	
i	R	m	f34	gav	liv	MXB	24m24			no dre		P=1.	
CHLORODIFLUOROMETHANE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
100	M	f	swi	inh	lun	ade	18m24			no dre		P=1.	-
a	M	f	swi	inh	tba	mal	18m24			no dre		P=1.	-
b	M	f	swi	inh	tba	mix	18m24			no dre		P=1.	-
101	M	m	swi	inh	lun	ade	18m24			no dre		P=1.	-
a	M	m	swi	inh	tba	mix	18m24			no dre		P=1.	-
b	M	m	swi	inh	tba	mal	18m24			98.3gm	*	P<.8	-
102	R	f	sda	inh	liv	ang	24m24			no dre		P=1.	-
a	R	f	sda	inh	tba	mix	24m24			26.0gm	*	P<1.	-
b	R	f	sda	inh	tba	mal	24m24			20.1gm	*	P<.8	-

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc		Citation or Pathology	Brkly Code
89	1883	393.mg	n.s.s.	0/10	400.mg	0/20	800.mg	3/20		Hasegawa;gann,79,320-328;1988/pers.comm.	
a	1883	488.mg	n.s.s.	0/10	400.mg	0/20	800.mg	2/20			
b	1883	658.mg	n.s.s.	0/10	400.mg	0/20	800.mg	1/20			
c	1883	275.mg	n.s.s.	0/10	400.mg	0/20	800.mg	0/20			
90	1900	206.mg	n.s.s.	0/10	400.mg	0/15	800.mg	0/15		Hirose;carc,8,1731-1735;1987/pers.comm.	
a	1900	206.mg	n.s.s.	0/10	400.mg	0/15	800.mg	0/15			
b	1900	206.mg	n.s.s.	0/10	400.mg	0/15	800.mg	0/15			
BUTYLATED HYDROXYTOLUENE*** (BHT, 2,6-DI-tert-butyl-p-cresol) 128-37-0											
91	1882	12.3gm	n.s.s.	1/41	1.13gm	2/44	2.25gm	2/40		Inai;gann,79,49-58;1988	
a	1882	20.6gm	n.s.s.	0/41	1.13gm	0/44	2.25gm	1/40			
b	1882	29.7gm	n.s.s.	2/41	1.13gm	1/44	2.25gm	0/40			
c	1882	13.0gm	n.s.s.	5/41	1.13gm	7/44	2.25gm	2/40			
d	1882	16.4gm	n.s.s.	4/41	1.13gm	5/44	2.25gm	1/40			
e	1882	14.6gm	n.s.s.	7/41	1.13gm	8/44	2.25gm	2/40			
f	1882	6.04gm	n.s.s.	35/41	1.13gm	33/44	2.25gm	22/40			
92	1882	1.90gm	17.7gm	6/32	1.04gm	16/42	2.08gm	25/47			
a	1882	1.42gm	n.s.s.	12/32	1.04gm	26/42	2.08gm	31/47			
b	1882	5.38gm	n.s.s.	4/32	1.04gm	6/42	2.08gm	10/47			
c	1882	20.9gm	n.s.s.	0/32	1.04gm	0/42	2.08gm	1/47			
d	1882	7.51gm	n.s.s.	7/32	1.04gm	11/42	2.08gm	8/47			
e	1882	21.5gm	n.s.s.	4/32	1.04gm	3/42	2.08gm	1/47			
f	1882	19.0gm	n.s.s.	1/32	1.04gm	3/42	2.08gm	0/47			
g	1882	1.72gm	n.s.s.	27/32	1.04gm	36/42	2.08gm	38/47			
93	1900	144.mg	n.s.s.	0/10	280.mg	0/10				Hirose;carc,8,1731-1735;1987/pers.comm.	
a	1900	144.mg	n.s.s.	0/10	280.mg	0/10					
b	1900	144.mg	n.s.s.	0/10	280.mg	0/10					
CADMIUM CHLORIDE 10108-64-2											
94	1907	8.89ug	18.8ug	0/38	3.34ug	6/39	6.68ug	20/38	13.4ug 25/35	Takenaka;jnci,70,367-373;1983	
a	1907	14.6ug	35.9ug	0/38	3.34ug	4/39	6.68ug	16/38	13.4ug 15/35		
b	1907	32.3ug	.158mg	0/38	3.34ug	2/39	6.68ug	5/38	13.4ug 8/35		
c	1907	95.5ug	n.s.s.	0/38	3.34ug	0/39	6.68ug	0/38	13.4ug 3/35		
d	1907	.118mg	n.s.s.	0/38	3.34ug	1/39	6.68ug	0/38	13.4ug 1/35		
e	1907	49.7ug	n.s.s.	2/38	3.34ug	8/39	6.68ug	4/38	13.4ug 4/35		
CATECHOL*** (1,2-dihydroxybenzene)*** 120-80-9											
95	1845	n.s.s.	35.6mg	0/10	335.mg	15/15				Hirose;gann,78,1144-1149;1987/pers.comm.	
a	1845	77.6mg	n.s.s.	0/10	335.mg	3/15					
b	1845	135.mg	n.s.s.	0/10	335.mg	1/15					
p-CHLOROANILINE.HCl 20265-96-7											
96	c02038	28.9mg	n.s.s.	36/50	2.11mg	26/50	7.04mg	21/50	21.1mg 31/50		
a	c02038	33.4mg	n.s.s.	6/50	2.11mg	9/50	7.04mg	8/50	21.1mg 11/50	liv:hpa,hpc,nnd.	
b	c02038	88.7mg	n.s.s.	6/50	2.11mg	2/50	7.04mg	1/50	21.1mg 4/50	lun:a/a,a/c.	
97	c02038	17.3mg	146.mg	3/50	2.11mg	7/50	7.04mg	11/50	21.1mg 17/50		S
a	c02038	33.5mg	n.s.s.	4/50	2.11mg	4/50	7.04mg	1/50	21.1mg 10/50		
b	c02038	16.4mg	n.s.s.	11/50	2.11mg	21/50	7.04mg	20/50	21.1mg 21/50	liv:hpa,hpc.	
c	c02038	16.8mg	n.s.s.	14/50	2.11mg	24/50	7.04mg	21/50	21.1mg 23/50	---:hes; liv:hpa,hpc.	P
d	c02038	14.6mg	n.s.s.	40/50	2.11mg	30/50	7.04mg	35/50	21.1mg 36/50		
e	c02038	16.4mg	n.s.s.	11/50	2.11mg	21/50	7.04mg	20/50	21.1mg 21/50	liv:hpa,hpc,nnd.	
f	c02038	43.1mg	n.s.s.	8/50	2.11mg	5/50	7.04mg	7/50	21.1mg 6/50	lun:a/a,a/c.	
98	c02038	29.5mg	n.s.s.	2/50	1.40mg	3/50	4.20mg	1/50	12.6mg 6/50		
a	c02038	57.0mg	n.s.s.	0/50	1.40mg	0/50	4.20mg	1/50	12.6mg 1/50	spl:fbs,ost.	
b	c02038	10.8mg	n.s.s.	37/50	1.40mg	30/50	4.20mg	34/50	12.6mg 40/50		
c	c02038	130.mg	n.s.s.	1/50	1.40mg	1/50	4.20mg	0/50	12.6mg 0/50	liv:hpa,hpc,nnd.	
99	c02038	5.14mg	11.8mg	0/49	1.40mg	1/50	4.20mg	3/50	12.6mg 38/50	spl:fbs,hes,ost.	
a	c02038	5.28mg	12.4mg	0/49	1.40mg	1/50	4.20mg	3/50	12.6mg 36/50	spl:fbs,ost.	S
b	c02038	6.01mg	494.mg	13/49	1.40mg	14/50	4.20mg	15/50	12.6mg 26/50	amd:pbb,phm,pob.	
c	c02038	9.01mg	29.7mg	0/49	1.40mg	0/50	4.20mg	1/50	12.6mg 19/50		S
d	c02038	10.1mg	31.2mg	0/49	1.40mg	1/50	4.20mg	2/50	12.6mg 19/50	spl:fbs,fib.	S
e	c02038	11.0mg	36.3mg	0/49	1.40mg	1/50	4.20mg	2/50	12.6mg 17/50		S
f	c02038	36.3mg	1.04gm	0/49	1.40mg	0/50	4.20mg	0/50	12.6mg 4/50		S
g	c02038	6.47mg	n.s.s.	13/49	1.40mg	14/50	4.20mg	14/50	12.6mg 25/50	amd:pbb,pob.	S
h	c02038	5.46mg	n.s.s.	42/49	1.40mg	42/50	4.20mg	39/50	12.6mg 48/50		
i	c02038	42.8mg	n.s.s.	1/49	1.40mg	6/50	4.20mg	5/50	12.6mg 0/50	liv:hpa,hpc,nnd.	
CHLORODIFLUOROMETHANE (fluorocarbon 22) 75-45-6											
100	bt606	30.0gm	n.s.s.	2/60	556.mg	3/60	2.78gm	0/60		Maltoni;anya,534,261-282;1988	
a	bt606	8.72gm	n.s.s.	12/60	556.mg	13/60	2.78gm	11/60			
b	bt606	10.4gm	n.s.s.	14/60	556.mg	19/60	2.78gm	11/60			
101	bt606	13.0gm	n.s.s.	6/60	463.mg	2/60	2.32gm	4/60			
a	bt606	8.02gm	n.s.s.	10/60	463.mg	10/60	2.32gm	9/60			
b	bt606	9.13gm	n.s.s.	1/60	463.mg	5/60	2.32gm	3/60			
102	bt605	10.6gm	n.s.s.	1/60	176.mg	1/60	882.mg	0/60			
a	bt605	718.mg	n.s.s.	45/60	176.mg	44/60	882.mg	45/60			
b	bt605	2.06gm	n.s.s.	13/60	176.mg	12/60	882.mg	14/60			

```
     Spe Strain  Site     Xpo+Xpt                                                                                 TD50     2Tailpvl
       Sex   Route   Hist      Notes                                                                                   DR      AuOp

103  R m sda inh liv ang 24m24                                                                             .>       no dre    P=1.    -
 a   R m sda inh tba mix 24m24                                                                                      6.54gm *  P<.6    -
 b   R m sda inh tba mal 24m24                                                                                      no dre    P=1.    -

CHLOROETHANE*                     100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
104  M f b6c inh ute car 23m23                                                                          :  +  :     1.81gm    P<.0005c
 a   M f b6c inh liv MXA 23m23                                                                                      7.22gm    P<.0005e
 b   M f b6c inh liv hpc 23m23                                                                                      7.58gm    P<.0005
 c   M f b6c inh --- MXA 23m23                                                                                      9.96gm    P<.002
 d   M f b6c inh lun MXA 23m23                                                                                      8.64gm    P<.02
 e   M f b6c inh TBA MXB 23m23                                                                                      1.38gm    P<.0005
 f   M f b6c inh liv MXB 23m23                                                                                      7.22gm    P<.0005
 g   M f b6c inh lun MXB 23m23                                                                                      8.64gm    P<.02
105  M m b6c inh lun MXA 23m23 s                                                                              :    #9.91gm    P<.005
 a   M m b6c inh lun a/a 23m23 s                                                                                    12.7gm    P<.005
 b   M m b6c inh TBA MXB 23m23 s                                                                                    10.1gm    P<.2
 c   M m b6c inh liv MXB 23m23 s                                                                                    34.1gm    P<.5
 d   M m b6c inh lun MXB 23m23 s                                                                                    9.91gm    P<.005
106  R f f34 inh ute pst 24m24                                                                                :     10.2gm    P<.05
 a   R f f34 inh bra asl 24m24                                                                                      21.0gm    P<.04  e
 b   R f f34 inh TBA MXB 24m24                                                                                      2.66gm    P<.2
 c   R f f34 inh liv MXB 24m24                                                                                      no dre    P=1.
107  R m f34 inh ski MXA 24m24                                                                           :    +     3.21gm    P<.004 e
 a   R m f34 inh ski bcc 24m24                                                                                      4.97gm    P<.02
 b   R m f34 inh TBA MXB 24m24                                                                                      1.60gm    P<.3
 c   R m f34 inh liv MXB 24m24                                                                                      47.7gm    P<.8

3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA*** ..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
108  M f b6c eat TBA MXB 24m24                                                                         :>           no dre    P=1.    -
 a   M f b6c eat liv MXB 24m24                                                                                      no dre    P=1.
 b   M f b6c eat lun MXB 24m24                                                                                      no dre    P=1.
109  M m b6c eat sub MXA 24m24                                                                          :   ±      #2.10gm    P<.02   -
 a   M m b6c eat sub MXA 24m24                                                                                      2.21gm    P<.04
 b   M m b6c eat TBA MXB 24m24                                                                                      no dre    P=1.
 c   M m b6c eat liv MXB 24m24                                                                                      no dre    P=1.
 d   M m b6c eat lun MXB 24m24                                                                                      17.6gm *  P<.7
110  R f f34 eat TBA MXB 24m24                                                                :>                    no dre    P=1.    -
 a   R f f34 eat liv MXB 24m24                                                                                      no dre    P=1.
111  R m f34 eat MXB MXB 24m24                                                              : +   :                 86.3mg *  P<.0005
 a   R m f34 eat kid MXA 24m24                                                                                      131.mg *  P<.0005c
 b   R m f34 eat kid tla 24m24                                                                                      272.mg *  P<.006 c
 c   R m f34 eat kid uac 24m24                                                                                      281.mg *  P<.003 c
 d   R m f34 eat liv MXA 24m24                                                                                      201.mg *  P<.04  c
 e   R m f34 eat TBA MXB 24m24                                                                                      no dre    P=1.
 f   R m f34 eat liv MXB 24m24                                                                                      201.mg *  P<.04

CIPROFIBRATE***                   100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
112  M m c5n eat liv mix 78w78 e                                                .    +    .                         4.17mg    P<.0005+
 a   M m c5n eat liv hpa 78w78 e                                                                                    5.89mg    P<.002 +
 b   M m c5n eat liv hpc 78w78 e                                                                                    12.3mg    P<.02  +
 c   M m c5n eat lun tum 78w78 e                                                                                    no dre    P=1.
113  M m c5n eat liv mix 89w91 ev                                                    .  +    .                      12.1mg    P<.0005+
 a   M m c5n eat liv hpa 89w91 ev                                                                                   19.2mg    P<.002 +
 b   M m c5n eat liv hpc 89w91 ev                                                                                   46.4mg    P<.04  +

CYCLOHEXANONE                     100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
114  M f b6c wat --- mly 24m25 ers                                                                        .   ±     3.69gm Z  P<.03
 a   M f b6c wat liv mix 24m25 ers                                                                                  no dre    P=1.
 b   M f b6c wat lun mix 24m25 ers                                                                                  no dre    P=1.
115  M m b6c wat liv mix 24m25 er                                                                             .>    no dre    P=1.
 a   M m b6c wat lun mix 24m25 er                                                                                   no dre    P=1.
116  R f f34 wat liv nnd 24m25 e                                                                          .>        6.30gm *  P<.5
117  R m f34 wat adr cca 24m25 e                                                                    .   ±           929.mg    P<.03
 a   R m f34 wat liv car 24m25 e                                                                                    no dre    P=1.
 b   R m f34 wat liv mix 24m25 e                                                                                    no dre    P=1.

3-DIAZOTYRAMINE.HCl               100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
118  R m f3d wat orc sqc 27m27 e                                                          . +  .                    37.6mg    P<.0005+

DICHLORODIFLUOROMETHANE           100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
119  M f swi inh --- leu 18m24                                                                            .    ±    4.10gm    P<.06   -
 a   M f swi inh lun ade 18m24                                                                                      91.9gm *  P<.4    -
 b   M f swi inh tba mal 18m24                                                                                      3.32gm    P<.03   -
 c   M f swi inh tba mix 18m24                                                                                      59.0gm *  P<.7    -
120  M m swi inh lun ade 18m24                                                                                      41.9gm *  P<.2    -
 a   M m swi inh tba mix 18m24                                                                                      12.1gm *  P<.02   -
 b   M m swi inh tba mal 18m24                                                                                      33.1gm *  P<.2    -
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
103	bt605	1.27gm	n.s.s.	0/60	124.mg	0/60	618.mg	0/60				
a	bt605	1.11gm	n.s.s.	19/60	124.mg	14/60	618.mg	20/60				
b	bt605	2.23gm	n.s.s.	9/60	124.mg	6/60	618.mg	8/60				
CHLOROETHANE* (ethyl chloride) 75-00-3												
104	c06224	823.mg	3.55gm	1/50	12.4gm	43/50						
a	c06224	2.24gm	38.5gm	3/50	12.4gm	8/50					liv:hpa,hpc.	
b	c06224	2.29gm	46.7gm	3/50	12.4gm	7/50						S
c	c06224	2.82gm	59.7gm	4/50	12.4gm	10/50					---:mlh,mlm,mlp,mlu,mly.	S
d	c06224	1.97gm	n.s.s.	5/50	12.4gm	4/50					lun:a/a,a/c.	S
e	c06224	721.mg	2.85gm	28/50	12.4gm	47/50						
f	c06224	2.24gm	38.5gm	3/50	12.4gm	8/50					liv:hpa,hpc,nnd.	
g	c06224	1.97gm	n.s.s.	5/50	12.4gm	4/50					lun:a/a,a/c.	
105	c06224	4.00gm	107.gm	5/50	10.4gm	10/50					lun:a/a,a/c.	S
a	c06224	4.89gm	159.gm	3/50	10.4gm	8/50						S
b	c06224	3.22gm	n.s.s.	27/50	10.4gm	20/50						
c	c06224	6.36gm	n.s.s.	15/50	10.4gm	10/50					liv:hpa,hpc,nnd.	
d	c06224	4.00gm	107.gm	5/50	10.4gm	10/50					lun:a/a,a/c.	
106	c06224	3.58gm	n.s.s.	2/50	2.88gm	7/50						S
a	c06224	6.08gm	n.s.s.	0/50	2.88gm	3/50						
b	c06224	936.mg	n.s.s.	45/50	2.88gm	48/50						
c	c06224	13.6gm	n.s.s.	1/50	2.88gm	0/50					liv:hpa,hpc,nnd.	
107	c06224	1.15gm	20.6gm	0/50	2.01gm	5/50					ski:bcc,sla,tri.	
a	c06224	1.39gm	n.s.s.	0/50	2.01gm	3/50						S
b	c06224	468.mg	n.s.s.	48/50	2.01gm	47/50						
c	c06224	2.58gm	n.s.s.	1/50	2.01gm	1/50					liv:hpa,hpc,nnd.	
3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA*** (Telvar, monuron) 150-68-5												
108	c02846	656.mg	n.s.s.	30/50	638.mg	21/50	(1.29gm	14/50)				
a	c02846	7.79gm	n.s.s.	6/50	638.mg	0/50	1.29gm	3/50			liv:hpa,hpc,nnd.	
b	c02846	5.33gm	n.s.s.	6/50	638.mg	7/50	1.29gm	3/50			lun:a/a,a/c.	
109	c02846	864.mg	n.s.s.	1/50	589.mg	8/50	(1.19gm	1/50)			sub:fbs,fib.	S
a	c02846	870.mg	n.s.s.	2/50	589.mg	9/50	(1.19gm	2/50)			sub:fbs,fib,srn.	S
b	c02846	1.01gm	n.s.s.	30/50	589.mg	22/50	(1.19gm	19/50)				
c	c02846	1.57gm	n.s.s.	12/50	589.mg	8/50	(1.19gm	6/50)			liv:hpa,hpc,nnd.	
d	c02846	2.72gm	n.s.s.	6/50	589.mg	5/50	1.19gm	10/50			lun:a/a,a/c.	
110	c02846	79.7mg	n.s.s.	41/50	36.8mg	45/50	73.6mg	37/50				
a	c02846	527.mg	n.s.s.	4/50	36.8mg	1/50	73.6mg	2/50			liv:hpa,hpc,nnd.	
111	c02846	52.1mg	225.mg	1/50	29.4mg	8/50	58.9mg	20/50			kid:tla,uac; liv:hpc,nnd.	C
a	c02846	75.2mg	286.mg	0/50	29.4mg	3/50	58.9mg	15/50			kid:tla,uac.	
b	c02846	128.mg	2.64gm	0/50	29.4mg	2/50	58.9mg	7/50				
c	c02846	132.mg	764.mg	0/50	29.4mg	1/50	58.9mg	8/50				
d	c02846	93.9mg	n.s.s.	1/50	29.4mg	6/50	58.9mg	9/50			liv:hpc,nnd.	
e	c02846	78.4mg	n.s.s.	36/50	29.4mg	41/50	58.9mg	36/50				
f	c02846	93.9mg	n.s.s.	1/50	29.4mg	6/50	58.9mg	9/50			liv:hpa,hpc,nnd.	
CIPROFIBRATE*** 52214-84-3												
112	1895m	1.50mg	15.8mg	0/12	15.0mg	6/8					Rao;bjca,58,46-51;1988/pers.comm.	
a	1895m	2.09mg	26.4mg	0/12	15.0mg	5/8						
b	1895m	3.65mg	n.s.s.	0/12	15.0mg	3/8						
c	1895m	13.9mg	n.s.s.	0/12	15.0mg	0/8						
113	1895n	5.16mg	37.1mg	0/12	25.4mg	8/12						
a	1895n	7.63mg	86.4mg	0/12	25.4mg	6/12						
b	1895n	13.9mg	n.s.s.	0/12	25.4mg	3/12						
CYCLOHEXANONE 108-94-1												
114	1850	1.54gm	n.s.s.	8/52	1.26gm	17/50	(2.53gm	4/50	4.86gm	0/41)	Lijinsky;jnci,77,941-949;1986	
a	1850	24.1gm	n.s.s.	3/52	1.26gm	6/50	2.53gm	3/50	4.86gm	2/41		
b	1850	36.8gm	n.s.s.	3/52	1.26gm	2/50	2.53gm	2/50	4.86gm	1/41		
115	1850	3.72gm	n.s.s.	16/52	1.05gm	25/51	2.11gm	13/46				
a	1850	4.90gm	n.s.s.	13/52	1.05gm	7/51	(2.11gm	3/47)				
116	1850	1.32gm	n.s.s.	3/52	183.mg	4/52	361.mg	5/52				
117	1850	364.mg	n.s.s.	1/52	160.mg	7/52	(316.mg	1/51)				
a	1850	1.20gm	n.s.s.	2/52	160.mg	0/52	316.mg	0/51				
b	1850	1.66gm	n.s.s.	6/52	160.mg	5/52	316.mg	4/51				
3-DIAZOTYRAMINE.HCl (4-(2-aminoethyl)-6-diazo-2,4-cyclohexadienone.HCl) ---												
118	1825	21.1mg	74.3mg	0/16	50.0mg	19/28					Fujita;carc,8,527-529;1987	
DICHLORODIFLUOROMETHANE (fluorocarbon 12) 75-71-8												
119	bt602	1.51gm	n.s.s.	8/90	777.mg	12/60	(3.89gm	6/60)			Maltoni;anya,534,261-282;1988	
a	bt602	19.1gm	n.s.s.	2/90	777.mg	1/60	3.89gm	3/60				
b	bt602	1.33gm	n.s.s.	9/90	777.mg	14/60	(3.89gm	6/60)				
c	bt602	8.68gm	n.s.s.	15/90	777.mg	15/60	3.89gm	13/60				
120	bt602	11.1gm	n.s.s.	3/90	648.mg	3/60	3.24gm	5/60				
a	bt602	5.11gm	n.s.s.	9/90	648.mg	9/60	3.24gm	15/60				
b	bt602	9.46gm	n.s.s.	5/90	648.mg	4/60	3.24gm	7/60				

```
     Spe Strain  Site    Xpo+Xpt                                                                                    TD50     2Tailpvl
       Sex   Route   Hist      Notes                                                                                    DR     AuOp

121  R f sda inh liv ang 24m24                                                                                    .31.3gm * P<.2   -
 a   R f sda inh tba mal 24m24                                                                                     no dre   P=1.   -
 b   R f sda inh tba mix 24m24                                                                                     no dre   P=1.   -
122  R m sda inh adr phe 24m24                                                                  .   ±             1.32gm   P<.02  -
 a   R m sda inh liv ang 24m24                                                                                     no dre   P=1.   -
 b   R m sda inh tba mix 24m24                                                                                     555.mg   P<.06  -
 c   R m sda inh tba mal 24m24                                                                                     no dre   P=1.   -

2,4-DICHLOROPHENOL              100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
123  M f b6c eat TBA MXB 24m24                                                                        :>          no dre   P=1.   -
 a   M f b6c eat liv MXB 24m24                                                                                     no dre   P=1.
 b   M f b6c eat lun MXB 24m24                                                                                     no dre   P=1.
124  M m b6c eat for MXA 24m24                                                                         :    #12.4gm * P<.04  -
 a   M m b6c eat TBA MXB 24m24                                                                                    no dre   P=1.
 b   M m b6c eat liv MXB 24m24                                                                                    458.gm * P<1.
 c   M m b6c eat lun MXB 24m24                                                                                    13.3gm * P<.5
125  R f f34 eat TBA MXB 24m24                                                                  :>                no dre   P=1.   -
 a   R f f34 eat liv MXB 24m24                                                                                    no dre   P=1.
126  R m f34 eat TBA MXB 24m24                                                                   :>               no dre   P=1.   -
 a   R m f34 eat liv MXB 24m24                                                                                    no dre   P=1.

DICHLORVOS***                   100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
127  M f b6c gav for MXA 24m24                                                          :  ±                      56.3mg * P<.02
 a   M f b6c gav for sqp 24m24                                                                                    61.3mg * P<.03  c
 b   M f b6c gav TBA MXB 24m24                                                                                    no dre   P=1.
 c   M f b6c gav liv MXB 24m24                                                                                    no dre   P=1.
 d   M f b6c gav lun MXB 24m24                                                                                    321.mg * P<.5
128  M m b6c gav for sqp 24m24                                                          :    ±                   82.8mg * P<.07  p
 a   M m b6c gav TBA MXB 24m24                                                                                    38.2mg * P<.6
 b   M m b6c gav liv MXB 24m24                                                                                    43.4mg * P<.3
 c   M m b6c gav lun MXB 24m24                                                                                    121.mg * P<.7
129  R f f34 gav mgl fba 24m24                                          :  ±                                     3.97mg   P<.03  e
 a   R f f34 gav mgl MXA 24m24                                                                                    8.51mg * P<.05
 b   R f f34 gav sub MXA 24m24                                                                                    27.3mg * P<.03
 c   R f f34 gav pan ade 24m24                                                                                    44.6mg * P<.2   e
 d   R f f34 gav TBA MXB 24m24                                                                                    13.9mg * P<.6
 e   R f f34 gav liv MXB 24m24                                                                                    83.9mg * P<.3
130  R m f34 gav MXB MXB 24m24                                          :  +        :                            3.21mg * P<.005
 a   R m f34 gav pan ade 24m24                                                                                    4.16mg * P<.005 p
 b   R m f34 gav --- mnl 24m24                                                                                    6.89mg * P<.02  p
 c   R m f34 gav lun a/a 24m24                                                                                    52.2mg * P<.04
 d   R m f34 gav TBA MXB 24m24                                                                                    12.3mg * P<.6
 e   R m f34 gav liv MXB 24m24                                                                                    56.2mg * P<.4

DIETHYLSTILBESTROL***           100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
131  M f c3v eat mgl mix 25m25 e                          .+ .                                                    24.7ug   P<.0005+
 a   M f c3v eat mgl adb 25m25 e                                                                                  30.2ug   P<.0005
 b   M f c3v eat mgl ada 25m25 e                                                                                  2.63mg   P<.5
 c   M f c3v eat lun act 25m25 e                                                                                 no dre   P=1.
 d   M f c3v eat liv ade 25m25 e                                                                                 no dre   P=1.
 e   M f c3v eat liv adc 25m25 e                                                                                 no dre   P=1.
132  M f c3v eat mgl mix 26m26 e                        .+.                                                     42.7ug   P<.0005+
 a   M f c3v eat mgl adb 26m26 e                                                                                 43.4ug   P<.0005
 b   M f c3v eat --- mso 26m26 e                                                                               .928mg   P<.003
 c   M f c3v eat ute ena 26m26 e                                                                               2.05mg   P<.05
 d   M f c3v eat cvu adc 26m26 e                                                                               2.47mg   P<.07
 e   M f c3v eat liv ade 26m26 e                                                                               no dre   P=1.
 f   M f c3v eat mgl ada 26m26 e                                                                               no dre   P=1.
 g   M f c3v eat liv adc 26m26 e                                                                               no dre   P=1.
 h   M f c3v eat lun act 26m26 e                                                                               no dre   P=1.
133  M f c3v eat mgl mix 29m29 e                          .+.                                                     87.2ug   P<.0005+
 a   M f c3v eat mgl adb 29m29 e                                                                                 95.6ug   P<.0005
 b   M f c3v eat --- mso 29m29 e                                                                               .520mg   P<.0005
 c   M f c3v eat cvu adc 29m29 e                                                                               1.17mg   P<.004
 d   M f c3v eat ute ena 29m29 e                                                                               1.71mg   P<.02
 e   M f c3v eat mgl ada 29m29 e                                                                               2.10mg   P<.3
 f   M f c3v eat liv ade 29m29 e                                                                               no dre   P=1.
 g   M f c3v eat liv adc 29m29 e                                                                               no dre   P=1.
 h   M f c3v eat lun act 29m29 e                                                                               no dre   P=1.
134  M f c3v eat mgl mix 29m29 e                           .+ .                                                   .115mg   P<.0005+
 a   M f c3v eat mgl adb 29m29 e                                                                               .118mg   P<.0005
 b   M f c3v eat --- mso 29m29 e                                                                               .487mg   P<.0005
 c   M f c3v eat cvu adc 29m29 e                                                                               1.66mg   P<.02
 d   M f c3v eat ute ena 29m29 e                                                                               1.87mg   P<.02
 e   M f c3v eat mgl ada 29m29 e                                                                               4.39mg   P<.5
 f   M f c3v eat liv ade 29m29 e                                                                               no dre   P=1.
 g   M f c3v eat liv adc 29m29 e                                                                               no dre   P=1.
 h   M f c3v eat lun act 29m29 e                                                                               no dre   P=1.
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
121	bt601	8.46gm	n.s.s.	1/150	247.mg	1/90	1.23gm	3/90		
a	bt601	6.91gm	n.s.s.	43/150	247.mg	24/90	1.23gm	18/90		
b	bt601	1.34gm	n.s.s.	124/150	247.mg	71/90	1.23gm	72/90		
122	bt601	529.mg	n.s.s.	6/150	173.mg	11/90	(864.mg	5/90)		
a	bt601	2.67gm	n.s.s.	1/150	173.mg	0/90	864.mg	0/90		
b	bt601	221.mg	n.s.s.	51/150	173.mg	42/90	(864.mg	27/90)		
c	bt601	6.54gm	n.s.s.	25/150	173.mg	16/90	864.mg	9/90		
2,4-DICHLOROPHENOL 120-83-2										
123	c55345	2.31gm	n.s.s.	26/50	638.mg	18/50	1.29gm	21/50		
a	c55345	8.98gm	n.s.s.	2/50	638.mg	3/50	1.29gm	0/50	liv:hpa,hpc,nnd.	
b	c55345	7.95gm	n.s.s.	3/50	638.mg	1/50	1.29gm	2/50	lun:a/a,a/c.	
124	c55345	3.77gm	n.s.s.	0/50	589.mg	0/50	1.19gm	3/50	for:sqc,sqp.	S
a	c55345	1.20gm	n.s.s.	29/50	589.mg	29/50	1.19gm	24/50		
b	c55345	1.93gm	n.s.s.	10/50	589.mg	12/50	1.19gm	9/50	liv:hpa,hpc,nnd.	
c	c55345	2.85gm	n.s.s.	3/50	589.mg	2/50	1.19gm	5/50	lun:a/a,a/c.	
125	c55345	254.mg	n.s.s.	47/50	123.mg	36/50	248.mg	44/50		
a	c55345	n.s.s.	n.s.s.	0/50	123.mg	1/50	248.mg	0/50	liv:hpa,hpc,nnd.	
126	c55345	343.mg	n.s.s.	48/50	196.mg	38/50	396.mg	41/50		
a	c55345	748.mg	n.s.s.	5/50	196.mg	1/50	(396.mg	1/50)	liv:hpa,hpc,nnd.	
DICHLORVOS*** (DDVP, Vapona) 62-73-7										
127	c00113	26.8mg	n.s.s.	5/50	14.0mg	6/50	28.0mg	19/50	for:sqc,sqp.	S
a	c00113	28.2mg	n.s.s.	5/50	14.0mg	6/50	28.0mg	18/50		
b	c00113	31.8mg	n.s.s.	37/50	14.0mg	26/50	28.0mg	37/50		
c	c00113	75.7mg	n.s.s.	6/50	14.0mg	4/50	28.0mg	7/50	liv:hpa,hpc,nnd.	
d	c00113	63.6mg	n.s.s.	3/50	14.0mg	3/50	28.0mg	6/50	lun:a/a,a/c.	
128	c00113	28.9mg	n.s.s.	1/50	7.01mg	1/50	14.0mg	5/50		
a	c00113	7.52mg	n.s.s.	37/50	7.01mg	41/50	14.0mg	37/50		
b	c00113	12.5mg	n.s.s.	16/50	7.01mg	18/50	14.0mg	20/50	liv:hpa,hpc,nnd.	
c	c00113	17.2mg	n.s.s.	10/50	7.01mg	15/50	14.0mg	10/50	lun:a/a,a/c.	
129	c00113	1.65mg	n.s.s.	9/50	2.80mg	19/50	(5.61mg	16/50)		
a	c00113	3.66mg	n.s.s.	9/50	2.80mg	19/50	5.61mg	17/50	mgl:ade,fba.	S
b	c00113	11.1mg	n.s.s.	0/50	2.80mg	3/50	5.61mg	3/50	sub:fbs,fib.	S
c	c00113	13.6mg	n.s.s.	1/50	2.80mg	1/50	5.61mg	4/50		
d	c00113	2.62mg	n.s.s.	47/50	2.80mg	46/50	5.61mg	46/50		
e	c00113	20.5mg	n.s.s.	0/50	2.80mg	1/50	5.61mg	1/50	liv:hpa,hpc,nnd.	
130	c00113	1.62mg	31.1mg	25/50	2.80mg	37/50	5.61mg	41/50	---:mnl; pan:ade.	P
a	c00113	2.09mg	44.6mg	16/50	2.80mg	25/50	5.61mg	30/50		
b	c00113	3.24mg	n.s.s.	11/50	2.80mg	20/50	5.61mg	21/50		
c	c00113	15.5mg	n.s.s.	0/50	2.80mg	0/50	5.61mg	3/50		S
d	c00113	2.34mg	n.s.s.	48/50	2.80mg	45/50	5.61mg	45/50		
e	c00113	12.7mg	n.s.s.	1/50	2.80mg	3/50	5.61mg	2/50	liv:hpa,hpc,nnd.	
DIETHYLSTILBESTROL*** (DES) 56-53-1										
131	1852m	19.0ug	32.3ug	4/73	83.2ug	167/182			Greenman;jnci,77,891-898;1986/pers.comm.	
a	1852m	23.7ug	38.9ug	2/73	83.2ug	158/182				
b	1852m	.673mg	n.s.s.	2/73	83.2ug	9/182				
c	1852m	1.97mg	n.s.s.	5/75	83.2ug	3/182				
d	1852m	3.29mg	n.s.s.	3/77	83.2ug	0/181				
e	1852m	2.93mg	n.s.s.	10/77	83.2ug	1/181				
132	1852n	33.7ug	55.3ug	4/73	83.2ug	151/189				
a	1852n	34.3ug	55.6ug	2/73	83.2ug	149/189				
b	1852n	.490mg	4.06mg	0/77	83.2ug	13/189				
c	1852n	.836mg	n.s.s.	0/77	83.2ug	6/189				
d	1852n	.936mg	n.s.s.	0/77	83.2ug	5/189				
e	1852n	3.74mg	n.s.s.	3/77	83.2ug	0/188				
f	1852n	2.13mg	n.s.s.	2/73	83.2ug	2/189				
g	1852n	2.24mg	n.s.s.	10/77	83.2ug	5/188				
h	1852n	1.71mg	n.s.s.	5/75	83.2ug	5/189				
133	1852o	67.3ug	.118mg	4/73	83.2ug	117/185				
a	1852o	73.9ug	.128mg	2/73	83.2ug	109/185				
b	1852o	.331mg	.932mg	0/77	83.2ug	28/191				
c	1852o	.616mg	5.24mg	0/77	83.2ug	13/191				
d	1852o	.804mg	n.s.s.	0/77	83.2ug	9/191				
e	1852o	.737mg	n.s.s.	2/73	83.2ug	12/185				
f	1852o	2.05mg	n.s.s.	3/77	83.2ug	4/191				
g	1852o	1.85mg	n.s.s.	10/77	83.2ug	10/191				
h	1852o	1.70mg	n.s.s.	5/75	83.2ug	7/191				
134	1852r	86.3ug	.164mg	4/73	83.2ug	96/182				
a	1852r	89.3ug	.163mg	2/73	83.2ug	92/182				
b	1852r	.312mg	.860mg	0/77	83.2ug	29/192				
c	1852r	.783mg	n.s.s.	0/77	83.2ug	9/192				
d	1852r	.849mg	n.s.s.	0/77	83.2ug	8/192				
e	1852r	1.04mg	n.s.s.	2/96	83.2ug	7/182				
f	1852r	2.00mg	n.s.s.	3/77	83.2ug	4/192				
g	1852r	1.81mg	n.s.s.	10/77	83.2ug	10/192				
h	1852r	1.00mg	n.s.s.	5/75	83.2ug	12/192				

```
     Spe Strain  Site    Xpo+Xpt                                                                                     TD50     2Tailpvl
       Sex   Route  Hist      Notes                                                                                        DR      AuOp

5,6-DIHYDRO-5-AZACYTIDINE         100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
135  R m f34 ipj liv tum 52w52 e                                                  .>                             no dre    P=1.
 a   R m f34 ipj tba tum 52w52 e                                                                                 20.7mg    P<.5

DIMETHOXANE, COMMERCIAL GRADE     100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
136  M f b6c gav TBA MXB 24m24                                                                     :>             3.38gm * P<.8    -
 a   M f b6c gav liv MXB 24m24                                                                                   no dre    P=1.
 b   M f b6c gav lun MXB 24m24                                                                                   10.4gm * P<.8
137  M m b6c gav for MXA 24m24                                                                       :   ±       1.44gm * P<.04   e
 a   M m b6c gav TBA MXB 24m24                                                                                   1.82gm * P<.7
 b   M m b6c gav liv MXB 24m24                                                                                   1.18gm * P<.3
 c   M m b6c gav lun MXB 24m24                                                                                   1.45gm * P<.2
138  R f f34 gav TBA MXB 24m24                                                                 :>                no dre    P=1.    -
 a   R f f34 gav liv MXB 24m24                                                                                   2.43gm * P<.2
139  R m f34 gav TBA MXB 24m24                                                             :>                    no dre    P=1.    -
 a   R m f34 gav liv MXB 24m24                                                                                   no dre    P=1.

5,6-DIMETHOXYSTERIGMATOCYSTIN     100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
140  R m ain eat liv nnd 38w80 e                                   <+                                            noTD50    P<.002
 a   R m ain eat liv mix 38w80 e                                                                                 noTD50    P<.002 +
 b   R m ain eat liv hpc 38w80 e                                                                                 .400mg    P<.002
 c   R m ain eat liv hms 38w80 e                                                                                 .566mg    P<.006
 d   R m ain eat bon ost 38w80 e                                                                                 1.36mg    P<.06

DIMETHYL METHYLPHOSPHONATE*       100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
141  M f b6c gav lun a/a 24m24 as                                                                        :    ±  #4.09gm * P<.04   -
 a   M f b6c gav TBA MXB 24m24 as                                                                                851.mg * P<.02
 b   M f b6c gav liv MXB 24m24 as                                                                                6.56gm * P<.4
 c   M f b6c gav lun MXB 24m24 as                                                                                7.25gm * P<.3
142  M m b6c gav liv MXA 23m24 as                                                                :  +      :     #458.mg * P<.002
 a   M m b6c gav liv hpa 23m24 as                                                                                563.mg * P<.003
 b   M m b6c gav TBA MXB 23m24 as                                                                                370.mg / P<.002
 c   M m b6c gav liv MXB 23m24 as                                                                                458.mg * P<.002
 d   M m b6c gav lun MXB 23m24 as                                                                                7.27gm / P<.5
143  R f f34 gav TBA MXB 24m24                                                                    :>             868.mg * P<.3    -
 a   R f f34 gav liv MXB 24m24                                                                                   no dre    P=1.
144  R m f34 gav tes ict 24m24                                                               :  +   :            169.mg * P<.0005
 a   R m f34 gav amd MXA 24m24                                                                                   306.mg * P<.0005
 b   R m f34 gav MXA MXA 24m24                                                                                   453.mg / P<.0005
 c   R m f34 gav MXB MXB 24m24                                                                                   520.mg * P<.0005
 d   R m f34 gav k/p MXA 24m24                                                                                   608.mg * P<.0005
 e   R m f34 gav k/p tpp 24m24                                                                                   700.mg * P<.0005p
 f   R m f34 gav thy ccr 24m24                                                                                   983.mg * P<.005
 g   R m f34 gav tnv men 24m24                                                                                   1.01gm * P<.0005
 h   R m f34 gav MXA MXA 24m24                                                                                   1.02gm * P<.005
 i   R m f34 gav thy MXA 24m24                                                                                   1.66gm * P<.004
 j   R m f34 gav kid uac 24m24                                                                                   2.24gm * P<.008 p
 k   R m f34 gav thy MXA 24m24                                                                                   1.14gm * P<.04
 l   R m f34 gav amd phm 24m24                                                                                   2.02gm * P<.05
 m   R m f34 gav TBA MXB 24m24                                                                                   178.mg * P<.0005
 n   R m f34 gav liv MXB 24m24                                                                                   1.63gm * P<.09

6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl ..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
145  M f b6c eat liv hct 25m25 e                                                             .>                  1.85gm * P<.9
 a   M f b6c eat lun mix 25m25 e                                                                                 no dre    P=1.
146  M m b6c eat liv hct 25m25 e                                                      .>                         no dre    P=1.
 a   M m b6c eat lun mix 25m25 e                                                                                 no dre    P=1.
147  R f f34 eat ute esp 25m25 e                                                        .  +          .          43.3mg * P<.006
 a   R f f34 eat liv nnd 25m25 e                                                                                 60.7mg * P<.007 +
 b   R f f34 eat liv hpc 25m25 e                                                                            +hist 260.mg * P<.1    +
148  R m f34 eat liv nnd 25m25 e                                                         .   ±                   77.3mg * P<.09   +
 a   R m f34 eat liv hpc 25m25 e                                                                            +hist 110.mg * P<.02   +

6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl    ....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
149  M f b6c eat pta ade 25m25 e                                                       .   ±                     42.5mg    P<.02   -
 a   M f b6c eat lun a/a 25m25 e                                                                                 371.mg * P<.09   -
 b   M f b6c eat liv hpa 25m25 e                                                                                 385.mg * P<.2    -
 c   M f b6c eat liv hpc 25m25 e                                                                                 no dre    P=1.    -
 d   M f b6c eat lun a/c 25m25 e                                                                                 no dre    P=1.    -
150  M m b6c eat liv hpc 25m25 e                                                             .>                  281.mg * P<.2    -
 a   M m b6c eat liv hpa 25m25 e                                                                                 2.13gm / P<.8    -
 b   M m b6c eat lun a/a 25m25 e                                                                                 no dre    P=1.    -
 c   M m b6c eat lun a/c 25m25 e                                                                                 no dre    P=1.    -
151  R f f34 eat liv nnd 25m25 e                                                                   .>            1.42gm * P<.4    -
152  R m f34 eat liv hpc 25m25 e                                                                  .>             1.09gm * P<.3    -
 a   R m f34 eat liv nnd 25m25 e                                                                                 no dre    P=1.    -
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
5,6-DIHYDRO-5-AZACYTIDINE (DHAC) 62488-57-7										
135	1906	9.94mg	n.s.s.	0/49	21.4mg	0/9			Carr;bjca,57,395-402;1988	
a	1906	3.21mg	n.s.s.	10/49	21.4mg	3/9				
DIMETHOXANE, COMMERCIAL GRADE 828-00-2										
136	c56213	322.mg	n.s.s.	32/50	176.mg	26/50	352.mg	33/50		
a	c56213	1.39gm	n.s.s.	8/50	176.mg	5/50	352.mg	4/50	liv:hpa,hpc,nnd.	
b	c56213	1.15gm	n.s.s.	4/50	176.mg	1/50	352.mg	5/50	lun:a/a,a/c.	
137	c56213	584.mg	n.s.s.	2/50	176.mg	3/50	352.mg	8/50	for:psq,sqc.	
a	c56213	237.mg	n.s.s.	38/50	176.mg	31/50	352.mg	37/50		
b	c56213	355.mg	n.s.s.	14/50	176.mg	12/50	352.mg	19/50	liv:hpa,hpc,nnd.	
c	c56213	462.mg	n.s.s.	8/50	176.mg	4/50	352.mg	13/50	lun:a/a,a/c.	
138	c56213	135.mg	n.s.s.	41/50	88.1mg	37/50	176.mg	32/50		
a	c56213	598.mg	n.s.s.	0/50	88.1mg	1/50	176.mg	1/50	liv:hpa,hpc,nnd.	
139	c56213	58.7mg	n.s.s.	39/50	44.0mg	36/50	88.1mg	32/50		
a	c56213	n.s.s.	n.s.s.	0/50	44.0mg	1/50	88.1mg	0/50	liv:hpa,hpc,nnd.	
5,6-DIMETHOXYSTERIGMATOCYSTIN 65176-75-2										
140	1889	n.s.s.	.364mg	0/10	.967mg	8/8			Mori;carc,9,1039-1042;1988	
a	1889	n.s.s.	.364mg	0/10	.967mg	8/8				
b	1889	.142mg	1.94mg	0/10	.967mg	5/8				
c	1889	.188mg	5.90mg	0/10	.967mg	4/8				
d	1889	.332mg	n.s.s.	0/10	.967mg	2/8				
DIMETHYL METHYLPHOSPHONATE* (DMMP) 756-79-6										
141	c54762	1.41gm	n.s.s.	1/50	701.mg	5/50	1.40gm	1/50		S
a	c54762	382.mg	n.s.s.	27/50	701.mg	31/50	1.40gm	8/50		
b	c54762	1.40gm	n.s.s.	3/50	701.mg	5/50	1.40gm	0/50	liv:hpa,hpc,nnd.	
c	c54762	1.69gm	n.s.s.	3/50	701.mg	5/50	1.40gm	1/50	lun:a/a,a/c.	
142	c54762	211.mg	2.42gm	17/50	701.mg	21/50	1.43gm	4/50	liv:hpa,hpc.	S
a	c54762	242.mg	4.34gm	12/50	701.mg	15/50	1.43gm	3/50		S
b	c54762	178.mg	1.95gm	34/50	701.mg	27/50	1.43gm	10/50		
c	c54762	211.mg	2.42gm	17/50	701.mg	21/50	1.43gm	4/50	liv:hpa,hpc,nnd.	
d	c54762	1.05gm	n.s.s.	6/50	701.mg	0/50	1.43gm	3/50	lun:a/a,a/c.	
143	c54762	280.mg	n.s.s.	40/50	350.mg	42/50	701.mg	40/50		
a	c54762	n.s.s.	n.s.s.	0/50	350.mg	2/50	701.mg	0/50	liv:hpa,hpc,nnd.	
144	c54762	93.5mg	500.mg	41/50	350.mg	39/50	701.mg	39/50		S
a	c54762	163.mg	899.mg	12/50	350.mg	18/50	701.mg	18/50	amd:phe,phm.	S
b	c54762	227.mg	1.58gm	10/50	350.mg	11/50	701.mg	17/50	mul:mnl; spl:mnl.	S
c	c54762	267.mg	1.18gm	0/50	350.mg	9/50	701.mg	6/50	k/p:tpp; kid:uac.	P
d	c54762	292.mg	1.66gm	0/50	350.mg	8/50	701.mg	3/50	k/p:tcc,tpp.	S
e	c54762	324.mg	2.07gm	0/50	350.mg	7/50	701.mg	3/50		
f	c54762	384.mg	9.77gm	1/50	350.mg	4/50	701.mg	4/50		S
g	c54762	438.mg	3.03gm	0/50	350.mg	4/50	701.mg	6/50		S
h	c54762	415.mg	10.2gm	2/50	350.mg	5/50	701.mg	6/50	mul:men,msm; tnv:men.	S
i	c54762	591.mg	11.5gm	0/50	350.mg	2/50	701.mg	3/50	thy:fca,fcc.	S
j	c54762	737.mg	44.7gm	0/50	350.mg	2/50	701.mg	3/50		
k	c54762	398.mg	n.s.s.	4/50	350.mg	4/50	701.mg	5/50	thy:cca,ccr.	S
l	c54762	647.mg	n.s.s.	0/50	350.mg	4/50	701.mg	0/50		S
m	c54762	97.5mg	549.mg	40/50	350.mg	36/50	701.mg	37/50		
n	c54762	498.mg	n.s.s.	1/50	350.mg	4/50	701.mg	1/50	liv:hpa,hpc,nnd.	
6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl (L-alpha-acetylmethadol.HCl, LAAM) ---										
145	1894	85.3mg	n.s.s.	6/50	7.60mg	8/50	30.0mg	7/50	Rosenkrantz;faat,11,626-639;1988/pers.comm.	
a	1894	186.mg	n.s.s.	5/50	7.60mg	0/50	30.0mg	3/50		
146	1894	13.4mg	n.s.s.	18/50	7.60mg	18/50	(30.0mg	5/50)		
a	1894	182.mg	n.s.s.	11/50	7.60mg	8/50	30.0mg	4/50		
147	1894	21.6mg	520.mg	2/50	5.70mg	10/50	16.6mg	12/50		
a	1894	28.2mg	999.mg	3/50	5.70mg	4/50	16.6mg	12/50		
b	1894	78.7mg	n.s.s.	0/50	5.70mg	1/50	16.6mg	2/50		
148	1894	27.2mg	n.s.s.	1/50	3.10mg	3/50	9.70mg	5/50		
a	1894	38.1mg	19.3gm	0/50	3.10mg	0/50	9.70mg	4/50		
6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl (DL-methadone.HCl) 1095-90-5										
149	1893	19.0mg	n.s.s.	5/50	15.0mg	15/50	(60.0mg	4/50)	Rosenkrantz;faat,11,640-651;1988/pers.comm.	
a	1893	132.mg	n.s.s.	1/50	15.0mg	5/50	60.0mg	6/50		
b	1893	124.mg	n.s.s.	3/50	15.0mg	6/50	60.0mg	8/50		
c	1893	217.mg	n.s.s.	5/50	15.0mg	6/50	60.0mg	5/50		
d	1893	128.mg	n.s.s.	1/50	15.0mg	0/50	60.0mg	0/50		
150	1893	86.0mg	n.s.s.	12/50	15.0mg	11/50	60.0mg	17/50		
a	1893	196.mg	n.s.s.	9/50	15.0mg	2/50	60.0mg	8/50		
b	1893	384.mg	n.s.s.	8/50	15.0mg	5/50	60.0mg	3/50		
c	1893	607.mg	n.s.s.	5/50	15.0mg	0/50	60.0mg	1/50		
151	1893	328.mg	n.s.s.	3/50	28.0mg	1/50	88.0mg	5/50		
152	1893	269.mg	n.s.s.	0/50	16.0mg	1/50	46.0mg	1/50		
a	1893	155.mg	n.s.s.	10/50	16.0mg	9/50	46.0mg	8/50		

```
     Spe Strain  Site    Xpo+Xpt                                                                                    TD50     2Tailpvl
       Sex   Route   Hist      Notes                                                                                    DR     AuOp

2-DIMETHYLAMINOETHANOL           100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
153  M f c3j wat liv tum 29m29 e                                                                  .>          6.72gm   P<.7   -
 a   M f c3j wat tba tum 29m29 e                                                                              no dre   P=1.   -
154  M f cen wat liv tum 24m24 e                                                              .>              2.99gm   P<.6   -
 a   M f cen wat tba tum 24m24 e                                                                             1.66gm   P<.8   -

N,N-DIMETHYLANILINE              100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
155  M f b6c gav for sqp 24m24                                                        :   ±                   99.3mg * P<.05  e
 a   M f b6c gav TBA MXB 24m24                                                                              108.mg / P<.7
 b   M f b6c gav liv MXB 24m24                                                                              163.mg * P<.4
 c   M f b6c gav lun MXB 24m24                                                                              276.mg * P<.5
156  M m b6c gav TBA MXB 24m24                                                    :>                         489.mg * P<1.   -
 a   M m b6c gav liv MXB 24m24                                                                              216.mg * P<.7
 b   M m b6c gav lun MXB 24m24                                                                              102.mg * P<.4
157  R f f34 gav TBA MXB 24m24                                                :>                             no dre   P=1.   -
 a   R f f34 gav liv MXB 24m24                                                                              no dre   P=1.
158  R m f34 gav srp MXA 24m24                                                        :   +         :        125.mg * P<.005 p
 a   R m f34 gav srp srn 24m24                                                                              175.mg * P<.02
 b   R m f34 gav TBA MXB 24m24                                                                              93.2mg * P<.7
 c   R m f34 gav liv MXB 24m24                                                                              no dre   P=1.

2,4-DINITROTOLUENE (PURIFIED)    100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
159  R m f34 eat liv mix 52w52 er                                                 .>                         90.2mg   P<.3   -
 a   R m f34 eat liv nnd 52w52 er                                                                           90.2mg   P<.3   -

2,6-DINITROTOLUENE               100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
160  R m f34 eat liv thc 52w52 er                                     .  + .                                 .574mg * P<.0005
 a   R m f34 eat liv hpc 52w52 er                                                                           .574mg * P<.0005+
 b   R m f34 eat liv nnd 52w52 er                                                                           .964mg * P<.0005+
 c   R m f34 eat liv clc 52w52 er                                                                           34.2mg * P<.8
 d   R m f34 eat liv hpd 52w52 er                                                                           68.9mg * P<.9

DINITROTOLUENE, TECHNICAL GRADE (2,4 (77%)- and 2,6 (19%)-)..:..100....:..1mg....:..10.....:..100....:..1g.....:..10
161  R m f34 eat liv nnd 52w52 er                                           .   +   .                       8.02mg   P<.0005+
 a   R m f34 eat liv thc 52w52 er                                                                           9.34mg   P<.0005+
 b   R m f34 eat liv clc 52w52 er                                                                           53.9mg   P<.09

DIPENTYLNITROSAMINE              100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
162  R f f34 eat liv hpc 23m24 er                                           . +  .                          7.57mg * P<.0005+
163  R m f34 eat liv hpc 21m24 er                                      . + .                                2.75mg * P<.0005+

DIPHENHYDRAMINE.HCl***           100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
164  M f b6c eat TBA MXB 24m24                                                    :>                         no dre   P=1.   -
 a   M f b6c eat liv MXB 24m24                                                                              363.mg * P<.5
 b   M f b6c eat lun MXB 24m24                                                                              357.mg * P<.3
165  M m b6c eat liv hpc 24m25                                                    :  ±                      #37.3mg   P<.02  -
 a   M m b6c eat TBA MXB 24m25                                                                              no dre   P=1.
 b   M m b6c eat liv MXB 24m25                                                                              201.mg * P<.6
 c   M m b6c eat lun MXB 24m25                                                                              447.mg   P<.9
166  R f f34 eat pta adn 24m24                                                :   ±                          20.5mg * P<.06  e
 a   R f f34 eat TBA MXB 24m24                                                                              65.1mg * P<.8
 b   R f f34 eat liv MXB 24m24                                                                              no dre   P=1.
167  R m f34 eat lun a/a 24m24                                                        :   +             :      66.1mg * P<.009
 a   R m f34 eat bra ast 24m24                                                                              140.mg / P<.01
 b   R m f34 eat lun MXA 24m24                                                                              57.3mg * P<.02  e
 c   R m f34 eat bra MXA 24m24                                                                              143.mg / P<.05  e
 d   R m f34 eat TBA MXB 24m24                                                                              17.8mg * P<.07
 e   R m f34 eat liv MXB 24m24                                                                              243.mg * P<.2

5,5-DIPHENYLHYDANTOIN***         100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
168  M f b6c eat liv hct 78w86 e                                                  .>                         151.mg * P<.3   -
 a   M f b6c eat liv hpa 78w86 e                                                                            229.mg * P<.8   -
 b   M f b6c eat liv hpc 78w86 e                                                                            457.mg * P<.3   -
 c   M f b6c eat lun act 78w86 e                                                                            2.06gm * P<1.   -
 d   M f b6c eat liv hem 78w86 e                                                                           no dre   P=1.   -
169  M m b6c eat liv hem 78w86 e                                                  .>                         321.mg * P<.7   -
 a   M m b6c eat liv hct 78w86 e                                                                            no dre   P=1.   -
 b   M m b6c eat liv hpa 78w86 e                                                                            no dre   P=1.   -
 c   M m b6c eat liv hpc 78w86 e                                                                            no dre   P=1.   -
 d   M m b6c eat lun act 78w86 e                                                                           no dre   P=1.   -
170  R f f3d eat liv nnd 24m26 e                                                          .>                 47.8gm * P<1.   -
 a   R f f3d eat liv hpc 24m26 e                                                                            no dre   P=1.   -
 b   R f f3d eat tba mal 24m26 e                                                                            110.mg * P<.2   -
171  R m f3d eat liv hpc 24m26 e                                                           .>                1.08gm * P<.3   -
 a   R m f3d eat liv nnd 24m26 e                                                                            no dre   P=1.   -
 b   R m f3d eat tba mal 24m26 e                                                                            98.7mg * P<.5   -
```

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
2-DIMETHYLAMINOETHANOL 108-01-0											
153 1877	931.mg	n.s.s.	4/44	268.mg	5/40					Stenback;made,42,129-138;1988	
a 1877	166.mg	n.s.s.	39/44	268.mg	35/40						
154 1877	478.mg	n.s.s.	6/58	178.mg	7/50						
a 1877	177.mg	n.s.s.	33/58	178.mg	30/50						
N,N-DIMETHYLANILINE 121-69-7											
155 c56428	39.3mg	n.s.s.	2/50	10.6mg	2/50	21.2mg	8/50				
a c56428	15.7mg	n.s.s.	39/50	10.6mg	27/50	21.2mg	41/50				
b c56428	40.2mg	n.s.s.	5/50	10.6mg	5/50	21.2mg	8/50				liv:hpa,hpc,nnd.
c c56428	54.8mg	n.s.s.	4/50	10.6mg	3/50	21.2mg	6/50				lun:a/a,a/c.
156 c56428	17.4mg	n.s.s.	32/50	10.6mg	37/50	21.2mg	33/50				
a c56428	28.3mg	n.s.s.	11/50	10.6mg	16/50	21.2mg	13/50				liv:hpa,hpc,nnd.
b c56428	26.7mg	n.s.s.	7/50	10.6mg	12/50	21.2mg	11/50				lun:a/a,a/c.
157 c56428	2.41mg	n.s.s.	48/50	2.12mg	42/50	(21.2mg	42/50)				
a c56428	n.s.s.	n.s.s.	0/50	2.12mg	0/50	21.2mg	0/50				liv:hpa,hpc,nnd.
158 c56428	42.5mg	1.09gm	0/50	2.12mg	0/50	21.2mg	4/50				srp:ost,srn.
a c56428	52.3mg	n.s.s.	0/50	2.12mg	0/50	21.2mg	3/50				S
b c56428	12.8mg	n.s.s.	42/50	2.12mg	35/50	21.2mg	39/50				
c c56428	126.mg	n.s.s.	1/50	2.12mg	1/50	21.2mg	0/50				liv:hpa,hpc,nnd.
2,4-DINITROTOLUENE (PURIFIED) 121-14-2											
159 1834	14.7mg	n.s.s.	0/20	27.0mg	1/20					Leonard;jnci,79,1313-1319;1987/pers.comm.	
a 1834	14.7mg	n.s.s.	0/20	27.0mg	1/20						
2,6-DINITROTOLUENE 606-20-2											
160 1834	.305mg	1.06mg	0/20	7.00mg	17/20	14.0mg	19/19			Leonard;jnci,79,1313-1319;1987/pers.comm.	
a 1834	.305mg	1.06mg	0/20	7.00mg	17/20	14.0mg	19/19				
b 1834	.587mg	1.65mg	0/20	7.00mg	18/20	14.0mg	15/19				
c 1834	8.41mg	n.s.s.	0/20	7.00mg	2/20	14.0mg	0/19				
d 1834	11.2mg	n.s.s.	0/20	7.00mg	1/20	14.0mg	0/19				
DINITROTOLUENE, TECHNICAL GRADE (2,4 (77%)- and 2,6 (19%)-) ---											
161 1834	3.82mg	20.9mg	0/20	35.0mg	10/19					Leonard;jnci,79,1313-1319;1987/pers.comm.	
a 1834	4.32mg	26.1mg	0/20	35.0mg	9/19						
b 1834	13.2mg	n.s.s.	0/20	35.0mg	2/19						
DIPENTYLNITROSAMINE 13256-06-9											
162 1824	4.75mg	12.7mg	0/144	2.50mg	3/24	7.50mg	8/24	22.5mg	24/24	Elashoff;jnci,79,509-526;1987	
163 1824	1.74mg	4.46mg	1/144	2.00mg	7/24	6.00mg	22/24	18.0mg	23/24		
DIPHENHYDRAMINE.HCl* (Benadryl) 147-24-0**											
164 c56075	33.1mg	n.s.s.	37/50	20.1mg	39/50	40.3mg	32/50				
a c56075	80.6mg	n.s.s.	5/50	20.1mg	5/50	40.3mg	7/50				liv:hpa,hpc,nnd.
b c56075	98.7mg	n.s.s.	3/50	20.1mg	2/50	40.3mg	6/50				lun:a/a,a/c.
165 c56075	16.0mg	n.s.s.	4/50	18.5mg	14/50	(37.2mg	5/50)				S
a c56075	31.3mg	n.s.s.	30/50	18.5mg	32/50	37.2mg	22/50				
b c56075	34.1mg	n.s.s.	12/50	18.5mg	18/50	37.2mg	12/50				liv:hpa,hpc,nnd.
c c56075	31.8mg	n.s.s.	6/50	18.5mg	7/50	(37.2mg	0/50)				lun:a/a,a/c.
166 c56075	8.55mg	n.s.s.	23/50	7.62mg	26/50	15.4mg	35/50				
a c56075	8.16mg	n.s.s.	47/50	7.62mg	46/50	15.4mg	46/50				
b c56075	n.s.s.	n.s.s.	0/50	7.62mg	0/50	15.4mg	0/50				liv:hpa,hpc,nnd.
167 c56075	29.3mg	1.71gm	0/50	12.3mg	5/50	24.6mg	3/50				S
a c56075	46.0mg	6.01gm	0/50	12.3mg	0/50	24.6mg	4/50				S
b c56075	25.0mg	n.s.s.	1/50	12.3mg	6/50	24.6mg	5/50				lun:a/a,a/c.
c c56075	45.5mg	n.s.s.	1/50	12.3mg	0/50	24.6mg	5/50				bra:ast,gln.
d c56075	7.16mg	n.s.s.	47/50	12.3mg	49/50	24.6mg	47/50				
e c56075	59.7mg	n.s.s.	0/50	12.3mg	1/50	24.6mg	1/50				liv:hpa,hpc,nnd.
5,5-DIPHENYLHYDANTOIN* (phenytoin) 57-41-0**											
168 1887	45.8mg	n.s.s.	0/49	7.07mg	2/49	14.1mg	1/45			Maeda;jtxe,24,111-119;1988	
a 1887	56.3mg	n.s.s.	0/49	7.07mg	2/49	14.1mg	0/45				
b 1887	74.5mg	n.s.s.	0/49	7.07mg	0/49	14.1mg	1/45				
c 1887	55.4mg	n.s.s.	1/49	7.07mg	2/49	14.1mg	1/45				
d 1887	97.3mg	n.s.s.	1/49	7.07mg	1/49	14.1mg	0/45				
169 1887	41.0mg	n.s.s.	3/47	6.53mg	0/44	13.1mg	4/43				
a 1887	22.3mg	n.s.s.	26/47	6.53mg	20/44	13.1mg	16/43				
b 1887	28.9mg	n.s.s.	19/47	6.53mg	12/44	13.1mg	11/43				
c 1887	28.7mg	n.s.s.	7/47	6.53mg	8/44	13.1mg	5/43				
d 1887	58.2mg	n.s.s.	6/47	6.53mg	3/44	13.1mg	2/43				
170 1855	241.mg	n.s.s.	1/50	11.6mg	0/47	23.2mg	1/48			Jang;fctx,25,697-702;1987	
a 1855	87.5mg	n.s.s.	0/50	11.6mg	0/47	23.2mg	0/48				
b 1855	37.0mg	n.s.s.	13/50	11.6mg	11/50	23.2mg	19/48				
171 1855	177.mg	n.s.s.	0/50	9.29mg	0/48	18.6mg	1/50				
a 1855	133.mg	n.s.s.	1/50	9.29mg	2/48	18.6mg	1/50				
b 1855	22.8mg	n.s.s.	22/50	9.29mg	22/48	18.6mg	26/50				

```
     Spe Strain  Site    Xpo+Xpt                                                                          TD50     2Tailpvl
       Sex    Route   Hist       Notes                                                                        DR       AuOp

1,2-EPOXYBUTANE                  100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
172  M f b6c inh TBA MXB 24m24 s                                                       :>                141.mg * P<.4    -
 a   M f b6c inh liv MXB 24m24 s                                                                         445.mg * P<.3
 b   M f b6c inh lun MXB 24m24 s                                                                         834.mg * P<.6
173  M m b6c inh TBA MXB 24m24                                                            :>             2.47gm * P<1.    -
 a   M m b6c inh liv MXB 24m24                                                                           8.60gm * P<1.
 b   M m b6c inh lun MXB 24m24                                                                           no dre   P=1.
174  R f f34 inh pta adn 24m24                                                         :  ±              83.8mg * P<.05
 a   R f f34 inh thy MXA 24m24                                                                           509.mg * P<.03
 b   R f f34 inh ova MXA 24m24                                                                           545.mg * P<.03
 c   R f f34 inh nas ppa 24m24                                                                           1.73gm * P<.09  e
 d   R f f34 inh TBA MXB 24m24                                                                           78.0mg * P<.2
 e   R f f34 inh liv MXB 24m24                                                                           no dre   P=1.
175  R m f34 inh MXB MXB 24m24                                                           :  +   :        106.mg * P<.0005
 a   R m f34 inh lun MXA 24m24                                                                           220.mg * P<.006 c
 b   R m f34 inh nas ppa 24m24                                                                           220.mg * P<.002 c
 c   R m f34 inh MXA MXA 24m24                                                                           30.7mg   P<.04
 d   R m f34 inh lun a/c 24m24                                                                           314.mg * P<.02  c
 e   R m f34 inh TBA MXB 24m24                                                                           79.6mg * P<.3
 f   R m f34 inh liv MXB 24m24                                                                           622.mg * P<.5

ERYTHROMYCIN STEARATE            100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
176  M f b6c eat TBA MXB 24m24                                                                  :>       no dre   P=1.    -
 a   M f b6c eat liv MXB 24m24                                                                           no dre   P=1.
 b   M f b6c eat lun MXB 24m24                                                                           no dre   P=1.
177  M m b6c eat TBA MXB 24m24                                                                    :>     no dre   P=1.    -
 a   M m b6c eat liv MXB 24m24                                                                           no dre   P=1.
 b   M m b6c eat lun MXB 24m24                                                                           no dre   P=1.
178  R f f34 eat TBA MXB 24m24                                                              :>           no dre   P=1.    -
 a   R f f34 eat liv MXB 24m24                                                                           5.85gm * P<.2
179  R m f34 eat TBA MXB 24m24                                                               :>          2.02gm * P<.8    -
 a   R m f34 eat liv MXB 24m24                                                                           3.95gm * P<.3

ETHOXYQUIN***                    100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
180  R m f3d eat eso tum 52w52 er                                                        .>              no dre   P=1.    -
 a   R m f3d eat for tum 52w52 er                                                                        no dre   P=1.    -
 b   R m f3d eat liv tum 52w52 er                                                                        no dre   P=1.    -

ETHYLENE OXIDE***                100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
181  M f b6c inh MXB MXB 24m24                                                       : +      :          39.2mg * P<.002

 a   M f b6c inh MXB MXB 24m24                                                                           45.8mg * P<.0005
 b   M f b6c inh lun MXA 24m24                                                                           61.8mg * P<.0005c
 c   M f b6c inh lun a/a 24m24                                                                           87.5mg * P<.002 c
 d   M f b6c inh lun a/c 24m24                                                                           200.mg * P<.004 c
 e   M f b6c inh liv hpa 24m24                                                                           75.8mg   P<.02
 f   M f b6c inh mgl MXA 24m24                                                                           76.3mg   P<.02  p
 g   M f b6c inh MXB MXB 24m24                                                                           79.2mg * P<.02

 h   M f b6c inh MXA MXA 24m24                                                                           139.mg * P<.06  p

 i   M f b6c inh hag pcy 24m24                                                                           142.mg * P<.04  c
 j   M f b6c inh ute MXA 24m24                                                                           250.mg * P<.02  p
 k   M f b6c inh ute acn 24m24                                                                           297.mg * P<.02  p
 l   M f b6c inh TBA MXB 24m24                                                                           103.mg * P<.4
 m   M f b6c inh liv MXB 24m24                                                                           149.mg   P<.4
 n   M f b6c inh lun MXB 24m24                                                                           61.8mg * P<.0005
182  M m b6c inh MXB MXB 24m24                                                       :  ±                51.2mg * P<.04
 a   M m b6c inh lun MXA 24m24                                                                           65.7mg * P<.06  c
 b   M m b6c inh lun a/c 24m24                                                                           110.mg * P<.08  c
 c   M m b6c inh hag pcy 24m24                                                                           110.mg * P<.04  c
 d   M m b6c inh lun a/a 24m24                                                                           181.mg * P<.3   c
 e   M m b6c inh TBA MXB 24m24                                                                           108.mg * P<.5
 f   M m b6c inh liv MXB 24m24                                                                           273.mg * P<.6
 g   M m b6c inh lun MXB 24m24                                                                           65.7mg * P<.06

DI(2-ETHYLHEXYL)PHTHALATE***     100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
183  R m f34 eat liv mix 95w95 er                                                               .   +     .     499.mg   P<.003 +
 a   R m f34 eat liv hpc 95w95 er                                                                        895.mg   P<.02
 b   R m f34 eat liv hpn 95w95 er                                                                        2.05gm   P<.2

ETHYNODIOL DIACETATE***          100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
184  R f win gav liv tum 60w60 er                                             .>                        no dre   P=1.    -

FORMALDEHYDE***                  100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
185  R f sda wat --- leu 24m34 er                                                                 .   ±      815.mg * P<.04  +
```

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly	Code
1,2-EPOXYBUTANE 106-88-7										
172 c55527	35.3mg	n.s.s.	35/50	45.5mg	29/50	90.9mg	20/50			
a c55527	118.mg	n.s.s.	4/50	45.5mg	3/50	90.9mg	5/50	liv:hpa,hpc,nnd.		
b c55527	135.mg	n.s.s.	4/50	45.5mg	3/50	90.9mg	3/50	lun:a/a,a/c.		
173 c55527	81.5mg	n.s.s.	28/50	37.9mg	26/50	75.8mg	24/50			
a c55527	137.mg	n.s.s.	14/50	37.9mg	13/50	75.8mg	12/50	liv:hpa,hpc,nnd.		
b c55527	228.mg	n.s.s.	11/50	37.9mg	9/50	75.8mg	6/50	lun:a/a,a/c.		
174 c55527	35.2mg	n.s.s.	25/50	43.3mg	26/50	86.6mg	32/50			S
a c55527	174.mg	n.s.s.	0/50	43.3mg	1/50	86.6mg	3/50	thy:fca,fcc.		S
b c55527	181.mg	n.s.s.	0/50	43.3mg	1/50	86.6mg	3/50	ova:gcc,gct,tcm.		S
c c55527	422.mg	n.s.s.	0/50	43.3mg	0/50	86.6mg	2/50			
d c55527	27.9mg	n.s.s.	45/50	43.3mg	47/50	86.6mg	47/50			
e c55527	601.mg	n.s.s.	1/50	43.3mg	0/50	86.6mg	0/50	liv:hpa,hpc,nnd.		
175 c55527	56.3mg	241.mg	0/50	30.3mg	2/50	60.6mg	12/50	lun:a/a,a/c; nas:ppa.		C
a c55527	92.8mg	684.mg	0/50	30.3mg	2/50	60.6mg	5/50	lun:a/a,a/c.		
b c55527	93.7mg	872.mg	0/50	30.3mg	0/50	60.6mg	7/50			
c c55527	12.5mg	n.s.s.	25/50	30.3mg	31/50	(60.6mg	22/50)	mul:mnl; spl:mnl.		S
d c55527	116.mg	n.s.s.	0/50	30.3mg	1/50	60.6mg	4/50			
e c55527	22.4mg	n.s.s.	46/50	30.3mg	48/50	60.6mg	47/50			
f c55527	120.mg	n.s.s.	2/50	30.3mg	2/50	60.6mg	3/50	liv:hpa,hpc,nnd.		
ERYTHROMYCIN STEARATE 643-22-1										
176 c55674	634.mg	n.s.s.	44/50	322.mg	41/50	644.mg	39/50			
a c55674	2.62gm	n.s.s.	4/50	322.mg	6/50	644.mg	2/50	liv:hpa,hpc,nnd.		
b c55674	3.34gm	n.s.s.	4/50	322.mg	3/50	644.mg	2/50	lun:a/a,a/c.		
177 c55674	1.02gm	n.s.s.	37/50	297.mg	26/50	594.mg	29/50			
a c55674	1.77gm	n.s.s.	15/50	297.mg	8/50	594.mg	11/50	liv:hpa,hpc,nnd.		
b c55674	2.30gm	n.s.s.	6/50	297.mg	5/50	594.mg	4/50	lun:a/a,a/c.		
178 c55674	153.mg	n.s.s.	49/50	248.mg	48/50	(495.mg	42/50)			
a c55674	1.77gm	n.s.s.	0/50	248.mg	1/50	495.mg	2/50	liv:hpa,hpc,nnd.		
179 c55674	197.mg	n.s.s.	45/50	198.mg	46/50	396.mg	47/50			
a c55674	957.mg	n.s.s.	1/50	198.mg	1/50	396.mg	3/50	liv:hpa,hpc,nnd.		
ETHOXYQUIN*** 91-53-2										
180 1900	51.5mg	n.s.s.	0/10	100.mg	0/10			Hirose;carc,8,1731-1735;1987/pers.comm.		
a 1900	51.5mg	n.s.s.	0/10	100.mg	0/10					
b 1900	51.5mg	n.s.s.	0/10	100.mg	0/10					
ETHYLENE OXIDE*** (EO) 75-21-8										
181 c50088	21.7mg	163.mg	13/50	27.8mg	22/50	55.6mg	43/50	duo:mno; hag:pcy; kid:mno; lun:a/a,a/c; mds:mno; mgl:acn,adq; mln:mno; mul:mlh,mno; spl:mno; ute:acn,adn,mno.		M
a c50088	27.3mg	120.mg	3/50	27.8mg	9/50	55.6mg	26/50	hag:pcy; lun:a/a,a/c.		C
b c50088	36.0mg	163.mg	2/50	27.8mg	5/50	55.6mg	22/50	lun:a/a,a/c.		
c c50088	47.0mg	362.mg	2/50	27.8mg	4/50	55.6mg	17/50			
d c50088	90.3mg	1.25gm	0/50	27.8mg	1/50	55.6mg	7/50			
e c50088	31.2mg	41.7gm	1/50	27.8mg	8/50	(55.6mg	3/50)			S
f c50088	31.5mg	n.s.s.	1/50	27.8mg	8/50	(55.6mg	6/50)	mgl:acn,adq.		
g c50088	38.7mg	n.s.s.	10/50	27.8mg	14/50	55.6mg	29/50	duo:mno; kid:mno; mds:mno; mgl:acn,adq; mln:mno; mul:mlh,mno; spl:mno; ute:acn,adn,mno.		P
h c50088	57.8mg	n.s.s.	9/50	27.8mg	6/50	55.6mg	22/50	duo:mno; kid:mno; mds:mno; mln:mno; mul:mlh,mno; spl:mno; ute:mno.		
i c50088	64.9mg	n.s.s.	1/50	27.8mg	6/50	55.6mg	8/50			
j c50088	107.mg	n.s.s.	0/50	27.8mg	2/50	55.6mg	5/50	ute:acn,adn.		
k c50088	120.mg	n.s.s.	0/50	27.8mg	1/50	55.6mg	5/50			
l c50088	27.6mg	n.s.s.	30/50	27.8mg	33/50	55.6mg	46/50			
m c50088	34.7mg	n.s.s.	6/50	27.8mg	9/50	(55.6mg	3/50)	liv:hpa,hpc,nnd.		
n c50088	36.0mg	163.mg	2/50	27.8mg	5/50	55.6mg	22/50	lun:a/a,a/c.		
182 c50088	22.5mg	n.s.s.	12/50	23.1mg	26/50	46.3mg	29/50	hag:pcy; lun:a/a,a/c.		C
a c50088	27.8mg	n.s.s.	11/50	23.1mg	19/50	46.3mg	26/50	lun:a/a,a/c.		
b c50088	44.0mg	n.s.s.	6/50	23.1mg	10/50	46.3mg	16/50			
c c50088	52.1mg	n.s.s.	1/50	23.1mg	9/50	46.3mg	8/50			
d c50088	54.5mg	n.s.s.	5/50	23.1mg	11/50	46.3mg	11/50			
e c50088	24.4mg	n.s.s.	29/50	23.1mg	38/50	46.3mg	41/50			
f c50088	53.7mg	n.s.s.	15/50	23.1mg	17/50	46.3mg	21/50	liv:hpa,hpc,nnd.		
g c50088	27.8mg	n.s.s.	11/50	23.1mg	19/50	46.3mg	26/50	lun:a/a,a/c.		
DI(2-ETHYLHEXYL)PHTHALATE*** (di-sec-octyl phthalate) 117-81-7										
183 1823	193.mg	2.61gm	0/8	800.mg	6/10			Rao;carc,8,1347-1350;1987		
a 1823	303.mg	n.s.s.	0/8	800.mg	4/10					
b 1823	501.mg	n.s.s.	0/8	800.mg	2/10					
ETHYNODIOL DIACETATE*** (Ovulen-50) 297-76-7										
184 1905	1.68mg	n.s.s.	0/6	4.08mg	0/6			Annapurna;ijbb,25,708-713;1988		
FORMALDEHYDE*** 50-00-0										
185 bt7001	316.mg	n.s.s.	3/50	.410mg	2/50	2.05mg	4/50	4.10mg 4/50 20.5mg 4/50 41.0mg 7/50 61.5mg 7/50		
								Soffritti;txih,5,699-730;1989		

```
     Spe Strain  Site  Xpo+Xpt                                                                                   TD50   2Tailpvl
       Sex   Route   Hist     Notes                                                                                    DR     AuOp

 a   R f sda wat --- lls 24m34 er                                                                                996.mg * P<.03  +

 b   R f sda wat git mix 24m34 er                                                                                2.96gm * P<.2   +

186  R m sda wat --- lls 24m34 er                                                               .  +     .       424.mg * P<.0005+

 a   R m sda wat --- leu 24m34 er                                                                                480.mg * P<.01  +

 b   R m sda wat git mix 24m34 er                                                                                1.41gm * P<.02  +


FUROSEMIDE                       100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
187  M f b6c eat mgl MXA 24m24                                                                   :   +       :   732.mg * P<.004 p
 a   M f b6c eat mgl mtm 24m24                                                                                   845.mg * P<.004
 b   M f b6c eat thy fca 24m24                                                                                   703.mg * P<.02
 c   M f b6c eat TBA MXB 24m24                                                                                   136.mg * P<.02
 d   M f b6c eat liv MXB 24m24                                                                                   3.97gm * P<.8
 e   M f b6c eat lun MXB 24m24                                                                                   2.71gm * P<.6
188  M m b6c eat TBA MXB 24m24                                                              :>                   393.mg * P<.5   -
 a   M m b6c eat liv MXB 24m24                                                                                   405.mg * P<.2
 b   M m b6c eat lun MXB 24m24                                                                                   no dre   P=1.
189  R f f34 eat thy MXA 24m24                                                         :  +      :              #47.1mg * P<.003 -
 a   R f f34 eat thy cca 24m24                                                                                   51.4mg * P<.004
 b   R f f34 eat TBA MXB 24m24                                                                                   20.9mg / P<.04
 c   R f f34 eat liv MXB 24m24                                                                                   no dre   P=1.
190  R m f34 eat pta adn 24m24                                                     :    ±                        27.0mg   P<.05
 a   R m f34 eat kid MXA 24m24                                                                                   370.mg * P<.7   e
 b   R m f34 eat brm mng 24m24                                                                                   no dre   P=1.   e
 c   R m f34 eat TBA MXB 24m24                                                                                   no dre   P=1.
 d   R m f34 eat liv MXB 24m24                                                                                   no dre   P=1.

GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE)  ....:..10.....:..100....:..1g.....:..10
191  M f b6c gav TBA MXB 23m24 as                                                              :  ±              353.mg * P<.02  -
 a   M f b6c gav liv MXB 23m24 as                                                                                2.73gm * P<.4
 b   M f b6c gav lun MXB 23m24 as                                                                                5.30gm * P<.4
192  M m b6c gav TBA MXB 23m24 as                                                               :  ±             485.mg / P<.04  -
 a   M m b6c gav liv MXB 23m24 as                                                                                647.mg / P<.005
 b   M m b6c gav lun MXB 23m24 as                                                                                5.26gm * P<.6
193  R f f34 gav TBA MXB 24m24                                                                           :>      no dre   P=1.   -
 a   R f f34 gav liv MXB 24m24                                                                                   45.1gm * P<.3
194  R m f34 gav tes ict 24m24 s                                                                   :  ±          772.mg * P<.03
 a   R m f34 gav ski MXA 24m24 s                                                                                 5.05gm * P<.05
 b   R m f34 gav ski sqp 24m24 s                                                                                 6.12gm * P<.06  e
 c   R m f34 gav kid tla 24m24 s                                                                                 20.2gm * P<.5   e
 d   R m f34 gav TBA MXB 24m24 s                                                                                 9.26gm * P<.8
 e   R m f34 gav liv MXB 24m24 s                                                                                 15.4gm * P<.2

N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID ..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
195  M f swa gav liv mix 12m31 e                                                                     .>          41.4gm   P<1.
 a   M f swa gav lun mix 12m31 e                                                                                 no dre   P=1.
 b   M f swa gav sub mix 12m31 e                                                                                 no dre   P=1.
196  M m swa gav sub fbs 12m31 e                                                               .  +  .           277.mg   P<.0005+
 a   M m swa gav lun mix 12m31 e                                                                                 250.mg   P<.05
 b   M m swa gav liv mix 12m31 e                                                                                 no dre   P=1.

HEXACHLOROBENZENE***             100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
197  R m cdr eat liv nnd 28m28 be                                                 .     ±                        27.3mg   P<.1
 a   R m cdr eat liv hpc 28m28 be                                                                                55.3mg   P<.3
 b   R m cdr eat liv blc 28m28 be                                                                                55.3mg   P<.3
198  R m cdr eat liv nnd 28m28 e                                                 .    ±                          17.9mg   P<.05
 a   R m cdr eat liv kcs 28m28 e                                                                                 55.3mg   P<.3

gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE***..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
199  M f baa eat lun tum 26w52 er                                                     .>                          1.26gm   P<1.
 a   M f baa eat liv hpc 26w52 er                                                                                no dre   P=1.   -
 b   M f baa eat liv hpa 26w52 er                                                                                no dre   P=1.   -
200  M f baa eat lun tum  6m24 er                                                           .>                    15.9gm   P<1.
 a   M f baa eat liv hpc  6m24 er                                                                                no dre   P=1.   -
 b   M f baa eat liv hpa  6m24 er                                                                                no dre   P=1.   -
201  M f baa eat liv hpa 52w52 er                                                           .>                    no dre   P=1.   -
 a   M f baa eat liv hpc 52w52 er                                                                                no dre   P=1.   -
 b   M f baa eat lun tum 52w52 er                                                                                no dre   P=1.
202  M f baa eat lun tum 24m24 er                                                                .>               1.33gm   P<.7   -
 a   M f baa eat liv hpc 24m24 er                                                                                no dre   P=1.   -
 b   M f baa eat liv hpa 24m24 er                                                                                no dre   P=1.   -
 c   M f baa eat liv mix 24m24 er                                                                                no dre   P=1.   -
203  M f pva eat lun tum 52w52 er                                                          .>                     no dre   P=1.
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc						Citation or Pathology	Brkly Code
a	bt7001	386.mg	n.s.s.	1/50	.410mg	1/50	2.05mg	3/50	4.10mg	2/50	20.5mg	2/50	41.0mg	5/50	
					61.5mg	5/50									
b	bt7001	753.mg	n.s.s.	0/50	.410mg	1/50	2.05mg	2/50	4.10mg	0/50	20.5mg	0/50	41.0mg	1/50	
					61.5mg	3/50									
186	bt7001	213.mg	1.73gm	4/50	.359mg	0/50	1.79mg	2/50	3.59mg	4/50	17.9mg	4/50	35.9mg	6/50	
					53.8mg	11/50									
a	bt7001	213.mg	63.8gm	5/50	.359mg	1/50	1.79mg	5/50	3.59mg	5/50	17.9mg	8/50	35.9mg	6/50	
					53.8mg	11/50									
b	bt7001	517.mg	n.s.s.	0/50	.359mg	2/50	1.79mg	0/50	3.59mg	0/50	17.9mg	0/50	35.9mg	1/50	
					53.8mg	5/50									
FUROSEMIDE		54-31-9													
187	c55936	310.mg	4.35gm	0/50	89.3mg	2/50	180.mg	5/50						mgl:acc,mtm.	
a	c55936	337.mg	5.57gm	0/50	89.3mg	1/50	180.mg	5/50							S
b	c55936	292.mg	n.s.s.	0/50	89.3mg	4/50	180.mg	3/50							S
c	c55936	62.7mg	n.s.s.	34/50	89.3mg	35/50	180.mg	39/50							
d	c55936	380.mg	n.s.s.	6/50	89.3mg	4/50	180.mg	5/50						liv:hpa,hpc,nnd.	
e	c55936	416.mg	n.s.s.	3/50	89.3mg	2/50	180.mg	3/50						lun:a/a,a/c.	
188	c55936	89.7mg	n.s.s.	33/50	82.4mg	34/50	166.mg	34/50							
a	c55936	133.mg	n.s.s.	15/50	82.4mg	16/50	166.mg	20/50						liv:hpa,hpc,nnd.	
b	c55936	471.mg	n.s.s.	5/50	82.4mg	3/50	166.mg	4/50						lun:a/a,a/c.	
189	c55936	22.2mg	296.mg	4/50	17.2mg	7/50	34.5mg	11/50						thy:cca,ccr.	S
a	c55936	23.6mg	375.mg	4/50	17.2mg	6/50	34.5mg	11/50							S
b	c55936	8.91mg	n.s.s.	48/50	17.2mg	45/50	34.5mg	46/50							
c	c55936	n.s.s.	n.s.s.	0/50	17.2mg	0/50	34.5mg	0/50						liv:hpa,hpc,nnd.	
190	c55936	10.0mg	n.s.s.	4/50	13.7mg	11/50	(27.7mg	8/50)							S
a	c55936	48.3mg	n.s.s.	1/50	13.7mg	4/50	27.7mg	2/50						kid:tla,uac.	
b	c55936	n.s.s.	n.s.s.	0/50	13.7mg	3/50	27.7mg	0/50							
c	c55936	15.6mg	n.s.s.	47/50	13.7mg	44/50	27.7mg	46/50							
d	c55936	n.s.s.	n.s.s.	0/50	13.7mg	0/50	27.7mg	0/50						liv:hpa,hpc,nnd.	
GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE) (CAS# 105-87-3 and 150-84-5) mixture															
191	c54728	146.mg	n.s.s.	20/50	354.mg	20/50	714.mg	6/50							
a	c54728	520.mg	n.s.s.	5/50	354.mg	4/50	714.mg	2/50						liv:hpa,hpc,nnd.	
b	c54728	779.mg	n.s.s.	1/50	354.mg	1/50	714.mg	1/50						lun:a/a,a/c.	
192	c54728	197.mg	n.s.s.	33/50	354.mg	33/50	714.mg	21/50							
a	c54728	296.mg	7.59gm	13/50	354.mg	17/50	714.mg	15/50						liv:hpa,hpc,nnd.	
b	c54728	766.mg	n.s.s.	6/50	354.mg	6/50	714.mg	3/50						lun:a/a,a/c.	
193	c54728	1.61gm	n.s.s.	38/50	707.mg	31/50	1.41gm	28/50							
a	c54728	7.34gm	n.s.s.	0/50	707.mg	0/50	1.41gm	1/50						liv:hpa,hpc,nnd.	
194	c54728	353.mg	n.s.s.	43/50	707.mg	44/50	1.41gm	44/50							S
a	c54728	2.06gm	n.s.s.	0/50	707.mg	5/50	1.41gm	1/50						ski:sqc,sqp.	S
b	c54728	2.32gm	n.s.s.	0/50	707.mg	4/50	1.41gm	1/50							
c	c54728	4.71gm	n.s.s.	0/50	707.mg	2/50	1.41gm	0/50							
d	c54728	867.mg	n.s.s.	36/50	707.mg	33/50	1.41gm	23/50							
e	c54728	3.79gm	n.s.s.	0/50	707.mg	1/50	1.41gm	1/50						liv:hpa,hpc,nnd.	
N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID (N2-[gamma-L(+)-GLUTAMYL]-4-CARBOXYPHENYLHYDRAZINE) 69644-85-5															
195	1832	666.mg	n.s.s.	1/46	78.2mg	1/42								Toth;acnr,6,917-920;1986	
a	1832	264.mg	n.s.s.	12/47	78.2mg	12/47									
b	1832	585.mg	n.s.s.	3/43	78.2mg	1/32									
196	1832	146.mg	632.mg	0/43	78.2mg	13/48									
a	1832	101.mg	n.s.s.	15/49	78.2mg	23/45									
b	1832	443.mg	n.s.s.	7/40	78.2mg	3/32									
HEXACHLOROBENZENE*** (HCB) 118-74-1															
197	1833m	6.71mg	n.s.s.	0/39	1.60mg	2/39								Arnold;fctx,23,779-793;1985	
a	1833m	9.00mg	n.s.s.	0/39	1.60mg	1/39									
b	1833m	9.00mg	n.s.s.	0/39	1.60mg	1/39									
198	1833n	5.43mg	n.s.s.	0/38	1.60mg	3/39									
a	1833n	9.00mg	n.s.s.	0/38	1.60mg	1/39									
gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE*** (lindane) 58-89-9															
199	1828m	14.6mg	n.s.s.	1/48	10.4mg	1/45								Wolff;carc,8,1889-1897;1987	
a	1828m	24.1mg	n.s.s.	0/48	10.4mg	0/45									
b	1828m	24.1mg	n.s.s.	0/48	10.4mg	0/45									
200	1828n	50.4mg	n.s.s.	2/96	5.20mg	2/95									
a	1828n	55.5mg	n.s.s.	3/96	5.20mg	2/95									
b	1828n	54.8mg	n.s.s.	6/96	5.20mg	3/95									
201	1828o	51.4mg	n.s.s.	0/48	20.8mg	0/48									
a	1828o	51.4mg	n.s.s.	0/48	20.8mg	0/48									
b	1828o	51.4mg	n.s.s.	1/48	20.8mg	0/48									
202	1828r	160.mg	n.s.s.	2/96	20.8mg	3/96									
a	1828r	297.mg	n.s.s.	3/96	20.8mg	1/96									
b	1828r	222.mg	n.s.s.	6/96	20.8mg	3/96									
c	1828r	219.mg	n.s.s.	9/96	20.8mg	4/96									
203	1828o	49.3mg	n.s.s.	1/46	20.8mg	0/46									

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes		TD50 DR	2Tailpvl AuOp
a	M f pva eat liv hpc 52w52 er		no dre	P=1. -
b	M f pva eat liv hpa 52w52 er		no dre	P=1. -
204	M f pva eat liv mix 24m24 er	. ±	132.mg	P<.05 +
a	M f pva eat lun tum 24m24 er		170.mg	P<.09 +
b	M f pva eat liv hpa 24m24 er		207.mg	P<.2
c	M f pva eat liv hpc 24m24 er		435.mg	P<.3
205	M f yva eat lun tum 26w52 er	.>	84.6mg	P<.3
a	M f yva eat liv hpc 26w52 er		no dre	P=1. -
b	M f yva eat liv hpa 26w52 er		no dre	P=1. -
206	M f yva eat lun tum 6m24 er	. ±	52.2mg	P<.1
a	M f yva eat liv hpa 6m24 er		62.3mg	P<.3 -
b	M f yva eat liv hpc 6m24 er		396.mg	P<.9 -
207	M f yva eat liv hpa 52w52 er	.>	162.mg	P<.7
a	M f yva eat lun tum 52w52 er		169.mg	P<.3
b	M f yva eat liv hpc 52w52 er		no dre	P=1.
208	M f yva eat liv mix 24m24 er	. + .	28.8mg	P<.0005+
a	M f yva eat liv hpa 24m24 er		41.6mg	P<.0005+
b	M f yva eat lun tum 24m24 er		85.3mg	P<.002 +
c	M f yva eat liv hpc 24m24 er		294.mg	P<.5 -
HEXACHLOROETHANE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
209	R f f34 gav TBA MXB 24m24	:>	no dre	P=1. -
a	R f f34 gav liv MXB 24m24		276.gm *	P<1.
210	R m f34 gav MXA MXA 24m24	: ±	8.02mg	P<.03 e
a	R m f34 gav MXA MXA 24m24		9.05mg	P<.04
b	R m f34 gav kid MXA 24m24		55.4mg *	P<.02 c
c	R m f34 gav kid ruc 24m24		159.mg *	P<.04
d	R m f34 gav TBA MXB 24m24		28.0mg *	P<.5
e	R m f34 gav liv MXB 24m24		1.34gm *	P<.9
4-HEXYLRESORCINOL		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
211	M f b6c gav TBA MXB 24m24	:>	no dre	P=1. -
a	M f b6c gav liv MXB 24m24		no dre	P=1.
b	M f b6c gav lun MXB 24m24		no dre	P=1.
212	M m b6c gav hag MXA 24m24	: ±	368.mg *	P<.03 e
a	M m b6c gav amd phe 24m24		519.mg *	P<.07 e
b	M m b6c gav TBA MXB 24m24		no dre	P=1.
c	M m b6c gav liv MXB 24m24		no dre	P=1.
d	M m b6c gav lun MXB 24m24		no dre	P=1.
213	R f f34 gav TBA MXB 24m24	:>	no dre	P=1. -
a	R f f34 gav liv MXB 24m24		128.gm *	P<1.
214	R m f34 gav TBA MXB 24m24	:>	615.mg	P<1. -
a	R m f34 gav liv MXB 24m24		1.53gm *	P<.3
HYDRAZINE SULFATE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
215	H m syg wat liv hpc 24m24 er	. + .	181.mg *	P<.0005+
a	H m syg wat liv mhs 24m24 er		2.58gm *	P<.3
b	H m syg wat liv hpa 24m24 er		2.59gm *	P<.5
c	H m syg wat liv rts 24m24 er		2.59gm *	P<.5
p-HYDRAZINOBENZOIC ACID.HCl		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
216	M f swa wat aol mix 28m28 e	. + .	1.07gm	P<.0005+
a	M f swa wat aol lei 28m28 e		1.97gm	P<.01 +
b	M f swa wat lun ade 28m28 e		1.17gm	P<.04
c	M f swa wat aol ley 28m28 e		2.66gm	P<.03 +
d	M f swa wat lun mix 28m28 e		1.14gm	P<.2
e	M f swa wat lun adc 28m28 e		11.2gm	P<.9
217	M m swa wat aol mix 28m28 e	. + .	380.mg	P<.0005+
a	M m swa wat aol lei 28m28 e		609.mg	P<.002 +
b	M m swa wat aol ley 28m28 e		1.49gm	P<.005 +
c	M m swa wat lun ade 28m28 e		597.mg	P<.07
d	M m swa wat lun mix 28m28 e		675.mg	P<.3
e	M m swa wat lun adc 28m28 e		no dre	P=1.
HYDROCHLOROTHIAZIDE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
218	M f b6c eat TBA MXB 24m24	:>	no dre	P=1. -
a	M f b6c eat liv MXB 24m24		no dre	P=1.
b	M f b6c eat lun MXB 24m24		no dre	P=1.
219	M m b6c eat liv MXA 24m24	: +	1.23gm *	P<.008 e
a	M m b6c eat liv hpa 24m24		1.49gm *	P<.007
b	M m b6c eat TBA MXB 24m24		3.82gm /	P<.7
c	M m b6c eat liv MXB 24m24		1.23gm *	P<.008
d	M m b6c eat lun MXB 24m24		19.8gm *	P<.9
220	R f f34 eat TBA MXB 24m25	:>	no dre	P=1. -
a	R f f34 eat liv MXB 24m25		no dre	P=1.
221	R f f34 eat pit mix 24m30	. + .	33.9mg	P<.0005
a	R f f34 eat adr phe 24m30		100.mg	P<.0005

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
a	1828o	51.4mg	n.s.s.	0/48	20.8mg	0/48						
b	1828o	51.4mg	n.s.s.	0/46	20.8mg	0/48						
204	1828r	53.5mg	n.s.s.	7/95	20.8mg	16/95						
a	1828r	62.5mg	n.s.s.	6/95	20.8mg	13/94						
b	1828r	71.0mg	n.s.s.	5/95	20.8mg	11/95						
c	1828r	113.mg	n.s.s.	2/95	20.8mg	5/95						
205	1828m	13.8mg	n.s.s.	0/48	10.4mg	1/48						
a	1828m	25.7mg	n.s.s.	0/48	10.4mg	0/48						
b	1828m	25.7mg	n.s.s.	2/48	10.4mg	0/48						
206	1828n	18.4mg	n.s.s.	4/95	5.20mg	10/95						
a	1828n	17.4mg	n.s.s.	8/93	5.20mg	13/95						
b	1828n	21.5mg	n.s.s.	12/93	5.20mg	13/95						
207	1828o	19.7mg	n.s.s.	2/48	20.8mg	3/48						
a	1828o	27.6mg	n.s.s.	0/48	20.8mg	1/48						
b	1828o	51.4mg	n.s.s.	0/48	20.8mg	0/48						
208	1828r	17.1mg	71.0mg	20/93	20.8mg	49/94						
a	1828r	24.6mg	97.7mg	8/93	20.8mg	33/94						
b	1828r	43.3mg	383.mg	4/95	20.8mg	18/95						
c	1828r	65.1mg	n.s.s.	12/93	20.8mg	16/94						
HEXACHLOROETHANE*** 67-72-1												
209	c04605	89.8mg	n.s.s.	50/50	56.1mg	44/50	111.mg	43/50				
a	c04605	384.mg	n.s.s.	1/50	56.1mg	3/50	111.mg	1/50			liv:hpa,hpc,nnd.	
210	c04605	3.35mg	n.s.s.	15/50	7.01mg	28/50	(14.0mg	21/50)			adr:pob; amd:pbb,phc,phm,pob.	
a	c04605	3.70mg	n.s.s.	14/50	7.01mg	26/50	(14.0mg	19/50)			adr:pob; amd:pbb,pob.	S
b	c04605	23.3mg	n.s.s.	1/50	7.01mg	2/50	14.0mg	7/50			kid:ade,rua,ruc.	
c	c04605	47.3mg	n.s.s.	0/50	7.01mg	0/50	14.0mg	3/50				S
d	c04605	6.04mg	n.s.s.	45/50	7.01mg	48/50	14.0mg	45/50				
e	c04605	53.9mg	n.s.s.	2/50	7.01mg	1/50	14.0mg	2/50			liv:hpa,hpc,nnd.	
4-HEXYLRESORCINOL 136-77-6												
211	c55787	124.mg	n.s.s.	39/50	43.8mg	22/50	87.6mg	31/50				
a	c55787	699.mg	n.s.s.	3/50	43.8mg	0/50	87.6mg	1/50			liv:hpa,hpc,nnd.	
b	c55787	585.mg	n.s.s.	5/50	43.8mg	0/50	87.6mg	2/50			lun:a/a,a/c.	
212	c55787	158.mg	n.s.s.	0/50	43.8mg	4/50	87.6mg	3/50			hag:adn,can.	
a	c55787	187.mg	n.s.s.	1/50	43.8mg	2/50	87.6mg	5/50				
b	c55787	72.4mg	n.s.s.	36/50	43.8mg	34/50	87.6mg	30/50				
c	c55787	115.mg	n.s.s.	21/50	43.8mg	9/50	(87.6mg	9/50)			liv:hpa,hpc,nnd.	
d	c55787	225.mg	n.s.s.	10/50	43.8mg	9/50	87.6mg	5/50			lun:a/a,a/c.	
213	c55787	76.1mg	n.s.s.	44/50	44.2mg	39/50	88.4mg	35/50				
a	c55787	548.mg	n.s.s.	1/50	44.2mg	0/50	88.4mg	1/50			liv:hpa,hpc,nnd.	
214	c55787	22.8mg	n.s.s.	44/50	44.2mg	44/50	(88.4mg	36/50)				
a	c55787	376.mg	n.s.s.	0/50	44.2mg	1/50	88.4mg	1/50			liv:hpa,hpc,nnd.	
HYDRAZINE SULFATE*** 10034-93-2												
215	1821	95.1mg	431.mg	0/31	20.4mg	0/31	40.8mg	4/31	61.2mg	9/31	Bosan;carc,8,439-444;1987	
a	1821	420.mg	n.s.s.	0/31	20.4mg	0/31	40.8mg	0/31	61.2mg	1/31		
b	1821	421.mg	n.s.s.	0/31	20.4mg	0/31	40.8mg	1/31	61.2mg	0/31		
c	1821	421.mg	n.s.s.	0/31	20.4mg	0/31	40.8mg	1/31	61.2mg	0/31		
p-HYDRAZINOBENZOIC ACID.HCl 24589-77-3												
216	1741	462.mg	3.77gm	0/45	250.mg	7/36					McManus;livt,57,78-85;1987	
a	1741	680.mg	212.gm	0/45	250.mg	4/36						
b	1741	469.mg	n.s.s.	5/48	250.mg	13/49						
c	1741	806.mg	n.s.s.	0/45	250.mg	3/36						
d	1741	385.mg	n.s.s.	12/48	250.mg	19/49						
e	1741	865.mg	n.s.s.	7/48	250.mg	8/49						
217	1741	216.mg	862.mg	2/46	208.mg	21/50						
a	1741	309.mg	2.24gm	2/46	208.mg	15/50						
b	1741	606.mg	11.3gm	0/46	208.mg	6/50						
c	1741	219.mg	n.s.s.	10/40	208.mg	15/33						
d	1741	191.mg	n.s.s.	15/39	208.mg	15/28						
e	1741	652.mg	n.s.s.	9/40	208.mg	6/33						
HYDROCHLOROTHIAZIDE 58-93-5												
218	c55925	846.mg	n.s.s.	36/50	320.mg	35/50	638.mg	27/50				
a	c55925	2.74gm	n.s.s.	3/50	320.mg	5/50	638.mg	1/50			liv:hpa,hpc,nnd.	
b	c55925	3.18gm	n.s.s.	4/50	320.mg	3/50	638.mg	2/50			lun:a/a,a/c.	
219	c55925	612.mg	24.4gm	7/50	296.mg	10/50	589.mg	21/50			liv:hpa,hpc.	
a	c55925	747.mg	20.3gm	3/50	296.mg	8/50	589.mg	14/50				S
b	c55925	610.mg	n.s.s.	30/50	296.mg	20/50	589.mg	34/50				
c	c55925	612.mg	24.4gm	7/50	296.mg	10/50	589.mg	21/50			liv:hpa,hpc,nnd.	
d	c55925	1.59gm	n.s.s.	8/50	296.mg	4/50	589.mg	9/50			lun:a/a,a/c.	
220	c55925	88.0mg	n.s.s.	49/50	12.4mg	39/50	24.6mg	39/50	99.1mg	37/50		
a	c55925	n.s.s.	n.s.s.	0/50	12.4mg	0/50	24.6mg	0/50	99.1mg	0/50	liv:hpa,hpc,nnd.	
221	1854	18.4mg	69.4mg	0/24	44.0mg	18/24					Lijinsky;txih,3,413-422;1987/pers.comm.	
a	1854	46.7mg	285.mg	0/24	44.0mg	9/24						

```
     Spe Strain  Site    Xpo+Xpt                                                                                   TD50     2Tailpvl
        Sex  Route   Hist      Notes                                                                                     DR      AuOp

 b   R f f34 eat liv hpc 24m30                                                                                     1.11gm   P<.3
 c   R f f34 eat liv nnd 24m30                                                                                     no dre   P=1.
 d   R f f34 eat liv mix 24m30                                                                                     no dre   P=1.
222  R m f34 eat TBA MXB 24m25                                                           :>                        214.mg * P<.7   -
 a   R m f34 eat liv MXB 24m25                                                                                     771.mg * P<.3
223  R m f34 eat tes car 24m30                                                         .  +  .                     35.6mg   P<.0005
 a   R m f34 eat pit mix 24m30                                                                                     71.3mg   P<.0005
 b   R m f34 eat adr phe 24m30                                                                                     271.mg   P<.4
 c   R m f34 eat liv mix 24m30                                                                                     no dre   P=1.
 d   R m f34 eat liv hpc 24m30                                                                                     no dre   P=1.
 e   R m f34 eat liv nnd 24m30                                                                                     no dre   P=1.

HYDROQUINONE                      100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
224  M f b6c gav liv hpa 24m24                                                            :  +     :               65.0mg   P<.002
 a   M f b6c gav liv MXA 24m24                                                                                     122.mg * P<.009 p
 b   M f b6c gav TBA MXB 24m24                                                                                     no dre   P=1.
 c   M f b6c gav liv MXB 24m24                                                                                     122.mg * P<.009
 d   M f b6c gav lun MXB 24m24                                                                                     19.2gm * P<1.
225  M m b6c gav TBA MXB 24m24                                                             :>                      497.mg * P<.8   -
 a   M m b6c gav liv MXB 24m24                                                                                     383.mg * P<.7
 b   M m b6c gav lun MXB 24m24                                                                                     no dre   P=1.
226  R f f34 gav --- mnl 24m24                                                           :  +          :           55.8mg * P<.006 p
 a   R f f34 gav TBA MXB 24m24                                                                                     51.6mg * P<.3
 b   R f f34 gav liv MXB 24m24                                                                                     no dre   P=1.
227  R m f34 gav kid rua 24m24                                                            :  +   :                 64.7mg * P<.0005p
 a   R m f34 gav amd MXA 24m24                                                                                     40.4mg * P<.03
 b   R m f34 gav amd MXA 24m24                                                                                     48.2mg * P<.05
 c   R m f34 gav TBA MXB 24m24                                                                                     41.8mg * P<.3
 d   R m f34 gav liv MXB 24m24                                                                                     5.71gm * P<1.

3-HYDROXY-p-BUTYROPHENETIDIDE     100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
228  M f b6c eat liv hpa 72w84 ae                                                                         .    ±   4.00gm   P<.02
 a   M f b6c eat lun act 72w84 ae                                                                                  11.3gm * P<.4
 b   M f b6c eat liv hpc 72w84 ae                                                                                  no dre   P=1.
229  M m b6c eat kid rcc 70w84 ae                                                                           .   +  5.53gm * P<.004 +
 a   M m b6c eat --- lkm 70w84 ae                                                                                  2.74gm   P<.04
 b   M m b6c eat kid rca 70w84 ae                                                                                  5.58gm * P<.02  +
 c   M m b6c eat lun act 70w84 ae                                                                                  5.28gm * P<.3
 d   M m b6c eat liv hpa 70w84 ae                                                                                  17.5gm   P<.9
 e   M m b6c eat ubl pam 70w84 ae                                                                                  46.4gm * P<.3
 f   M m b6c eat liv hem 70w84 ae                                                                                  406.gm * P<1.
 g   M m b6c eat liv hpc 70w84 ae                                                                                  no dre   P=1.

1-(2-HYDROXYETHYL)-1-NITROSOUREA***    ..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
230  R f f34 gav mgl adc 37w60 j                                   .   +      .                                    .452mg   P<.003 +
 a   R f f34 gav col ade 37w60 j                                                                                   1.53mg   P<.1
 b   R f f34 gav for sqc 37w60 j                                                                                   3.15mg   P<.3
 c   R f f34 gav zym car 37w60 j                                                                                   3.15mg   P<.3
 d   R f f34 gav for mix 37w60 j                                                                                   no dre   P=1.
 e   R f f34 gav lun a/a 37w60 j                                                                                   no dre   P=1.
231  R m f34 gav lun mix 37w55 j                            .  +   .                                               77.6ug   P<.0005+
 a   R m f34 gav for mix 37w55 j                                                                                   .203mg   P<.0005+
 b   R m f34 gav col mix 37w55 j                                                                                   .240mg   P<.002 +
 c   R m f34 gav for sqc 37w55 j                                                                                   .637mg   P<.04
 d   R m f34 gav col adc 37w55 j                                                                                   .983mg   P<.1
 e   R m f34 gav zym mix 37w55 j                                                                                   .568mg   P<.3
 f   R m f34 gav lun mal 37w55 j                                                                                   .602mg   P<.2
 g   R m f34 gav zym car 37w55 j                                                                                   .879mg   P<.4

ISOFLURANE                        100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
232  M f sww inh lun ala 78w81                                                                                    .30.0gm * P<.3   -
 a   M f sww inh liv bsa 78w81                                                                                     no dre   P=1.   -
233  M m sww inh lun ala 78w81                                                                                     no dre   P=1.   -
 a   M m sww inh liv bsa 78w81                                                                                     no dre   P=1.   -

LASIOCARPINE***                   100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
234  R f f34 eat liv hpc 21m24 er                                           . +  .                                 .938mg Z P<.0005+
235  R m f34 eat liv hpc 23m24 er                                           . + .                                  .800mg * P<.0005+

MALONALDEHYDE, SODIUM SALT***     100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
236  M f b6c gav TBA MXB 24m24                                                                :>                   274.mg * P<.5   -
 a   M f b6c gav liv MXB 24m24                                                                                     568.mg * P<.2
 b   M f b6c gav lun MXB 24m24                                                                                     4.41gm * P<.9
237  M m b6c gav TBA MXB 24m24                                                             :>                      217.mg * P<.6   -
 a   M m b6c gav liv MXB 24m24                                                                                     230.mg * P<.4
 b   M m b6c gav lun MXB 24m24                                                                                     1.13gm * P<.8
238  R f f34 gav thy MXA 24m24                                                                :    ±               252.mg / P<.02  c
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc		Citation or Pathology	Brkly Code
b	1854	180.mg	n.s.s.	0/24	44.0mg	1/24					
c	1854	194.mg	n.s.s.	4/24	44.0mg	2/24					
d	1854	152.mg	n.s.s.	4/24	44.0mg	3/24					
222	c55925	29.2mg	n.s.s.	50/50	9.91mg	43/50	19.8mg	44/50	79.2mg 45/50		
a	c55925	143.mg	n.s.s.	1/50	9.91mg	0/50	19.8mg	1/50	79.2mg 2/50	liv:hpa,hpc,nnd.	
223	1854	19.3mg	72.9mg	0/24	46.2mg	18/24				Lijinsky;txih,3,413-422;1987/pers.comm.	
a	1854	36.1mg	169.mg	0/24	46.2mg	12/24					
b	1854	64.1mg	n.s.s.	6/24	46.2mg	9/24					
c	1854	357.mg	n.s.s.	3/24	46.2mg	0/24					
d	1854	357.mg	n.s.s.	1/24	46.2mg	0/24					
e	1854	357.mg	n.s.s.	2/24	46.2mg	0/24					
HYDROQUINONE 123-31-9											
224	c55834	32.3mg	305.mg	2/55	35.0mg	15/55	(70.0mg	12/55)			S
a	c55834	62.8mg	4.53gm	3/55	35.0mg	16/55	70.0mg	13/55		liv:hpa,hpc.	
b	c55834	63.5mg	n.s.s.	43/55	35.0mg	42/55	70.0mg	39/55			
c	c55834	62.8mg	4.53gm	3/55	35.0mg	16/55	70.0mg	13/55		liv:hpa,hpc,nnd.	
d	c55834	203.mg	n.s.s.	4/55	35.0mg	6/55	70.0mg	4/55		lun:a/a,a/c.	
225	c55834	45.4mg	n.s.s.	39/55	35.3mg	46/55	70.5mg	44/55			
a	c55834	63.4mg	n.s.s.	20/55	35.3mg	29/55	70.5mg	25/55		liv:hpa,hpc,nnd.	
b	c55834	183.mg	n.s.s.	14/55	35.3mg	11/55	70.5mg	10/55		lun:a/a,a/c.	
226	c55834	27.9mg	747.mg	9/55	17.6mg	15/55	35.3mg	22/55			
a	c55834	15.6mg	n.s.s.	47/55	17.6mg	49/55	35.3mg	50/55			
b	c55834	n.s.s.	n.s.s.	0/55	17.6mg	0/55	35.3mg	0/55		liv:hpa,hpc,nnd.	
227	c55834	32.1mg	181.mg	0/55	17.6mg	4/55	35.2mg	8/55			
a	c55834	17.7mg	n.s.s.	14/55	17.6mg	19/55	35.2mg	21/55		amd:pbb,phm,pob.	S
b	c55834	19.9mg	n.s.s.	13/55	17.6mg	17/55	35.2mg	19/55		amd:pbb,pob.	S
c	c55834	12.7mg	n.s.s.	49/55	17.6mg	46/55	35.2mg	48/55			
d	c55834	82.6mg	n.s.s.	3/55	17.6mg	2/55	35.2mg	2/55		liv:hpa,hpc,nnd.	
3-HYDROXY-p-BUTYROPHENETIDIDE (betadid, bucetin) 1083-57-4											
228	1835	1.38gm	n.s.s.	0/46	795.mg	4/47	(1.76gm	0/46)		Togei;jnci,79,1151-1158;1987	
a	1835	3.06gm	n.s.s.	1/46	795.mg	6/47	1.76gm	3/46			
b	1835	8.72gm	n.s.s.	0/46	795.mg	1/47	1.76gm	0/46			
229	1835	2.50gm	32.0gm	0/47	745.mg	2/45	1.54gm	6/46			
a	1835	997.mg	n.s.s.	1/47	745.mg	6/45	(1.54gm	1/46)			
b	1835	2.53gm	n.s.s.	0/47	745.mg	4/45	1.54gm	4/46			
c	1835	1.60gm	n.s.s.	6/47	745.mg	12/45	1.54gm	10/46			
d	1835	833.mg	n.s.s.	14/47	745.mg	14/45	(1.54gm	0/46)			
e	1835	7.55gm	n.s.s.	0/47	745.mg	0/45	1.54gm	1/46			
f	1835	5.29gm	n.s.s.	3/47	745.mg	1/45	1.54gm	3/46			
g	1835	6.91gm	n.s.s.	7/47	745.mg	4/45	1.54gm	2/46			
1-(2-HYDROXYETHYL)-1-NITROSOUREA*** (N-nitroso-2-hydroxethylurea, NHEU) 13743-07-2											
230	1792m	.183mg	2.36mg	0/20	.707mg	6/20				Lijinsky;gann,79,181-186;1988/1986	
a	1792m	.376mg	n.s.s.	0/20	.707mg	2/20					
b	1792m	.512mg	n.s.s.	0/20	.707mg	1/20					
c	1792m	.512mg	n.s.s.	0/20	.707mg	1/20					
d	1792m	.461mg	n.s.s.	2/20	.707mg	2/20					
e	1792m	.581mg	n.s.s.	1/20	.707mg	1/20					
231	1792m	38.9ug	.188mg	1/20	.540mg	15/20					
a	1792m	90.6ug	.641mg	0/20	.540mg	8/20					
b	1792m	.103mg	.910mg	0/20	.540mg	7/20					
c	1792m	.192mg	n.s.s.	0/20	.540mg	3/20					
d	1792m	.241mg	n.s.s.	0/20	.540mg	2/20					
e	1792m	.153mg	n.s.s.	2/20	.540mg	5/20					
f	1792m	.170mg	n.s.s.	1/20	.540mg	4/20					
g	1792m	.183mg	n.s.s.	2/20	.540mg	4/20					
ISOFLURANE 26675-46-7											
232	1879	8.67gm	n.s.s.	15/92	1.52gm	14/83	6.09gm	19/83		Baden;anes,69,750-753;1988	
a	1879	36.0gm	n.s.s.	1/92	1.52gm	2/83	6.09gm	1/83			
233	1879	16.1gm	n.s.s.	18/89	1.27gm	23/84	5.08gm	12/82			
a	1879	27.2gm	n.s.s.	4/89	1.27gm	7/84	5.08gm	2/82			
LASIOCARPINE*** 303-34-4											
234	1824	.521mg	1.94mg	0/144	.350mg	9/24	.750mg	7/24	(1.50mg 3/23)	Elashoff;jnci,79,509-526;1987	
235	1824	.507mg	1.36mg	1/144	.280mg	5/24	.600mg	11/24	1.20mg 14/23		
MALONALDEHYDE, SODIUM SALT*** (3-hydroxy-2-propenal, sodium salt) 24382-04-5											
236	c54842	64.5mg	n.s.s.	27/50	42.0mg	31/50	84.9mg	26/50			
a	c54842	184.mg	n.s.s.	2/50	42.0mg	3/50	84.9mg	5/50		liv:hpa,hpc,nnd.	
b	c54842	200.mg	n.s.s.	5/50	42.0mg	7/50	84.9mg	4/50		lun:a/a,a/c.	
237	c54842	36.0mg	n.s.s.	39/50	42.4mg	37/50	84.9mg	31/50			
a	c54842	55.8mg	n.s.s.	17/50	42.4mg	21/50	84.9mg	17/50		liv:hpa,hpc,nnd.	
b	c54842	102.mg	n.s.s.	10/50	42.4mg	5/50	84.9mg	8/50		lun:a/a,a/c.	
238	c54842	98.7mg	n.s.s.	2/50	35.0mg	1/50	70.7mg	7/50		thy:fca,fcc.	

	Spe	Sex	Strain	Route	Site	Hist	Xpo+Xpt	Notes		TD50	DR	2Tailpvl	AuOp
a	R	f	f34	gav	TBA	MXB	24m24			164.mg	*	P<.5	
b	R	f	f34	gav	liv	MXB	24m24			1.95gm	*	P<.2	
239	R	m	f34	gav	MXB	MXB	24m24		: + :	67.7mg	*	P<.0005	
a	R	m	f34	gav	pni	isa	24m24			80.5mg		P<.0005	c
b	R	m	f34	gav	pni	MXA	24m24			90.3mg		P<.005	
c	R	m	f34	gav	thy	MXA	24m24			113.mg	*	P<.002	c
d	R	m	f34	gav	tes	ict	24m24			39.8mg	*	P<.02	
e	R	m	f34	gav	amd	phe	24m24			184.mg	*	P<.05	
f	R	m	f34	gav	sub	MXA	24m24			195.mg	*	P<.04	
g	R	m	f34	gav	thy	fca	24m24			206.mg	*	P<.02	
h	R	m	f34	gav	thy	fcc	24m24			236.mg	*	P<.02	
i	R	m	f34	gav	adr	coa	24m24			566.mg	*	P<.03	
j	R	m	f34	gav	TBA	MXB	24m24			41.8mg	/	P<.008	
k	R	m	f34	gav	liv	MXB	24m24			665.mg	*	P<.4	
2-MERCAPTOBENZOTHIAZOLE***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
240	M	f	b6c	gav	liv	MXA	24m24		:>	2.16gm	*	P<.3	e
a	M	f	b6c	gav	TBA	MXB	24m24			no dre		P=1.	
b	M	f	b6c	gav	liv	MXB	24m24			2.16gm	*	P<.3	
c	M	f	b6c	gav	lun	MXB	24m24			no dre		P=1.	
241	M	m	b6c	gav	TBA	MXB	24m24		:>	3.33gm	*	P<.8	-
a	M	m	b6c	gav	liv	MXB	24m24			3.70gm	*	P<.7	
b	M	m	b6c	gav	lun	MXB	24m24			no dre		P=1.	
242	R	f	f34	gav	MXB	MXB	24m24		: ±	247.mg	*	P<.03	
a	R	f	f34	gav	pta	adn	24m24			343.mg	*	P<.07	p
b	R	f	f34	gav	amd	phe	24m24			805.mg	*	P<.04	p
c	R	f	f34	gav	TBA	MXB	24m24			576.mg	*	P<.6	
d	R	f	f34	gav	liv	MXB	24m24			no dre		P=1.	
243	R	m	f34	gav	MXB	MXB	24m24		: + :	157.mg		P<.0005	
a	R	m	f34	gav	tes	ict	24m24			240.mg	*	P<.005	
b	R	m	f34	gav	pta	adn	24m24			333.mg		P<.009	
c	R	m	f34	gav	pan	ana	24m24			345.mg		P<.0005	p
d	R	m	f34	gav	amd	MXA	24m24			394.mg	*	P<.003	p
e	R	m	f34	gav	mul	mnl	24m24			401.mg		P<.004	p
f	R	m	f34	gav	pre	adn	24m24			1.71gm	*	P<.004	
g	R	m	f34	gav	pre	MXA	24m24			1.58gm	*	P<.02	p
h	R	m	f34	gav	sub	MXA	24m24			1.73gm	*	P<.04	
i	R	m	f34	gav	sub	MXA	24m24			1.90gm	*	P<.03	
j	R	m	f34	gav	sub	fib	24m24			2.20gm	*	P<.04	
k	R	m	f34	gav	MXA	MXA	24m24			3.20gm	*	P<.02	
l	R	m	f34	gav	TBA	MXB	24m24			136.mg		P<.002	
m	R	m	f34	gav	liv	MXB	24m24			no dre		P=1.	
8-METHOXYPSORALEN									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
244	R	f	f34	gav	MXA	MXA	24m24		: ±	#333.mg	*	P<.02	-
a	R	f	f34	gav	TBA	MXB	24m24			45.6mg	*	P<.09	
b	R	f	f34	gav	liv	MXB	24m24			5.14gm	*	P<.9	
245	R	m	f34	gav	tes	ict	24m24		: + :	14.6mg	*	P<.0005	
a	R	m	f34	gav	MXB	MXB	24m24			27.3mg	*	P<.0005	
b	R	m	f34	gav	kid	MXA	24m24			32.4mg	*	P<.0005	c
c	R	m	f34	gav	kid	tla	24m24			43.2mg	*	P<.0005	c
d	R	m	f34	gav	lun	a/a	24m24			57.1mg	*	P<.003	e
e	R	m	f34	gav	sub	MXA	24m24			70.2mg	*	P<.0005	
f	R	m	f34	gav	sub	fib	24m24			72.6mg	*	P<.002	e
g	R	m	f34	gav	kid	uac	24m24			167.mg	*	P<.008	c
h	R	m	f34	gav	zym	MXA	24m24			101.mg	*	P<.02	c
i	R	m	f34	gav	pan	ana	24m24			113.mg	*	P<.04	
j	R	m	f34	gav	TBA	MXB	24m24			16.1mg	*	P<.002	
k	R	m	f34	gav	liv	MXB	24m24			no dre		P=1.	
METHYL CARBAMATE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
246	M	f	b6c	gav	TBA	MXB	24m24		:>	no dre		P=1.	-
a	M	f	b6c	gav	liv	MXB	24m24			4.70gm	*	P<.4	
b	M	f	b6c	gav	lun	MXB	24m24			no dre		P=1.	
247	M	m	b6c	gav	TBA	MXB	24m24		:>	5.22gm	*	P<.8	-
a	M	m	b6c	gav	liv	MXB	24m24			5.08gm	*	P<.7	
b	M	m	b6c	gav	lun	MXB	24m24			no dre		P=1.	
248	R	f	f34	gav	liv	MXA	24m24		: +	:839.mg	*	P<.006	c
a	R	f	f34	gav	liv	nnd	24m24			979.mg	*	P<.02	
b	R	f	f34	gav	TBA	MXB	24m24			no dre		P=1.	
c	R	f	f34	gav	liv	MXB	24m24			839.mg	*	P<.006	
249	R	m	f34	gav	liv	MXA	24m24		:>	2.03gm	/	P<.6	c
a	R	m	f34	gav	TBA	MXB	24m24			no dre		P=1.	
b	R	m	f34	gav	liv	MXB	24m24			2.03gm	/	P<.6	
N-METHYL-N'-NITRO-N-NITROSOGUANIDINE***									..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
250	R	m	wis	wat	duo	adc	75w75	e	. + .	.910mg		P<.0005	+

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	c54842	34.5mg	n.s.s.	37/50	35.0mg	37/50	70.7mg	21/50		
b	c54842	318.mg	n.s.s.	0/50	35.0mg	0/50	70.7mg	1/50	liv:hpa,hpc,nnd.	
239	c54842	37.4mg	216.mg	4/50	35.4mg	17/50	70.7mg	13/50	pni:isa; thy:fca,fcc.	C
a	c54842	37.9mg	219.mg	0/50	35.4mg	9/50	(70.7mg	1/50)		
b	c54842	39.6mg	876.mg	1/50	35.4mg	9/50	(70.7mg	1/50)	pni:isa,isc.	S
c	c54842	56.2mg	545.mg	4/50	35.4mg	8/50	70.7mg	13/50	thy:fca,fcc.	
d	c54842	18.5mg	n.s.s.	40/50	35.4mg	45/50	70.7mg	36/50		S
e	c54842	70.8mg	n.s.s.	5/50	35.4mg	6/50	70.7mg	8/50		S
f	c54842	81.3mg	n.s.s.	1/50	35.4mg	7/50	70.7mg	3/50	sub:fbs,fib.	S
g	c54842	86.5mg	n.s.s.	3/50	35.4mg	3/50	70.7mg	9/50		S
h	c54842	98.2mg	n.s.s.	1/50	35.4mg	5/50	70.7mg	5/50		S
i	c54842	186.mg	n.s.s.	0/50	35.4mg	1/50	70.7mg	3/50		S
j	c54842	20.2mg	889.mg	40/50	35.4mg	40/50	70.7mg	41/50		
k	c54842	133.mg	n.s.s.	3/50	35.4mg	2/50	70.7mg	3/50	liv:hpa,hpc,nnd.	
2-MERCAPTOBENZOTHIAZOLE*** (Captax, rotax) 149-30-4										
240	c56519	629.mg	n.s.s.	4/50	265.mg	12/50	531.mg	4/50	liv:hpa,hpc.	
a	c56519	697.mg	n.s.s.	38/50	265.mg	33/50	531.mg	15/50		
b	c56519	629.mg	n.s.s.	4/50	265.mg	12/50	531.mg	4/50	liv:hpa,hpc,nnd.	
c	c56519	2.14gm	n.s.s.	3/50	265.mg	1/50	531.mg	2/50	lun:a/a,a/c.	
241	c56519	359.mg	n.s.s.	31/50	265.mg	39/50	531.mg	25/50		
a	c56519	557.mg	n.s.s.	16/50	265.mg	21/50	531.mg	14/50	liv:hpa,hpc,nnd.	
b	c56519	1.06gm	n.s.s.	7/50	265.mg	9/50	531.mg	5/50	lun:a/a,a/c.	
242	c56519	112.mg	n.s.s.	16/50	133.mg	28/50	265.mg	29/50	amd:phe; pta:adn.	P
a	c56519	140.mg	n.s.s.	15/50	133.mg	24/50	265.mg	25/50		
b	c56519	347.mg	n.s.s.	1/50	133.mg	5/50	265.mg	6/50		
c	c56519	116.mg	n.s.s.	37/50	133.mg	46/50	265.mg	40/50		
d	c56519	3.30gm	n.s.s.	1/50	133.mg	0/50	265.mg	0/50	liv:hpa,hpc,nnd.	
243	c56519	82.2mg	543.mg	24/50	265.mg	38/50	(531.mg	31/50)	amd:phe,phm; mul:mnl; pan:ana; pre:adn,can.	P
a	c56519	121.mg	2.27gm	48/50	265.mg	48/50	531.mg	48/50		S
b	c56519	146.mg	13.6gm	14/50	265.mg	21/50	(531.mg	12/50)		S
c	c56519	167.mg	1.10gm	2/50	265.mg	13/50	(531.mg	6/50)		
d	c56519	203.mg	2.31gm	18/50	265.mg	27/50	531.mg	24/50	amd:phe,phm.	
e	c56519	183.mg	2.99gm	7/50	265.mg	16/50	(531.mg	3/50)		
f	c56519	749.mg	10.5gm	0/50	265.mg	4/50	531.mg	4/50		S
g	c56519	684.mg	n.s.s.	1/50	265.mg	6/50	531.mg	5/50	pre:adn,can.	
h	c56519	686.mg	n.s.s.	3/50	265.mg	6/50	531.mg	7/50	sub:fbs,fib,nfm,srn.	S
i	c56519	744.mg	n.s.s.	2/50	265.mg	4/50	531.mg	6/50	sub:fib,nfm.	S
j	c56519	822.mg	n.s.s.	2/50	265.mg	3/50	531.mg	6/50		S
k	c56519	1.14gm	n.s.s.	0/50	265.mg	2/50	531.mg	3/50	mul:msm; tna:men.	S
l	c56519	69.9mg	617.mg	37/50	265.mg	47/50	(531.mg	41/50)		
m	c56519	1.94gm	n.s.s.	3/50	265.mg	2/50	531.mg	1/50	liv:hpa,hpc,nnd.	
8-METHOXYPSORALEN (8-MOP) 298-81-7										
244	c55903	108.mg	n.s.s.	0/50	26.3mg	1/50	52.8mg	3/50	pal:sqp; ton:sqp.	S
a	c55903	17.5mg	n.s.s.	46/50	26.3mg	43/50	52.8mg	37/50		
b	c55903	240.mg	n.s.s.	1/50	26.3mg	0/50	52.8mg	1/50	liv:hpa,hpc,nnd.	
245	c55903	8.08mg	43.1mg	38/50	26.3mg	44/50	52.8mg	43/50		S
a	c55903	15.5mg	59.4mg	2/50	26.3mg	16/50	52.8mg	14/50	kid:tla,uac; zym:can,sqc.	C
b	c55903	17.6mg	73.7mg	1/50	26.3mg	12/50	52.8mg	11/50	kid:tla,uac.	
c	c55903	22.2mg	120.mg	1/50	26.3mg	11/50	52.8mg	8/50		
d	c55903	25.5mg	397.mg	4/50	26.3mg	9/50	52.8mg	9/50		
e	c55903	32.1mg	265.mg	1/50	26.3mg	5/50	52.8mg	8/50	sub:fib,srn.	S
f	c55903	32.6mg	316.mg	1/50	26.3mg	5/50	52.8mg	7/50		
g	c55903	52.4mg	3.38gm	0/50	26.3mg	1/50	52.8mg	3/50		
h	c55903	41.2mg	n.s.s.	1/50	26.3mg	7/50	52.8mg	4/50	zym:can,sqc.	
i	c55903	39.2mg	n.s.s.	2/50	26.3mg	3/50	52.8mg	4/50		S
j	c55903	8.23mg	76.0mg	44/50	26.3mg	41/50	52.8mg	41/50		
k	c55903	n.s.s.	n.s.s.	0/50	26.3mg	0/50	52.8mg	0/50	liv:hpa,hpc,nnd.	
METHYL CARBAMATE 598-55-0										
246	c55594	700.mg	n.s.s.	32/50	354.mg	28/50	707.mg	27/50		
a	c55594	1.20gm	n.s.s.	4/50	354.mg	7/50	707.mg	6/50	liv:hpa,hpc,nnd.	
b	c55594	2.30gm	n.s.s.	7/50	354.mg	5/50	707.mg	4/50	lun:a/a,a/c.	
247	c55594	495.mg	n.s.s.	27/50	354.mg	35/50	707.mg	28/50		
a	c55594	780.mg	n.s.s.	14/50	354.mg	17/50	707.mg	16/50	liv:hpa,hpc,nnd.	
b	c55594	1.61gm	n.s.s.	11/50	354.mg	8/50	707.mg	8/50	lun:a/a,a/c.	
248	c55594	342.mg	8.57gm	0/50	70.7mg	0/50	142.mg	6/50	liv:hpc,nnd.	
a	c55594	372.mg	n.s.s.	0/50	70.7mg	0/50	142.mg	5/50		S
b	c55594	146.mg	n.s.s.	47/50	70.7mg	43/50	142.mg	42/50		
c	c55594	342.mg	8.57gm	0/50	70.7mg	0/50	142.mg	6/50	liv:hpa,hpc,nnd.	
249	c55594	357.mg	n.s.s.	4/50	70.7mg	0/50	142.mg	7/50	liv:hpc,nnd.	
a	c55594	56.6mg	n.s.s.	47/50	70.7mg	45/50	(142.mg	40/50)		
b	c55594	357.mg	n.s.s.	4/50	70.7mg	0/50	142.mg	7/50	liv:hpa,hpc,nnd.	
N-METHYL-N'-NITRO-N-NITROSOGUANIDINE*** (MNNG) 70-25-7										
250	1822	.505mg	1.85mg	0/30	2.13mg	17/30			Fujii;nutc,9,185-193;1987	

	Spe	Sex	Strain	Route	Site	Hist	Xpo+Xpt	Notes		TD50	DR	2Tailpvl	AuOp
a	R	m	wis	wat	gam	adc	75w75	e		5.31mg		P<.02	+
b	R	m	wis	wat	eso	sqc	75w75	e		11.0mg		P<.1	+
c	R	m	wis	wat	liv	tum	75w75	e		no dre		P=1.	
d	R	m	wis	wat	tba	mix	75w75	e		no dre		P=1.	
N-METHYL-2-PYRROLIDONE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
251	R	f	cdr	inh	liv	tum	24m24	e	.>	no dre		P=1.	-
252	R	m	cdr	inh	liv	tum	24m24	e	.>	no dre		P=1.	-
alpha-METHYLDOPA SESQUIHYDRATE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
253	M	f	b6c	eat	TBA	MXB	24m24		:>	no dre		P=1.	-
a	M	f	b6c	eat	liv	MXB	24m24			no dre		P=1.	
b	M	f	b6c	eat	lun	MXB	24m24			25.0gm	*	P<.5	
254	M	m	b6c	eat	kid	MXA	24m24		:>	20.1gm	*	P<.2	e
a	M	m	b6c	eat	TBA	MXB	24m24			no dre		P=1.	
b	M	m	b6c	eat	liv	MXB	24m24			no dre		P=1.	
c	M	m	b6c	eat	lun	MXB	24m24			no dre		P=1.	
255	R	f	f34	eat	TBA	MXB	24m24		:>	592.mg	*	P<.5	-
a	R	f	f34	eat	liv	MXB	24m24			no dre		P=1.	
256	R	m	f34	eat	TBA	MXB	24m24		:>	no dre		P=1.	-
a	R	m	f34	eat	liv	MXB	24m24			no dre		P=1.	
N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER.HCl									....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
257	R	f	cdr	gav	adr	cca	24m24		.>	no dre		P=1.	-
a	R	f	cdr	gav	pit	ade	24m24			no dre		P=1.	-
b	R	f	cdr	gav	mgl	adc	24m24			no dre		P=1.	-
c	R	f	cdr	gav	mgl	ade	24m24			no dre		P=1.	-
d	R	f	cdr	gav	adr	phm	24m24			no dre		P=1.	-
258	R	m	cdr	gav	pit	ade	24m24		. + .	30.2mg	Z	P<.002	-
a	R	m	cdr	gav	adr	phm	24m24			no dre		P=1.	-
b	R	m	cdr	gav	adr	cca	24m24			no dre		P=1.	-
METHYLENE CHLORIDE***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
259	M	f	swi	gav	lun	ade	15m24	s	.>	7.05gm	*	P<.9	
a	M	f	swi	gav	liv	hpt	15m24	s		no dre		P=1.	
b	M	f	swi	gav	tba	mal	15m24	s		no dre		P=1.	
c	M	f	swi	gav	tba	mix	15m24	s		no dre		P=1.	
260	M	m	swi	gav	lun	ade	15m24	s	. ±	916.mg	*	P<.05	
a	M	m	swi	gav	liv	hpt	15m24	s		no dre		P=1.	
b	M	m	swi	gav	tba	mal	15m24	s		no dre		P=1.	
c	M	m	swi	gav	tba	mix	15m24	s		no dre		P=1.	
261	R	f	sda	gav	mam	mal	15m24	s	. ±	1.13gm	*	P<.07	
a	R	f	sda	gav	mam	mix	15m24	s		1.03gm	*	P<.7	
b	R	f	sda	gav	tba	mal	15m24	s		1.74gm	*	P<.6	
c	R	f	sda	gav	tba	mix	15m24	s		no dre		P=1.	
262	R	f	sda	inh	mam	mix	24m24	gv	. + .	37.8mg		P<.009	
a	R	f	sda	inh	tba	mix	24m24	gv		32.1mg		P<.03	
b	R	f	sda	inh	tba	mal	24m24	gv		477.mg		P<.7	
263	R	m	sda	gav	tba	mix	15m24	s	.>	no dre		P=1.	
a	R	m	sda	gav	tba	mal	15m24	s		935.mg		P<.9	
264	R	f	sss	inh	mgl	fba	24m24	e	.>	631.mg	*	P<.7	
a	R	f	sss	inh	mgl	ben	24m24	e		1.55gm	*	P<.9	
b	R	f	sss	inh	liv	kcs	24m24	e		9.34gm	*	P<.8	-
c	R	f	sss	inh	liv	hpc	24m24	e		9.52gm	*	P<.7	-
d	R	f	sss	inh	liv	nnd	24m24	e		no dre		P=1.	-
e	R	f	sss	inh	mgl	adc	24m24	e		no dre		P=1.	-
265	R	f	sss	inh	mgl	fba	12m24	e	. ±	37.7mg		P<.05	
a	R	f	sss	inh	mgl	ben	12m24	e		38.1mg		P<.05	
b	R	f	sss	inh	mgl	adc	12m24	e		1.14gm		P<.6	-
c	R	f	sss	inh	liv	nnd	12m24	e		no dre		P=1.	-
d	R	f	sss	inh	liv	hpc	12m24	e		no dre		P=1.	-
266	R	m	sss	inh	liv	tum	86w86	e	.>	no dre		P=1.	-
4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-BUTANOL									....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
267	R	m	f34	wat	lun	mix	26m26		. + .	.103mg		P<.0005	+
a	R	m	f34	wat	lun	adc	26m26			.409mg		P<.0005	
b	R	m	f34	wat	lun	adq	26m26			.577mg		P<.0005	
c	R	m	f34	wat	pae	mix	26m26			.668mg		P<.0005	+
d	R	m	f34	wat	pae	aod	26m26			1.09mg		P<.0005	
e	R	m	f34	wat	amd	tum	26m26			1.39mg		P<.002	
f	R	m	f34	wat	lun	ade	26m26			1.38mg		P<.04	
g	R	m	f34	wat	pae	ana	26m26			2.14mg		P<.05	
h	R	m	f34	wat	liv	hpt	26m26			5.86mg		P<.2	
i	R	m	f34	wat	liv	mix	26m26			7.25mg		P<.7	
j	R	m	f34	wat	liv	ade	26m26			no dre		P=1.	

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology / Brkly Code
a	1822	1.83mg	n.s.s.	0/30	2.13mg	4/30			
b	1822	2.71mg	n.s.s.	0/30	2.13mg	2/30			
c	1822	6.86mg	n.s.s.	0/30	2.13mg	0/30			
d	1822	.764mg	n.s.s.	20/30	2.13mg	20/30			
N-METHYL-2-PYRROLIDONE 872-50-4									
251	1818	513.mg	n.s.s.	0/83	30.4mg	0/82			Lee;faat,9,222-235;1987/pers.comm.
252	1818	372.mg	n.s.s.	0/82	21.2mg	0/85			
alpha-METHYLDOPA SESQUIHYDRATE 41372-08-1									
253	c55721	3.22gm	n.s.s.	33/50	811.mg	22/50	1.61gm	21/50	
a	c55721	5.13gm	n.s.s.	4/50	811.mg	1/50	(1.61gm	0/50)	liv:hpa,hpc,nnd.
b	c55721	4.97gm	n.s.s.	4/50	811.mg	1/50	1.61gm	6/50	lun:a/a,a/c.
254	c55721	6.08gm	n.s.s.	0/50	749.mg	2/50	1.49gm	1/50	kid:tla,uac.
a	c55721	4.11gm	n.s.s.	32/50	749.mg	15/50	1.49gm	17/50	
b	c55721	7.29gm	n.s.s.	15/50	749.mg	5/50	1.49gm	6/50	liv:hpa,hpc,nnd.
c	c55721	4.94gm	n.s.s.	10/50	749.mg	5/50	1.49gm	7/50	lun:a/a,a/c.
255	c55721	140.mg	n.s.s.	45/50	154.mg	47/50	312.mg	47/50	
a	c55721	n.s.s.	n.s.s.	0/50	154.mg	1/50	312.mg	0/50	liv:hpa,hpc,nnd.
256	c55721	216.mg	n.s.s.	46/50	123.mg	31/50	250.mg	42/50	
a	c55721	351.mg	n.s.s.	6/50	123.mg	3/50	(250.mg	1/50)	liv:hpa,hpc,nnd.
N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER.HCl (ibopamine.HCl) 75011-65-3									
257	1875	164.mg	n.s.s.	71/200	30.0mg	26/100	(90.0mg	22/100	180.mg 19/100) Walker;neag,9,291-301;1988/pers.comm.
a	1875	249.mg	n.s.s.	163/200	30.0mg	83/100	90.0mg	92/100	180.mg 75/100
b	1875	626.mg	n.s.s.	31/200	30.0mg	17/100	90.0mg	11/100	(180.mg 1/100)
c	1875	1.22gm	n.s.s.	67/200	30.0mg	30/100	90.0mg	27/100	180.mg 23/100
d	1875	2.59gm	n.s.s.	11/200	30.0mg	1/100	90.0mg	3/100	180.mg 3/100
258	1875	15.5mg	142.mg	125/200	30.0mg	81/100	(90.0mg	59/100	180.mg 41/100)
a	1875	850.mg	n.s.s.	45/200	30.0mg	11/100	90.0mg	13/100	(180.mg 7/100)
b	1875	145.mg	n.s.s.	50/200	30.0mg	21/100	(90.0mg	11/100	180.mg 10/100)
METHYLENE CHLORIDE*** (dichloromethane, Freon 30) 75-09-2									
259	bt3003	502.mg	n.s.s.	10/60	39.6mg	8/50	198.mg	9/50	Maltoni;anya,534,352-366;1988
a	bt3003	340.mg	n.s.s.	0/60	39.6mg	0/50	198.mg	0/50	
b	bt3003	586.mg	n.s.s.	15/60	39.6mg	8/50	198.mg	10/50	
c	bt3003	427.mg	n.s.s.	31/60	39.6mg	17/50	198.mg	20/50	
260	bt3003	345.mg	n.s.s.	3/60	39.6mg	6/50	198.mg	9/50	
a	bt3003	1.27gm	n.s.s.	5/60	39.6mg	2/50	198.mg	2/50	
b	bt3003	1.18gm	n.s.s.	12/60	39.6mg	4/50	198.mg	4/50	
c	bt3003	477.mg	n.s.s.	18/60	39.6mg	10/50	198.mg	13/50	
261	bt3002	403.mg	n.s.s.	4/50	39.6mg	3/50	198.mg	9/50	
a	bt3002	151.mg	n.s.s.	28/50	39.6mg	37/50	198.mg	33/50	
b	bt3002	320.mg	n.s.s.	14/50	39.6mg	12/50	198.mg	16/50	
c	bt3002	141.mg	n.s.s.	39/50	39.6mg	41/50	198.mg	39/50	
262	bt4005	17.7mg	1.23gm	24/60	29.4mg	35/54			
a	bt4005	13.6mg	n.s.s.	35/60	29.4mg	42/54			
b	bt4005	70.6mg	n.s.s.	9/60	29.4mg	10/54			
263	bt3002	47.0mg	n.s.s.	37/50	39.6mg	33/50	(198.mg	22/50)	
a	bt3002	68.6mg	n.s.s.	15/50	39.6mg	16/50	(198.mg	6/50)	
264	1890m	84.1mg	n.s.s.	51/69	13.0mg	57/69	52.0mg	60/69	130.mg 55/69 Nitschke;faat,11,48-59;1988/pers.comm.
a	1890m	93.8mg	n.s.s.	52/70	13.0mg	58/70	52.0mg	61/70	130.mg 55/70
b	1890m	1.52gm	n.s.s.	0/70	13.0mg	0/70	52.0mg	1/70	130.mg 0/70
c	1890m	1.09gm	n.s.s.	1/70	13.0mg	0/70	52.0mg	2/70	130.mg 1/70
d	1890m	813.mg	n.s.s.	4/70	13.0mg	4/70	52.0mg	3/70	130.mg 4/70
e	1890m	859.mg	n.s.s.	3/69	13.0mg	5/69	52.0mg	4/69	130.mg 3/69
265	1890n	11.8mg	n.s.s.	51/69	65.0mg	23/25			
a	1890n	11.9mg	n.s.s.	52/70	65.0mg	23/25			
b	1890n	149.mg	n.s.s.	3/69	65.0mg	2/25			
c	1890n	220.mg	n.s.s.	4/70	65.0mg	1/25			
d	1890n	335.mg	n.s.s.	1/70	65.0mg	0/25			
266	1890m	66.5mg	n.s.s.	0/70	9.10mg	0/70	36.4mg	0/70	91.0mg 0/70
4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-BUTANOL ---									
267	1866	56.5ug	.199mg	6/80	.250mg	26/30			Rivenson;canr,48,6912-6917;1988/pers.comm.
a	1866	.203mg	1.07mg	2/80	.250mg	12/30			
b	1866	.265mg	1.76mg	1/80	.250mg	9/30			
c	1866	.294mg	2.29mg	1/80	.250mg	8/30			
d	1866	.413mg	4.54mg	0/80	.250mg	5/30			
e	1866	.479mg	7.65mg	0/80	.250mg	4/30			
f	1866	.445mg	n.s.s.	3/80	.250mg	5/30			
g	1866	.589mg	n.s.s.	1/80	.250mg	3/30			
h	1866	.954mg	n.s.s.	0/80	.250mg	1/30			
i	1866	.712mg	n.s.s.	6/80	.250mg	3/30			
j	1866	.935mg	n.s.s.	6/80	.250mg	2/30			

```
     Spe Strain  Site    Xpo+Xpt                                                                    TD50     2Tailpvl
       Sex   Route   Hist      Notes                                                                    DR     AuOp

4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-(BUTANONE)..:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
268  R m f34 wat lun mix 27m30                                  . + .                                    .182mg * P<.0005+
 a   R m f34 wat lun ade 27m30                                                                         .343mg Z P<.002
 b   R m f34 wat pae mix 27m30                                                                        .490mg Z P<.006 +
 c   R m f34 wat liv mix 27m30                                                                        .651mg * P<.0005+
 d   R m f34 wat lun adc 27m30                                                                        .672mg * P<.0005
 e   R m f34 wat liv ade 27m30                                                                        .871mg * P<.0005
 f   R m f34 wat lun adq 27m30                                                                        1.46mg Z P<.0005
 g   R m f34 wat nas mix 27m30                                                                       1.66mg * P<.0005
 h   R m f34 wat lun sqc 27m30                                                                       3.40mg * P<.005
 i   R m f34 wat --- mix 27m30                                                                       .140mg Z P<.02
 j   R m f34 wat liv hpt 27m30                                                                       2.74mg * P<.03
 k   R m f34 wat pae aod 27m30                                                                       6.93mg * P<.08
 l   R m f34 wat pae ana 27m30                                                                       29.2mg * P<1.

N-METHYLOLACRYLAMIDE                 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
269  M f b6c gav MXB MXB 24m24                                          :  +    :                    27.8mg * P<.0005
 a   M f b6c gav hag MXA 24m24                                                                        44.6mg * P<.0005
 b   M f b6c gav hag MXA 24m24                                                                        55.5mg * P<.002 c
 c   M f b6c gav liv hpa 24m24                                                                        66.9mg / P<.0005c
 d   M f b6c gav liv MXA 24m24                                                                       74.8mg * P<.009
 e   M f b6c gav ova gcb 24m24                                                                       119.mg * P<.006 c
 f   M f b6c gav lun MXA 24m24                                                                      111.mg * P<.06  c
 g   M f b6c gav TBA MXB 24m24                                                                      30.9mg * P<.03
 h   M f b6c gav liv MXB 24m24                                                                       74.8mg * P<.009
 i   M f b6c gav lun MXB 24m24                                                                       111.mg * P<.06
270  M m b6c gav MXB MXB 24m24                                        : +   :                      13.3mg * P<.0005
 a   M m b6c gav hag MXA 24m24                                                                       17.4mg * P<.0005
 b   M m b6c gav hag ade 24m24                                                                      17.5mg * P<.0005c
 c   M m b6c gav liv MXA 24m24                                                                      29.4mg * P<.003 c
 d   M m b6c gav lun MXA 24m24                                                                      38.5mg * P<.002 c
 e   M m b6c gav liv hpa 24m24                                                                      50.2mg / P<.008
 f   M m b6c gav lun a/a 24m24                                                                      66.0mg * P<.009
 g   M m b6c gav lun a/c 24m24                                                                      75.1mg * P<.006
 h   M m b6c gav liv hpc 24m24                                                                      63.4mg * P<.05
 i   M m b6c gav TBA MXB 24m24                                                                      22.3mg * P<.02
 j   M m b6c gav liv MXB 24m24                                                                      29.4mg * P<.003
 k   M m b6c gav lun MXB 24m24                                                                      38.5mg * P<.002
271  R f f34 gav TBA MXB 24m24                                       :>                             no dre   P=1.   -
 a   R f f34 gav liv MXB 24m24                                                                      no dre   P=1.
272  R m f34 gav ski ker 24m24                                      :   ±                          #13.0mg   P<.03  -
 a   R m f34 gav TBA MXB 24m24                                                                      3.12gm * P<1.
 b   R m f34 gav liv MXB 24m24                                                                      no dre   P=1.

p-METHYLSTYRENE                      100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
273  M f swi gav lun ade 78w83                                                          .>             616.mg * P<.2   -
 a   M f swi gav liv hpt 78w83                                                                       no dre   P=1.   -
 b   M f swi gav tba mix 78w83                                                                       343.mg * P<.2   -
 c   M f swi gav tba mal 78w83                                                                       no dre   P=1.   -
274  M m swi gav lun ade 78w83                                                           .>            962.mg * P<.3   -
 a   M m swi gav liv hpt 78w83                                                                       no dre   P=1.   -
 b   M m swi gav tba mal 78w83                                                                       no dre   P=1.   -
 c   M m swi gav tba mix 78w83                                                                       no dre   P=1.   -

MISOPROSTOL                          100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
275  M f cd1 gav lun ala 91w91 e                                                        .>             2.35gm * P<.9   -
 a   M f cd1 gav liv hpa 91w91 e                                                                     no dre   P=1.   -
 b   M f cd1 gav liv hem 91w91 e                                                                     no dre   P=1.   -
 c   M f cd1 gav lun alc 91w91 e                                                                     no dre   P=1.   -
 d   M f cd1 gav tba mix 91w91 e                                                                    .130mg Z P<.0005-
276  M m cd1 gav liv hpa 91w91 e                                    .>                              no dre   P=1.   -
 a   M m cd1 gav liv hpc 91w91 e                                                                     no dre   P=1.   -
 b   M m cd1 gav lun ala 91w91 e                                                                     no dre   P=1.   -
 c   M m cd1 gav lun alc 91w91 e                                                                     no dre   P=1.   -
 d   M m cd1 gav liv hem 91w91 e                                                                     no dre   P=1.   -
 e   M m cd1 gav tba mix 91w91 e                                                                     no dre   P=1.   -
277  R f cdr gav liv hcs 24m24 e                                      .>                            9.53gm * P<1.   -
 a   R f cdr gav liv hpc 24m24 e                                                                     no dre   P=1.   -
 b   R f cdr gav mgl fba 24m24 e                                                                     no dre   P=1.   -
 c   R f cdr gav tba mix 24m24 e                                                                     no dre   P=1.   -
278  R m cdr gav liv hcs 24m24 e                                      .>                            no dre   P=1.   -
 a   R m cdr gav tba mix 24m24 e                                                                     no dre   P=1.   -

NALIDIXIC ACID                       100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
279  M f b6c eat amd phe 24m24                                                                 :   ±   #3.63gm * P<.03  -
 a   M f b6c eat TBA MXB 24m24                                                                       1.69gm * P<.6
 b   M f b6c eat liv MXB 24m24                                                                       3.16gm * P<.3
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-(BUTANONE) 64091-91-4												
268	1866	.123mg	.297mg	6/80	25.0ug	9/80	50.0ug	20/80	.250mg	27/30	Rivenson;canr,48,6912-6917;1988/pers.comm.	
a	1866	.181mg	1.52mg	3/80	25.0ug	5/80	50.0ug	16/80	(.250mg	2/30)		
b	1866	.241mg	5.70mg	1/80	25.0ug	5/80	50.0ug	9/80	(.250mg	2/30)		
c	1866	.345mg	1.90mg	6/80	25.0ug	3/80	50.0ug	11/80	.250mg	12/30		
d	1866	.375mg	1.53mg	2/80	25.0ug	3/80	50.0ug	4/80	.250mg	13/30		
e	1866	.427mg	3.37mg	6/80	25.0ug	2/80	50.0ug	9/80	.250mg	10/30		
f	1866	.677mg	4.26mg	1/80	25.0ug	0/80	50.0ug	0/80	.250mg	9/30		
g	1866	.751mg	5.90mg	0/80	25.0ug	1/80	50.0ug	2/80	.250mg	5/30		
h	1866	1.17mg	42.2mg	0/80	25.0ug	1/80	50.0ug	0/80	.250mg	3/30		
i	1866	63.5ug	n.s.s.	9/80	25.0ug	21/80	(50.0ug	10/80	.250mg	2/30)		
j	1866	1.04mg	n.s.s.	0/80	25.0ug	1/80	50.0ug	2/80	.250mg	2/30		
k	1866	1.70mg	n.s.s.	0/80	25.0ug	0/80	50.0ug	1/80	.250mg	1/30		
l	1866	.859mg	n.s.s.	1/80	25.0ug	5/80	50.0ug	8/80	.250mg	1/30		
N-METHYLOLACRYLAMIDE (N-(hydroxymethyl)-acrylamide) 924-42-5												
269	c60333	15.8mg	89.4mg	14/50	17.5mg	20/50	35.0mg	37/50			hag:ade,anb; liv:hpa; lun:a/a,a/c; ova:gcb.	C
a	c60333	25.3mg	141.mg	5/50	17.5mg	11/50	35.0mg	22/50			hag:ade,anb,car.	S
b	c60333	29.9mg	222.mg	5/50	17.5mg	8/50	35.0mg	20/50			hag:ade,anb.	
c	c60333	35.6mg	241.mg	3/50	17.5mg	4/50	35.0mg	17/50				
d	c60333	35.7mg	2.08gm	6/50	17.5mg	7/50	35.0mg	17/50			liv:hpa,hpc.	S
e	c60333	58.1mg	996.mg	0/50	17.5mg	5/50	35.0mg	5/50				
f	c60333	45.2mg	n.s.s.	6/50	17.5mg	8/50	35.0mg	13/50			lun:a/a,a/c.	
g	c60333	13.9mg	n.s.s.	33/50	17.5mg	41/50	35.0mg	47/50				
h	c60333	35.7mg	2.08gm	6/50	17.5mg	7/50	35.0mg	17/50			liv:hpa,hpc,nnd.	
i	c60333	45.2mg	n.s.s.	6/50	17.5mg	8/50	35.0mg	13/50			lun:a/a,a/c.	
270	c60333	8.07mg	32.0mg	16/50	17.5mg	30/50	35.0mg	43/50			hag:ade; liv:hpa,hpc; lun:a/a,a/c.	C
a	c60333	11.4mg	30.6mg	2/50	17.5mg	14/50	35.0mg	30/50			hag:ade,car.	S
b	c60333	11.7mg	29.4mg	1/50	17.5mg	14/50	35.0mg	29/50				
c	c60333	15.2mg	186.mg	12/50	17.5mg	17/50	35.0mg	26/50			liv:hpa,hpc.	
d	c60333	20.4mg	163.mg	5/50	17.5mg	10/50	35.0mg	18/50			lun:a/a,a/c.	
e	c60333	23.3mg	1.15gm	8/50	17.5mg	4/50	35.0mg	19/50				S
f	c60333	30.7mg	2.27gm	3/50	17.5mg	6/50	35.0mg	11/50				S
g	c60333	35.1mg	897.mg	2/50	17.5mg	4/50	35.0mg	10/50				S
h	c60333	27.1mg	n.s.s.	6/50	17.5mg	13/50	35.0mg	12/50				S
i	c60333	10.2mg	n.s.s.	35/50	17.5mg	39/50	35.0mg	47/50				
j	c60333	15.2mg	186.mg	12/50	17.5mg	17/50	35.0mg	26/50			liv:hpa,hpc,nnd.	
k	c60333	20.4mg	163.mg	5/50	17.5mg	10/50	35.0mg	18/50			lun:a/a,a/c.	
271	c60333	6.33mg	n.s.s.	45/50	4.20mg	36/50	8.41mg	42/50				
a	c60333	n.s.s.	n.s.s.	0/50	4.20mg	0/50	8.41mg	0/50			liv:hpa,hpc,nnd.	
272	c60333	4.72mg	n.s.s.	1/50	4.20mg	6/50	(8.41mg	3/50)				S
a	c60333	5.39mg	n.s.s.	45/50	4.20mg	40/50	8.41mg	45/50				
b	c60333	11.0mg	n.s.s.	4/50	4.20mg	2/50	(8.41mg	0/50)			liv:hpa,hpc,nnd.	
p-METHYLSTYRENE 622-97-9												
273	bt107	200.mg	n.s.s.	13/60	6.71mg	5/60	33.6mg	10/60	168.mg	15/60	Conti;anya,534,203-234;1988	
a	bt107	42.6mg	n.s.s.	0/60	6.71mg	0/60	33.6mg	0/60	168.mg	0/60		
b	bt107	104.mg	n.s.s.	33/60	6.71mg	18/60	33.6mg	33/60	168.mg	33/60		
c	bt107	343.mg	n.s.s.	19/60	6.71mg	10/60	33.6mg	20/60	168.mg	13/60		
274	bt107	262.mg	n.s.s.	7/60	6.71mg	5/60	33.6mg	7/60	168.mg	10/60		
a	bt107	793.mg	n.s.s.	5/60	6.71mg	4/60	33.6mg	6/60	168.mg	2/60		
b	bt107	583.mg	n.s.s.	12/60	6.71mg	7/60	33.6mg	9/60	168.mg	6/60		
c	bt107	320.mg	n.s.s.	20/60	6.71mg	14/60	33.6mg	18/60	168.mg	15/60		
MISOPROSTOL 59122-46-2												
275	1841	106.mg	n.s.s.	1/64	.160mg	1/64	1.60mg	0/64	16.0mg	1/64	Port;txpy,15,134-142;1987/pers.comm.	
a	1841	110.mg	n.s.s.	0/64	.160mg	3/64	1.60mg	0/64	16.0mg	1/64		
b	1841	176.mg	n.s.s.	2/64	.160mg	2/64	1.60mg	0/64	16.0mg	0/64		
c	1841	96.2mg	n.s.s.	0/64	.160mg	2/64	1.60mg	2/64	16.0mg	1/64		
d	1841	69.7ug	.481mg	22/64	.160mg	42/64	(1.60mg	21/64	16.0mg	18/64)		
276	1841	5.97mg	n.s.s.	15/64	.160mg	11/64	1.60mg	9/64	(16.0mg	2/64)		
a	1841	109.mg	n.s.s.	2/64	.160mg	1/64	1.60mg	1/64	16.0mg	1/64		
b	1841	148.mg	n.s.s.	0/64	.160mg	1/64	1.60mg	1/64	16.0mg	0/64		
c	1841	167.mg	n.s.s.	2/64	.160mg	4/64	1.60mg	1/64	16.0mg	0/64		
d	1841	176.mg	n.s.s.	1/64	.160mg	1/64	1.60mg	0/64	16.0mg	0/64		
e	1841	2.86mg	n.s.s.	34/64	.160mg	27/64	1.60mg	27/64	(16.0mg	15/64)		
277	1840	18.1mg	n.s.s.	0/60	24.0ug	2/60	.240mg	1/59	2.40mg	1/60	Dodd;txpy,15,125-133;1987/pers.comm.	
a	1840	22.4mg	n.s.s.	0/60	24.0ug	0/60	.240mg	1/59	2.40mg	0/60		
b	1840	5.70mg	n.s.s.	23/60	24.0ug	27/60	.240mg	37/59	2.40mg	24/60		
c	1840	2.28mg	n.s.s.	56/60	24.0ug	58/60	.240mg	54/59	2.40mg	52/60		
278	1840	18.8mg	n.s.s.	2/60	24.0ug	0/60	.240mg	1/60	2.40mg	1/60		
a	1840	.350mg	n.s.s.	47/60	24.0ug	49/60	.240mg	42/60	(2.40mg	24/60)		
NALIDIXIC ACID 389-08-2												
279	c56199	1.38gm	n.s.s.	0/50	258.mg	2/50	515.mg	3/50				S
a	c56199	344.mg	n.s.s.	36/50	258.mg	39/50	515.mg	35/50				
b	c56199	963.mg	n.s.s.	4/50	258.mg	6/50	515.mg	7/50			liv:hpa,hpc,nnd.	

	Spe	Sex	Strain	Route	Site	Hist	Xpo+Xpt	Notes		TD50	DR	2Tailpvl	AuOp
c	M	f	b6c	eat	lun	MXB	24m24			4.90gm	*	P<.4	
280	M	m	b6c	eat	sub	MXA	24m24		: ±	1.21gm	*	P<.04	e
a	M	m	b6c	eat	TBA	MXB	24m24			1.33gm	*	P<.4	
b	M	m	b6c	eat	liv	MXB	24m24			no dre		P=1.	
c	M	m	b6c	eat	lun	MXB	24m24			4.60gm	*	P<.6	
281	R	f	f34	eat	cli	MXA	24m24		: ±	372.mg	*	P<.05	c
a	R	f	f34	eat	TBA	MXB	24m24			no dre		P=1.	
b	R	f	f34	eat	liv	MXB	24m24			no dre		P=1.	
282	R	m	f34	eat	pre	MXA	24m24		: + :	138.mg	*	P<.0005	c
a	R	m	f34	eat	pre	can	24m24			211.mg	*	P<.0005	
b	R	m	f34	eat	pre	adn	24m24			301.mg	*	P<.02	
c	R	m	f34	eat	pre	MXA	24m24			358.mg	*	P<.05	
d	R	m	f34	eat	TBA	MXB	24m24			7.60gm	*	P<1.	
e	R	m	f34	eat	liv	MXB	24m24			no dre		P=1.	
NEOSUGAR									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
283	R	f	f3d	eat	spl	leu	24m24		.>	25.5gm	*	P<.5	-
a	R	f	f3d	eat	pit	ade	24m24			no dre		P=1.	-
284	R	m	f3d	eat	pit	ade	24m24		. +	3.55gm	*	P<.007	-
NITRITE, SODIUM***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
285	H	f	syg	eat	liv	cgf	97w97	e	.>	no dre		P=1.	
a	H	f	syg	eat	tba	tum	97w97	e		477.mg		P<.6	
286	H	m	syg	eat	liv	tum	24m24	e	.>	no dre		P=1.	
a	H	m	syg	eat	tba	tum	24m24	e		no dre		P=1.	
287	R	f	f34	eat	liv	mix	24m30		. + .	136.mg		P<.003	
a	R	f	f34	eat	liv	nnd	24m30			218.mg		P<.03	
b	R	f	f34	eat	liv	hpc	24m30			516.mg		P<.02	
288	R	m	f34	eat	liv	mix	24m30		.>	641.mg		P<.3	
a	R	m	f34	eat	liv	nnd	24m30			674.mg		P<.3	
b	R	m	f34	eat	liv	hpc	24m30			no dre		P=1.	
5-NITRO-2-FURALDEHYDE SEMICARBAZONE***									..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
289	M	f	b6c	eat	ova	MXB	24m24		: + :	22.4mg	*	P<.0005	
a	M	f	b6c	eat	ova	MXA	24m24			29.8mg	*	P<.0005	
b	M	f	b6c	eat	ova	mtb	24m24			30.8mg	*	P<.0005	c
c	M	f	b6c	eat	ova	gct	24m24			124.mg	*	P<.005	c
d	M	f	b6c	eat	TBA	MXB	24m24			66.2mg	*	P<.3	
e	M	f	b6c	eat	liv	MXB	24m24			no dre		P=1.	
f	M	f	b6c	eat	lun	MXB	24m24			241.mg	*	P<.3	
290	M	m	b6c	eat	sub	MXA	24m24		: ±	#154.mg	*	P<.05	-
a	M	m	b6c	eat	TBA	MXB	24m24			89.3mg	*	P<.4	
b	M	m	b6c	eat	liv	MXB	24m24			152.mg		P<.7	
c	M	m	b6c	eat	lun	MXB	24m24			1.38gm	*	P<.9	
291	R	f	f34	eat	mgl	fba	24m24		: + :	15.7mg	*	P<.0005	c
a	R	f	f34	eat	TBA	MXB	24m24			no dre		P=1.	
b	R	f	f34	eat	liv	MXB	24m24			253.mg	*	P<.2	
292	R	m	f34	eat	tnv	MXA	24m24		: + :	44.0mg		P<.003	e
a	R	m	f34	eat	ski	MXA	24m24			151.mg	*	P<.006	e
b	R	m	f34	eat	pre	can	24m24			65.5mg	*	P<.03	e
c	R	m	f34	eat	ski	sea	24m24			177.mg	*	P<.02	
d	R	m	f34	eat	TBA	MXB	24m24			33.8mg	*	P<.3	
e	R	m	f34	eat	liv	MXB	24m24			no dre		P=1.	
3-NITRO-4-HYDROXYPHENYLARSONIC ACID***									..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
293	M	f	b6c	eat	TBA	MXB	24m24		:>	no dre		P=1.	-
a	M	f	b6c	eat	liv	MXB	24m24			no dre		P=1.	
b	M	f	b6c	eat	lun	MXB	24m24			193.mg	*	P<.6	
294	M	m	b6c	eat	MXA	MXA	24m24		: ±	#138.mg	*	P<.03	-
a	M	m	b6c	eat	TBA	MXB	24m24			no dre		P=1.	
b	M	m	b6c	eat	liv	MXB	24m24			no dre		P=1.	
c	M	m	b6c	eat	lun	MXB	24m24			no dre		P=1.	
295	R	f	f34	eat	TBA	MXB	24m24		:>	no dre		P=1.	-
a	R	f	f34	eat	liv	MXB	24m24			no dre		P=1.	
296	R	m	f34	eat	pit	pda	24m24		: ±	3.40mg		P<.05	
a	R	m	f34	eat	pni	ade	24m24			16.5mg	*	P<.02	
b	R	m	f34	eat	pan	ade	24m24			19.0mg	*	P<.07	e
c	R	m	f34	eat	TBA	MXB	24m24			7.20mg	*	P<.5	
d	R	m	f34	eat	liv	MXB	24m24			no dre		P=1.	
1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN***									.1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
297	M	f	b6c	eat	ova	MXB	24m24	s	: + :	866.mg	*	P<.003	
a	M	f	b6c	eat	ova	MXA	24m24	s		1.40gm	/	P<.004	c
b	M	f	b6c	eat	ova	tua	24m24	s		2.53gm	*	P<.03	c
c	M	f	b6c	eat	ova	mtb	24m24	s		3.38gm	*	P<.05	c
d	M	f	b6c	eat	ova	MXA	24m24	s	+hist	2.56gm	*	P<.4	c
e	M	f	b6c	eat	ova	gcb	24m24	s	+hist	8.47gm	*	P<.9	c

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
c	c56199	1.27gm	n.s.s.	1/50	258.mg	5/50	515.mg	2/50			lun:a/a,a/c.	
280	c56199	536.mg	n.s.s.	5/50	238.mg	9/50	475.mg	14/50			sub:fbs,fib.	
a	c56199	342.mg	n.s.s.	26/50	238.mg	24/50	475.mg	32/50				
b	c56199	1.07gm	n.s.s.	10/50	238.mg	12/50	475.mg	7/50			liv:hpa,hpc,nnd.	
c	c56199	848.mg	n.s.s.	6/50	238.mg	5/50	475.mg	8/50			lun:a/a,a/c.	
281	c56199	165.mg	n.s.s.	5/50	99.0mg	15/50	198.mg	16/50			cli:adn,can,ppc,ppn.	
a	c56199	102.mg	n.s.s.	47/50	99.0mg	43/50	(198.mg	41/50)				
b	c56199	1.14gm	n.s.s.	1/50	99.0mg	0/50	198.mg	1/50			liv:hpa,hpc,nnd.	
282	c56199	82.0mg	416.mg	3/50	79.2mg	19/50	159.mg	20/50			pre:adn,can,ppn.	
a	c56199	126.mg	458.mg	0/50	79.2mg	10/50	159.mg	12/50				S
b	c56199	145.mg	n.s.s.	2/50	79.2mg	10/50	159.mg	10/50				S
c	c56199	155.mg	n.s.s.	3/50	79.2mg	10/50	159.mg	10/50			pre:adn,ppn.	S
d	c56199	94.9mg	n.s.s.	44/50	79.2mg	45/50	159.mg	44/50				
e	c56199	746.mg	n.s.s.	2/50	79.2mg	1/50	159.mg	1/50			liv:hpa,hpc,nnd.	
NEOSUGAR	88385-81-3											
283	1880	5.05gm	n.s.s.	4/50	400.mg	7/50	1.00gm	12/50	2.50gm	7/50	Clevenger;jact,7,643-662;1988	
a	1880	8.67gm	n.s.s.	24/50	400.mg	19/50	1.00gm	19/50	2.50gm	14/50		
284	1880	1.71gm	59.6gm	10/50	320.mg	13/50	800.mg	19/50	2.00gm	22/50		
NITRITE, SODIUM***	7632-00-0											
285	1831	402.mg	n.s.s.	1/14	149.mg	0/15					Ernst;carc,8,1843-1845;1987/pers.comm.	
a	1831	78.7mg	n.s.s.	5/14	149.mg	7/15						
286	1831	391.mg	n.s.s.	0/16	131.mg	0/15						
a	1831	134.mg	n.s.s.	10/16	131.mg	6/15						
287	1854	62.3mg	897.mg	4/24	87.9mg	14/24					Lijinsky;txih,3,413-422;1987/pers.comm.	
a	1854	86.7mg	n.s.s.	4/24	87.9mg	11/24						
b	1854	178.mg	n.s.s.	0/24	87.9mg	4/24						
288	1854	164.mg	n.s.s.	3/24	92.3mg	6/24						
a	1854	180.mg	n.s.s.	2/24	92.3mg	5/24						
b	1854	429.mg	n.s.s.	1/24	92.3mg	1/24						
5-NITRO-2-FURALDEHYDE SEMICARBAZONE*** (nitrofurazone) 59-87-0												
289	c56064	15.4mg	37.7mg	1/50	19.3mg	20/50	39.9mg	29/50			ova:gct,mtb.	C
a	c56064	20.1mg	48.8mg	0/50	19.3mg	18/50	39.9mg	20/50			ova:mtb,tua.	S
b	c56064	20.7mg	50.6mg	0/50	19.3mg	17/50	39.9mg	20/50				
c	c56064	60.2mg	1.14gm	1/50	19.3mg	4/50	39.9mg	9/50				
d	c56064	19.9mg	n.s.s.	36/50	19.3mg	43/50	39.9mg	42/50				
e	c56064	214.mg	n.s.s.	3/50	19.3mg	3/50	39.9mg	1/50			liv:hpa,hpc,nnd.	
f	c56064	73.0mg	n.s.s.	3/50	19.3mg	7/50	39.9mg	6/50			lun:a/a,a/c.	
290	c56064	60.1mg	n.s.s.	3/50	17.8mg	3/50	36.8mg	8/50			sub:fbs,fib,nfs,srn.	S
a	c56064	23.9mg	n.s.s.	28/50	17.8mg	26/50	36.8mg	26/50				
b	c56064	20.2mg	n.s.s.	16/50	17.8mg	15/50	(36.8mg	5/50)			liv:hpa,hpc,nnd.	
c	c56064	69.1mg	n.s.s.	8/50	17.8mg	7/50	36.8mg	6/50			lun:a/a,a/c.	
291	c56064	9.47mg	44.2mg	8/50	15.4mg	36/50	30.7mg	36/50				
a	c56064	20.3mg	n.s.s.	44/50	15.4mg	47/50	30.7mg	46/50				
b	c56064	87.3mg	n.s.s.	0/50	15.4mg	2/50	30.7mg	2/50			liv:hpa,hpc,nnd.	
292	c56064	18.8mg	195.mg	0/50	12.3mg	7/50	(24.6mg	2/50)			tnv:men,msm.	
a	c56064	55.2mg	548.mg	0/50	12.3mg	0/50	24.6mg	5/50			ski:sea,tri.	
b	c56064	29.4mg	n.s.s.	1/50	12.3mg	8/50	24.6mg	5/50				
c	c56064	59.1mg	n.s.s.	0/50	12.3mg	0/50	24.6mg	4/50				S
d	c56064	9.75mg	n.s.s.	47/50	12.3mg	46/50	24.6mg	40/50				
e	c56064	73.2mg	n.s.s.	7/50	12.3mg	4/50	24.6mg	3/50			liv:hpa,hpc,nnd.	
3-NITRO-4-HYDROXYPHENYLARSONIC ACID*** (roxarsone) 121-19-7												
293	c56508	32.7mg	n.s.s.	24/50	12.8mg	11/50	25.5mg	18/50				
a	c56508	196.mg	n.s.s.	3/50	12.8mg	0/50	25.5mg	0/50			liv:hpa,hpc,nnd.	
b	c56508	34.8mg	n.s.s.	3/50	12.8mg	4/50	25.5mg	5/50			lun:a/a,a/c.	
294	c56508	56.5mg	n.s.s.	0/50	11.8mg	2/50	23.5mg	4/50			acx:csa; adr:cca.	S
a	c56508	29.5mg	n.s.s.	35/50	11.8mg	30/50	23.5mg	34/50				
b	c56508	71.9mg	n.s.s.	12/50	11.8mg	15/50	23.5mg	7/50			liv:hpa,hpc,nnd.	
c	c56508	63.0mg	n.s.s.	11/50	11.8mg	5/50	23.5mg	10/50			lun:a/a,a/c.	
295	c56508	4.18mg	n.s.s.	48/50	2.45mg	47/50	4.93mg	46/50				
a	c56508	n.s.s.	n.s.s.	0/50	2.45mg	1/50	4.93mg	0/50			liv:hpa,hpc,nnd.	
296	c56508	1.28mg	n.s.s.	6/50	1.96mg	13/50	(3.92mg	8/50)				S
a	c56508	6.87mg	n.s.s.	0/50	1.96mg	3/50	3.92mg	4/50				S
b	c56508	6.46mg	n.s.s.	1/50	1.96mg	1/50	3.92mg	5/50				
c	c56508	1.58mg	n.s.s.	46/50	1.96mg	48/50	3.92mg	47/50				
d	c56508	18.5mg	n.s.s.	2/50	1.96mg	2/50	3.92mg	1/50			liv:hpa,hpc,nnd.	
1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN*** (macrodantin, nitrofurantoin) 67-20-9												
297	c55196	466.mg	3.57gm	0/50	166.mg	3/50	319.mg	11/50			ova:gcb,gcm,mtb,tua.	C
a	c55196	660.mg	3.82gm	0/50	166.mg	0/50	319.mg	9/50			ova:mtb,tua.	
b	c55196	960.mg	n.s.s.	0/50	166.mg	0/50	319.mg	5/50				
c	c55196	1.16gm	n.s.s.	0/50	166.mg	0/50	319.mg	4/50				
d	c55196	972.mg	n.s.s.	0/50	166.mg	3/50	319.mg	2/50			ova:gcb,gcm.	
e	c55196	1.12gm	n.s.s.	0/50	166.mg	3/50	319.mg	1/50				

	Spe	Sex	Strain	Route	Site	Hist	Xpo+Xpt	Notes	Plot	TD50	DR	2Tailpvl	AuOp
f	M	f	b6c	eat	TBA	MXB	24m24	s		no dre		P=1.	
g	M	f	b6c	eat	liv	MXB	24m24	s		2.33gm	*	P<.2	
h	M	f	b6c	eat	lun	MXB	24m24	s		no dre		P=1.	
298	M	m	b6c	eat	TBA	MXB	24m24		:>	no dre		P=1.	-
a	M	m	b6c	eat	liv	MXB	24m24			no dre		P=1.	
b	M	m	b6c	eat	lun	MXB	24m24			no dre		P=1.	
299	R	f	f34	eat	cli	ade	24m24		: ±	#93.7mg		P<.03	-
a	R	f	f34	eat	TBA	MXB	24m24			no dre		P=1.	
b	R	f	f34	eat	liv	MXB	24m24			no dre		P=1.	
300	R	m	f34	eat	sub	fib	24m24		: ±	303.mg	*	P<.02	
a	R	m	f34	eat	kid	MXA	24m24		+hist	698.mg	*	P<.05	p
b	R	m	f34	eat	TBA	MXB	24m24			no dre		P=1.	
c	R	m	f34	eat	liv	MXB	24m24			332.mg		P<.2	
1-NITROPROPANE***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
301	R	m	sda	gav	liv	hpa	26w77	ev	.>	.872mg		P<1.	-
3-NITROSO-2-OXAZOLIDINONE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
302	R	m	mrw	wat	itn	mix	64w64	e	<+	noTD50		P<.0005+	
a	R	m	mrw	wat	liv	mix	64w64	e		.582mg		P<.0005+	
b	R	m	mrw	wat	tba	tum	64w64	e		noTD50		P<.0005	
303	R	m	mrw	wat	itn	mix	70w70	ev	. + .	.729mg		P<.0005+	
a	R	m	mrw	wat	liv	mix	70w70	ev		1.15mg		P<.0005+	
b	R	m	mrw	wat	tba	tum	70w70	ev		.335mg		P<.0005	
N-NITROSODIETHANOLAMINE***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
304	R	m	sda	wat	liv	mix	38m39	a	. + .	38.4mg	*	P<.0005+	
a	R	m	sda	wat	liv	hpc	38m39	a		70.4mg	*	P<.0005+	
b	R	m	sda	wat	liv	hmb	38m39	a		126.mg	*	P<.06	+
c	R	m	sda	wat	ner	tum	38m39	a		42.5mg	*	P<.3	+
d	R	m	sda	wat	---	tum	38m39	a		55.6mg	*	P<.2	+
e	R	m	sda	wat	git	mix	38m39	a		143.mg	*	P<.6	+
f	R	m	sda	wat	liv	hpa	38m39	a		347.mg	*	P<.3	+
g	R	m	sda	wat	tba	ben	38m39	a		7.93mg	*	P<.2	
h	R	m	sda	wat	tba	mal	38m39	a		23.5mg	*	P<.3	+
N-NITROSODIETHYLAMINE***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
305	R	m	sda	wat	liv	mix	35m37	a	. + .	.270mg	Z	P<.0005+	
a	R	m	sda	wat	git	mix	35m37	a		.401mg	*	P<.0005+	
b	R	m	sda	wat	liv	hpc	35m37	a		.541mg	Z	P<.0005+	
c	R	m	sda	wat	eso	pam	35m37	a		.715mg	Z	P<.0005+	
d	R	m	sda	wat	liv	hmm	35m37	a		.719mg	*	P<.0005+	
e	R	m	sda	wat	eso	sqc	35m37	a		3.38mg	*	P<.002	+
f	R	m	sda	wat	unt	tum	35m37	a		6.51mg	*	P<.3	+
g	R	m	sda	wat	tba	mal	35m37	a		.188mg	*	P<.0005+	
h	R	m	sda	wat	tba	ben	35m37	a		no dre		P=1.	
N-NITROSODIMETHYLAMINE***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
306	R	m	f34	gav	lun	mix	30w65	e	. + .	76.5ug		P<.0005+	
a	R	m	f34	gav	lun	a/a	30w65	e		.106mg		P<.0005+	
b	R	m	f34	gav	kid	mnp	30w65	e		.189mg		P<.0005+	
c	R	m	f34	gav	liv	mix	30w65	e		.189mg		P<.0005+	
d	R	m	f34	gav	liv	bht	30w65	e		.372mg		P<.003	
e	R	m	f34	gav	lun	sqc	30w65	e		.372mg		P<.003	
f	R	m	f34	gav	liv	cab	30w65	e		.822mg		P<.04	
g	R	m	f34	gav	liv	hes	30w65	e		.822mg		P<.04	
N-NITROSODITHIAZINE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
307	R	f	f34	gav	nac	car	11m26	e	. ±	5.11mg		P<.1	
a	R	f	f34	gav	liv	hpc	11m26	e		10.5mg		P<.3	-
NITROSOETHYLMETHYLAMINE***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
308	R	m	f34	gav	liv	bht	30w55	e	. + .	50.3ug		P<.0005	
a	R	m	f34	gav	liv	mix	30w55	e		50.3ug		P<.0005+	
b	R	m	f34	gav	liv	hes	30w55	e		.120mg		P<.0005	
c	R	m	f34	gav	nac	tum	30w55	e		.201mg		P<.0005+	
d	R	m	f34	gav	lun	a/a	30w55	e		.242mg		P<.0005+	
N-NITROSOGUVACOLINE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
309	R	m	f34	wat	pae	ana	30m30		. ±	7.95mg		P<.02	
a	R	m	f34	wat	liv	ade	30m30			no dre		P=1.	
N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE									..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
310	R	m	f34	gav	liv	hpc	69w69	es	. + .	1.29mg		P<.003	+
a	R	m	f34	gav	nas	sqc	69w69	es		2.06mg		P<.02	+
b	R	m	f34	gav	liv	hes	69w69	es		8.97mg		P<.3	
c	R	m	f34	gav	nas	sqp	69w69	es		8.97mg		P<.3	
d	R	m	f34	gav	liv	nnd	69w69	es		no dre		P=1.	

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
f	c55196	368.mg	n.s.s.	30/50	166.mg	35/50	319.mg	41/50		
g	c55196	764.mg	n.s.s.	2/50	166.mg	2/50	319.mg	8/50	liv:hpa,hpc,nnd.	
h	c55196	822.mg	n.s.s.	3/50	166.mg	2/50	(319.mg	0/50)	lun:a/a,a/c.	
298	c55196	357.mg	n.s.s.	31/50	153.mg	27/50	294.mg	33/50		
a	c55196	567.mg	n.s.s.	10/50	153.mg	12/50	294.mg	11/50	liv:hpa,hpc,nnd.	
b	c55196	787.mg	n.s.s.	6/50	153.mg	4/50	294.mg	7/50	lun:a/a,a/c.	
299	c55196	36.2mg	n.s.s.	1/50	29.4mg	7/50	(63.8mg	4/50)		S
a	c55196	45.2mg	n.s.s.	49/50	29.4mg	48/50	63.8mg	46/50		
b	c55196	n.s.s.	n.s.s.	0/50	29.4mg	1/50	63.8mg	0/50	liv:hpa,hpc,nnd.	
300	c55196	142.mg	n.s.s.	0/50	51.3mg	5/50	98.1mg	4/50		S
a	c55196	240.mg	n.s.s.	0/50	51.3mg	1/50	98.1mg	3/50	kid:rua,ruc.	
b	c55196	62.1mg	n.s.s.	48/50	51.3mg	47/50	98.1mg	45/50		
c	c55196	90.0mg	n.s.s.	1/50	51.3mg	4/50	(98.1mg	0/50)	liv:hpa,hpc,nnd.	
1-NITROPROPANE*** 108-03-2										
301	1837	16.8ug	n.s.s.	1/29	9.59ug	1/26			Fiala;carc,8,1947-1949;1987/pers.comm.	
3-NITROSO-2-OXAZOLIDINONE 38347-74-9										
302	1813m	n.s.s.	.262mg	0/17	2.14mg	26/26			Mirvish;jnci,78,387-393;1987/pers.comm.	
a	1813m	.315mg	1.22mg	0/17	2.14mg	16/26				
b	1813m	n.s.s.	.281mg	2/17	2.14mg	26/26				
303	1813n	.389mg	1.57mg	0/17	2.15mg	15/25				
a	1813n	.571mg	3.09mg	0/17	2.15mg	11/25				
b	1813n	.171mg	.750mg	2/17	2.15mg	22/25				
N-NITROSODIETHANOLAMINE*** 1116-54-7										
304	1838	16.0mg	201.mg	3/500	.143mg	2/80	.450mg	1/80	1.43mg 6/80	Berger;carc,8,1635-1643;1987/pers.comm.
a	1838	24.3mg	368.mg	0/500	.143mg	0/80	.450mg	1/80	1.43mg 3/80	
b	1838	30.8mg	n.s.s.	1/500	.143mg	1/80	.450mg	0/80	1.43mg 2/80	
c	1838	11.5mg	n.s.s.	54/500	.143mg	8/80	.450mg	16/80	1.43mg 11/80	
d	1838	15.3mg	n.s.s.	23/500	.143mg	8/80	.450mg	5/80	1.43mg 7/80	
e	1838	20.7mg	n.s.s.	26/500	.143mg	7/80	.450mg	3/80	1.43mg 6/80	
f	1838	47.6mg	n.s.s.	1/500	.143mg	0/80	.450mg	0/80	1.43mg 1/80	
g	1838	2.58mg	n.s.s.	362/500	.143mg	61/80	.450mg	60/80	1.43mg 64/80	
h	1838	6.85mg	n.s.s.	144/500	.143mg	29/80	.450mg	29/80	1.43mg 28/80	
N-NITROSODIETHYLAMINE*** (DEN) 55-18-5										
305	1838	.183mg	.422mg	3/500	7.14ug	2/80	22.9ug	3/80	71.4ug 36/80	Berger;carc,8,1635-1643;1987/pers.comm.
a	1838	.241mg	.807mg	26/500	7.14ug	9/80	22.9ug	7/80	71.4ug 25/80	
b	1838	.326mg	.991mg	0/500	7.14ug	1/80	22.9ug	0/80	71.4ug 21/80	
c	1838	.405mg	1.44mg	0/500	7.14ug	0/80	22.9ug	0/80	71.4ug 17/80	
d	1838	.408mg	1.45mg	0/500	7.14ug	0/80	22.9ug	2/80	71.4ug 15/80	
e	1838	1.13mg	26.3mg	1/500	7.14ug	0/80	22.9ug	0/80	71.4ug 4/80	
f	1838	1.32mg	n.s.s.	1/500	7.14ug	2/80	22.9ug	1/80	71.4ug 1/80	
g	1838	.118mg	.370mg	144/500	7.14ug	23/80	22.9ug	27/80	71.4ug 52/80	
h	1838	.368mg	n.s.s.	362/500	7.14ug	58/80	22.9ug	54/80	71.4ug 53/80	
N-NITROSODIMETHYLAMINE*** (DMN) 62-75-9										
306	1864	37.7ug	.169mg	0/19	.527mg	16/19			Lijinsky;canr,47,3968-3972;1987/pers.comm.	
a	1864	53.3ug	.240mg	0/19	.527mg	14/19				
b	1864	89.9ug	.494mg	0/19	.527mg	10/19				
c	1864	89.9ug	.494mg	0/19	.527mg	10/19				
d	1864	.151mg	1.92mg	0/19	.527mg	6/19				
e	1864	.151mg	1.92mg	0/19	.527mg	6/19				
f	1864	.248mg	n.s.s.	0/19	.527mg	3/19				
g	1864	.248mg	n.s.s.	0/19	.527mg	3/19				
N-NITROSODITHIAZINE 114282-83-6										
307	1884	1.25mg	n.s.s.	0/20	.702mg	2/20			Lijinsky;fctx,26,3-7;1988	
a	1884	1.71mg	n.s.s.	0/20	.702mg	1/20				
NITROSOETHYLMETHYLAMINE*** (N-nitrosomethylethylamine) 10595-95-6										
308	1864	19.8ug	.125mg	0/19	.727mg	15/16			Lijinsky;canr,47,3968-3972;1987/pers.comm.	
a	1864	19.8ug	.125mg	0/19	.727mg	15/16				
b	1864	56.8ug	.302mg	0/19	.727mg	11/16				
c	1864	88.9ug	.602mg	0/19	.727mg	8/16				
d	1864	.103mg	.821mg	0/19	.727mg	7/16				
N-NITROSOGUVACOLINE 55557-02-3										
309	1866	2.57mg	n.s.s.	1/80	1.00mg	4/30			Rivenson;canr,48,6912-6917;1988/pers.comm.	
a	1866	9.37mg	n.s.s.	6/80	1.00mg	0/30				
N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE 26921-68-6										
310	1904	.522mg	6.74mg	0/20	1.53mg	6/20			Koepke;canr,48,1533-1536;1988/pers.comm.	
a	1904	.710mg	n.s.s.	0/20	1.53mg	4/20				
b	1904	1.46mg	n.s.s.	0/20	1.53mg	1/20				
c	1904	1.46mg	n.s.s.	0/20	1.53mg	1/20				
d	1904	1.45mg	n.s.s.	3/20	1.53mg	2/20				

```
     Spe Strain  Site     Xpo+Xpt                                                                                       TD50     2Tailpvl
       Sex    Route   Hist       Notes                                                                                       DR      AuOp

N-NITROSOMETHYL-(3-HYDROXYPROPYL)AMINE ..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
311  R f f34 gav liv nnd 30m30 e                                        .   +       .                     3.48mg   P<.004 +
 a   R f f34 gav lun mix 30m30 e                                                                          8.06mg   P<.06  +
 b   R f f34 gav lun a/c 30m30 e                                                                          24.9mg   P<.1   +
 c   R f f34 gav lun a/a 30m30 e                                                                          14.4mg   P<.3
312  R m f34 gav lun mix 30m30 e                                    . +    .                              1.09mg   P<.0005+
 a   R m f34 gav tes ict 30m30 e                                                                          2.26mg   P<.0005
 b   R m f34 gav lun a/c 30m30 e                                                                          2.46mg   P<.0005+
 c   R m f34 gav liv nnd 30m30 e                                                                          4.78mg   P<.06  +
 d   R m f34 gav lun a/a 30m30 e                                                                          8.46mg   P<.3

N-NITROSOMETHYL-(2-TOSYLOXYETHYL)AMINE ..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
313  R f f34 gav liv mix 28m28 e                                         .  +    .                        3.47mg   P<.0005+
 a   R f f34 gav liv hpc 28m28 e                                                                          7.55mg   P<.0005+
 b   R f f34 gav liv hes 28m28 e                                                                          12.8mg   P<.003 +
 c   R f f34 gav liv nnd 28m28 e                                                                          22.3mg   P<.3
314  R m f34 gav liv hes 28m28 e                                             .   +         .              11.8mg   P<.007 +
 a   R m f34 gav liv mix 28m28 e                                                                          7.79mg   P<.04  +
 b   R m f34 gav tes ict 28m28 e                                                                          11.1mg   P<.04
 c   R m f34 gav pit ade 28m28 e                                                                          11.1mg   P<.04
 d   R m f34 gav liv hpc 28m28 e                                                                          32.2mg   P<.1   +
 e   R m f34 gav liv nnd 28m28 e                                                                          12.6mg   P<.2

N-NITROSOMORPHOLINE***          100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
315  R f f34 wat liv mix 10m29 es                              . + .                                      .140mg * P<.0005+

 a   R f f34 wat amd phe 10m29 es                                                                         .325mg Z P<.007

 b   R f f34 wat thy ccr 10m29 es                                                                         .363mg Z P<.0005

 c   R f f34 wat liv hpc 10m29 es                                                                         .564mg Z P<.0005+

 d   R f f34 wat liv hes 10m29 es                                                                         .666mg * P<.0005+

 e   R f f34 wat liv nnd 10m29 es                                                                         1.28mg Z P<.0005+

 f   R f f34 wat eso mix 10m29 es                                                                         1.97mg Z P<.0005

 g   R f f34 wat eso sqp 10m29 es                                                                         2.53mg Z P<.0005

 h   R f f34 wat ton mix 10m29 es                                                                         6.54mg Z P<.003

 i   R f f34 wat ton sqp 10m29 es                                                                         50.2mg * P<.3

 j   R f f34 wat thy fca 10m29 es                                                                         no dre   P=1.

316  R f f34 wat liv mix 23m29 e                               . +.                                       .127mg * P<.0005+

 a   R f f34 wat liv nnd 23m29 e                                                                          .239mg * P<.0005+

 b   R f f34 wat liv hpc 23m29 e                                                                          .431mg * P<.0005+

 c   R f f34 wat thy fca 23m29 e                                                                          .581mg Z P<.0005

 d   R f f34 wat liv hes 23m29 e                                                                          .630mg * P<.0005+

 e   R f f34 wat amd phe 23m29 e                                                                          1.07mg * P<.06

 f   R f f34 wat ton sqp 23m29 e                                                                          3.49mg * P<.02


N-NITROSOPYRROLIDINE***         100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
317  R m sda wat liv mix 37m38 a                                        . +  .                            2.43mg * P<.0005+
 a   R m sda wat liv hpc 37m38 a                                                                          4.06mg * P<.0005+
 b   R m sda wat liv hpa 37m38 a                                                                          8.13mg * P<.0005+
 c   R m sda wat unt tum 37m38 a                                                                          7.03mg Z P<.1   +
 d   R m sda wat git mix 37m38 a                                                                          14.9mg * P<.4   +
 e   R m sda wat liv hmm 37m38 a                                                                          55.7mg * P<.3
 f   R m sda wat tba mal 37m38 a                                                                          2.03mg * P<.007 +
 g   R m sda wat tba ben 37m38 a                                                                          no dre   P=1.

N-NITROSOTHIALDINE              100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
318  R f f34 gav eso sqa 43w90 e                                  .  +  .                                 .483mg   P<.0005+
 a   R f f34 gav eso sqc 43w90 e                                                                          1.63mg   P<.003
 b   R f f34 gav ton sqa 43w90 e                                                                          1.53mg   P<.02  +
 c   R f f34 gav liv hpa 43w90 e                                                                          2.61mg   P<.02  +
 d   R f f34 gav liv cho 43w90 e                                                                          3.58mg   P<.04  +
 e   R f f34 gav ton sqc 43w90 e                                                                          no dre   P=1.
```

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology / Brkly Code
N-NITROSOMETHYL-(3-HYDROXYPROPYL)AMINE 70415-59-7								
311	1904	1.55mg	24.4mg	3/20	2.45mg	12/20		Koepke;canr,48,1533-1536;1988/pers.comm.
a	1904	2.85mg	n.s.s.	2/20	2.45mg	7/20		
b	1904	6.11mg	n.s.s.	0/20	2.45mg	2/20		
c	1904	3.87mg	n.s.s.	2/20	2.45mg	5/20		
312	1904	.511mg	2.98mg	3/20	1.71mg	16/19		
a	1904	1.06mg	7.37mg	1/20	1.71mg	11/19		
b	1904	1.17mg	6.40mg	0/20	1.71mg	10/19		
c	1904	1.69mg	n.s.s.	3/20	1.71mg	8/19		
d	1904	2.28mg	n.s.s.	3/20	1.71mg	6/19		
N-NITROSOMETHYL-(2-TOSYLOXYETHYL)AMINE ---								
313	1904	1.64mg	10.3mg	3/20	5.22mg	15/19		Koepke;canr,48,1533-1536;1988/pers.comm.
a	1904	3.49mg	21.1mg	0/20	5.22mg	9/19		
b	1904	5.17mg	61.8mg	0/20	5.22mg	6/19		
c	1904	6.01mg	n.s.s.	3/20	5.22mg	6/19		
314	1904	4.45mg	136.mg	0/20	3.66mg	5/20		
a	1904	2.94mg	n.s.s.	3/20	3.66mg	9/20		
b	1904	4.04mg	n.s.s.	1/20	3.66mg	6/20		
c	1904	4.04mg	n.s.s.	1/20	3.66mg	6/20		
d	1904	7.91mg	n.s.s.	0/20	3.66mg	2/20		
e	1904	3.88mg	n.s.s.	3/20	3.66mg	7/20		
N-NITROSOMORPHOLINE* 59-89-2**								
315	1886m	95.6ug	.222mg	1/80	7.29ug	6/48	17.8ug	7/48 42.1ug 15/48 .104mg 14/24 .338mg 22/23
				1.06mg	23/24	2.83mg	24/24	Lijinsky;canr,48,2089-2095;1988
a	1886m	.146mg	6.40mg	8/80	7.29ug	10/48	17.8ug	3/48 42.1ug 15/48 .104mg 7/24 (.338mg 5/24
				1.06mg	2/24	2.83mg	0/24)	
b	1886m	.185mg	1.38mg	2/80	7.29ug	1/48	17.8ug	4/48 42.1ug 8/48 .104mg 5/24 (.338mg 2/24
				1.06mg	2/24	2.83mg	0/24)	
c	1886m	.382mg	.871mg	0/80	7.29ug	0/48	17.8ug	1/48 42.1ug 5/48 .104mg 7/24 .338mg 15/23
				1.06mg	16/24	(2.83mg	15/24)	
d	1886m	.432mg	1.05mg	0/80	7.29ug	0/48	17.8ug	0/48 42.1ug 1/48 .104mg 0/24 .338mg 8/23
				1.06mg	23/24	2.83mg	24/24	
e	1886m	.793mg	2.31mg	1/80	7.29ug	6/48	17.8ug	6/48 42.1ug 11/48 .104mg 9/24 .338mg 15/23
				1.06mg	11/24	2.83mg	20/24	
f	1886m	1.09mg	4.07mg	0/80	7.29ug	0/48	17.8ug	0/48 42.1ug 0/48 .104mg 0/24 .338mg 3/24
				1.06mg	13/24	(2.83mg	5/24)	
g	1886m	1.33mg	5.72mg	0/80	7.29ug	0/48	17.8ug	0/48 42.1ug 0/48 .104mg 0/24 .338mg 2/24
				1.06mg	11/24	(2.83mg	5/24)	
h	1886m	2.44mg	63.6mg	2/80	7.29ug	2/48	17.8ug	0/48 42.1ug 0/48 .104mg 1/24 .338mg 2/24
				1.06mg	4/24	(2.83mg	0/24)	
i	1886m	14.1mg	n.s.s.	0/80	7.29ug	1/48	17.8ug	0/48 42.1ug 0/48 .104mg 0/24 .338mg 1/24
				1.06mg	2/24	2.83mg	0/24	
j	1886m	20.0mg	n.s.s.	0/80	7.29ug	1/48	17.8ug	0/48 42.1ug 4/48 .104mg 1/24 .338mg 3/24
				1.06mg	0/24	2.83mg	0/24	
316	1886n	89.3ug	.192mg	1/80	2.27ug	6/100	5.83ug	5/99 14.6ug 7/47 35.6ug 9/48 84.2ug 22/48
				.249mg	23/24			
a	1886n	.156mg	.411mg	1/80	2.27ug	5/100	5.83ug	5/99 14.6ug 6/47 35.6ug 8/48 84.2ug 15/48
				.249mg	15/24			
b	1886n	.266mg	.761mg	0/80	2.27ug	1/100	5.83ug	0/99 14.6ug 0/47 35.6ug 1/48 84.2ug 7/48
				.249mg	16/24			
c	1886n	.299mg	1.95mg	0/80	2.27ug	0/100	5.83ug	2/100 14.6ug 3/48 35.6ug 0/48 84.2ug 7/48
				(.249mg	2/24)			
d	1886n	.361mg	1.24mg	0/80	2.27ug	0/100	5.83ug	0/99 14.6ug 0/47 35.6ug 0/48 84.2ug 5/48
				.249mg	13/24			
e	1886n	.377mg	n.s.s.	8/80	2.27ug	22/100	5.83ug	18/100 14.6ug 8/48 35.6ug 12/48 84.2ug 13/48
				.249mg	7/24			
f	1886n	1.08mg	n.s.s.	0/80	2.27ug	1/100	5.83ug	1/100 14.6ug 0/48 35.6ug 1/48 84.2ug 1/48
				.249mg	2/24			
N-NITROSOPYRROLIDINE* 930-55-2**								
317	1838	1.44mg	4.68mg	3/500	28.6ug	1/80	95.0ug	4/80 .286mg 17/80 Berger;carc,8,1635-1643;1987/pers.comm.
a	1838	2.14mg	9.15mg	0/500	28.6ug	1/80	95.0ug	0/80 .286mg 12/80
b	1838	3.42mg	31.2mg	1/500	28.6ug	0/80	95.0ug	2/80 .286mg 5/80
c	1838	1.78mg	n.s.s.	1/500	28.6ug	2/80	95.0ug	1/80 (.286mg 0/80)
d	1838	3.25mg	n.s.s.	26/500	28.6ug	6/80	95.0ug	7/80 .286mg 6/80
e	1838	9.07mg	n.s.s.	0/500	28.6ug	0/80	95.0ug	1/80 .286mg 0/80
f	1838	.933mg	38.1mg	144/500	28.6ug	23/80	95.0ug	28/80 .286mg 35/80
g	1838	1.18mg	n.s.s.	362/500	28.6ug	63/80	95.0ug	59/80 .286mg 55/80
N-NITROSOTHIALDINE 81795-07-5								
318	1884	.247mg	1.09mg	0/20	1.13mg	14/20		Lijinsky;fctx,26,3-7;1988
a	1884	.661mg	8.52mg	0/20	1.13mg	6/20		
b	1884	.603mg	n.s.s.	1/20	1.13mg	7/20		
c	1884	.897mg	n.s.s.	0/20	1.13mg	4/20		
d	1884	1.08mg	n.s.s.	0/20	1.13mg	3/20		
e	1884	2.09mg	n.s.s.	1/20	1.13mg	1/20		

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
OCHRATOXIN A***				
319	R f f34 gav kid MXA 24m24	: + :	.485mg *	P<.0005c
a	R f f34 gav kid rua 24m24		.813mg *	P<.003 c
b	R f f34 gav kid ruc 24m24		1.31mg *	P<.02 c
c	R f f34 gav MXB MXB 24m24		.386mg *	P<.3
d	R f f34 gav mgl fba 24m24		.550mg *	P<.5 c
e	R f f34 gav TBA MXB 24m24		no dre	P=1.
f	R f f34 gav liv MXB 24m24		no dre	P=1.
320	R m f34 gav kid MXA 24m24	:+ :	57.9ug *	P<.0005c
a	R m f34 gav kid MXA 24m24		75.6ug *	P<.0005c
b	R m f34 gav kid MXA 24m24		.241mg *	P<.0005c
c	R m f34 gav TBA MXB 24m24		86.3ug *	P<.007
d	R m f34 gav liv MXB 24m24		2.50mg *	P<.3
C.I. ACID ORANGE 3		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
321	M f b6c gav lun a/a 24m24	: ±	#2.59gm *	P<.05 -
a	M f b6c gav TBA MXB 24m24		no dre	P=1.
b	M f b6c gav liv MXB 24m24		7.55gm *	P<.8
c	M f b6c gav lun MXB 24m24		11.6gm *	P<.8
322	M m b6c gav liv hpc 24m24	: ±	#184.mg	P<.02 -
a	M m b6c gav TBA MXB 24m24		372.mg *	P<.4
b	M m b6c gav liv MXB 24m24		no dre	P=1.
c	M m b6c gav lun MXB 24m24		5.86gm *	P<.9
323	R f f34 gav kid tcc 24m24 s	: + :	1.71gm /	P<.0005c
a	R f f34 gav TBA MXB 24m24 s		361.mg *	P<.05
b	R f f34 gav liv MXB 24m24 s		5.09gm *	P<.5
324	R m f34 gav TBA MXB 23m24 ans	: ±	270.mg /	P<.03 -
a	R m f34 gav liv MXB 23m24 ans		no dre	P=1.
C.I. ACID ORANGE 10		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
325	M f b6c eat TBA MXB 24m24	:>	no dre	P=1. -
a	M f b6c eat liv MXB 24m24		no dre	P=1.
b	M f b6c eat lun MXB 24m24		no dre	P=1.
326	M m b6c eat TBA MXB 24m24	:>	no dre	P=1. -
a	M m b6c eat liv MXB 24m24		no dre	P=1.
b	M m b6c eat lun MXB 24m24		22.0gm *	P<.8
327	R f f34 eat TBA MXB 24m24	:>	no dre	P=1. -
a	R f f34 eat liv MXB 24m24		no dre	P=1.
328	R m f34 eat tnv MXA 24m24	: ±	#915.mg *	P<.05 -
a	R m f34 eat TBA MXB 24m24		2.71gm *	P<.9
b	R m f34 eat liv MXB 24m24		620.mg *	P<.06
PENICILLIN VK		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
329	M f b6c gav TBA MXB 24m24	:>	no dre	P=1. -
a	M f b6c gav liv MXB 24m24		10.2gm *	P<.6
b	M f b6c gav lun MXB 24m24		16.6gm *	P<.7
330	M m b6c gav TBA MXB 24m24	:>	no dre	P=1. -
a	M m b6c gav liv MXB 24m24		no dre	P=1.
b	M m b6c gav lun MXB 24m24		no dre	P=1.
331	R f f34 gav thy MXA 24m24 s	: ±	#1.36gm *	P<.03 -
a	R f f34 gav thy cca 24m24 s		1.62gm *	P<.05
b	R f f34 gav cli adn 24m24 s		3.65gm *	P<.02
c	R f f34 gav TBA MXB 24m24 s		503.mg *	P<.08
d	R f f34 gav liv MXB 24m24 s		no dre	P=1.
332	R m f34 gav pta MXA 24m24 s	: ±	#874.mg *	P<.02 -
a	R m f34 gav pta adn 24m24 s		949.mg *	P<.03
b	R m f34 gav TBA MXB 24m24 s		544.mg *	P<.08
c	R m f34 gav liv MXB 24m24 s		12.2gm *	P<.5
2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7)***		....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
333	M f b6c eat MXB MXB 24m24	: + :	28.7mg *	P<.0005
a	M f b6c eat liv MXA 24m24		38.3mg *	P<.0005c
b	M f b6c eat amd MXA 24m24		38.8mg Z	P<.0005c
c	M f b6c eat amd MXA 24m24		40.3mg Z	P<.0005
d	M f b6c eat liv hpa 24m24		40.6mg *	P<.0005
e	M f b6c eat --- MXA 24m24		187.mg *	P<.0005
f	M f b6c eat --- hes 24m24		200.mg *	P<.002 c
g	M f b6c eat TBA MXB 24m24		86.1mg Z	P<.2
h	M f b6c eat liv MXB 24m24		38.3mg *	P<.0005
i	M f b6c eat lun MXB 24m24		12.8gm *	P<1.
334	M m b6c eat amd MXA 24m24	: + :	17.4mg *	P<.0005
a	M m b6c eat amd MXA 24m24		17.5mg *	P<.0005c
b	M m b6c eat MXB MXB 24m24		24.9mg Z	P<.0005
c	M m b6c eat liv hpa 24m24		36.2mg *	P<.0005
d	M m b6c eat liv MXA 24m24		38.3mg Z	P<.003 c
e	M m b6c eat TBA MXB 24m24		57.8mg *	P<.09
f	M m b6c eat liv MXB 24m24		38.3mg Z	P<.003
g	M m b6c eat lun MXB 24m24		1.94gm *	P<.9

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
OCHRATOXIN A*** 303-47-9											
319	c56586	.235mg	1.40mg	0/50	14.8ug	0/51	49.4ug	2/50	.148mg	8/50	kid:rua,ruc.	
a	c56586	.331mg	4.82mg	0/50	14.8ug	0/51	49.4ug	1/50	.148mg	5/50		
b	c56586	.448mg	n.s.s.	0/50	14.8ug	0/51	49.4ug	1/50	.148mg	3/50		
c	c56586	.103mg	n.s.s.	17/50	14.8ug	23/51	49.4ug	24/50	.148mg	30/50	kid:rua,ruc; mgl:fba.	C
d	c56586	.116mg	n.s.s.	17/50	14.8ug	23/51	49.4ug	22/50	.148mg	28/50		
e	c56586	.117mg	n.s.s.	39/50	14.8ug	44/51	49.4ug	40/50	.148mg	45/50		
f	c56586	n.s.s.	n.s.s.	0/50	14.8ug	0/51	49.4ug	0/50	.148mg	0/50	liv:hpa,hpc,nnd.	
320	c56586	40.6ug	87.9ug	1/50	14.8ug	1/51	49.3ug	20/51	.148mg	36/50	kid:rua,ruc,rue,tcb.	
a	c56586	51.8ug	.115mg	0/50	14.8ug	0/51	49.3ug	16/51	.148mg	30/50	kid:ruc,tcb.	
b	c56586	.127mg	.729mg	1/50	14.8ug	1/51	49.3ug	6/51	.148mg	10/50	kid:rua,rue.	
c	c56586	40.9ug	1.42mg	43/50	14.8ug	38/51	49.3ug	44/51	.148mg	50/50		
d	c56586	.495mg	n.s.s.	1/50	14.8ug	0/51	49.3ug	0/51	.148mg	2/50	liv:hpa,hpc,nnd.	
C.I. ACID ORANGE 3 6373-74-6												
321	c54911	868.mg	n.s.s.	0/50	177.mg	1/50	354.mg	3/50				S
a	c54911	165.mg	n.s.s.	35/50	177.mg	27/50	(354.mg | 23/50)				
b	c54911	707.mg	n.s.s.	3/50	177.mg	4/50	354.mg	4/50			liv:hpa,hpc,nnd.	
c	c54911	1.10gm	n.s.s.	2/50	177.mg	2/50	354.mg	3/50			lun:a/a,a/c.	
322	c54911	79.4mg	n.s.s.	7/50	88.4mg	16/50	(177.mg | 10/50)				S
a	c54911	96.8mg	n.s.s.	42/50	88.4mg	36/50	177.mg	39/50				
b	c54911	224.mg	n.s.s.	21/50	88.4mg	20/50	177.mg	15/50			liv:hpa,hpc,nnd.	
c	c54911	266.mg	n.s.s.	13/50	88.4mg	9/50	177.mg	10/50			lun:a/a,a/c.	
323	c54911	683.mg	6.26gm	0/50	264.mg	0/50	531.mg	6/50				
a	c54911	149.mg	n.s.s.	45/50	264.mg	44/50	531.mg	19/50				
b	c54911	945.mg	n.s.s.	1/50	264.mg	3/50	531.mg	0/50			liv:hpa,hpc,nnd.	
324	c54911	113.mg	n.s.s.	42/50	265.mg	33/50	536.mg	13/50				
a	c54911	1.65gm	n.s.s.	2/50	265.mg	0/50	536.mg	0/50			liv:hpa,hpc,nnd.	
C.I. ACID ORANGE 10 1936-15-8												
325	c53838	709.mg	n.s.s.	25/50	386.mg	27/50	(773.mg | 19/50)				
a	c53838	3.72gm	n.s.s.	3/50	386.mg	3/50	773.mg	3/50			liv:hpa,hpc,nnd.	
b	c53838	2.15gm	n.s.s.	2/50	386.mg	1/50	(773.mg | 0/50)			lun:a/a,a/c.	
326	c53838	1.45gm	n.s.s.	30/50	360.mg	19/50	720.mg	25/50				
a	c53838	2.09gm	n.s.s.	15/50	360.mg	7/50	720.mg	12/50			liv:hpa,hpc,nnd.	
b	c53838	2.56gm	n.s.s.	1/50	360.mg	3/50	720.mg	2/50			lun:a/a,a/c.	
327	c53838	89.9mg	n.s.s.	68/90	49.5mg	33/50	(149.mg | 31/50)				
a	c53838	967.mg	n.s.s.	3/90	49.5mg	2/50	149.mg	1/50			liv:hpa,hpc,nnd.	
328	c53838	346.mg	n.s.s.	0/90	39.6mg	3/50	119.mg	2/50			tnv:men,msm.	S
a	c53838	125.mg	n.s.s.	61/90	39.6mg	31/50	119.mg	34/50				
b	c53838	223.mg	n.s.s.	5/90	39.6mg	3/50	119.mg	8/50			liv:hpa,hpc,nnd.	
PENICILLIN VK 132-98-9												
329	c56100	754.mg	n.s.s.	38/50	357.mg	26/50	714.mg	30/50				
a	c56100	1.66gm	n.s.s.	3/50	357.mg	4/50	714.mg	4/50			liv:hpa,hpc,nnd.	
b	c56100	2.19gm	n.s.s.	4/50	357.mg	1/50	714.mg	5/50			lun:a/a,a/c.	
330	c56100	719.mg	n.s.s.	36/50	357.mg	35/50	714.mg	29/50				
a	c56100	657.mg	n.s.s.	19/50	357.mg	18/50	(714.mg | 8/50)			liv:hpa,hpc,nnd.	
b	c56100	1.81gm	n.s.s.	10/50	357.mg	9/50	714.mg	6/50			lun:a/a,a/c.	
331	c56100	576.mg	n.s.s.	6/50	354.mg	7/50	707.mg	11/50			thy:cca,ccr.	S
a	c56100	638.mg	n.s.s.	6/50	354.mg	6/50	707.mg	10/50				S
b	c56100	1.25gm	n.s.s.	0/50	354.mg	1/50	707.mg	3/50				S
c	c56100	197.mg	n.s.s.	44/50	354.mg	45/50	707.mg	38/50				
d	c56100	n.s.s.	n.s.s.	0/50	354.mg	1/50	707.mg	0/50			liv:hpa,hpc,nnd.	
332	c56100	390.mg	n.s.s.	10/50	354.mg	11/50	707.mg	14/50			pta:adn,can.	S
a	c56100	406.mg	n.s.s.	10/50	354.mg	11/50	707.mg	13/50				S
b	c56100	210.mg	n.s.s.	42/50	354.mg	40/50	707.mg	31/50				
c	c56100	1.99gm	n.s.s.	0/50	354.mg	1/50	707.mg	0/50			liv:hpa,hpc,nnd.	
2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7)*** (Dowicide 7, penta, PCP) 87-86-5												
333	c55389	19.4mg	47.8mg	1/35	12.8mg	6/50	25.6mg	9/50	76.9mg	42/50	---:hes; amd:pbb,phm,pob; liv:hpa,hpc.	C
a	c55389	24.4mg	71.6mg	1/35	12.8mg	4/50	25.6mg	6/50	76.9mg	31/50	liv:hpa,hpc.	
b	c55389	25.7mg	61.2mg	0/35	12.8mg	2/50	25.6mg	2/50	76.9mg	38/50	amd:pbb,phm,pob.	
c	c55389	26.6mg	64.0mg	0/35	12.8mg	1/50	25.6mg	2/50	76.9mg	38/50	amd:pbb,pob.	S
d	c55389	25.8mg	75.3mg	1/35	12.8mg	3/50	25.6mg	6/50	76.9mg	30/50		S
e	c55389	93.8mg	646.mg	0/35	12.8mg	1/50	25.6mg	3/50	76.9mg	9/50	---:hem,hes.	S
f	c55389	97.8mg	878.mg	0/35	12.8mg	1/50	25.6mg	3/50	76.9mg	8/50		
g	c55389	29.6mg	n.s.s.	24/35	12.8mg	29/50	25.6mg	25/50	76.9mg	46/50		
h	c55389	24.4mg	71.6mg	1/35	12.8mg	4/50	25.6mg	6/50	76.9mg	31/50	liv:hpa,hpc,nnd.	
i	c55389	221.mg	n.s.s.	2/35	12.8mg	3/50	25.6mg	1/50	76.9mg	3/50	lun:a/a,a/c.	
334	c55389	12.4mg	25.6mg	0/35	11.8mg	4/50	23.7mg	21/50	71.0mg	44/50	amd:pbb,pob.	S
a	c55389	12.2mg	28.2mg	1/35	11.8mg	4/50	23.7mg	21/50	71.0mg	45/50	amd:pbb,phm,pmb,pob.	
b	c55389	13.9mg	72.0mg	7/35	11.8mg	21/50	23.7mg	27/50	71.0mg	45/50	amd:pbb,phm,pmb,pob; liv:hpa,hpc.	C
c	c55389	19.2mg	128.mg	5/35	11.8mg	13/50	23.7mg	17/50	71.0mg	32/50		S
d	c55389	18.8mg	224.mg	6/35	11.8mg	19/50	23.7mg	21/50	71.0mg	34/50	liv:hpa,hpc.	
e	c55389	21.2mg	n.s.s.	20/35	11.8mg	32/50	23.7mg	33/50	71.0mg	46/50		
f	c55389	18.8mg	224.mg	6/35	11.8mg	19/50	23.7mg	21/50	71.0mg	34/50	liv:hpa,hpc,nnd.	
g	c55389	143.mg	n.s.s.	5/35	11.8mg	1/50	23.7mg	2/50	71.0mg	5/50	lun:a/a,a/c.	

```
     Spe Strain  Site    Xpo+Xpt                                                                                    TD50     2Tailpvl
       Sex   Route   Hist      Notes                                                                                    DR     AuOp

2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE   ....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
335  M f b6c eat --- hes 24m24                                                  :   +          :        106.mg * P<.007 p
 a   M f b6c eat MXB MXB 24m24                                                                        50.4mg * P<.02
 b   M f b6c eat liv MXA 24m24                                                                        90.1mg * P<.2   p
 c   M f b6c eat TBA MXB 24m24                                                                        79.3mg / P<.5
 d   M f b6c eat liv MXB 24m24                                                                        90.1mg * P<.2
 e   M f b6c eat lun MXB 24m24                                                                        395.mg * P<.4
336  M m b6c eat MXB MXB 24m24                                          :  +      :                   10.5mg * P<.002
 a   M m b6c eat amd MXA 24m24                                                                       12.9mg * P<.0005c
 b   M m b6c eat liv hpa 24m24                                                                       13.5mg * P<.002
 c   M m b6c eat liv MXA 24m24                                                                       13.7mg * P<.005 c
 d   M m b6c eat TBA MXB 24m24                                                                       22.6mg * P<.2
 e   M m b6c eat liv MXB 24m24                                                                       13.7mg * P<.005
 f   M m b6c eat lun MXB 24m24                                                                       154.mg * P<.5

PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE..:..100....:..1mg....:..10.....:..100....:..1g.....:..10
337  M f b6c eat TBA MXB 24m24                                                                     :no dre   P=1.   -
 a   M f b6c eat liv MXB 24m24                                                                      no dre   P=1.
 b   M f b6c eat lun MXB 24m24                                                                      82.0gm * P<.5
338  M m b6c eat TBA MXB 24m24                                                                     no dre   P=1.   -
 a   M m b6c eat liv MXB 24m24                                                                     no dre   P=1.
 b   M m b6c eat lun MXB 24m24                                                                     no dre   P=1.
339  R f f34 eat zym MXA 24m25                                                              :    ±  5.03gm * P<.04  e
 a   R f f34 eat thy MXA 24m25                                                                      5.80gm * P<.03
 b   R f f34 eat zym ade 24m25                                                                      11.1gm * P<.1   e
 c   R f f34 eat zym car 24m25                                                                      9.20gm * P<.2   e
 d   R f f34 eat TBA MXB 24m25                                                                     416.mg * P<.04
 e   R f f34 eat liv MXB 24m25                                                                     no dre   P=1.
340  R m f34 eat amd phm 24m25                                                                 :   12.2gm * P<.04
 a   R m f34 eat zym MXA 24m25                                                                     13.6gm * P<.2   e
 b   R m f34 eat zym car 24m25                                                                     20.6gm * P<.2   e
 c   R m f34 eat zym ade 24m25                                                                     no dre   P=1.   e
 d   R m f34 eat TBA MXB 24m25                                                                     24.0gm / P<1.
 e   R m f34 eat liv MXB 24m25                                                                     no dre   P=1.

PENTANAL METHYLFORMYLHYDRAZONE    100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
341  M f swa gav lun mix 12m33 e                                    . +   .                          3.12mg   P<.0005+
 a   M f swa gav lun ade 12m33 e                                                                     5.64mg   P<.0005
 b   M f swa gav lun adc 12m33 e                                                                     9.29mg   P<.0005
 c   M f swa gav liv bhp 12m33 e                                                                     11.8mg   P<.003 +
342  M m swa gav lun mix 12m31 e                                   . +    .                          3.79mg   P<.0005+
 a   M m swa gav lun ade 12m31 e                                                                     5.52mg   P<.002
 b   M m swa gav pre mix 12m31 e                                                                    16.2mg   P<.007 +
 c   M m swa gav lun adc 12m31 e                                                                     11.0mg   P<.02
 d   M m swa gav pre sqc 12m31 e                                                                    19.8mg   P<.02
 e   M m swa gav liv hpt 12m31 e                                                                    33.1mg   P<.3   +
 f   M m swa gav pre sqp 12m31 e                                                                    106.mg   P<.3

PHENOBARBITAL***                  100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
343  M m chg eat liv tum 52w52 r                                   .   +       .                    5.56mg   P<.002 +
344  M m chh eat liv tum 52w52 r                                                                    noTD50   P<.09
345  R m f34 eat liv mix 52w52 er                                          .>                       no dre   P=1.   -

PHENYL-beta-NAPHTHYLAMINE***      100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
346  M f b6c eat kid MXA 24m24                                                              :     10.8gm * P<.1   e
 a   M f b6c eat TBA MXB 24m24                                                                      no dre   P=1.
 b   M f b6c eat liv MXB 24m24                                                                      5.63gm * P<.4
 c   M f b6c eat lun MXB 24m24                                                                      no dre   P=1.
347  M m b6c eat sub MXA 24m24                                                          :   ±     #2.38gm * P<.04  -
 a   M m b6c eat TBA MXB 24m24                                                                      4.51gm * P<.8
 b   M m b6c eat liv MXB 24m24                                                                      1.35gm * P<.2
 c   M m b6c eat lun MXB 24m24                                                                      no dre   P=1.
348  R f f34 eat TBA MXB 24m24                                                 :>                   no dre   P=1.   -
 a   R f f34 eat liv MXB 24m24                                                                      no dre   P=1.
349  R m f34 eat TBA MXB 24m24                                                :>                   no dre   P=1.   -
 a   R m f34 eat liv MXB 24m24                                                                      no dre   P=1.

PHENYLBUTAZONE                    100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
350  R f don eat adr phe 24m26 e                                                        .   ±          707.mg * P<.03  -
 a   R f don eat liv nnd 24m26 e                                                                     1.14gm * P<.06  -
 b   R f don eat kid tum 24m26 e                                                                     no dre   P=1.   -
 c   R f don eat tba mix 24m26 e                                                                     no dre   P=1.   -
351  R m don eat kid tum 24m26 e                                                    .>                no dre   P=1.   -
 a   R m don eat liv hpc 24m26 e                                                                    no dre   P=1.   -
 b   R m don eat liv nnd 24m26 e                                                                    no dre   P=1.   -
 c   R m don eat tba mix 24m26 e                                                                    no dre   P=1.   -
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly	Code
2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE (penta, PCP) 87-86-5											
335	c55378	49.9mg	1.32gm	0/35	12.8mg	3/50	25.5mg	6/50			
a	c55378	25.0mg	n.s.s.	3/35	12.8mg	11/50	25.5mg	14/50	---:hes; liv:hpa,hpc.		P
b	c55378	34.1mg	n.s.s.	3/35	12.8mg	9/50	25.5mg	9/50	liv:hpa,hpc.		
c	c55378	17.5mg	n.s.s.	27/35	12.8mg	30/50	25.5mg	37/50			
d	c55378	34.1mg	n.s.s.	3/35	12.8mg	9/50	25.5mg	9/50	liv:hpa,hpc,nnd.		
e	c55378	89.9mg	n.s.s.	1/35	12.8mg	1/50	25.5mg	3/50	lun:a/a,a/c.		
336	c55378	5.89mg	51.5mg	7/35	11.8mg	29/50	23.5mg	41/50	amd:pbb,pob; liv:hpa,hpc.		C
a	c55378	8.42mg	24.2mg	0/35	11.8mg	10/50	23.5mg	23/50	amd:pbb,pob.		
b	c55378	7.57mg	66.9mg	5/35	11.8mg	20/50	23.5mg	33/50			S
c	c55378	7.30mg	123.mg	7/35	11.8mg	26/50	23.5mg	37/50	liv:hpa,hpc.		
d	c55378	7.67mg	n.s.s.	17/35	11.8mg	38/50	23.5mg	45/50			
e	c55378	7.30mg	123.mg	7/35	11.8mg	26/50	23.5mg	37/50	liv:hpa,hpc,nnd.		
f	c55378	36.5mg	n.s.s.	2/35	11.8mg	2/50	23.5mg	6/50	lun:a/a,a/c.		
PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE (PETN, NF) 78-11-5											
337	c55743	9.43gm	n.s.s.	37/50	3.19gm	29/50	6.38gm	28/50			
a	c55743	13.6gm	n.s.s.	6/50	3.19gm	2/50	(6.38gm	1/50)	liv:hpa,hpc,nnd.		
b	c55743	17.0gm	n.s.s.	3/50	3.19gm	3/50	6.38gm	5/50	lun:a/a,a/c.		
338	c55743	10.4gm	n.s.s.	36/50	2.94gm	28/50	5.89gm	32/50			
a	c55743	14.5gm	n.s.s.	11/50	2.94gm	11/50	5.89gm	11/50	liv:hpa,hpc,nnd.		
b	c55743	9.00gm	n.s.s.	11/50	2.94gm	8/50	(5.89gm	7/50)	lun:a/a,a/c.		
339	c55743	1.66gm	n.s.s.	0/50	304.mg	1/50	616.mg	3/50	zym:ade,car.		
a	c55743	1.71gm	n.s.s.	0/50	304.mg	0/50	616.mg	3/50	thy:fca,fcc.		S
b	c55743	2.72gm	n.s.s.	0/50	304.mg	0/50	616.mg	2/50			
c	c55743	2.10gm	n.s.s.	0/50	304.mg	1/50	616.mg	1/50			
d	c55743	182.mg	n.s.s.	46/50	304.mg	47/50	616.mg	50/50			
e	c55743	n.s.s.	n.s.s.	0/50	304.mg	0/50	616.mg	0/50	liv:hpa,hpc,nnd.		
340	c55743	4.24gm	n.s.s.	0/50	981.mg	2/50	1.97gm	3/50			S
a	c55743	4.84gm	n.s.s.	0/50	981.mg	3/50	1.97gm	2/50	zym:ade,car.		
b	c55743	7.00gm	n.s.s.	0/50	981.mg	2/50	1.97gm	2/50			
c	c55743	n.s.s.	n.s.s.	0/50	981.mg	1/50	1.97gm	0/50			
d	c55743	1.02gm	n.s.s.	47/50	981.mg	43/50	1.97gm	48/50			
e	c55743	11.4gm	n.s.s.	3/50	981.mg	0/50	1.97gm	1/50	liv:hpa,hpc,nnd.		
PENTANAL METHYLFORMYLHYDRAZONE 57590-20-2											
341	1859	1.80mg	6.98mg	13/50	2.58mg	36/48			Toth;myco,98,83-89;1987/pers.comm.		
a	1859	2.94mg	22.1mg	12/50	2.58mg	28/48					
b	1859	4.88mg	26.7mg	2/50	2.58mg	16/48					
c	1859	5.31mg	52.3mg	0/23	2.58mg	8/32					
342	1859	2.04mg	11.7mg	11/41	2.77mg	30/44					
a	1859	2.84mg	23.2mg	8/41	2.77mg	24/44					
b	1859	6.61mg	193.mg	0/27	2.77mg	6/34					
c	1859	4.82mg	n.s.s.	5/41	2.77mg	15/44					
d	1859	7.52mg	n.s.s.	0/27	2.77mg	5/34					
e	1859	5.38mg	n.s.s.	0/8	2.77mg	1/11					
f	1859	17.2mg	n.s.s.	0/27	2.77mg	1/34					
PHENOBARBITAL*** (phenobarbitone) 50-06-6											
343	1891	2.31mg	38.5mg	42/139	24.0mg	14/21			Mizutani;clet,39,233-237;1988		
344	1891	n.s.s.	n.s.s.	42/56	24.0mg	31/31					
345	1834	20.6mg	n.s.s.	0/20	20.0mg	0/20			Leonard;jnci,79,1313-1319;1987/pers.comm.		
PHENYL-beta-NAPHTHYLAMINE*** (Agerite powder, N-phenyl-2-naphthylamine) 135-88-6											
346	c02915	2.66gm	n.s.s.	0/50	322.mg	0/50	644.mg	2/50	kid:tla,uac.		
a	c02915	830.mg	n.s.s.	42/50	322.mg	23/50	644.mg	33/50			
b	c02915	1.41gm	n.s.s.	4/50	322.mg	3/50	644.mg	7/50	liv:hpa,hpc,nnd.		
c	c02915	3.31gm	n.s.s.	5/50	322.mg	1/50	644.mg	3/50	lun:a/a,a/c.		
347	c02915	992.mg	n.s.s.	2/50	297.mg	4/50	594.mg	8/50	sub:fbs,nfs,srn.		S
a	c02915	437.mg	n.s.s.	34/50	297.mg	30/50	594.mg	32/50			
b	c02915	487.mg	n.s.s.	11/50	297.mg	16/50	594.mg	17/50	liv:hpa,hpc,nnd.		
c	c02915	1.36gm	n.s.s.	11/50	297.mg	9/50	594.mg	7/50	lun:a/a,a/c.		
348	c02915	175.mg	n.s.s.	46/50	124.mg	38/50	(248.mg	33/50)			
a	c02915	3.10gm	n.s.s.	2/50	124.mg	0/50	248.mg	0/50	liv:hpa,hpc,nnd.		
349	c02915	108.mg	n.s.s.	48/50	99.0mg	40/50	(198.mg	42/50)			
a	c02915	1.11gm	n.s.s.	2/50	99.0mg	3/50	198.mg	0/50	liv:hpa,hpc,nnd.		
PHENYLBUTAZONE 50-33-9											
350	1815	283.mg	n.s.s.	4/96	59.1mg	6/50	118.mg	6/42	Maekawa;jnci,79,577-584;1987/pers.comm.		
a	1815	396.mg	n.s.s.	2/96	59.1mg	3/50	118.mg	4/42			
b	1815	427.mg	n.s.s.	0/96	59.1mg	0/50	118.mg	0/42			
c	1815	151.mg	n.s.s.	85/96	59.1mg	43/50	118.mg	32/42			
351	1815	335.mg	n.s.s.	0/93	47.3mg	0/47	95.4mg	0/44			
a	1815	335.mg	n.s.s.	1/93	47.3mg	0/47	95.4mg	0/44			
b	1815	778.mg	n.s.s.	4/93	47.3mg	0/47	95.4mg	2/44			
c	1815	159.mg	n.s.s.	69/93	47.3mg	36/47	95.4mg	27/44			

```
     Spe Strain  Site     Xpo+Xpt                                                                                          TD50      2Tailpvl
       Sex    Route    Hist       Notes                                                                                         DR        AuOp

m-PHENYLENEDIAMINE                100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
352  M f b6c wat liv hem 78w84 e                                                                 .>            916.mg * P<.2    -
 a   M f b6c wat liv hct 78w84 e                                                                               no dre   P=1.    -
 b   M f b6c wat liv hnd 78w84 e                                                                               no dre   P=1.    -
 c   M f b6c wat lun ade 78w84 e                                                                               no dre   P=1.    -
353  M m b6c wat liv hem 78w84 e                                                               .>              2.73gm * P<.9    -
 a   M m b6c wat liv hct 78w84 e                                                                               no dre   P=1.    -
 b   M m b6c wat liv hnd 78w84 e                                                                               no dre   P=1.    -
 c   M m b6c wat lun ade 78w84 e                                                                               no dre   P=1.    -

PROPYL GALLATE***                 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
354  R m f3d eat eso tum 52w52 er                                                               .>             no dre   P=1.    -
 a   R m f3d eat for tum 52w52 er                                                                              no dre   P=1.    -
 b   R m f3d eat liv tum 52w52 er                                                                              no dre   P=1.    -

PROPYLENE***                      100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
355  M f swi inh lun ade 18m24                                                                               . 19.8gm * P<.09   -
 a   M f swi inh liv hpt 18m24                                                                                 286.gm * P<.6    -
 b   M f swi inh lun adc 18m24                                                                                 1.17kg   P<.9    -
 c   M f swi inh tba mix 18m24                                                                                 10.1gm * P<.08   -
 d   M f swi inh tba mal 18m24                                                                                 20.1gm * P<.3    -
356  M m swi inh lun ade 18m24                                                                                 no dre   P=1.    -
 a   M m swi inh lun adc 18m24                                                                                 no dre   P=1.    -
 b   M m swi inh liv hpt 18m24                                                                                 no dre   P=1.    -
 c   M m swi inh tba mix 18m24                                                                                 no dre   P=1.    -
 d   M m swi inh tba mal 18m24                                                                                 no dre   P=1.    -

1,2-PROPYLENE OXIDE***            100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
357  R f wsr inh mgl fba 29m29 e                                                         .  +       .          92.6mg * P<.003 +
 a   R f wsr inh mgl adc 29m29 e                                                                               813.mg * P<.2
 b   R f wsr inh liv cho 29m29                                                                                 2.46gm * P<.5
 c   R f wsr inh res car 29m29 e                                                                               no dre   P=1.
 d   R f wsr inh tba tum 29m29 e                                                                               25.7mg * P<.0005
 e   R f wsr inh tba mal 29m29 e                                                                               150.mg * P<.0005
358  R m wsr inh res car 29m29 e                                                                .    +    +hist 896.mg * P<.005
 a   R m wsr inh liv nnd 29m29                                                                                 no dre   P=1.
 b   R m wsr inh liv clc 29m29                                                                                 no dre   P=1.
 c   R m wsr inh tba mal 29m29 e                                                                               101.mg * P<.002
 d   R m wsr inh tba tum 29m29 e                                                                               79.3mg Z P<.02

FD & C RED NO. 3***               100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
359  M f cd1 eat tba mix 24m24 e                                                                               no dre   P=1.    -
 a   M f cd1 eat tba ben 24m24 e                                                                               no dre   P=1.    -
 b   M f cd1 eat tba mal 24m24 e                                                                               no dre   P=1.    -
360  M m cd1 eat --- lcl 24m24 e                                                                     .   ±     3.14gm Z P<.02   -
 a   M m cd1 eat tba mix 24m24 e                                                                               17.0gm   P<.3
 b   M m cd1 eat tba ben 24m24 e                                                                               25.9gm * P<.3    -
 c   M m cd1 eat tba mal 24m24 e                                                                               87.6gm * P<.8    -

RETINOL ACETATE***                100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
361  R m f3d wat for neo 52w52                                                               .>                no dre   P=1.    -
 a   R m f3d wat liv tum 52w52                                                                                 no dre   P=1.

RETINOL PALMITATE                 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
362  R m cdr eat liv tum 28m28 e                                                        .>                     no dre   P=1.

ROTENONE***                       100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
363  M f b6c eat TBA MXB 24m24                                                                    :>           no dre   P=1.    -
 a   M f b6c eat liv MXB 24m24                                                                                 no dre   P=1.
 b   M f b6c eat lun MXB 24m24                                                                                 15.0gm * P<1.
364  M m b6c eat TBA MXB 24m24                                                              :>                 no dre   P=1.    -
 a   M m b6c eat liv MXB 24m24                                                                                 no dre   P=1.
 b   M m b6c eat lun MXB 24m24                                                                                 no dre   P=1.
365  R f f34 eat TBA MXB 24m24                                             :>                                  no dre   P=1.    -
 a   R f f34 eat liv MXB 24m24                                                                                 no dre   P=1.
366  R m f34 eat pty adn 24m24                                                  :>                             35.6mg * P<.3    e
 a   R m f34 eat TBA MXB 24m24                                                                                 no dre   P=1.
 b   R m f34 eat liv MXB 24m24                                                                                 no dre   P=1.

SALBUTAMOL***                     100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
367  R f cdr eat meo ley 80w80 ekr                                                      .  +   .               36.3mg   P<.0005+

STYRENE***                        100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
368  R f sda inh mam mal 12m24                                                            .  +      .          57.1mg * P<.002 +

 a   R f sda inh mam mix 12m24                                                                                 23.3mg * P<.02  +
 b   R f sda inh tba mix 12m24                                                                                 48.7mg * P<.3
```

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc					Citation or Pathology Brkly Code
m-PHENYLENEDIAMINE 108-45-2												
352 1888	277.mg	n.s.s.	0/50	37.1mg	1/50	74.3mg	2/59					Amo;fctx,26,893-897;1988
a 1888	175.mg	n.s.s.	3/50	37.1mg	0/50	74.3mg	0/59					
b 1888	175.mg	n.s.s.	0/50	37.1mg	0/50	74.3mg	0/59					
c 1888	406.mg	n.s.s.	4/50	37.1mg	2/50	74.3mg	2/59					
353 1888	165.mg	n.s.s.	4/50	31.0mg	4/50	61.9mg	5/56					
a 1888	112.mg	n.s.s.	20/50	31.0mg	7/50	(61.9mg	3/56)					
b 1888	98.2mg	n.s.s.	7/50	31.0mg	4/50	(61.9mg	1/56)					
c 1888	123.mg	n.s.s.	8/50	31.0mg	3/50	(61.9mg	1/56)					
PROPYL GALLATE*** 121-79-9												
354 1900	206.mg	n.s.s.	0/10	400.mg	0/10							Hirose;carc,8,1731-1735;1987/pers.comm.
a 1900	206.mg	n.s.s.	0/10	400.mg	0/10							
b 1900	206.mg	n.s.s.	0/10	400.mg	0/10							
PROPYLENE*** 115-07-1												
355 bt702	6.88gm	n.s.s.	6/100	94.7mg	10/100	474.mg	13/100	2.37gm	15/100			Ciliberti;anya,534,235-245;1988
a bt702	30.2gm	n.s.s.	0/100	94.7mg	1/100	474.mg	0/100	2.37gm	1/100			
b bt702	34.8gm	n.s.s.	1/100	94.7mg	1/100	474.mg	0/100	2.37gm	1/100			
c bt702	3.79gm	n.s.s.	24/100	94.7mg	34/100	474.mg	31/100	2.37gm	39/100			
d bt702	5.89gm	n.s.s.	18/100	94.7mg	20/100	474.mg	19/100	2.37gm	25/100			
356 bt702	26.0gm	n.s.s.	10/100	78.9mg	8/100	395.mg	9/100	1.97gm	3/100			
a bt702	29.9gm	n.s.s.	0/100	78.9mg	0/100	395.mg	1/100	1.97gm	0/100			
b bt702	44.5gm	n.s.s.	4/100	78.9mg	2/100	395.mg	1/100	1.97gm	0/100			
c bt702	1.99gm	n.s.s.	26/100	78.9mg	17/100	395.mg	19/100	(1.97gm	6/100)			
d bt702	2.63gm	n.s.s.	14/100	78.9mg	11/100	395.mg	10/100	(1.97gm	2/100)			
1,2-PROPYLENE OXIDE*** (1,2-epoxypropane) 75-56-9												
357 1830	46.7mg	602.mg	32/69	5.33mg	30/71	17.8mg	39/69	53.3mg	47/70			Kuper;fctx,29,159-167;1988
a 1830	235.mg	n.s.s.	3/69	5.33mg	6/71	17.8mg	5/69	53.3mg	8/70			
b 1830	447.mg	n.s.s.	2/69	5.33mg	1/71	17.8mg	2/69	53.3mg	3/70			
c 1830	77.4mg	n.s.s.	0/69	5.33mg	0/71	17.8mg	0/69	53.3mg	0/70			
d 1830	14.0mg	69.4mg	52/69	5.33mg	49/71	17.8mg	61/69	53.3mg	67/70			
e 1830	81.1mg	510.mg	6/69	5.33mg	15/71	17.8mg	14/69	53.3mg	26/70			
358 1830	310.mg	7.93gm	0/70	3.73mg	0/69	12.4mg	0/71	37.3mg	4/70			
a 1830	604.mg	n.s.s.	0/70	3.73mg	0/69	12.4mg	1/71	37.3mg	0/70			
b 1830	630.mg	n.s.s.	1/70	3.73mg	0/69	12.4mg	2/71	37.3mg	0/70			
c 1830	51.3mg	569.mg	19/70	3.73mg	17/69	12.4mg	22/71	37.3mg	34/70			
d 1830	35.9mg	n.s.s.	49/70	3.73mg	28/69	12.4mg	34/71	37.3mg	53/70			
FD & C RED NO. 3*** (erythrosine) 16423-68-0												
359 1811	11.7gm	n.s.s.	67/120	3.90gm	25/60							Borzelleca;fctx,25,735-737;1987
a 1811	14.4gm	n.s.s.	40/120	390.mg	13/60	1.30gm	9/60	3.90gm	16/60			
b 1811	16.0gm	n.s.s.	35/120	390.mg	14/60	1.30gm	17/60	3.90gm	12/60			
360 1811	1.11gm	n.s.s.	1/120	360.mg	5/60	(1.20gm	2/60	3.60gm	2/60)			
a 1811	4.50gm	n.s.s.	46/120	3.60gm	28/60							
b 1811	7.34gm	n.s.s.	29/120	360.mg	5/60	1.20gm	12/60	3.60gm	17/60			
c 1811	9.15gm	n.s.s.	17/120	360.mg	18/60	1.20gm	12/60	3.60gm	12/60			
RETINOL ACETATE*** (vitamin A, acetate) 127-47-9												
361 1883	64.4mg	n.s.s.	0/10	125.mg	0/10							Hasegawa;gann,79,320-328;1988/pers.comm.
a 1883	64.4mg	n.s.s.	0/10	125.mg	0/10							
RETINOL PALMITATE (vitamin A, palmitate) 79-81-2												
362 1833	16.8mg	n.s.s.	0/38	1.60mg	0/39							Arnold;fctx,23,779-793;1985
ROTENONE*** (tubatoxin) 83-79-4												
363 c55210	345.mg	n.s.s.	26/50	77.3mg	16/50	155.mg	22/50					
a c55210	658.mg	n.s.s.	4/50	77.3mg	3/50	155.mg	4/50					liv:hpa,hpc,nnd.
b c55210	607.mg	n.s.s.	4/50	77.3mg	2/50	155.mg	5/50					lun:a/a,a/c.
364 c55210	88.4mg	n.s.s.	25/50	71.3mg	26/50	(143.mg	18/50)					
a c55210	139.mg	n.s.s.	12/50	71.3mg	12/50	(143.mg	1/50)					liv:hpa,hpc,nnd.
b c55210	346.mg	n.s.s.	6/50	71.3mg	12/50	143.mg	8/50					lun:a/a,a/c.
365 c55210	2.86mg	n.s.s.	45/50	1.88mg	43/50	3.71mg	45/50					
a c55210	36.7mg	n.s.s.	1/50	1.88mg	0/50	3.71mg	0/50					liv:hpa,hpc,nnd.
366 c55210	9.37mg	n.s.s.	1/50	1.51mg	0/50	2.97mg	4/50					
a c55210	2.98mg	n.s.s.	48/50	1.51mg	36/50	2.97mg	47/50					
b c55210	12.0mg	n.s.s.	3/50	1.51mg	1/50	2.97mg	3/50					liv:hpa,hpc,nnd.
SALBUTAMOL*** 18559-94-9												
367 1734m	17.7mg	93.4mg	0/105	20.0mg	10/50							Gopinath;enhp,73,107-113;1987/Jack 1983/pers.comm.
STYRENE*** 100-42-5												
368 bt101	28.9mg	316.mg	6/60	2.66mg	6/30	5.31mg	4/30	10.6mg	9/30	21.2mg	12/30	31.9mg 9/30 Conti; anya,534,203-234;1988
a bt101	10.5mg	8.37gm	34/60	2.66mg	24/30	5.31mg	21/30	10.6mg	23/30	21.2mg	24/30	31.9mg 25/30
b bt101	13.0mg	n.s.s.	43/60	2.66mg	24/30	5.31mg	25/30	10.6mg	26/30	21.2mg	24/30	31.9mg 25/30

```
     Spe Strain  Site     Xpo+Xpt                                                                        TD50      2Tailpvl
       Sex    Route    Hist        Notes                                                                     DR       AuOp

 c    R f sda inh tba mal 12m24                                                                          205.mg * P<.5
369   R f sda gav tba mix 12m24                                           .  ±                           12.0mg   P<.03
 a    R f sda gav tba mal 12m24                                                                          no dre   P=1.
370   R m sda inh tba mix 12m24                                                 .>                       107.mg * P<.4
 a    R m sda inh tba mal 12m24                                                                          no dre   P=1.
371   R m sda gav tba mix 12m24                                                        .>                1.22gm * P<.7
 a    R m sda gav tba mal 12m24                                                                          1.09gm * P<.5

STYRENE OXIDE***                  100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
372   R f sda gav for mix 12m36 ej                                                  . + .                96.5mg * P<.0005+
 a    R f sda gav for sqc 12m36 ej                                                                       102.mg * P<.0005+
 b    R f sda gav for sqn 12m36 ej                                                                       129.mg * P<.0005+
 c    R f sda gav for sqi 12m36 ej                                                                       301.mg * P<.0005+
 d    R f sda gav for ben 12m36 ej                                                                       503.mg * P<.009 +
 e    R f sda gav tba mix 12m36 j                                                                        164.mg * P<.009
 f    R f sda gav tba mal 12m36 j                                                                        166.mg * P<.002
373   R m sda gav for sqc 12m36 ej                                                . +   .                63.0mg   P<.0005+
 a    R m sda gav for mix 12m36 ej                                                                       99.6mg * P<.0005+
 b    R m sda gav for sqn 12m36 ej                                                                       140.mg * P<.0005+
 c    R m sda gav for sqi 12m36 ej                                                                       267.mg * P<.004 +
 d    R m sda gav for ben 12m36 ej                                                                       354.mg * P<.003 +
 e    R m sda gav tba mal 12m36 j                                                                        189.mg * P<.004
 f    R m sda gav tba mix 12m36 j                                                                        191.mg * P<.02

TETRACYCLINE.HCl                  100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
374   M f b6c eat TBA MXB 24m24                                                                      :> no dre   P=1.    -
 a    M f b6c eat liv MXB 24m24                                                                         no dre   P=1.
 b    M f b6c eat lun MXB 24m24                                                                         37.2gm * P<.4
375   M m b6c eat TBA MXB 24m24                                                                    :>   no dre   P=1.    -
 a    M m b6c eat liv MXB 24m24                                                                         no dre   P=1.
 b    M m b6c eat lun MXB 24m24                                                                         no dre   P=1.
376   R f f34 eat TBA MXB 24m24                                                              :>         no dre   P=1.    -
 a    R f f34 eat liv MXB 24m24                                                                         no dre   P=1.
377   R m f34 eat TBA MXB 24m24                                                              :>         no dre   P=1.    -
 a    R m f34 eat liv MXB 24m24                                                                         6.09gm * P<.06

3,4,5,6-TETRAHYDROURIDINE         100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
378   R m f34 ipj liv tum 52w52 e                                          .>                           no dre   P=1.
 a    R m f34 ipj tba tum 52w52 e                                                                       15.7mg   P<.6

THIOACETAMIDE***                  100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
379   R m don eat liv mix 40w80 er                                         .  ±                         11.5mg   P<.02  +
 a    R m don eat liv thc 40w80 er                                                                      21.8mg   P<.08
 b    R m don eat liv pac 40w80 er                                                                      27.6mg   P<.2

DL-alpha-TOCOPHEROL               100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
380   R m f3d eat eso tum 52w52 er                                                      .>              no dre   P=1.    -
 a    R m f3d eat for tum 52w52 er                                                                      no dre   P=1.    -
 b    R m f3d eat liv tum 52w52 er                                                                      no dre   P=1.    -

TRIBROMOMETHANE                   100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
381   M f b6c gav MXA MXA 24m25 s                                                        :    ±        #1.11gm * P<.04  -
 a    M f b6c gav TBA MXB 24m25 s                                                                       no dre   P=1.
 b    M f b6c gav liv MXB 24m25 s                                                                       570.mg * P<.3
 c    M f b6c gav lun MXB 24m25 s                                                                       no dre   P=1.
382   M m b6c gav sub MXA 24m25                                                  :   ±                 #81.9mg   P<.02  -
 a    M m b6c gav TBA MXB 24m25                                                                         41.0mg   P<.2
 b    M m b6c gav liv MXB 24m25                                                                         53.6mg   P<.07
 c    M m b6c gav lun MXB 24m25                                                                         2.45gm   P<1.
383   R f f34 gav lgi MXA 24m25                                                         :  +    :  +hist 469.mg * P<.002 c
 a    R f f34 gav lgi pla 24m25                                                                         632.mg * P<.004
 b    R f f34 gav.TBA MXB 24m25                                                                         no dre   P=1.
 c    R f f34 gav liv MXB 24m25                                                                         676.mg * P<.06
384   R m f34 gav tes MXA 24m24 s                                                 :  ±                  75.0mg * P<.03
 a    R m f34 gav thy fcc 24m24 s                                                                       656.mg * P<.03
 b    R m f34 gav lgi MXA 24m24 s                                                                 +hist 1.05gm * P<.02  p
 c    R m f34 gav TBA MXB 24m24 s                                                                       513.mg * P<.7
 d    R m f34 gav liv MXB 24m24 s                                                                       no dre   P=1.

1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE  .....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
385   R f cdr inh pni isa 24m24 e                                                                       160.gm * P<.005 -
386   R m cdr inh pni isa 24m24 e                                                                       9.14kg   P<1.   -

1,1,1-TRICHLOROETHANE, TECHNICAL GRADE*** ..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
387   M f b6c inh liv mix 24m24 e                                                                       no dre   P=1.    -
 a    M f b6c inh liv hpc 24m24 e                                                                       no dre   P=1.    -
 b    M f b6c inh liv hpa 24m24 e                                                                       no dre   P=1.    -
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc						Citation or Pathology	Brkly Code
c	bt101	41.7mg	n.s.s.	16/60	2.66mg	9/30	5.31mg	9/30	10.6mg	13/30	21.2mg	10/30	31.9mg	10/30	
369	bt102	4.97mg	n.s.s.	25/40	16.1mg	34/40	(80.4mg	19/40)							
a	bt102	176.mg	n.s.s.	9/40	16.1mg	15/40	80.4mg	9/40							
370	bt101	27.7mg	n.s.s.	17/60	1.86mg	12/30	3.72mg	6/30	7.44mg	11/30	14.9mg	10/30	22.3mg	12/30	
a	bt101	75.8mg	n.s.s.	10/60	1.86mg	5/30	3.72mg	5/30	7.44mg	8/30	14.9mg	3/30	22.3mg	4/30	
371	bt102	143.mg	n.s.s.	9/40	16.1mg	8/40	80.4mg	10/40							
a	bt102	206.mg	n.s.s.	2/40	16.1mg	3/40	80.4mg	4/40							
STYRENE OXIDE*** 96-09-3															
372	bt105	60.6mg	167.mg	0/40	10.7mg	7/37	53.6mg	21/38						Conti;anya,534,203-234;1988/Maltoni 1981	
a	bt105	63.7mg	180.mg	0/40	10.7mg	7/37	53.6mg	20/38							
b	bt105	78.0mg	264.mg	0/40	10.7mg	7/37	53.6mg	16/38							
c	bt105	151.mg	755.mg	0/40	10.7mg	1/37	53.6mg	10/38							
d	bt105	217.mg	19.7gm	0/40	10.7mg	2/37	53.6mg	5/38							
e	bt105	74.1mg	7.47gm	10/40	10.7mg	16/40	53.6mg	22/40							
f	bt105	83.2mg	771.mg	7/40	10.7mg	9/40	53.6mg	20/40							
373	bt105	29.6mg	184.mg	0/39	10.7mg	9/39	(53.6mg	16/39)							
a	bt105	63.2mg	194.mg	0/39	10.7mg	10/39	53.6mg	19/39							
b	bt105	84.3mg	284.mg	0/39	10.7mg	6/39	53.6mg	16/39							
c	bt105	141.mg	2.30gm	0/39	10.7mg	5/39	53.6mg	8/39							
d	bt105	172.mg	2.23gm	0/39	10.7mg	3/39	53.6mg	7/39							
e	bt105	89.2mg	1.75gm	6/40	10.7mg	11/40	53.6mg	18/40							
f	bt105	84.0mg	n.s.s.	9/40	10.7mg	14/40	53.6mg	20/40							
TETRACYCLINE.HCl 64-75-5															
374	c55561	5.96gm	n.s.s.	35/50	1.61gm	19/50	3.22gm	26/50							
a	c55561	36.7gm	n.s.s.	10/50	1.61gm	0/50	3.22gm	0/50							liv:hpa,hpc,nnd.
b	c55561	8.64gm	n.s.s.	4/50	1.61gm	1/50	3.22gm	7/50							lun:a/a,a/c.
375	c55561	3.44gm	n.s.s.	31/50	1.49gm	23/50	(2.97gm	21/50)							
a	c55561	8.76gm	n.s.s.	12/50	1.49gm	12/50	2.97gm	10/50							liv:hpa,hpc,nnd.
b	c55561	12.9gm	n.s.s.	6/50	1.49gm	6/50	2.97gm	4/50							lun:a/a,a/c.
376	c55561	712.mg	n.s.s.	46/50	619.mg	44/50	(1.24gm	41/50)							
a	c55561	15.0gm	n.s.s.	1/50	619.mg	0/50	1.24gm	0/50							liv:hpa,hpc,nnd.
377	c55561	722.mg	n.s.s.	46/50	495.mg	49/50	990.mg	45/50							
a	c55561	2.28gm	n.s.s.	0/50	495.mg	2/50	990.mg	3/50							liv:hpa,hpc,nnd.
3,4,5,6-TETRAHYDROURIDINE 18771-50-1															
378	1906	6.07mg	n.s.s.	0/49	11.8mg	0/10								Carr;bjca,57,395-402;1988	
a	1906	2.06mg	n.s.s.	10/49	11.8mg	3/10									
THIOACETAMIDE*** 62-55-5															
379	1836	5.38mg	n.s.s.	0/15	7.00mg	9/41								Kuroda;jnci,79,1047-1051;1987	
a	1836	8.28mg	n.s.s.	0/15	7.00mg	5/41									
b	1836	9.55mg	n.s.s.	0/15	7.00mg	4/41									
DL-alpha-TOCOPHEROL (vitamin E) 10191-41-0															
380	1900	206.mg	n.s.s.	0/10	400.mg	0/10								Hirose;carc,8,1731-1735;1987/pers.comm.	
a	1900	206.mg	n.s.s.	0/10	400.mg	0/10									
b	1900	206.mg	n.s.s.	0/10	400.mg	0/10									
TRIBROMOMETHANE (bromoform) 75-25-2															
381	c55130	311.mg	n.s.s.	0/50	69.4mg	0/50	140.mg	3/50							liv:hes; spl:hes. S
a	c55130	109.mg	n.s.s.	24/50	69.4mg	18/50	140.mg	18/50							
b	c55130	152.mg	n.s.s.	4/50	69.4mg	6/50	140.mg	6/50							liv:hpa,hpc,nnd.
c	c55130	349.mg	n.s.s.	3/50	69.4mg	1/50	140.mg	2/50							lun:a/a,a/c.
382	c55130	28.0mg	17.5gm	2/50	34.9mg	8/50	(69.7mg	4/50)							sub:fbs,sar. S
a	c55130	13.8mg	n.s.s.	34/50	34.9mg	33/50	(69.7mg	27/50)							
b	c55130	18.1mg	n.s.s.	16/50	34.9mg	19/50	(69.7mg	14/50)							liv:hpa,hpc,nnd.
c	c55130	44.0mg	n.s.s.	11/50	34.9mg	7/50	(69.7mg	2/50)							lun:a/a,a/c.
383	c55130	219.mg	1.55gm	0/50	69.4mg	1/50	139.mg	8/50							lgi:adc,pla.
a	c55130	270.mg	3.60gm	0/50	69.4mg	1/50	139.mg	6/50							S
b	c55130	104.mg	n.s.s.	47/50	69.4mg	37/50	139.mg	38/50							
c	c55130	276.mg	n.s.s.	0/50	69.4mg	4/50	139.mg	2/50							liv:hpa,hpc,nnd.
384	c55130	33.3mg	n.s.s.	46/50	69.7mg	45/50	140.mg	37/50							tes:iab,ica. S
a	c55130	237.mg	n.s.s.	0/50	69.7mg	3/50	140.mg	2/50							S
b	c55130	298.mg	n.s.s.	0/50	69.7mg	0/50	140.mg	3/50							lgi:adc,pla.
c	c55130	71.8mg	n.s.s.	45/50	69.7mg	37/50	140.mg	25/50							
d	c55130	541.mg	n.s.s.	5/50	69.7mg	2/50	140.mg	1/50							liv:hpa,hpc,nnd.
1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE (fluorocarbon 113) 76-13-1															
385	1876	60.9gm	1.25kg	0/85	1.15gm	0/36	5.74gm	0/30	11.5gm	5/86				Trochimowicz;faat,11,68-75;1988	
386	1876	95.1gm	n.s.s.	2/88	803.mg	1/64	4.02gm	0/58	8.03gm	2/87					
1,1,1-TRICHLOROETHANE, TECHNICAL GRADE*** (methyl chloroform) 71-55-6															
387	1892	11.4gm	n.s.s.	13/50	257.mg	10/50	858.mg	10/50	2.57gm	7/50				Quast;faat,11,611-625;1988	
a	1892	13.2gm	n.s.s.	4/50	257.mg	1/50	858.mg	5/50	2.57gm	2/50					
b	1892	14.2gm	n.s.s.	10/50	257.mg	9/50	858.mg	5/50	2.57gm	5/50					

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes		TD50 2Tailpvl DR AuOp
388	M m b6c inh liv hpc 24m24 e	.>	66.3gm * P<.9 -
a	M m b6c inh liv hpa 24m24 e		no dre P=1. -
b	M m b6c inh liv mix 24m24 e		no dre P=1. -
389	R f f34 inh liv hpc 24m24 e	.>	no dre P=1. -
a	R f f34 inh liv nnd 24m24 e		no dre P=1. -
390	R m f34 inh liv hpc 24m24 e	. ±	2.07gm Z P<.03 -
a	R m f34 inh liv nnd 24m24 e		5.12gm * P<.09 -
	TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)* ....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
391	M f b6c gav liv MXA 24m24	: + :	411.mg P<.0005c
a	M f b6c gav liv hpa 24m24		579.mg P<.0005c
b	M f b6c gav liv hpc 24m24		673.mg P<.0005c
c	M f b6c gav lun a/a 24m24		2.78gm P<.009
d	M f b6c gav MXA MXA 24m24		1.35gm P<.03
e	M f b6c gav MXA MXA 24m24		1.47gm P<.04
f	M f b6c gav mul mlp 24m24		4.88gm P<.04
g	M f b6c gav TBA MXB 24m24		359.mg P<.0005
h	M f b6c gav liv MXB 24m24		411.mg P<.0005
i	M f b6c gav lun MXB 24m24		3.85gm P<.1
392	M m b6c gav liv MXA 24m24	: + :	239.mg P<.0005
a	M m b6c gav liv hpc 24m24		294.mg P<.0005c
b	M m b6c gav liv hpa 24m24		855.mg P<.006
c	M m b6c gav hag MXA 24m24		3.83gm P<.02
d	M m b6c gav TBA MXB 24m24		332.mg P<.002
e	M m b6c gav liv MXB 24m24		239.mg P<.0005
f	M m b6c gav lun MXB 24m24		4.25gm P<.5
393	R f f34 gav TBA MXB 24m24	:>	5.71gm * P<.9 -
a	R f f34 gav liv MXB 24m24		9.98gm * P<.2
394	R m f34 gav kid MXA 24m24 s	: +	#2.78gm * P<.009
a	R m f34 gav per MXA 24m24 s		1.49gm P<.04
b	R m f34 gav per msm 24m24 s		1.49gm P<.04
c	R m f34 gav kid uac 24m24 s		3.92gm * P<.02
d	R m f34 gav TBA MXB 24m24 s		2.24gm * P<.6
e	R m f34 gav liv MXB 24m24 s		12.2gm * P<.2
395	R f aci gav TBA MXB 24m24 s	:>	61.7gm * P<1.
a	R f aci gav liv MXB 24m24 s		no dre P=1.
396	R m aci gav TBA MXB 24m24 s	:>	820.mg * P<.4
a	R m aci gav liv MXB 24m24 s		9.40gm * P<.5
397	R f aug gav TBA MXB 24m24	:>	no dre P=1.
a	R f aug gav liv MXB 24m24		no dre P=1.
398	R m aug gav sub MXA 24m24	: ±	#3.73gm * P<.03
a	R m aug gav TBA MXB 24m24		no dre P=1.
b	R m aug gav liv MXB 24m24		6.44gm * P<.2
399	R f mar gav TBA MXB 24m24 s	:>	709.mg * P<.3
a	R f mar gav liv MXB 24m24 s		no dre P=1.
400	R m mar gav tes MXA 24m24 s	: + :	#153.mg * P<.0005
a	R m mar gav TBA MXB 24m24 s		199.mg * P<.002
b	R m mar gav liv MXB 24m24 s		no dre P=1.
401	R f osm gav adr coa 24m24 s	: ±	#556.mg * P<.04
a	R f osm gav TBA MXB 24m24 s		372.mg * P<.07
b	R f osm gav liv MXB 24m24 s		3.50gm * P<.05
402	R m osm gav kid tla 24m24	: + :	#628.mg P<.003
a	R m osm gav kid MXA 24m24		628.mg P<.003
b	R m osm gav TBA MXB 24m24		1.49gm * P<.6
c	R m osm gav liv MXB 24m24		8.95gm * P<.5
	TRICHLOROFLUOROMETHANE*** 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
403	M f swi inh mam car 18m24		31.6gm * P<.01 -
a	M f swi inh --- leu 18m24		23.7gm * P<.09 -
b	M f swi inh lun ade 18m24		34.9gm * P<.06 -
c	M f swi inh tba mix 18m24		11.1gm * P<.02 -
d	M f swi inh tba mal 18m24		14.6gm * P<.02 -
404	M m swi inh lun ade 18m24		.no dre P=1. -
a	M m swi inh tba mal 18m24		7.54gm P<.2 -
b	M m swi inh tba mix 18m24		13.4gm P<.6 -
405	M m swi inh lun ade 18m24		no dre P=1. -
a	M m swi inh tba mix 18m24		no dre P=1. -
b	M m swi inh tba mal 18m24		no dre P=1. -
406	R f sda inh liv ang 24m24		no dre P=1. -
a	R f sda inh tba mix 24m24		no dre P=1. -
b	R f sda inh tba mal 24m24		no dre P=1. -
407	R m sda inh liv ang 24m24	.>	no dre P=1. -
a	R m sda inh tba mix 24m24		631.mg P<.06 -
b	R m sda inh tba mal 24m24		no dre P=1. -

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
388	1892	4.67gm	n.s.s.	12/50	214.mg	10/50	715.mg	12/50	2.14gm 12/50	
a	1892	5.83gm	n.s.s.	26/50	214.mg	13/50	715.mg	19/50	2.14gm 16/50	
b	1892	3.43gm	n.s.s.	29/50	214.mg	22/50	715.mg	28/50	2.14gm 24/50	
389	1892	451.mg	n.s.s.	1/50	61.3mg	0/50	204.mg	0/50	613.mg 0/50	
a	1892	7.94gm	n.s.s.	1/50	61.3mg	1/50	204.mg	0/50	613.mg 0/50	
390	1892	627.mg	n.s.s.	0/50	42.9mg	0/50	143.mg	3/50	(429.mg 0/50)	
a	1892	1.57gm	n.s.s.	1/50	42.9mg	1/50	143.mg	1/50	429.mg 4/50	
TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)* (TCE. c04547 is NTP TR# 243; 04546 (b,d,e & f) are NTP TR# 273) 79-01-6										
391	c04547	215.mg	1.10gm	6/50	704.mg	22/50			liv:hpa,hpc.	
a	c04547	283.mg	1.89gm	4/50	704.mg	16/50				
b	c04547	314.mg	2.22gm	2/50	704.mg	13/50				
c	c04547	877.mg	81.4gm	0/50	704.mg	4/50				S
d	c04547	538.mg	n.s.s.	7/50	704.mg	14/50			liv:mlh; mul:mlh,mlm,mlp,mlu,mno,myo; spl:mno.	S
e	c04547	558.mg	n.s.s.	7/50	704.mg	13/50			liv:mlh; mul:mlh,mlm,mlp,mlu,mno; spl:mno.	S
f	c04547	1.48gm	n.s.s.	0/50	704.mg	3/50				S
g	c04547	187.mg	1.19gm	21/50	704.mg	38/50				
h	c04547	215.mg	1.10gm	6/50	704.mg	22/50			liv:hpa,hpc,nnd.	
i	c04547	1.04gm	n.s.s.	1/50	704.mg	4/50			lun:a/a,a/c.	
392	c04547	134.mg	539.mg	14/50	701.mg	39/50			liv:hpa,hpc.	S
a	c04547	163.mg	672.mg	8/50	701.mg	31/50				
b	c04547	365.mg	11.6gm	7/50	701.mg	14/50				S
c	c04547	1.29gm	n.s.s.	0/50	701.mg	4/50			hag:adn,ana,ppa.	S
d	c04547	165.mg	1.55gm	33/50	701.mg	45/50				
e	c04547	134.mg	539.mg	14/50	701.mg	39/50			liv:hpa,hpc,nnd.	
f	c04547	744.mg	n.s.s.	7/50	701.mg	6/50			lun:a/a,a/c.	
393	c04547	486.mg	n.s.s.	38/50	354.mg	31/50	714.mg	30/50		
a	c04547	2.46gm	n.s.s.	0/50	354.mg	1/50	714.mg	1/50	liv:hpa,hpc,nnd.	
394	c04547	1.03gm	116.gm	0/50	357.mg	2/50	714.mg	3/50	kid:tla,uac.	S
a	c04547	497.mg	n.s.s.	1/50	357.mg	5/50	(714.mg	1/50)	per:men,msm.	S
b	c04547	497.mg	n.s.s.	1/50	357.mg	5/50	(714.mg	0/50)		S
c	c04547	1.19gm	n.s.s.	0/50	357.mg	0/50	714.mg	3/50		S
d	c04547	392.mg	n.s.s.	33/50	357.mg	26/50	714.mg	18/50		
e	c04547	1.99gm	n.s.s.	0/50	357.mg	0/50	714.mg	1/50	liv:hpa,hpc,nnd.	
395	d04546	461.mg	n.s.s.	33/50	349.mg	21/50	707.mg	18/50		
a	d04546	4.26gm	n.s.s.	2/50	349.mg	0/50	707.mg	0/50	liv:hpa,hpc,nnd.	
396	d04546	198.mg	n.s.s.	44/50	354.mg	27/50	707.mg	17/50		
a	d04546	1.47gm	n.s.s.	1/50	354.mg	1/50	707.mg	1/50	liv:hpa,hpc,nnd.	
397	e04546	660.mg	n.s.s.	43/50	354.mg	35/50	707.mg	29/50		
a	e04546	5.95gm	n.s.s.	2/50	354.mg	0/50	707.mg	0/50	liv:hpa,hpc,nnd.	
398	e04546	1.24gm	n.s.s.	0/50	354.mg	1/50	707.mg	3/50	sub:spm,srn.	S
a	e04546	347.mg	n.s.s.	45/50	354.mg	32/50	707.mg	27/50		
b	e04546	1.55gm	n.s.s.	0/50	354.mg	1/50	707.mg	1/50	liv:hpa,hpc,nnd.	
399	b04546	196.mg	n.s.s.	47/50	354.mg	32/50	707.mg	22/50		
a	b04546	n.s.s.	n.s.s.	0/50	354.mg	0/50	707.mg	0/50	liv:hpa,hpc,nnd.	
400	b04546	90.6mg	316.mg	17/50	354.mg	21/50	707.mg	32/50	tes:ict,itm.	S
a	b04546	101.mg	906.mg	38/50	354.mg	23/50	707.mg	32/50		
b	b04546	n.s.s.	n.s.s.	0/50	354.mg	0/50	707.mg	0/50	liv:hpa,hpc,nnd.	
401	f04546	217.mg	n.s.s.	16/50	354.mg	13/50	711.mg	19/50		S
a	f04546	143.mg	n.s.s.	40/50	354.mg	36/50	711.mg	37/50		
b	f04546	839.mg	n.s.s.	0/50	354.mg	0/50	711.mg	2/50	liv:hpa,hpc,nnd.	
402	f04546	253.mg	3.23gm	0/50	354.mg	6/50	(707.mg	1/50)		S
a	f04546	253.mg	3.23gm	0/50	354.mg	6/50	(707.mg	2/50)	kid:tla,uac.	S
b	f04546	257.mg	n.s.s.	37/50	354.mg	35/50	707.mg	29/50		
c	f04546	1.46gm	n.s.s.	1/50	354.mg	0/50	707.mg	2/50	liv:hpa,hpc,nnd.	
TRICHLOROFLUOROMETHANE*** (fluorocarbon 11) 75-69-4										
403	bt604m	12.6gm	4.71kg	1/90	883.mg	2/60	4.42gm	6/60	Maltoni;anya,534,261-282;1988	
a	bt604m	8.28gm	n.s.s.	8/90	883.mg	10/60	4.42gm	12/60		
b	bt604m	12.1gm	n.s.s.	2/90	883.mg	4/60	4.42gm	6/60		
c	bt604m	4.82gm	n.s.s.	15/90	883.mg	20/60	4.42gm	22/60		
d	bt604m	6.27gm	n.s.s.	9/90	883.mg	12/60	4.42gm	16/60		
404	bt604m	9.10gm	n.s.s.	3/90	736.mg	0/60				
a	bt604m	2.11gm	n.s.s.	5/90	736.mg	7/60				
b	bt604m	2.23gm	n.s.s.	9/90	736.mg	8/60				
405	bt604n	32.9gm	n.s.s.	4/90	3.68gm	1/60				
a	bt604n	30.7gm	n.s.s.	9/90	3.68gm	2/60				
b	bt604n	35.1gm	n.s.s.	6/90	3.68gm	1/60				
406	bt603	20.8gm	n.s.s.	1/150	280.mg	2/90	1.40gm	0/90		
a	bt603	1.77gm	n.s.s.	124/150	280.mg	65/90	1.40gm	70/90		
b	bt603	9.88gm	n.s.s.	43/150	280.mg	23/90	1.40gm	15/90		
407	bt603	3.03gm	n.s.s.	1/150	196.mg	0/90	981.mg	0/90		
a	bt603	252.mg	n.s.s.	51/150	196.mg	42/90	(981.mg	25/90)		
b	bt603	6.05gm	n.s.s.	25/150	196.mg	16/90	981.mg	11/90		

Spe Strain Site Xpo+Xpt Sex Route Hist Notes		TD50 DR	2Tailpvl AuOp
VINYL CHLORIDE***	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
408 R f sda inh bra neu 18m24 gv	. + .	299.mg	P<.0005+
a R f sda inh liv ang 18m24 gv		387.mg	P<.0005+
b R f sda inh liv hpc 18m24 gv		2.76gm	P<.006 +
c R f sda inh tba mal 18m24 gv		85.7mg	P<.0005
d R f sda inh tba mix 18m24 gv		111.mg	P<.0005
FD & C YELLOW NO. 5***	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
409 M f cd1 eat --- mlp 24m24 e	. + .	1.43gm Z	P<.0005-
a M f cd1 eat liv hpa 24m24 e		200.gm *	P<.2 -
b M f cd1 eat liv hpd 24m24 e		no dre	P=1. -
c M f cd1 eat lun a/a 24m24 e		no dre	P=1. -
d M f cd1 eat lun acb 24m24 e		no dre	P=1. -
e M f cd1 eat tba mal 24m24 e		1.56gm Z	P<.0005-
f M f cd1 eat tba ben 24m24 e		no dre	P=1. -
410 M m cd1 eat liv hpa 24m24 e	. ±	2.15gm Z	P<.02 -
a M m cd1 eat --- mlp 24m24 e		11.8gm Z	P<.02 -
b M m cd1 eat lun a/a 24m24 e		42.5gm *	P<.4 -
c M m cd1 eat liv hpd 24m24 e		61.1gm *	P<.3 -
d M m cd1 eat lun acb 24m24 e		no dre	P=1. -
e M m cd1 eat tba ben 24m24 e		388.mg Z	P<.0005-
f M m cd1 eat tba mal 24m24 e		1.81gm Z	P<.0005-
411 R f f3d wat ute esp 24m26 e	.>	5.78gm *	P<.2 -
a R f f3d wat liv nnd 24m26 e		no dre	P=1. -
b R f f3d wat tba tum 24m26 e		no dre	P=1. -
412 R m f3d wat abc mso 24m26 e	. +	2.82gm	P<.004 -
a R m f3d wat liv hpc 24m26 e		no dre	P=1. -
b R m f3d wat liv nnd 24m26 e		no dre	P=1. -
c R m f3d wat tba tum 24m26 e		noTD50	P<.4 -

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology / Brkly Code
VINYL CHLORIDE*** 75-01-4											
408	bt4001	192.mg	496.mg	0/60	392.mg	32/54					Maltoni;anya,534,145-159;1988
a	bt4001	242.mg	671.mg	0/60	392.mg	27/54					
b	bt4001	1.05gm	29.9gm	0/60	392.mg	5/54					
c	bt4001	47.0mg	151.mg	9/60	392.mg	52/54					
d	bt4001	53.6mg	270.mg	35/60	392.mg	52/54					
FD & C YELLOW NO. 5*** (tartrazine) 1934-21-0											
409	1869	616.mg	5.36gm	3/120	650.mg	8/28	(1.95gm	4/30	6.50gm	2/60)	Borzelleca;fctx,26,189-194;1988
a	1869	40.6gm	n.s.s.	1/120	650.mg	0/28	1.95gm	0/30	6.50gm	2/60	
b	1869	53.6gm	n.s.s.	3/120	650.mg	0/28	1.95gm	1/30	6.50gm	1/60	
c	1869	44.4gm	n.s.s.	29/120	650.mg	7/28	1.95gm	7/30	6.50gm	6/60	
d	1869	46.9gm	n.s.s.	3/120	650.mg	1/28	1.95gm	2/30	6.50gm	1/60	
e	1869	813.mg	4.84gm	34/120	650.mg	15/28	1.95gm	20/30	(6.50gm	15/60)	
f	1869	32.4gm	n.s.s.	52/120	650.mg	14/28	1.95gm	10/30	6.50gm	15/60	
410	1869	732.mg	n.s.s.	7/120	600.mg	6/27	(1.80gm	3/33	6.00gm	2/60)	
a	1869	3.96gm	n.s.s.	2/120	600.mg	1/27	1.80gm	4/33	(6.00gm	3/60)	
b	1869	10.3gm	n.s.s.	23/120	600.mg	11/27	1.80gm	11/33	6.00gm	17/60	
c	1869	14.8gm	n.s.s.	9/120	600.mg	4/27	1.80gm	7/33	6.00gm	8/60	
d	1869	73.5gm	n.s.s.	3/120	600.mg	0/27	1.80gm	1/33	6.00gm	0/60	
e	1869	182.mg	1.36gm	43/120	600.mg	21/27	(1.80gm	13/33	6.00gm	22/60)	
f	1869	961.mg	5.11gm	27/120	600.mg	6/27	1.80gm	22/33	(6.00gm	20/60)	
411	1857	1.98gm	n.s.s.	5/47	531.mg	13/50	1.06gm	10/49			Maekawa;fctx,25,891-896;1987
a	1857	9.15gm	n.s.s.	1/47	531.mg	1/50	1.06gm	1/49			
b	1857	2.13gm	n.s.s.	39/47	531.mg	41/50	1.06gm	30/49			
412	1857	1.15gm	18.3gm	0/48	464.mg	6/49	(929.mg	0/49)			
a	1857	8.82gm	n.s.s.	0/48	464.mg	1/49	929.mg	0/49			
b	1857	9.84gm	n.s.s.	3/48	464.mg	3/49	929.mg	0/49			
c	1857	n.s.s.	n.s.s.	47/48	464.mg	49/49	929.mg	49/49			

APPENDIX 1: CHEMICAL NAMES AND SYNONYMS IN THIS PLOT

CAS NUMBER	CHEMICAL NAME
75-07-0	ACETALDEHYDE
107-29-9	ACETALDOXIME
53-96-3	2-ACETYLAMINOFLUORENE
---	L-alpha-ACETYLMETHADOL.HCl (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl)
107-02-8	ACROLEIN
3054-95-3	ACROLEIN DIETHYLACETAL
5314-33-0	ACROLEIN OXIME
107-13-1	ACRYLONITRILE
1162-65-8	AFLATOXIN B1
135-88-6	AGERITE POWDER (see PHENYL-beta-NAPHTHYLAMINE)
107-18-6	ALLYL ALCOHOL
77500-04-0	2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE
99-57-0	2-AMINO-4-NITROPHENOL
121-88-0	2-AMINO-5-NITROPHENOL
---	4-(2-AMINOETHYL)-6-DIAZO-2,4-CYCLOHEXADIENONE.HCl (see 3-DIAZOTYRAMINE.HCl)
134-03-2	L-ASCORBATE, SODIUM
34031-32-8	AURANOFIN
320-67-2	5-AZACYTIDINE
3131-60-0	6-AZACYTIDINE
25843-45-2	AZOXYMETHANE
17697-55-1	1-AZOXYPROPANE
17697-53-9	2-AZOXYPROPANE
147-24-0	BENADRYL (see DIPHENHYDRAMINE.HCl)
71-43-2	BENZENE
271-89-6	BENZOFURAN
100-51-6	BENZYL ALCOHOL
25013-16-5	BHA (see BUTYLATED HYDROXYANISOLE)
128-37-0	BHT (see BUTYLATED HYDROXYTOLUENE)
2784-94-3	HC BLUE NO. 1
2784-94-3	HC BLUE NO. 1 (PURIFIED)
10043-35-3	BORIC ACID
7758-01-2	BROMATE, POTASSIUM
75-27-4	BROMODICHLOROMETHANE
74-96-4	BROMOETHANE
75-25-2	BROMOFORM (see TRIBROMOMETHANE)
106-99-0	1,3-BUTADIENE
128-37-0	2,6-DI-tert-BUTYL-p-CRESOL (see BUTYLATED HYDROXYTOLUENE)
25013-16-5	2(3)-tert-BUTYL-4-HYDROXYANISOLE (see BUTYLATED HYDROXYANISOLE)
25013-16-5	BUTYLATED HYDROXYANISOLE
128-37-0	BUTYLATED HYDROXYTOLUENE
35658-65-2	CADMIUM CHLORIDE
149-30-4	CAPTAX (see 2-MERCAPTOBENZOTHIAZOLE)
120-80-9	CATECHOL
20265-96-7	p-CHLOROANILINE.HCl
75-45-6	CHLORODIFLUOROMETHANE
75-00-3	CHLOROETHANE
150-68-5	3-(p-CHLOROPHENYL)-1, 1-DIMETHYLUREA
52214-84-3	CIPROFIBRATE
108-94-1	CYCLOHEXANONE
62-73-7	DDVP (see DICHLORVOS)
55-18-5	DEN (see N-NITROSODIETHYLAMINE)
56-53-1	DES (see DIETHYLSTILBESTROL)
62488-57-7	DHAC (see 5,6-DIHYDRO-5-AZACYTIDINE)
---	3-DIAZOTYRAMINE.HCl
75-27-4	DICHLOROBROMOMETHANE (see BROMODICHLOROMETHANE)
75-71-8	DICHLORODIFLUOROMETHANE
75-09-2	DICHLOROMETHANE (see METHYLENE CHLORIDE)
120-83-2	2,4-DICHLOROPHENOL
62-73-7	DICHLORVOS
56-53-1	4,4'-(1,2-DIETHYL-1,2-ETHENEDIYL)BIS-PHENOL (see DIETHYLSTILBESTROL)
55-18-5	DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
55-18-5	N,N-DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
56-53-1	DIETHYLSTILBESTROL
62488-57-7	5,6-DIHYDRO-5-AZACYTIDINE
120-80-9	1,2-DIHYDROXYBENZENE (see CATECHOL)
828-00-2	DIMETHOXANE, COMMERCIAL GRADE
65176-75-2	5,6-DIMETHOXYSTERIGMATOCYSTIN
756-79-6	DIMETHYL METHYLPHOSPHONATE
---	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl
1095-90-5	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl
108-01-0	2-DIMETHYLAMINOETHANOL
121-69-7	N,N-DIMETHYLANILINE
62-75-9	DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
62-75-9	N,N-DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
121-14-2	2,4-DINITROTOLUENE (PURIFIED)
606-20-2	2,6-DINITROTOLUENE
---	DINITROTOLUENE, TECHNICAL GRADE (2,4 (77%)- and 2,6 (19%)-)
13256-06-9	DIPENTYLNITROSAMINE
147-24-0	DIPHENHYDRAMINE.HCl
57-41-0	5,5-DIPHENYLHYDANTOIN
756-79-6	DMMP (see DIMETHYL METHYLPHOSPHONATE)
62-75-9	DMN (see N-NITROSODIMETHYLAMINE)
87-86-5	DOWICIDE 7 (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))
87-86-5	DOWICIDE EC-7 (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))
75-21-8	EO (see ETHYLENE OXIDE)
106-88-7	1,2-EPOXYBUTANE
75-56-9	1,2-EPOXYPROPANE (see 1,2-PROPYLENE OXIDE)
643-22-1	ERYTHROMYCIN STEARATE
16423-68-0	ERYTHROSINE (see FD & C RED NO. 3)
91-53-2	ETHOXYQUIN
74-96-4	ETHYL BROMIDE (see BROMOETHANE)
75-00-3	ETHYL CHLORIDE (see CHLOROETHANE)
75-21-8	ETHYLENE OXIDE
117-81-7	DI(2-ETHYLHEXYL)PHTHALATE
297-76-7	ETHYNODIOL DIACETATE
53-96-3	FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)
53-96-3	N-2-FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)
75-69-4	FLUOROCARBON 11 (see TRICHLOROFLUOROMETHANE)
75-71-8	FLUOROCARBON 12 (see DICHLORODIFLUOROMETHANE)
75-45-6	FLUOROCARBON 22 (see CHLORODIFLUOROMETHANE)
50-00-0	FORMALDEHYDE
75-09-2	FREON 30 (see METHYLENE CHLORIDE)
54-31-9	FUROSEMIDE
mixture	GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE) (CAS NUMBERS 105-87-3 and 150-84-5)
69644-85-5	N2-[gamma-L(+)-GLUTAMYL]-4-CARBOXYPHENYLHYDRAZINE (see N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID)
69644-85-5	N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID
118-74-1	HCB (see HEXACHLOROBENZENE)
118-74-1	HEXACHLOROBENZENE
58-89-9	gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
67-72-1	HEXACHLOROETHANE
136-77-6	4-HEXYLRESORCINOL
10034-93-2	HYDRAZINE SULFATE
69644-85-5	p-HYDRAZINOBENZOIC ACID, N2-gamma-GLUTAMYL (see N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID)
24589-77-3	p-HYDRAZINOBENZOIC ACID.HCl
58-93-5	HYDROCHLOROTHIAZIDE
123-31-9	HYDROQUINONE
1083-57-4	3-HYDROXY-p-BUTYROPHENETIDIDE
24382-04-5	3-HYDROXY-2-PROPENAL, SODIUM SALT (see MALONALDEHYDE, SODIUM SALT)
13743-07-2	1-(2-HYDROXYETHYL)-1-NITROSOUREA
924-42-5	N-(HYDROXYMETHYL)-ACRYLAMIDE (see N-METHYLOLACRYLAMIDE)
75011-65-3	IBOPAMINE.HCl (see N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER, HCl)
26675-46-7	ISOFLURANE
---	LAAM (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl)
303-34-4	LASIOCARPINE
58-89-9	LINDANE (see gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE)
67-20-9	MACRODANTIN (see 1-[(5-NITROFURFURYLIDENE)AMINO] HYDANTOIN)
24382-04-5	MALONALDEHYDE, SODIUM SALT
77500-04-0	MeIQx (see 2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE)
149-30-4	2-MERCAPTOBENZOTHIAZOLE
1095-90-5	DL-METHADONE.HCl (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl)
298-81-7	8-METHOXYPSORALEN
25843-45-2	Z-METHYL-O,N,N-AZOXYMETHANE (see AZOXYMETHANE)
598-55-0	METHYL CARBAMATE
71-55-6	METHYL CHLOROFORM (see 1,1,1-TRICHLOROETHANE, TECHNICAL GRADE)
70-25-7	N-METHYL-N'-NITRO-N-NITROSOGUANIDINE
872-50-4	N-METHYL-2-PYRROLIDONE

CAS NUMBER	CHEMICAL NAME
41372-08-1	alpha-METHYLDOPA SESQUIHYDRATE
75011-65-3	N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER.HCl
75-09-2	METHYLENE CHLORIDE
---	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-BUTANOL
64091-91-4	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-(BUTANONE)
924-42-5	N-METHYLOLACRYLAMIDE
622-97-9	p-METHYLSTYRENE
59122-46-2	MISOPROSTOL
70-25-7	MNNG (see N-METHYL-N'-NITRO-N-NITROSOGUANIDINE)
150-68-5	MONURON (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)
298-81-7	8-MOP (see 8-METHOXYPSORALEN)
389-08-2	NALIDIXIC ACID
88385-81-3	NEOSUGAR
13743-07-2	NHEU (see 1-(2-HYDROXYETHYL)-1-NITROSOUREA))
7632-00-0	NITRITE, SODIUM
59-87-0	5-NITRO-2-FURALDEHYDE SEMICARBAZONE
121-19-7	3-NITRO-4-HYDROXYPHENYLARSONIC ACID
67-20-9	NITROFURANTOIN (see 1-[(5-NITROFURFURYLIDENE) AMINO]HYDANTOIN)
59-87-0	NITROFURAZONE (see 5-NITRO-2-FURALDEHYDE SEMICARBAZONE)
67-20-9	1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN
108-03-2	1-NITROPROPANE
13743-07-2	N-NITROSO-2-HYDROXYETHYLUREA (see 1-(2-HYDROXYETHYL)-1-NITROSOUREA))
38347-74-9	3-NITROSO-2-OXAZOLIDINONE
1116-54-7	N-NITROSODIETHANOLAMINE
55-18-5	N-NITROSODIETHYLAMINE
62-75-9	N-NITROSODIMETHYLAMINE
114282-83-6	N-NITROSODITHIAZINE
10595-95-6	NITROSOETHYLMETHYLAMINE
55557-02-3	N-NITROSOGUVACOLINE
26921-68-6	N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE
70415-59-7	N-NITROSOMETHYL-(3-HYDROXYPROPYL)AMINE
---	N-NITROSOMETHYL-(2-TOSYLOXYETHYL)AMINE
10595-95-6	N-NITROSOMETHYLETHYLAMINE (see NITROSOETHYLMETHYLAMINE)
59-89-2	NITROSOMORPHOLINE (see N-NITROSOMORPHOLINE)
59-89-2	N-NITROSOMORPHOLINE
930-55-2	NITROSOPYRROLIDINE (see N-NITROSOPYRROLIDINE)
930-55-2	N-NITROSOPYRROLIDINE
81795-07-5	N-NITROSOTHIALDINE
303-47-9	OCHRATOXIN A
117-81-7	DI-sec-OCTYL PHTHALATE (see DI(2-ETHYLHEXYL)PHTHALATE)
6373-74-6	C.I. ACID ORANGE 3
1936-15-8	C.I. ACID ORANGE 10
297-76-7	OVULEN-50 (see ETHYNODIOL DIACETATE)
132-98-9	PENICILLIN VK
87-86-5	PENTA (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))
87-86-5	2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7)
87-86-5	2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE
78-11-5	PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE
57590-20-2	PENTANAL METHYLFORMYLHYDRAZONE
78-11-5	PETN, NF (see PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE)
50-06-6	PHENOBARBITAL
50-06-6	PHENOBARBITONE (see PHENOBARBITAL)
135-88-6	PHENYL-beta-NAPHTHYLAMINE
135-88-6	N-PHENYL-2-NAPHTHYLAMINE (see PHENYL-beta-NAPHTHYLAMINE)
50-33-9	PHENYLBUTAZONE
108-45-2	m-PHENYLENEDIAMINE
50-06-6	PHENYLETHYLBARBITURIC ACID (see PHENOBARBITAL)
57-41-0	PHENYTOIN (see 5,5-DIPHENYLHYDANTOIN)
7758-01-2	POTASSIUM BROMATE (see BROMATE, POTASSIUM)
121-79-9	PROPYL GALLATE
115-07-1	PROPYLENE
75-56-9	1,2-PROPYLENE OXIDE
16423-68-0	FD & C RED NO. 3
79-81-2	RETINOL PALMITATE
127-47-9	RETINOL ACETATE
149-30-4	ROTAX (see 2-MERCAPTOBENZOTHIAZOLE)
83-79-4	ROTENONE
121-19-7	ROXARSONE (see 3-NITRO-4-HYDROXYPHENYLARSONIC ACID)
18559-94-9	SALBUTAMOL
7632-00-0	SODIUM NITRITE (see NITRITE, SODIUM)
100-42-5	STYRENE
96-09-3	STYRENE OXIDE
1934-21-0	TARTRAZINE (see FD & C YELLOW NO. 5)
79-01-6	TCE (see TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN))
150-68-5	TELVAR (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)
34031-32-8	2,3,4,6-TETRA-O-ACETYL-1-THIO-1-beta-D-GLUCOPYRANOSATO-S) (TRIETHYLPHOSPHINE) GOLD (see AURANOFIN)
64-75-5	TETRACYCLINE.HCl
18771-50-1	3,4,5,6-TETRAHYDROURIDINE
62-55-5	THIOACETAMIDE
10191-41-0	DL-alpha-TOCOPHEROL
75-25-2	TRIBROMOMETHANE
76-13-1	1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE
71-55-6	1,1,1-TRICHLOROETHANE, TECHNICAL GRADE
79-01-6	TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN) (TCE. c04547 is NTP TR# 243; 04546 (b,d,e & f) are NTP TR# 273)
75-69-4	TRICHLOROFLUOROMETHANE
83-79-4	TUBATOXIN (see ROTENONE)
62-73-7	VAPONA (see DICHLORVOS)
75-01-4	VINYL CHLORIDE
127-47-9	VITAMIN A, ACETATE (see RETINOL ACETATE)
79-81-2	VITAMIN A, PALMITATE (see RETINOL PALMITATE)
134-03-2	VITAMIN C, SODIUM (see L-ASCORBATE, SODIUM)
10191-41-0	VITAMIN E (see DL-alpha-TOCOPHEROL)
1934-21-0	FD & C YELLOW NO. 5

CAS NUMBER = Chemical Abstracts Service registry number

APPENDIX 2: CHEMICAL NAMES IN THIS PLOT LISTED BY CAS NUMBER

CAS NUMBER	CHEMICAL NAME
mixture	GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE) (CAS NUMBERS 105-87-3 and 150-84-5)
50-00-0	FORMALDEHYDE
50-06-6	PHENOBARBITAL (phenobarbitone)
50-33-9	PHENYLBUTAZONE
53-96-3	2-ACETYLAMINOFLUORENE (N-2-fluorenylacetamide)
54-31-9	FUROSEMIDE
55-18-5	N-NITROSODIETHYLAMINE (DEN)
56-53-1	DIETHYLSTILBESTROL (DES)
57-41-0	5,5-DIPHENYLHYDANTOIN (phenytoin)
58-89-9	gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE (lindane)
58-93-5	HYDROCHLOROTHIAZIDE
59-87-0	5-NITRO-2-FURALDEHYDE SEMICARBAZONE (nitrofurazone)
59-89-2	N-NITROSOMORPHOLINE
62-55-5	THIOACETAMIDE
62-73-7	DICHLORVOS (DDVP, Vapona)
62-75-9	N-NITROSODIMETHYLAMINE (DMN)
64-75-5	TETRACYCLINE.HCl
67-20-9	1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN (macrodantin, nitrofurantoin)
67-72-1	HEXACHLOROETHANE
70-25-7	N-METHYL-N'-NITRO-N-NITROSOGUANIDINE (MNNG)
71-43-2	BENZENE
71-55-6	1,1,1-TRICHLOROETHANE, TECHNICAL GRADE (methyl chloroform)
74-96-4	BROMOETHANE (ethyl bromide)
75-00-3	CHLOROETHANE (ethyl chloride)
75-01-4	VINYL CHLORIDE
75-07-0	ACETALDEHYDE
75-09-2	METHYLENE CHLORIDE (dichloromethane, Freon 30)
75-21-8	ETHYLENE OXIDE (EO)
75-25-2	TRIBROMOMETHANE (bromoform)
75-27-4	BROMODICHLOROMETHANE (dichlorobromomethane)
75-45-6	CHLORODIFLUOROMETHANE (fluorocarbon 22)
75-56-9	1,2-PROPYLENE OXIDE (1,2-epoxypropane)
75-69-4	TRICHLOROFLUOROMETHANE (fluorocarbon 11)
75-71-8	DICHLORODIFLUOROMETHANE (fluorocarbon 12)
76-13-1	1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE (fluorocarbon 113)
78-11-5	PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE (PETN, NF)
79-01-6	TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN) (TCE)
79-81-2	RETINOL PALMITATE (vitamin A, palmitate)
83-79-4	ROTENONE (tubatoxin)
87-86-5	2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7) (Dowicide 7, penta, PCP)
87-86-5	2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE (penta, PCP)
91-53-2	ETHOXYQUIN
96-09-3	STYRENE OXIDE
99-57-0	2-AMINO-4-NITROPHENOL
100-42-5	STYRENE
100-51-6	BENZYL ALCOHOL
106-88-7	1,2-EPOXYBUTANE
106-99-0	1,3-BUTADIENE
107-02-8	ACROLEIN
107-13-1	ACRYLONITRILE
107-18-6	ALLYL ALCOHOL
107-29-9	ACETALDOXIME
108-01-0	2-DIMETHYLAMINOETHANOL
108-03-2	1-NITROPROPANE
108-45-2	m-PHENYLENEDIAMINE
108-94-1	CYCLOHEXANONE
115-07-1	PROPYLENE
117-81-7	DI(2-ETHYLHEXYL)PHTHALATE (di-sec-octyl phthalate)
118-74-1	HEXACHLOROBENZENE (HCB)
120-80-9	CATECHOL (1,2-dihydroxybenzene)
120-83-2	2,4-DICHLOROPHENOL
121-14-2	2,4-DINITROTOLUENE (PURIFIED)
121-19-7	3-NITRO-4-HYDROXYPHENYLARSONIC ACID (roxarsone)
121-69-7	N,N-DIMETHYLANILINE
121-79-9	PROPYL GALLATE
121-88-0	2-AMINO-5-NITROPHENOL
123-31-9	HYDROQUINONE
127-47-9	RETINOL ACETATE (vitamin A, acetate)
128-37-0	BUTYLATED HYDROXYTOLUENE (BHT, 2,6-DI-tert-butyl-p-cresol)
132-98-9	PENICILLIN VK
134-03-2	L-ASCORBATE, SODIUM (vitamin C, sodium)
135-88-6	PHENYL-beta-NAPHTHYLAMINE (Agerite powder, N-phenyl-2-naphthylamine)
136-77-6	4-HEXYLRESORCINOL
147-24-0	DIPHENHYDRAMINE.HCl (Benadryl)
149-30-4	2-MERCAPTOBENZOTHIAZOLE (Captax, rotax)
150-68-5	3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA (Telvar, monuron)
271-89-6	BENZOFURAN
297-76-7	ETHYNODIOL DIACETATE (Ovulen-50)
298-81-7	8-METHOXYPSORALEN (8-MOP)
303-34-4	LASIOCARPINE
303-47-9	OCHRATOXIN A
320-67-2	5-AZACYTIDINE
389-08-2	NALIDIXIC ACID
598-55-0	METHYL CARBAMATE
606-20-2	2,6-DINITROTOLUENE
622-97-9	p-METHYLSTYRENE
643-22-1	ERYTHROMYCIN STEARATE
756-79-6	DIMETHYL METHYLPHOSPHONATE (DMMP)
828-00-2	DIMETHOXANE, COMMERCIAL GRADE
872-50-4	N-METHYL-2-PYRROLIDONE
924-42-5	N-METHYLOLACRYLAMIDE
930-55-2	N-NITROSOPYRROLIDINE
1083-57-4	3-HYDROXY-p-BUTYROPHENETIDIDE (betadid, bucetin)
1095-90-5	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl (DL-methadone.HCl)
1116-54-7	N-NITROSODIETHANOLAMINE
1162-65-8	AFLATOXIN B1
1934-21-0	FD & C YELLOW NO. 5 (tartrazine)
1936-15-8	C.I. ACID ORANGE 10
2784-94-3	HC BLUE NO. 1
2784-94-3	HC BLUE NO. 1 (PURIFIED)
3054-95-3	ACROLEIN DIETHYLACETAL
3131-60-0	6-AZACYTIDINE
5314-33-0	ACROLEIN OXIME
6373-74-6	C.I. ACID ORANGE 3
7632-00-0	NITRITE, SODIUM
7758-01-2	BROMATE, POTASSIUM
10034-93-2	HYDRAZINE SULFATE
10043-35-3	BORIC ACID
10191-41-0	DL-alpha-TOCOPHEROL (vitamin E)
10595-95-6	NITROSOETHYLMETHYLAMINE (N-nitrosomethylethylamine)
13256-06-9	DIPENTYLNITROSAMINE
13743-07-2	1-(2-HYDROXYETHYL)-1-NITROSOUREA .(N-nitroso-2-hydroxyethylurea, NHEU)
16423-68-0	FD & C RED NO. 3 (erythrosine)
17697-53-9	2-AZOXYPROPANE
17697-55-1	1-AZOXYPROPANE
18559-94-9	SALBUTAMOL
18771-50-1	3,4,5,6-TETRAHYDROURIDINE
20265-96-7	p-CHLOROANILINE.HCl
24382-04-5	MALONALDEHYDE, SODIUM SALT (3-hydroxy-2-propenal, sodium salt)
24589-77-3	p-HYDRAZINOBENZOIC ACID.HCl
25013-16-5	BUTYLATED HYDROXYANISOLE (BHA, 2(3)-tert-butyl-4-hydroxyanisole)
25843-45-2	AZOXYMETHANE (Z-methyl-O,N,N-azoxymethane)
26675-46-7	ISOFLURANE
26921-68-6	N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE
34031-32-8	AURANOFIN ((2,3,4,6-tetra-O-acetyl-1-thio-1-beta-D-glucopyranosato-S) (triethylphosphine) gold)
35658-65-2	CADMIUM CHLORIDE
38347-74-9	3-NITROSO-2-OXAZOLIDINONE
41372-08-1	alpha-METHYLDOPA SESQUIHYDRATE
52214-84-3	CIPROFIBRATE
55557-02-3	N-NITROSOGUVACOLINE
57590-20-2	PENTANAL METHYLFORMYLHYDRAZONE
59122-46-2	MISOPROSTOL
62488-57-7	5,6-DIHYDRO-5-AZACYTIDINE (DHAC)
64091-91-4	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-(BUTANONE)
65176-75-2	5,6-DIMETHOXYSTERIGMATOCYSTIN
69644-85-5	N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID (N2-

APPENDIX 2: *continued.*

CAS NUMBER	CHEMICAL NAME
	[gamma-L(+)-GLUTAMYL]-4-CARBOXYPHENYLHYDRAZINE)
70415-59-7	N-NITROSOMETHYL-(3-HYDROXYPROPYL)AMINE
75011-65-3	N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER.HCl (ibopamine.HCl)
77500-04-0	2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE (MeIQx)
81795-07-5	N-NITROSOTHIALDINE
88385-81-3	NEOSUGAR
114282-83-6	N-NITROSODITHIAZINE
---	3-DIAZOTYRAMINE.HCl (4-(2-aminoethyl)-6-diazo-2,4-cyclohexadienone.HCl)
---	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl (L-alpha-acetylmethadol.HCl, LAAM)
---	DINITROTOLUENE, TECHNICAL GRADE (2,4 (77%)- and 2,6 (19%)-)
---	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-BUTANOL
---	N-NITROSOMETHYL-(2-TOSYLOXYETHYL)AMINE

APPENDIX 3: STRAIN CODES AND DEFINITIONS

Code	Strain
aci	ACI
ain	ACI/n
aug	August
b6c	B6C3F$_1$
baa	Black a/a (YS x VY)F$_1$
bal	BALB/c
bcn	BALB/c StCrlfC3Hf/Nctr
c3j	C3H/HeJ
c3v	C3H/HeN-MTV-/Nctr
c5n	C57BL/6N
cd1	Charles River CD1
cdf	CDF$_1$
cdr	Charles River CD
cen	C3H/HeN
chg	C3H/He germfree
chh	C3H/He
don	Donryu
f34	Fischer 344
f3d	F344/DuCrj
mar	Marshall
mrw	MRC-Wistar
osm	Osborne-Mendel
pva	Lean pseudoagouti Avy/a
sda	Sprague-Dawley
sss	Sprague-Dawley Spartan
swa	Swiss albino
swi	Swiss
sww	Swiss Webster
syg	Syrian Golden
win	Wistar/NIN
wis	Wistar
wsr	Wistar-random
yva	Obese yellow Avy/a

APPENDIX 4: ROUTE OF ADMINISTRATION CODES AND DEFINITIONS

Code	Route of Administration
eat	diet
gav	gavage
inh	inhalation
ipj	intraperitoneal injection
wat	water

APPENDIX 5: SITE CODES AND DEFINITIONS

Code	Site
---	all target sites
abc	abdominal cavity
acx	adrenal cortex
adr	adrenal gland
amd	adrenal medulla
aol	aorta and large arteries
bon	bone
bra	brain
brm	brain/meninges
cli	clitoral gland
col	colon
duo	duodenum
eso	esophagus
fgr	forestomach, greater curvature
fls	forestomach, lesser curvature
for	forestomach
gam	gastric mucosa
git	gastrointestinal tract
hag	Harderian gland
itn	intestine
k/c	kidney/cortex
k/p	kidney/pelvis
kid	kidney
lgi	large intestine
liv	liver
lmr	lymphoreticular system
mam	mammary tissue (other than or including more than mammary gland)
lun	lung
mds	mediastinum
meo	mesovarium
mgl	mammary gland
mln	mesenteric lymph node
mul	multiple organs
MXA	more than one site, combined by NCI/NTP
MXB	more than one site, combined by Berkeley
nac	nasal mucosa
nas	nasal cavity
ner	nervous system
orc	oral cavity
ova	ovary
pae	pancreas, exocrine
pal	palate
pan	pancreas
per	peritoneum
pit	pituitary gland
pni	pancreatic islets
pre	preputial gland
pta	pituitary gland, anterior
pty	parathyroid
rec	rectum
res	respiratory system
ski	skin
spl	spleen
stg	stomach, glandular
srp	splenic red pulp
sub	subcutaneous tissue
TBA	all tumor bearing animals, NCI/NTP
tba	all tumor bearing animals
tes	testis
thy	thyroid gland

Code	Site
tna	tunica albuginea
tnv	tunica vaginalis
ton	tongue
ubl	urinary bladder
unt	urinary tract
ute	uterus
zym	Zymbal's gland

APPENDIX 6: HISTOPATHOLOGY CODES AND DEFINITIONS

Code	Histopathology
a/a	alveolar/bronchiolar adenoma
a/c	alveolar/bronchiolar carcinoma
acb	adenocarcinoma, bronchalveolar
acc	acinar-cell carcinoma
acn	adenocarcinoma, NOS
act	alveolar-cell tumor
ada	adenocarcinoma, type A
adb	adenocarcinoma, type B
adc	adenocarcinoma
ade	adenoma
adn	adenoma, NOS
adq	adenosquamous carcinoma
ala	alveolar-cell adenoma
alc	alveolar-cell carcinoma
ana	acinar-cell adenoma
anb	adenoma, bilateral
ang	angiosarcoma
aod	adenocarcinoma, acinar or ductal
apn	adenomatous polyp, NOS
asl	astrocytoma, malignant
ast	astrocytoma
ata	atypic adenoma
bcc	basal-cell carcinoma
ben	benign tumor
bhp	hepatoma, benign
bht	hepatocellular tumor, benign
blc	biliary cystadenoma
bsa	basophil adenoma
cab	cholangiocellular tumor, benign
can	carcinoma, NOS
car	carcinoma
cca	c-cell adenoma
ccr	c-cell carcinoma
cgf	cholangiofibroma
cho	cholangioma
clc	cholangiocarcinoma
coa	cortical adenoma
csa	cortical subcapsular adenoma
ena	endometrial adenocarcinoma
ene	esthesioneuroepithelioma
epc	epidermoid carcinoma
esp	endometrial stromal polyp
exa	exocrine adenoma
fba	fibroadenoma
fbs	fibrosarcoma
fca	follicular-cell adenoma
fcc	follicular-cell carcinoma
fct	follicular-cell tumor
fib	fibroma
gcb	granulosa-cell tumor, benign
gcc	granulosa-cell carcinoma
gcl	granulosa-cell tumor, NOS
gcm	granulosa-cell tumor, malignant
gct	granulosa-cell tumor
gli	glioma
gln	glioma, NOS
hcs	histiocytic sarcoma
hct	hepatocellular tumor
hem	hemangioma
hes	hemangiosarcoma
hmb	hemangioendothelioma, benign
hmm	hemangioendothelioma, malignant
hms	hemangioendothelial sarcoma
hnd	hyperplastic nodule
hpa	hepatocellular adenoma
hpb	hepatoblastoma
hpc	hepatocellular carcinoma
hpd	hepatocellular adenocarcinoma
hpn	hepatocellular neoplastic nodule
hpt	hepatoma
iab	interstitial-cell adenoma, bilateral
ica	interstitial-cell adenoma
ict	interstitial-cell tumor
isa	islet-cell adenoma
isc	islet-cell carcinoma
itm	interstitial-cell tumor, malignant
kcs	Kupffer-cell sarcoma
ker	keratoacanthoma
lcl	lymphocytic lymphoma
ldc	Leydig-cell tumor
lei	leiomyosarcoma
leu	leukemia
ley	leiomyoma
lkm	lymphoma leukemia
lls	lymphoblastic leukemia-lymphosarcoma
mal	malignant tumor
mec	muco-epidermoid carcinoma
men	mesothelioma, NOS
mhs	histiocytoma, malignant
mix	more than one tumor type; tumor types specified in published paper
mlh	malignant lymphoma, histiocytic type
mlm	malignant lymphoma, mixed type
mlp	malignant lymphoma, lymphocytic type
mlu	malignant lymphoma, undifferentiated type
mly	malignant lymphoma
mng	meningioma
mnl	mononuclear-cell leukemia
mno	malignant lymphoma, NOS
mnp	mesenchymal neoplasm
msm	mesothelioma, malignant
mso	mesothelioma
mtb	mixed tumor, benign
mtm	mixed tumor, malignant
MXA	more than one tumor type, combined by NCI/NTP
MXB	more than one tumor type, combined by Berkeley
myo	myelomonocytic leukemia
neo	neoplasm
neu	neuroblastoma
nfm	neurofibroma
nfs	neurofibrosarcoma
nlm	neurilemoma, malignant
nnd	neoplastic nodule
oli	oligodendroglioma

Code	Histopathology
ost	osteosarcoma
pac	papillary adenocarcinoma
pam	papilloma
pbb	pheochromocytoma benign, bilateral
pbm	pheochromocytoma, benign/malignant
pcy	papillary cystadenoma, NOS
pda	pars distalis adenoma
phc	pheochromocytoma, complex
phe	pheochromocytoma
phm	pheochromocytoma, malignant
pla	polypoid adenoma
pmb	pheochromocytoma malignant, bilateral
pob	pheochromocytoma, benign
ppa	papillary adenoma
ppc	papillary carcinoma
ppn	papilloma, NOS
pst	stromal polyp
rca	renal-cell adenoma
rcc	renal-cell carcinoma
rct	renal-cell tumor
rts	reticulum-cell sarcoma
rua	tubule adenoma
ruc	tubule carcinoma
rue	tubule epithelium adenoma
sar	sarcoma
sea	sebaceous adenoma
sla	sebaceous gland adenoma
spm	sarcoma, NOS, unclear primary or metastatic
sqa	squamous-cell tumor
sqc	squamous-cell carcinoma
sqp	squamous-cell papilloma
srn	sarcoma, NOS
tcb	tubular-cell carcinoma, bilateral
tcc	transitional-cell carcinoma
tcm	thecoma
thc	hepatocellular carcinoma, trabecular
tla	tubular-cell adenoma
tpp	transitional-cell papilloma
tri	trichoepithelioma
tua	tubular adenoma
tum	tumor or more than one tumor type; tumor types not specified in published paper
uac	tubular-cell adenocarcinoma
ulc	undifferentiated carcinoma

APPENDIX 7: NOTECODES AND DEFINITIONS

Code	Definition
a	The exposure time reported on the plot is an average of the different exposure times of the individual dose groups in the experiment. For NCI/NTP, both exposure and experiment times have been averaged because of differential survival among the dose groups. (In the TD_{50} calculation for the NCI/NTP bioassays, full lifetable data have been used.)
b	Diet was specially prepared to be deficient in one or more vitamins.
e	For the general literature we have used an effective number of animals in a group whenever possible. This effective number is either: (1) the number of animals alive at the time of appearance of the first tumor, or if that is not reported, then (2) the number of animals examined.
g	Some or all of the animals were used as breeders during the course of the experiment.
j	The data for this test have been previously published in the database. The experimental results have been revised and republished by the authors. In the database, we give the same reference number to the test in both publications.
k	For interim and serial sacrifice experiments, we have reported, as a separate experiment with a k notecode, each sacrifice time that otherwise met the inclusion rules of the database. Wherever possible, we have included unscheduled deaths with the terminal sacrifice data, and when this has been done, there is no k notecode for the terminal sacrifice experiment.
n	NTP considered one dose group inadequate for detecting a carcinogenic response.
o	Chemical was administered as an aerosol.
r	Restricted site analysis; the authors either examined or chose to report data for only a few selected tissues.
s	Authors noted that survival was decreased due to toxicity, disease, or accidental death.
v	Variable or irregular dosing schedules have been used, e.g. dose level changed during the experiment.

APPENDIX 8: DOSE-RESPONSE CURVE SYMBOLS AND DEFINITIONS

Code	Dose-Response Curve
*	consistent with linearity
/	significant departure from linearity, upward curvature
\	significant departure from linearity, downward curvature
Z	significant departure from linearity, more than three dose groups including controls
blank	either no dose-related effect, or only two dose groups including controls, so not enough information to determine a curve shape

APPENDIX 9: REFERENCE CODES AND DEFINITIONS

Code	Reference
acnr	Anticancer Research
amih	American Industrial Hygiene
anes	Anesthesiology
anya	Annals of the New York Academy of Sciences
bjca	British Journal of Cancer
canr	Cancer Research
carc	Carcinogenesis
clet	Cancer Letters
enhp	Environmental Health Perspectives
faat	Fundamental and Applied Toxicology
fctx	Food and Chemical Toxicology (formerly Food and Cosmetics Toxicology, until 1982)
gann	Japanese Journal of Cancer Research (formerly Gann through Vol. 75, 1984)
ijbb	Indian Journal of Biochemistry & Biophysics
jact	Journal of the American College of Toxicology
jnci	Journal of the National Cancer Institute (U.S. National Cancer Institute Journal)

Code	Reference
jtxe	Journal of Toxicology and Environmental Health
livt	Laboratory Investigation
made	Mechanisms of Ageing and Development
myco	Mycopathologia
neag	Neurobiology of Aging
nutc	Nutrition and Cancer
pavt	Veterinary Pathology (formerly Pathologia Veterinaria)
txcy	Toxicology
txih	Toxicology and Industrial Health
txpy	Toxicologic Pathology

APPENDIX 10: NCI/NTP BIOASSAYS EVALUATED AS INADEQUATE IN TECHNICAL REPORTS

Chemical Name	Experiments Evaluated as Inadequate
CHLOROETHANE	male mice
DIMETHYL METHYLPHOSPHONATE	male mice
TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)	rats (b, d, e and f 04546), male rats (c04547)

APPENDIX 11: AUTHOR'S OPINION CODES AND DEFINITIONS

Code	Author's Opinion for Each Site
c	NTP evaluation is *clear evidence* of carcinogenic activity: studies that are interpreted as showing a dose-related (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
e	NTP evaluation is *equivocal evidence* of carcinogenic activity: studies that are interpreted as showing a marginal increase of neoplasms that may be chemically related.
p	NTP evaluation is *some evidence* of carcinogenic activity: studies that are interpreted as showing a chemically related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence.
+	Author in general literature evaluated site as positive.
-	NTP evaluation is *no evidence* of carcinogenic activity: studies that are interpreted as showing no chemically related increases in malignant or benign neoplasms; or author in general literature evaluated site as negative.
blank	For NTP and general literature: all other sites.

APPENDIX 12 Bibliography: General Literature

1. Amo, H., Matsuyama, M., Amano, H., Yamada, C., Kawai, M., Miyata, N., and Nakadate, M. Carcinogenicity and toxicity study of *m*-phenylenediamine administered in the drinking-water to (C57BL/6 × C3H/He)F_1 mice. Food Chem. Toxicol. 26: 893-897(1988).
2. Annapurna, V. V., Mukundan, M. A., Sesikeran, B., and Bamji, M. S. Long-term effects of female sex steroids on female rat liver in an initiator-promoter model of hepatocarcinogenesis. Indian J. Biochem. Biophys. 25: 708-713(1988).
3. Arnold, D. L., Moodie, C. A., Charbonneau, S. M., Grice, H. C., McGuire, P. F., Bryce, F. R., Collins, B. T., Zawidzka, Z. Z., Krewski, D. R., Nera, E. A., and Munro, I. C. Long-term toxicity of hexachlorobenzene in the rat and the effect of dietary vitamin A. Food Chem. Toxicol. 23: 779-793(1985).
4. Baden, J. M., Kundomal, Y. R., Mazze, R. I., and Kosek, J. C. Carcinogen bioassay of isoflurane in mice. Anesthesiology 69: 750-753(1988).
5. Barten, M. The effects of different MNNG (*N*-methyl-*N*'-nitro-*N*-nitrosoguanidine)-doses on the stomach and the upper small intestine of the rat. Exp. Pathol. 31: 147-152(1987).
6. Berger, M. R., Schmahl, D., and Zerban, H. Combination experiments with very low doses of three genotoxic *N*-nitrosamines with similar organotropic carcinogenicity in rats. Carcinogenesis 8: 1635-1643(1987).
7. Borzelleca, J. F., and Hallagan, J. B. A chronic toxicity/carcinogenicity study of FD & C Yellow No. 5 (tartrazine) in mice. Food Chem. Toxicol. 26: 189-194(1988).
8. Borzelleca, J. F., and Hallagan, J. B. Lifetime toxicity/carcinogenicity study of FD & C Red No. 3 (erythrosine) in mice. Food Chem. Toxicol. 25: 735-737(1987).
9. Bosan, W. S., Shank, R. C., MacEwen, J. D., Gaworski, C. L., and Newberne, P. M. Methylation of DNA guanine during the course of induction of liver cancer in hamsters by hydrazine or dimethylnitrosamine. Carcinogenesis 8: 439-444(1987).
10. Burnett, C. M., and Corbett, J. F. Failure of short-term in vitro mutagenicity tests to predict the animal carcinogenicity of hair dyes. Food Chem. Toxicol. 25: 703-707(1987).
11. Carr, B. I., Rahbar, S., Asmeron, Y., Riggs, A., and Winberg, C. D. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. Br. J. Cancer 57: 395-402(1988).
12. Cavaliere, A., Bufalari, A., and Vitali, R. 5-azacytidine carcinogenesis in BALB/c mice. Cancer Lett. 37: 51-58(1987).
13. Ciliberti, A., Maltoni, C., and Perino, G. Long-term carcinogenicity bioassays on propylene administered by inhalation to Sprague-Dawley rats and Swiss mice. Ann. N. Y. Acad. Sci. 534: 235-245(1988).
14. Clevenger, M. A., Turnbull, D., Inoue, H., Enomoto, M., Allen, J. A., Henderson, L. M., and Jones, E. Toxicological evaluation of neosugar: Genotoxicity, carcinogenicity, and chronic toxicity. J. Am. Coll. Toxicol. 7: 643-662(1988).
15. Conti, B., Maltoni, C., Perino, G., and Ciliberti, A. Long-term carcinogenicity bioassays on styrene administered by inhalation, ingestion and injection and styrene oxide administered by ingestion in Sprague-Dawley rats, and para-methylstyrene administered by ingestion in Sprague-Dawley rats and Swiss mice. Ann. N. Y. Acad. Sci. 534: 203-234(1988).
16. Dodd, D. C., Port, C. D., Deslex, P., Regnier, B., Sanders, P., and Indacochea-Redmond, N. Two-year evaluation of misoprostol for carcinogenicity in CD Sprague-Dawley rats. Toxicol. Pathol. 15: 125-133(1987).
17. Elashoff, R. M., Fears, T. R., and Schneiderman, M. A. Statistical analysis of a carcinogen mixture experiment. I. Liver carcinogens. J. Nat. Cancer Inst. 79: 509-526(1987).
18. Ernst, H., Ohshima, H., Bartsch, H., Mohr, U., and Reichart, P. Tumorigenicity study in Syrian hamsters fed areca nut together with nitrite. Carcinogenesis 8: 1843-1845(1987).
19. Fiala, E. S., Czerniak, R., Castonguay, A., Conaway, C. C., and Rivenson, A. Assay of 1-nitropropane, 2-nitropropane, 1-azoxypropane and 2-azoxypropane for carcinogenicity by

gavage in Sprague-Dawley rats. Carcinogenesis 8: 1947-1949(1987).
20. Fujii, K., Nomoto, K., Ishidate, M., Jr., and Nakamura, K. Chronic toxicity of charred fish meat in Wistar rats. Nutr. Cancer 9: 185-193(1987).
21. Fujita, Y., Wakabayashi, K., Takayama, S., Nagao, M., and Sugimura, T. Induction of oral cavity cancer by 3-diazotyramine, a nitrosated product of tyramine present in foods. Carcinogenesis 8: 527-529(1987).
22. Gallagher, G. T., Maull, E. A., Kovacs, K., and Szabo, S. Neoplasms in rats ingesting acrylonitrile for two years. J. Am. Coll. Toxicol. 7: 603-615(1988).
23. Gopinath, C., and Gibson, W. A. Mesovarian leiomyomas in the rat. Environ. Health Perspect. 73: 107-113(1987).
24. Greenman, D. L., Highman, B., Chen, J. J., Schieferstein, G. J., and Norvell, M. J. Influence of age on induction of mammary tumors by diethylstilbestrol in C3H/HeN mice with low murine mammary tumor virus titer. J. Nat. Cancer Inst. 77: 891-898(1986).
25. Hasegawa, R., Takahashi, M., Furukawa, F., Toyoda, K., Sato, H., and Hayashi, Y. Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole. Jpn. J. Cancer Res. 79: 320-328(1988).
26. Hirose, M., Fukushima, S., Shirai, T., Hasegawa, R., Kato, T., Tanaka, H., Asakawa, E., and Ito, N. Stomach carcinogenicity of caffeic acid, sesamol and catechol in rats and mice. Jpn. J. Cancer Res. 81: 207-212(1990).
27. Hirose, M., Kurata, Y., Tsuda, H., Fukushima, S., and Ito, N. Catechol strongly enhances rat stomach carcinogenesis: A possible new environmental stomach carcinogen. Jpn. J. Cancer Res. 78: 1144-1149(1987).
28. Hirose, M., Masuda, A., Tsuda, H., Uwagawa, S., and Ito, N. Enhancement of bha-induced proliferative rat forestomach lesion development by simultaneous treatment with other antioxidants. Carcinogenesis 8: 1731-1735(1987).
29. Inai, K., Kobuke, T., Nambu, S., Takemoto, T., Kou, E., Nishina, H., Fujihara, M., Yonehara, S., Suehiro, S., Tsuya, T., Horiuchi, K., and Tokuoka, S. Hepatocellular tumorigenicity of butylated hydroxytoluene administered orally to $B6C3F_1$ mice. Jpn. J. Cancer Res. 79: 49-58(1988).
30. Jack, D., Poynter, D., and Spurling, N. W. Beta-adrenoceptor stimulants and mesovarian leiomyomas in the rat. Toxicology 27: 315-320(1983).
31. Jang, J. J., Takahashi, M., Furukawa, F., Toyoda, K., Hasegawa, R., Sato, H., and Hayashi, Y. Long-term in vivo carcinogenicity study of phenytoin (5,5-diphenylhydantoin) in F344 rats. Food Chem. Toxicol. 25: 697-702(1987).
32. Kato, T., Ohgaki, H., Hasegawa, H., Sato, S., Takayama, S., and Sugimura, T. Carcinogenicity in rats of a mutagenic compound, 2-amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline. Carcinogenesis 9: 71-73(1988).
33. Koepke, S. R., Creasia, D. R., Knutsen, G. L., and Michejda, C. J. Carcinogenicity of hydroxyalkylnitrosamines in F344 rats: Contrasting behavior of β- and γ-hydroxylated nitrosamines. Cancer Res. 48: 1533-1536(1988).
34. Kuper, C. F., Reuzel, P. G. J., Feron, V. J., and Verschuuren, H. Chronic inhalation toxicity and carcinogenicity study of propylene oxide in Wistar rats. Food Chem. Toxicol. 29: 159-167(1988).
35. Kuroda, K., Terao, K., and Akao, M. Inhibitory effect of fumaric acid on hepatocarcinogenesis by thioacetamide in rats. J. Nat. Cancer Inst. 79: 1047-1051(1987).
36. Kurokawa, Y., Aoki, S., Matsushima, Y., Takamura, N., Imazawa, T., and Hayashi, Y. Dose-response studies on the carcinogenicity of potassium bromate in F344 rats after long-term oral administration. J. Nat. Cancer Inst. 77: 977-982(1986).
37. Kurokawa, Y., Matsushima, Y., Takamura, N., Imazawa, T., and Hayashi, Y. Relationship between the duration of treatment and the incidence of renal cell tumors in male F344 rats administered potassium bromate. Jpn. J. Cancer Res. 78: 358-364(1987).
38. Lee, K. P., Chromey, N. C., Culik, R., Barnes, J. R., and Schneider, P. W. Toxicity of *N*-methyl-2-pyrrolidone (NMP): Teratogenic, subchronic, and two-year inhalation studies. Fundam. Appl. Toxicol. 9: 222-235(1987).
39. Leonard, T. B., Graichen, M. E., and Popp, J. A. Dinitrotoluene isomer-specific hepatocarcinogenesis in F344 rats. J. Nat. Cancer Inst. 79: 1313-1319(1987).
40. Lijinsky, W., Kovatch, R. M., and Singer, S. S. Carcinogenesis in F-344 rats induced by nitrosohydroxyalkylchloroethylureas. Cancer Res. Clin. Oncol. 112: 221-228(1986).
41. Lijinsky, W., and Kovatch, R. M. Chronic toxicity study of cyclohexanone in rats and mice. J. Nat. Cancer Inst. 77: 941-949(1986).
42. Lijinsky, W., and Kovatch, R. M. Carcinogenesis by nitrosohydroxyethylurea and nitrosomethoxyethylurea in F344 rats. Jpn. J. Cancer Res. 79: 181-186(1988).
43. Lijinsky, W., Kovatch, R. M., Keefer, L. K., Saavedra, J. E., Hansen, T. J., Miller, A. J., and Fiddler, W. Carcinogenesis in rats by cyclic *N*-nitrosamines containing sulphur. Food Chem. Toxicol. 26: 3-7(1988).
44. Lijinsky, W., Kovatch, R. M., and Riggs, C. W. Carcinogenesis by nitrosodialkylamines and azoxyalkanes given by gavage to rats and hamsters. Cancer Res. 47: 3968-3972(1987).
45. Lijinsky, W., Kovatch, R. M., Riggs, C. W., and Walters, P. T. Dose response study with *N*-nitrosomorpholine in drinking water of F-344 rats. Cancer Res. 48: 2089-2095(1988).
46. Lijinsky, W., and Reuber, M. D. Chronic carcinogenesis studies of acrolein and related compounds. Toxicol. Ind. Health 3: 337-345(1987).
47. Lijinsky, W., and Reuber, M. D. Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. Toxicol. Ind. Health 3: 413-422(1987).
48. Maeda, T., Sano, N., Togei, K., Shibata, M., Izumi, K., and Otsuka, H. Lack of carcinogenicity of phenytoin in $(C57BL/6 \times C3H)F_1$ mice. J. Toxicol. Environ. Health 24: 111-119(1988).
49. Maekawa, A., Matsuoka, C., Onodera, H., Tanigawa, H., Furuta, K., Kanno, J., Jang, J. J., Hayashi, Y., and Ogiu, T. Lack of carcinogenicity of tartrazine (FD & C Yellow No. 5) in the F344 rat. Food Chem. Toxicol. 25: 891-896(1987).
50. Maekawa, A., Onodera, H., Tanigawa, H., Furuta, K., Kanno, J., Matsuoka, C., Ogiu, T., and Hayashi, Y. Long-term studies on carcinogenicity and promoting effect of phenylbutazone in Donryu rats. J. Nat. Cancer Inst. 79: 577-584(1987).
51. Maltoni, C. Early results of the experimental assessments of the carcinogenic effects of one epoxy solvent: styrene oxide. Adv. Mod. Environ. Toxicol. 2: 97-110(1981).
52. Maltoni, C., Ciliberti, A., Cotti, G., and Perino G. Long-term carcinogenicity bioassays on acrylonitrile administered by inhalation and by ingestion to Sprague-Dawley rats. Ann. N. Y. Acad. Sci. 534: 179-202(1988).
53. Maltoni, C., Conti, B., Perino, G., and Di Maio, V. Further evidence of benzene carcinogenicity; results on Wistar rats and mice treated by injection. Ann. N. Y. Acad. Sci. 534: 412-426(1988).
54. Maltoni, C., and Cotti, G. Carcinogenicity of vinyl chloride in Sprague-Dawley rats after prenatal and postnatal exposure. Ann. N. Y. Acad. Sci. 534: 145-159(1988).
55. Maltoni, C., Cotti, G., and Perino, G. Long-term carcino-

genicity bioassays on methylene chloride administered by ingestion to Sprague-Dawley rats and Swiss mice and by inhalation to Sprague-Dawley rats. Ann. N. Y. Acad. Sci. 534: 352-366(1988).
56. Maltoni, C., Lefemine, G., Tovoli, D., and Perino, G. Long-term carcinogenicity bioassays on three chlorofluorocarbons (trichlorofluoromethane, FC11; dichlorodifluoromethane, FC12; chlorodifluoromethane, FC22) administered by inhalation to Sprague-Dawley rats and Swiss mice. Ann. N. Y. Acad. Sci. 534: 261-282(1988).
57. Markiewicz, V. R., Saunders, L. Z., Geus, R. J., Payne, B. J., and Hook, J. B. Carcinogenicity study of auranofin, an orally administered gold compound, in mice. Fundam. Appl. Toxicol. 11: 277-284(1988).
58. McManus, B. M., Toth, B., and Patil, K. D. Aortic rupture and aortic smooth muscle tumors in mice: Induction by *p*-hydrazinobenzoic acid hydrochloride of the cultivated mushroom *Agaricus bisporus*. Lab. Invest. 57: 78-85(1987).
59. Mirvish, S. S., Weisenburger, D. D., Salmasi, S., and Kaplan, P. A. Carcinogenicity of 1-(2-hydroxyethyl)-1-nitrosourea and 3-nitroso-2-oxazolidinone administered in drinking water to male MRC-Wistar rats: Induction of bone, hematopoietic, intestinal, and liver tumors. J. Nat. Cancer Inst. 78: 387-393(1987).
60. Mizutani, T., and Mitsuoka, T. Effect of dietary phenobarbital on spontaneous hepatic tumorigenesis in germfree C3H/He male mice. Cancer Lett. 39: 233-237(1988).
61. Mori, H., Sugie, S., Yoshimi, N., Kuniyasu, T., Iwata, H., Kawai, K., and Hamasaki, T. Potential carcinogenicity of 5,6-dimethoxysterigmatocystin in rats. Carcinogenesis 9: 1039-1042 (1988).
62. Nera, E. A., Iverson, F., Lok, E., Armstrong, C. L., Karpinski, K., and Clayson, D. B. A carcinogenesis reversibility study of the effects of butylated hydroxyanisole on the forestomach and urinary bladder in male Fischer 344 rats. Toxicology 53: 251-268 (1988).
63. Nitschke, K. D., Burek, J. D., Bell, T. J., Kociba, R. J., Rampy, L. W., and McKenna, M. J. Methylene chloride: A 2-year inhalation toxicity and oncogenicity study in rats. Fundam. Appl. Toxicol. 11: 48-59(1988).
64. Nonoyama, T., Fullerton, F., Reznik, G., Bucci, T. J., and Ward, J. M. Mouse hepatoblastomas: A histologic, ultrastructural, and immunohistochemical study. Pathol. Vet. 25: 286-296(1988).
65. Ohgaki, H., Hasegawa, H., Suenaga, M., Sato, S., Takayama, S., and Sugimura, T. Carcinogenicity in mice of a mutagenic compound, 2-amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline (MeIQx) from cooked foods. Carcinogenesis 8: 665-668(1987).
66. Owen, P. E., Glaister, J. R., Gaunt, I. F., and Pullinger, D. H. Inhalation toxicity studies with 1,3-butadiene 3 two year toxicity/carcinogenicity study in rats. Am. Ind. Hyg. Assoc. J. 48: 407-413(1987).
67. Port, C. D., Dodd, D. C., Deslex, P., Regnier, B., Sanders, P., and Indacochea-Redmond, N. Twenty-one month evaluation of misoprostol for carcinogenicity in CD-1 mice. Toxicol. Pathol. 15: 134-142(1987).
68. Quast, J. F., Calhoun, L. L., and Frauson, L. E. 1,1,1-trichloroethane formulation: A chronic inhalation toxicity and oncogenicity study in Fischer 344 rats and B6C3F_1 mice. Fundam. Appl. Toxicol. 11: 611-625(1988).
69. Rao, M. S., Dwivedi, R. S., Subbarao, V., and Reddy, J. K. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound. Br. J. Cancer 58: 46-51(1988).
70. Rao, M. S., Usuda, N., Subbarao, V., and Reddy, J. K. Absence of γ-glutamyl transpeptidase activity in neoplastic lesions induced in the liver of male F-344 rats by di-(2-ethylhexyl)phthalate, a peroxisome proliferator. Carcinogenesis 8: 1347-1350(1987).
71. Rivenson, A., Hoffmann, D., Prokopczyk, B., Amin, S., and Hecht, S. S. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and areca-derived *N*-nitrosamines. Cancer Res. 48: 6912-6917(1988).
72. Rosenkrantz, H., and Fleischman, R. W. In vivo carcinogenesis assay of DL-methadone.*HCl* in rodents. Fundam. Appl. Toxicol. 11: 640-651(1988).
73. Rosenkrantz, H., and Fleischman, R. W. In vivo carcinogenesis assay of *l*-α-acetylmethadol.*HCl* in rodents. Fundam. Appl. Toxicol. 11: 626-639(1988).
74. Soffritti, M., Maltoni, C., Maffei, F., and Biagi, R. Formaldehyde: An experimental multipotential carcinogen. Toxicol. Ind. Health 5: 699-730(1989).
75. Stenback, F., Weisburger, J. H., and Williams, G. M. Effect of lifetime administration of dimethylaminoethanol on longevity, aging changes, and cryptogenic neoplasms in C3H mice. Mech. Ageing Dev. 42: 129-138(1988).
76. Togei, K., Sano, N., Maeda, T., Shibata, M., and Otsuka, H. Carcinogenicity of bucetin in (C57BL/6 × C3H)F_1 mice. J. Nat. Cancer Inst. 79: 1151-1158(1987).
77. Toth, B. Carciogenesis by *N*2-[γ-*L*(+)-glutamyl]-4-carboxy-phenylhydrazine of *Agaricus bisporus* in mice. Anticancer Res. 6: 917-920(1986).
78. Toth, B., and Raha, C. R. Carcinogenesis by pentanal methylformylhydrazone of *Gyromitra esculenta* in mice. Mycopathologia 98: 83-89(1987).
79. Trochimowicz, H. J., Rusch, G. M., Chiu, T., and Wood, C. K. Chronic inhalation toxicity/carcinogenicity study in rats exposed to Fluorocarbon 113 (FC-113). Fundam. Appl. Toxicol. 11: 68-75(1988).
80. Truhaut, R., Le Bourhis, B., Attia, M., Glomot, R., Newman, J., and Caldwell, J. Chronic toxicity/carcinogenicity study of trans-anethole in rats. Food Chem. Toxicol. 27: 11-19(1989).
81. Walker, R. F., Weideman, C. A., and Wheeldon, E. B. Reduced disease in aged rats treated chronically with ibopamine, a catecholaminergic drug. Neurobiol. Aging 9: 291-301(1988).
82. Wolff, G. L., Roberts, D. W., Morrissey, R. L., Greenman, D. L., Allen, R. R., Campbell, W. L., Bergman, H., Nesnow, S., and Frith, C. H. Tumorigenic responses to lindane in mice: Potentiation by a dominant mutation. Carcinogenesis 8: 1889-1897(1987).
83. Woutersen, R. A., Appelman, L. M., Van Gardenen-Hoetmer, A., and Feron, V. J. Inhalation toxicity of acetaldehyde in rats. III. Carcinogenicity study. Toxicology 41: 213-231(1986).
84. Woutersen, R. A., and Feron, V. J. Inhalation toxicity of acetaldehyde in rats. IV. progression and regression of nasal lesions after discontinuation of exposure. Toxicology 47: 295-305(1987).

APPENDIX 13

Bibliography: National Cancer Institute/ National Toxicology Program Technical Reports

CHEMICAL NAME	TECHNICAL REPORT NUMBER	PUBLICATION DATE
2-AMINO-4-NITROPHENOL	339	1988
2-AMINO-5-NITROPHENOL	334	1988
BENZOFURAN	370	1989
BENZYL ALCOHOL	343	1989
BORIC ACID	324	1987
BROMODICHLOROMETHANE	321	1987
BROMOETHANE	363	1989
PARA-CHLOROANILINE HYDROCHLORIDE	351	1989
CHLOROETHANE	346	1989
2,4-DICHLOROPHENOL	353	1989
DICHLORVOS	342	1989
DIMETHOXANE	354	1989
DIMETHYL METHYLPHOSPHONATE	323	1987
N,N-DIMETHYLANILINE	360	1989
DIPHENHYDRAMINE HYDROCHLORIDE	355	1989
1,2-EPOXYBUTANE	329	1988
ERYTHROMYCIN STEARATE	338	1988
ETHYLENE OXIDE	326	1987
FUROSEMIDE	356	1989
FOOD GRADE GERANYL ACETATE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE)	252	1987
HEXACHLOROETHANE	361	1989
4-HEXYLRESORCINOL	330	1988
HYDROCHLOROTHIAZIDE	357	1989
HYDROQUINONE	366	1989
MALONALDEHYDE, SODIUM SALT	331	1988
2-MERCAPTOBENZOTHIAZOLE	332	1988
8-METHOXYPSORALEN	359	1989
METHYL CARBAMATE	328	1987
alpha-METHYLDOPA SESQUIHYDRATE	348	1989
N-METHYLOLACRYLAMIDE	352	1989
MONURON	266	1988
NALIDIXIC ACID	368	1989
NITROFURANTOIN	341	1989
NITROFURAZONE	337	1988
OCHRATOXIN A	358	1989
C.I. ACID ORANGE 3	335	1988
C.I. ACID ORANGE 10	211	1987
PENICILLIN VK	336	1988
PENTACHLOROPHENOL, TWO TECHNICAL GRADE MIXTURES	349	1989
PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE	365	1989
N-PHENYL-2-NAPHTHYLAMINE	333	1988
ROTENONE	320	1988
ROXARSONE	345	1989
TETRACYCLINE HYDROCHLORIDE	344	1989
TRIBROMOMETHANE	350	1989
TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)	273	1988
TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)	243	1990

APPENDIX 14: INDEX TO ALL CHEMICALS IN THE FIVE PLOTS OF THE CARCINOGENIC POTENCY DATABASE AND RESULTS FOR POTENCY (TD_{50}) AND POSITIVITY

Appendix 14 is both an index to chemicals in the CPDB and a tabular compilation of results on positivity and potency in rats and mice. Chemical names and common synonyms are listed alphabetically for the 1136 chemicals in the database, Chemical Abstracts Service registry (CAS) number is reported, and the plots that include experimental results on the chemical are listed by plot number.

Positivity. For each chemical, a result is reported in male rats (MR), female rats (FR), male mice (MM), and female mice (FM). If there is no experiment in the CPDB for that sex-species group, this is indicated by "NT." When all four sex-species groups are NT, the chemical was tested only in a species other than rats or mice (see footnotes "g" and "h" below). The classification of positivity is based on a positive result in at least one experiment, and we classify an experiment as either positive or negative on the basis of the author's opinion in the published paper. We use the author's opinion to determine positivity because it often takes into account more information than statistical significance alone, such as historical control rates for particular sites, survival and latency, and/or dose response. Generally, this designation by author's opinion corresponds well with the results of statistical tests for the significance of the dose-response effect. The strongest level of evidence of carcinogenicity in any experiment in the sex-species group is reported in Appendix 14 for each chemical. We indicate whether the compound was tested in each group and list the strongest level of evidence for carcinogenicity based upon any author's evaluation in either the general literature or the NCI/NTP. In the general literature, a (+) indicates a positive author's opinion, and a (-) indicates either that "no opinion" was reported for this experiment or that the opinion was negative. In the NCI/NTP the strongest evaluation is clear evidence of carcinogenicity (+). When there was no such evaluation in one of the sex-species groups, but the compound was tested by NCI/NTP and their evaluation was stronger than "no evidence of carcinogenicity" (-), we indicate whether that NCI/NTP evaluation was "some evidence of carcinogenicity" (P), " equivocal" (E) or "inadequate bioassay" (I). For older NCI/NTP tests the evaluation (A) indicates "associated with carcinogenicity," and we do not interpret this as positive. These evaluations correspond to the opinions reported in our published plots. The abbreviations for positivity in Appendix 14 are as follows:

NT = No Test in the CPDB in this group
\+ = The CPDB contains at least one experiment in which the compound was evaluated as a carcinogen by the published author. For NCI/NTP tests, the evaluation was "clear evidence of carcinogenicity."
P = The strongest level of evidence in the CPDB was an NTP evaluation of "some evidence of carcinogenicity."
I = No tests in the CPDB in this sex-species group were evaluated as positive; however, the NCI/NTP test was evaluated as inadequate.
A = The strongest level of evidence in the CPDB was an NCI/NTP evaluation of "associated with carcinogenicity."
E = The strongest level of evidence in the CPDB was an NTP evaluation of "equivocal."
\- = All tests in this group were negative.
B+ = In the only positive test in the sex-species, results were reported only for males and females combined.
B- = In the only test in the sex-species, results were reported only for males and females combined, and the test was negative.

Carcinogenic Potency. For the purposes of Appendix 14, TD_{50} values for a chemical are reported only for a species with a positive evaluation of carcinogenicity in at least one test. In any given positive experiment we select the lowest TD_{50} value from among positively evaluated target sites with a statistically significant dose response (two-tailed $p < 0.1$). If no positive sites have a significant dose response, then we select the most potent (lowest TD_{50} from among positively evaluated sites with $p \geq 0.1$. This method provides a single TD_{50} to represent an experiment. For chemicals with more than one positive experiment, we summarize potency in a species by selecting the lowest significant TD_{50} value from among those representing each experiment. If none is significant, the lowest his chosen from among the nonsignificant values with a positive author's opinion (see footnote "b" below). In some experiments, no TD_{50} could be estimated because all dosed animals had the tumor of interest, and the only data available were for crude percentages of animals with a tumor. For these cases we use the 99% upper confidence limit of TD_{50} as a replacement for the TD_{50}.

In a series of footnotes, we provide additional information about TD_{50} values and test results in the CPDB. These are as follows:

a = The CPDB contains more than one positive test in the species.
b = The reported TD_{50} is not statistically significant (i.e., $p \geq 0.1$), and all results evaluated as positive in the species are not significant.
c = Only an upper bound and no TD_{50} could be estimated because all dosed animals had the tumor of interest and only summary data were available. The reported value is the 99% upper confidence limit.
d = All positive results for this species in the CPDB are from tests in which the compound was administered by either IP or IV injection.
e = The reported TD_{50} from a test in which the compound was administered by IP or IV injection; however, the CPDB also contains a positive test in this species

with a less potent TD_{50} value from a test where the route was oral or inhalation.

f = TD_{50} values from different significant, positive experiments in this species vary by more than 10-fold from one another. The most potent TD_{50} value is reported here.

g = The CPDB includes tests in a species other than rats or mice, and at least one test is positive.

h = The CPDB includes tests in a species other than rats or mice, and all tests are negative.

i = Data on four NCI bioassays are included in Appendix 14 but are excluded from the analyses and tables in this and previous papers: C.I. Direct Black 38, C.I. Direct Blue 6, and C.I. Direct Brown 95, were only tested subchronically; 3 -Amino-9-ethylcarbazole• HCL and 3-amino-9-ethylcarbazole mixture were tested by NCI in one bioassay but we separated them in the CPDB because slightly different chemicals were used for different dose groups; we combined them for our analyses, as NCI had done.

The experimental results used in Appendix 14 appear in the five plots of the CPDB:

1 = Gold, L. S., Sawyer, C. B., Magaw, R., Backman, G. M., de Veciana, M., Levinson, R., Hooper, N. K., Havender, W. R., Bernstein, L., Peto, R., Pike, M. C., and Ames, B. N. A carcinogenic potency database of the standardized results of animal bioassays. Environ. Health Perspect. 58: 9–319 (1984).

2 = Gold, L. S., de Veciana, M., Backman, G. M., Magaw, R., Lopipero, P., Smith, M., Blumenthal, M., Levinson, R., Bernstein, L., and Ames, B. N. Chronological supplement to the carcinogenic potency database: standardized results of animal bioassays published through December 1982. Environ. Health Perspect. 67: 161–200 (1986).

3 = Gold, L. S., Slone, T. H., Backman, G. M., Magaw, R., Da Costa, M., Lopipero, P., Blumenthal, M., and Ames, B. N. Second Chronological Supplement to the Carcinogenic Potency Database: Standardized Results of Animal Bioassays Published through December 1984 and by the National Toxicology Program through May 1986. Environ. Health Perspect. 74: 237–329 (1987).

4 = Gold, L. S., Slone, T. H., Backman, G. M., Eisenberg, S., Da Costa, M., Wong, M., Manley, N. B., Rohrbach, L., and Ames, B. N. Third chronological supplement to the Carcinogenic Potency Database: sandardized results of animal bioassays published through December 1986 and by the National Toxicology Program through June 1987. Environ. Health Perspect. 84: 215–285 (1990).

5 = This publication.

APPENDIX 14. INDEX TO CHEMICALS IN THE 5 PLOTS OF THE CARCINOGENIC POTENCY DATABASE AND RESULTS FOR POTENCY (TD_{50}) AND POSITIVITY

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								A-alpha-C (see 2-AMINO-9H-PYRIDO(2,3-b)INDOLE)
88.5[a]	NT	+	+	NT	NT	4,5	75-07-0	ACETALDEHYDE[g]
NT	1.61[a]	NT	NT	+	+	2	16568-02-8	ACETALDEHYDE METHYLFORMYLHYDRAZONE
–	NT	–	NT	NT	NT	5	107-29-9	ACETALDOXIME
104[a]	3010	+	+	+	–	1	60-35-5	ACETAMIDE
440[a]	1010[a]	+	+	+	+	1,3,4	103-90-2	ACETAMINOPHEN
–	–	–	–	–	–	1	968-81-0	ACETOHEXAMIDE
6.05	NT	NT	+	NT	NT	1	18523-69-8	ACETONE[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] HYDRAZONE
12.1	NT	+	–	NT	NT	2	127-06-0	ACETOXIME
11.4[af]	72.9[af]	+	+	+	+	1	3688-53-7	AF-2[g]
21.1[a]	–	+	NT	–	NT	1	34627-78-6	1'-ACETOXYSAFROLE
NT	208[a]	NT	NT	+	+	1	65734-38-5	N'-ACETYL-4-(HYDROXYMETHYL) PHENYLHYDRAZINE
NT	319[a]	NT	NT	+	+	1	1078-38-2	1-ACETYL-2-ISONICOTINOYLHYDRAZINE
NT	–	NT	NT	–	–	1	520-45-6	3-ACETYL-6-METHYL-2,4-PYRANDIONE
NT	44.8[a]	NT	NT	+	+	1	114-83-0	1-ACETYL-2-PHENYLHYDRAZINE
1.18	NT	NT	+	NT	NT	1	4075-79-0	4-ACETYLAMINOBIPHENYL
–	NT	NT	–	NT	NT	1	28314-03-6	1-ACETYLAMINOFLUORENE
0.64[a]	4.78[af]	+	+	+	+	1-5	53-96-3	2-ACETYLAMINOFLUORENE[g]
–	NT	NT	–	NT	NT	1	28322-02-3	4-ACETYLAMINOFLUORENE
–	NT	–	–	NT	NT	1	---	ACETYLATED DIAMYLOPECTIN PHOSPHATE
–	NT	–	–	NT	NT	1	68130-14-3	ACETYLATED DISTARCH ADIPATE
–	NT	–	–	NT	NT	1	53123-84-5	ACETYLATED DISTARCH GLYCEROL
–	NT	–	–	NT	NT	1	---	ACETYLATED DISTARCH PHOSPHATE
								L-alpha-ACETYLMETHADOL.HCl (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl)
								C.I. ACID RED 14, DISODIUM SALT (see C.I. FOOD RED 3)
–	NT	–	–	NT	NT	5	107-02-8	ACROLEIN
–	NT	–	–	NT	NT	5	3054-95-3	ACROLEIN DIETHYLACETAL
–	NT	–	–	NT	NT	5	5314-33-0	ACROLEIN OXIME
0.395[ad]	NT	+	+	I	I	1	7008-42-6	ACRONYCINE
4.21[a]	NT	+	+	NT	NT	4	79-06-1	ACRYLAMIDE
5.31[af]	NT	+	+	NT	NT	1,5	107-13-1	ACRYLONITRILE
–	NT	–	NT	NT	NT	1	8052-16-2	ACTINOMYCIN C
7.69E-4[ad]	NT	+	+	NT	NT	1	50-76-0	ACTINOMYCIN D
–	–	–	–	–	–	1	628-94-4	ADIPAMIDE
0.00247	NT	+	NT	NT	NT	1	29611-03-8	AFLATOXICOL
9.32E-4[af]	–	+	+	–	–	1,3,5	1162-65-8	AFLATOXIN B1[g]
0.00187[a]	0.343	+	NT	+	NT	1	---	AFLATOXIN, CRUDE
–	–	–	–	–	–	2	9002-18-0	AGAR
								AGARITINE (see beta-N-[gamma-L(+)-GLUTAMYL]-4-HYDROXYMETHYLPHENYLHYDRAZINE)
								AGERITE 150 (see p-ISOPROPOXYDIPHENYLAMINE)
								AGERITE ALBA (see HYDROQUINONE MONOBENZYL ETHER)
								AGERITE DPPD (see DIPHENYL-p-PHENYLENEDIAMINE)
								AGERITE POWDER (see PHENYL-beta-NAPHTHYLAMINE)
								AGERITE WHITE (see sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE)
								ALDERLIN (see PRONETHALOL)
								ALDERLIN.HCl (see PRONETHALOL.HCl)
–	–	–	–	–	–	1	116-06-3	ALDICARB
–	0.741[a]	–	–	+	B+	1	309-00-2	ALDRIN

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
–	NT	–	–	NT	NT	1	---	ALKYLBENZENESULFONATE, LINEAR
–	NT	–	–	NT	NT	4	mixture	ALKYLDIMETHYLAMINE OXIDES, COMMERCIAL GRADE
–	NT	–	–	NT	NT	3	97-59-6	ALLANTOIN
–	NT	–	–	NT	NT	5	107-18-6	ALLYL ALCOHOL
NT	–	I	I	A	A	1	107-05-1	ALLYL CHLORIDE
96	–	+	A	–	–	2	57-06-7	ALLYL ISOTHIOCYANATE
123	62.8	+	–	–	+	3	2835-39-4	ALLYL ISOVALERATE
								1-ALLYL-3-METHOXY-4-HYDROXYBENZENE (see EUGENOL)
NT	30.9[a]	NT	NT	+	+	1	52207-83-7	ALLYLHYDRAZINE.HCl
								ALTAX (see BENZOTHIAZYL DISULFIDE)
–	–	–	–	–	–	1	10043-67-1	ALUMINUM POTASSIUM SULFATE
								AMARANTH (see FD & C RED NO. 2)
								AMAX (see N-OXYDIETHYLENEBENZOTHIAZOLE-2-SULFENAMIDE)
								2-AMINO-5-AZOTOLUENE (see o-AMINOAZOTOLUENE)
0.574[a]	25[a]	+	+	+	+	1,4	75104-43-7	3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE
								4-AMINO-2,3-DIMETHYLAZOBENZENE (see o-AMINOAZOTOLUENE)
NT	10.7[a]	NT	NT	+	+	4	77094-11-2	2-AMINO-3,4-DIMETHYLIMIDAZO[4,5-f]QUINOLINE
1.26[a]	14.2[a]	+	+	+	+	5	77500-04-0	2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE
–	2070	–	–	+	–	1	17026-81-2	3-AMINO-4-ETHOXYACETANILIDE
28.1[a]	33[a]	+	+	+	+	1	6109-97-3	3-AMINO-9-ETHYLCARBAZOLE.HCl
11.8[a]	30.5[a]	+	+	+	+	1	mixture	3-AMINO-9-ETHYLCARBAZOLE MIXTURE
								4-AMINO-3-HYDROXYBIPHENYL (see 3-HYDROXY-4-AMINOBIPHENYL)
								4-AMINO-N10-METHYL-PTEROYLGLUTAMIC ACID (see METHOTREXATE)
NT	15.6[a]	NT	NT	+	+	3	68006-83-7	2-AMINO-3-METHYL-9H-PYRIDO-[2,3-b]-INDOLE
5.32	6.81[af]	–	+	+	+	1	72254-58-1	3-AMINO-1-METHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE
34.1[a]	174	+	+	–	+	1	82-28-0	1-AMINO-2-METHYLANTHRAQUINONE
3.25[a]	5.08[a]	+	+	+	+	3	67730-11-4	2-AMINO-6-METHYLDIPYRIDO[1,2-a:3′,2′-d]IMIDAZOLE
3.57[a]	17.5[a]	+	+	+	+	3,4	76180-96-6	2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE
3.29	NT	NT	+	NT	NT	4	---	2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE.HCl
3.67	NT	NT	+	NT	NT	1	3775-55-1	2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE
0.662	NT	NT	+	NT	NT	1	712-68-5	2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOLE
5.85	7.87	NT	+	NT	+	1,2	38514-71-5	2-AMINO-4-(5-NITRO-2-FURYL)THIAZOLE
NT	105[a]	NT	NT	+	+	3	28754-68-9	trans-5-AMINO-3[2-(5-NITRO-2-FURYL)VINYL-1,2,4-OXADIAZOLE
839	–	P	–	–	–	5	99-57-0	2-AMINO-4-NITROPHENOL
111	–	P	–	–	–	5	121-88-0	2-AMINO-5-NITROPHENOL
309	–	+	A	–	–	1	119-34-6	4-AMINO-2-NITROPHENOL
NT	9.95	NT	NT	NT	+	1	2104-09-8	2-AMINO-4-(p-NITROPHENYL)THIAZOLE
44.6	–	A	+	–	–	1	121-66-4	2-AMINO-5-NITROTHIAZOLE
–	NT	NT	–	NT	NT	1	18968-99-5	2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2
NT	35.6[a]	NT	NT	+	+	3	26148-68-5	2-AMINO-9H-PYRIDO(2,3-b)INDOLE
101	755[a]	+	–	+	+	1	117-79-3	2-AMINOANTHRAQUINONE
3.7[a]	–	+	+	–	NT	1	97-56-3	o-AMINOAZOTOLUENE
								AMINOBENZOIC ACID (see ANTHRANILIC ACID)
								4-AMINOBIPHENYL (see 4-AMINODIPHENYL)
NT	0.993[a]	NT	NT	+	+	1	92-67-1	4-AMINODIPHENYL
0.98	32.6[a]	NT	+	+	+	4	2113-61-3	4-AMINODIPHENYL.HCl
NT	3.36[ac]	NT	NT	+	+	1	3693-22-9	2-AMINODIPHENYLENE OXIDE
33.8[a]	12[a]	+	+	+	+	3	67730-10-3	2-AMINODIPYRIDO[1,2-a:3′,2′-d]IMIDAZOLE
								4-(2-AMINOETHYL)-6-DIAZO-2,4-CYCLOHEXADIENONE.HCl (see 3-DIAZOTYRAMINE.HCl)
								p-AMINONITROPHENOL (see 4-AMINO-2-NITROPHENOL)
8.75[a]	24.5[a]	+	+	+	+	1,3	61-82-5	3-AMINOTRIAZOLE[h]

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
833	–	+	–	–	–	2	2432-99-7	11-AMINOUNDECANOIC ACID
								AMITROL (see 3-AMINOTRIAZOLE)
NT	–	NT	NT	NT	–	1	12125-02-9	AMMONIUM CHLORIDE
–	NT	–	NT	NT	NT	1	3012-65-5	AMMONIUM CITRATE
NT	–	NT	NT	–	–	1	1336-21-6	AMMONIUM HYDROXIDE
–	NT	–	NT	NT	NT	4	57-43-2	AMOBARBITAL
–	–	E	–	–	–	4	7177-48-2	AMPICILLIN TRIHYDRATE
0.532[a]	NT	+	+	NT	NT	1	10589-74-9	1-AMYL-1-NITROSOUREA
								1-AMYL-1-NITROSOURETHAN (see NITROSOAMYLURETHAN)
								n-AMYLHYDRAZINE.HCl (see n-PENTYLHYDRAZINE.HCl)
280[a]	NT	+	NT	NT	NT	4	9047-13-6	AMYLOPECTIN SULFATE
NT	–	NT	NT	NT	–	3	104-46-1	ANETHOLE
NT	–	NT	NT	–	–	1	15879-93-3	ANHYDROGLUCOCHLORAL
–	–	–	–	–	–	1	101-05-3	ANILAZINE
–	NT	–	NT	NT	NT	1	62-53-3	ANILINE
88[af]	–	+	+	–	–	1	142-04-1	ANILINE.HCl
27.8[a]	935[a]	+	+	+	+	1	134-29-2	o-ANISIDINE.HCl
–	–	A	–	–	–	1	20265-97-8	p-ANISIDINE.HCl
–	–	–	–	–	–	1	118-92-3	ANTHRANILIC ACID
NT	–	NT	NT	–	–	1	84-65-1	9,10-ANTHRAQUINONE
NT	–	NT	NT	B–	B–	1	28300-74-5	ANTIMONY POTASSIUM TARTRATE
								ANTIMYCIN (see CITRININ)
								ANTIPYRINE (see PHENAZONE)
								ANTU (see 1-(1-NAPHTHYL)-2-THIOUREA)
								APC (see ASPIRIN, PHENACETIN, AND CAFFEINE)
61.8[a]	158	B+	B+	+	–	1	140-57-8	ARAMITE
NT	33.6[a]	NT	NT	+	+	3	61-94-9	ARECOLINE.HCl
–	9.58	A	A	+	NT	1	27323-18-8	AROCLOR 1254
1.04[a]	NT	+	+	NT	NT	1,3	11096-82-5	AROCLOR 1260
–	NT	B–	B–	NT	NT	1	7631-89-2	ARSENATE, SODIUM
								ARSENIC TRIOXIDE (see ARSENIOUS OXIDE)
NT	–	NT	NT	–	–	1	1327-53-3	ARSENIOUS OXIDE
–	–	B–	B–	B–	B–	1	7784-46-5	ARSENITE, SODIUM
–	NT	–	NT	NT	NT	5	134-03-2	L-ASCORBATE, SODIUM
–	–	–	–	–	–	3	50-81-7	L-ASCORBIC ACID
–	NT	–	–	NT	NT	1	22839-47-0	ASPARTAME
–	–	–	B–	–	–	1,3,4	50-78-2	ASPIRIN
–	–	–	–	–	–	1	8003-03-0	ASPIRIN, PHENACETIN, AND CAFFEINE
NT	–	NT	NT	–	–	1	1912-24-9	ATRAZINE
–	NT	–	–	NT	NT	1	51-55-8	ATROPINE
11	39.2[a]	+	NT	+	+	1	2465-27-2	AURAMINE-O
NT	–	NT	NT	–	–	5	34031-32-8	AURANOFIN
								AVADEX (see DIALLATE)
0.17[d]	0.0569[ad]	+	I	+	+	1,5	320-67-2	5-AZACYTIDINE
–	NT	–	NT	NT	NT	5	3131-60-0	6-AZACYTIDINE
0.793[d]	NT	B+	B+	NT	NT	1,3	115-02-6	AZASERINE
–	NT	NT	–	NT	NT	3	446-86-6	AZATHIOPRINE
–	NT	–	–	NT	NT	1	26628-22-8	AZIDE, SODIUM
–	–	A	–	–	–	1	86-50-0	AZINPHOSMETHYL
19.2[a]	–	+	+	–	–	1	103-33-3	AZOBENZENE
0.0302[a]	NT	+	NT	NT	NT	3,5	25843-45-2	AZOXYMETHANE
2.41E-4[c]	NT	+	NT	NT	NT	5	---	1-AZOXYPROPANE
0.00268	NT	+	NT	NT	NT	5	---	2-AZOXYPROPANE
–	NT	–	NT	NT	NT	4	67-52-7	BARBITURIC ACID
–	–	–	–	–	–	1	543-80-6	BARIUM ACETATE
								BCME (see BIS-(CHLOROMETHYL)ETHER)
								BENADRYL (see DIPHENHYDRAMINE.HCl)
51.1[a]	15.1[af]	+	+	+	+	1,3-5	71-43-2	BENZENE
								alpha-BENZENE HEXACHLORIDE (see alpha-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE)
NT	NT	NT	NT	NT	NT	2	369-57-3	BENZENEDIAZONIUM TETRAFLUOROBORATE[h]

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
NT	–	NT	NT	NT	–	1	5351-65-5	BENZENESULPHONOHYDRAZIDE
								BENZHYDRAZIDE (see BENZOYL HYDRAZINE)
1.73	NT	B+	B+	NT	NT	1	92-87-5	BENZIDINE
NT	8.99[a]	NT	NT	+	+	2,3	531-85-1	BENZIDINE.2HCl
0.956	11	B+	B+	+	–	1-3	50-32-8	BENZO(a)PYRENE
–	NT	–	–	NT	NT	1	532-32-1	BENZOATE, SODIUM
424	19.8[a]	–	P	+	+	5	271-89-6	BENZOFURAN
–	–	–	NT	–	–	1	91-76-9	BENZOGUANAMINE
–	–	–	–	–	–	2	119-53-9	BENZOIN
NT	NT	NT	NT	NT	NT	1	91-64-5	1,2-BENZOPYRONE[h]
								1-(2'-BENZOTHIAZOLYL)-3-METHYL-3-NITROSOUREA (see N-NITROSOBENZTHIAZURON)
NT	–	NT	NT	–	–	1	120-78-5	BENZOTHIAZYL DISULFIDE
–	–	A	A	–	A	1	95-14-7	1H-BENZOTRIAZOLE
NT	7.35[a]	NT	NT	+	+	1	613-94-5	BENZOYL HYDRAZINE
								BENZPYRENE (see BENZO(a)PYRENE)
								3,4-BENZPYRENE (see BENZO(a)PYRENE)
–	702[a]	E	–	P	P	4	140-11-4	BENZYL ACETATE
–	–	–	–	–	–	5	100-51-6	BENZYL ALCOHOL
–	49.6[a]	–	–	+	+	4	100-44-7	BENZYL CHLORIDE
								BENZYL VIOLET 4B (see FD & C VIOLET NO. 1)
NT	85.3	NT	NT	–	+	1	20570-96-1	BENZYLHYDRAZINE.2HCl
–	–	–	–	–	–	1	13510-49-1	BERYLLIUM SULFATE
								BHA (see BUTYLATED HYDROXYANISOLE)
								BHT (see BUTYLATED HYDROXYTOLUENE)
NT	–	NT	NT	–	–	1	92-52-4	BIPHENYL
–	1120	–	–	A	+	2	2185-92-4	2-BIPHENYLAMINE.HCl
–	138[a]	–	–	+	+	1,2	108-60-1	BIS(2-CHLORO-1-METHYLETHYL)ETHER
NT	8.19[a]	NT	NT	+	–	1	111-44-4	BIS-2-CHLOROETHYLETHER
NT	–	NT	NT	NT	–	1	13483-19-7	BIS-1,4-(CHLOROMETHOXY)BUTANE
NT	4.62[d]	NT	NT	NT	+	1	13483-18-6	BIS-1,2-(CHLOROMETHOXY)ETHANE
NT	–	NT	NT	NT	–	1	56894-92-9	BIS-1,6-(CHLOROMETHOXY)HEXANE
NT	3.11[d]	NT	NT	NT	+	1	56894-91-8	BIS-1,4-(CHLOROMETHOXY)-p-XYLENE
0.00357	0.182[ac]	+	NT	+	+	1	542-88-1	BIS-(CHLOROMETHYL)ETHER
3.14	NT	+	NT	NT	NT	1	---	4-BIS(2-HYDROXYETHYL)AMINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE
–	NT	NT	–	NT	NT	1	58139-47-2	4-BIS(2-HYDROXYETHYL)AMINO-2-(2-THIENYL) QUINAZOLINE
NT	34.5[a]	NT	NT	+	–	1	23746-34-1	BIS-2-HYDROXYETHYLDITHIOCARBAMIC ACID, POTASSIUM
								N-BIS(2-HYDROXYPROPYL)NITROSAMINE (see N-NITROSOBIS(2-HYDROXYPROPYL)AMINE)
								2,5-BIS(2,2,2-TRIFLUORETHOXYL)-N-(2-PIPERIDYLMETHYL) BENZAMIDE ACETATE (see FLECAINIDE ACETATE)
								BISMATE (see BISMUTH DIMETHYLDITHIOCARBAMATE)
NT	–	NT	NT	–	–	1	21260-46-8	BISMUTH DIMETHYLDITHIOCARBAMATE
–	NT	B–	B–	NT	NT	1	7787-59-9	BISMUTH OXYCHLORIDE
–	–	–	–	–	–	2	80-05-7	BISPHENOL A
–	–	–	–	–	–	1	2519-30-4	BLACK PN
0.945[a]	NT	+	+	NT	NT	1	1937-37-7	C.I. DIRECT BLACK 38
1.18[a]	NT	+	+	NT	NT	1	2602-46-2	C.I. DIRECT BLUE 6
89.3[a]	–	+	+	E	–	3	2475-45-8	C.I. DISPERSE BLUE 1
–	NT	B–	B–	NT	NT	1	3844-45-9	FD & C BLUE NO. 1
–	–	B–	B–	–	–	1,4	860-22-0	FD & C BLUE NO. 2
702	41.3[a]	E	P	+	+	3,5	2784-94-3	HC BLUE NO. 1
–	–	–	–	–	–	3	33229-34-4	HC BLUE NO. 2
NT	70.6[a]	NT	NT	NT	+	5	2784-94-3	HC BLUE NO. 1 (PURIFIED)
								BOH (see 2-HYDROXYETHYLHYDRAZINE)
NT	–	NT	NT	–	–	5	10043-35-3	BORIC ACID
								BOTRAN (see 2,6-DICHLORO-4-NITROANILINE)
								BRILLIANT BLACK BN (see BLACK PN)

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								BRILLIANT BLUE FCF (see FD & C BLUE NO. 1)
								BRILLIANT RED (see D & C RED NO. 9)
4.81[a]	–	+	+	–	–	1,3-5	7758-01-2	BROMATE, POTASSIUM
NT	–	NT	NT	–	–	4	17157-48-1	BROMOACETALDEHYDE
30.3[af]	28.9[a]	+	+	+	+	4,5	75-27-4	BROMODICHLOROMETHANE
								BROMODIETHYLACETYLUREA (see CARBROMAL)
149[b]	535	P	E	E	+	5	74-96-4	BROMOETHANE
NT	69.7[a]	NT	NT	+	+	4	---	BROMOETHANOL
								BROMOFORM (see TRIBROMOMETHANE)
2.07	NT	–	+	NT	NT	1	16071-86-6	C.I. DIRECT BROWN 95
								BSH (see BENZENESULPHONOHYDRAZIDE)
								BUSULFAN (see MYLERAN)
								BUTACIDE (see PIPERONYL BUTOXIDE IN SOLVENT)
133[af]	28.8[a]	+	+	+	+	3,5	106-99-0	1,3-BUTADIENE
								trans-2-BUTENAL (see CROTONALDEHYDE)
–	–	I	A	–	–	2	85-68-7	BUTYL BENZYL PHTHALATE
								BUTYL-BUTANOL-NITROSAMINE (see N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE)
–	–	–	–	–	–	3	109-69-3	N-BUTYL CHLORIDE
								2,6-DI-tert-BUTYL-p-CRESOL (see BUTYLATED HYDROXYTOLUENE)
NT	–	NT	NT	–	–	1	88-85-7	2-sec-BUTYL-4,6-DINITROPHENOL
NT	19.2[a]	NT	NT	+	+	1	---	N-N-BUTYL-N-FORMYLHYDRAZINE
								2(3)-tert-BUTYL-4-HYDROXYANISOLE (see BUTYLATED HYDROXYANISOLE)
NT	–	NT	NT	–	–	4	94-26-8	BUTYL p-HYDROXYBENZOATE
0.175[af]	NT	+	NT	NT	NT	1,3,4	3817-11-6	N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE
–	NT	–	–	NT	NT	1	---	DI-tert-BUTYL-4-HYDROXYMETHYL PHENOL
–	NT	–	NT	NT	NT	1	13010-08-7	N-BUTYL-N'-NITRO-N-NITROSOGUANIDINE
0.91[a]	NT	+	+	NT	NT	3	869-01-2	N-N-BUTYL-N-NITROSOUREA
								BUTYL ZIMATE (see ZINC DIBUTYLDITHIOCARBAMATE)
349[af]	–	+	+	B–	B–	2-5	25013-16-5	BUTYLATED HYDROXYANISOLE
–	368[a]	–	–	+	–	1,2,5	128-37-0	BUTYLATED HYDROXYTOLUENE
NT	38.1[a]	NT	NT	+	+	1	---	1,1-DI-N-BUTYLHYDRAZINE
NT	9.03[a]	NT	NT	+	+	1	56795-65-4	N-BUTYLHYDRAZINE.HCl
NT	34.5[a]	NT	NT	+	+	1	78776-28-0	1,2-DI-N-BUTYLHYDRAZINE.2HCl
–	–	–	–	–	–	1	592-31-4	N-BUTYLUREA
13.8	NT	NT	+	NT	NT	1	3068-88-0	beta-BUTYROLACTONE
								CACODYLIC ACID (see DIMETHYLARSINIC ACID)
–	–	B–	B–	–	–	1	543-90-8	CADMIUM ACETATE
0.0127	NT	+	NT	NT	NT	5	10108-64-2	CADMIUM CHLORIDE
–	NT	–	–	NT	NT	1	35658-65-2	CADMIUM CHLORIDE MONOHYDRATE
NT	–	NT	NT	–	–	1	14239-68-0	CADMIUM DIETHYLDITHIOCARBAMATE
–	–	–	NT	–	NT	1	7790-84-3	CADMIUM SULPHATE (1:1) HYDRATE (3:8)
–	–	–	–	–	–	1-3	58-08-2	CAFFEINE
								CAFFEINE, ASPIRIN, AND PHENACETIN (see ASPIRIN, PHENACETIN, AND CAFFEINE)
NT	39.6[b]	NT	NT	NT	+	1	50-14-6	CALCIFEROL
–	NT	–	NT	NT	NT	4	62-54-4	CALCIUM ACETATE
								CALCIUM CYANAMIDE (see CYANAMIDE, CALCIUM)
–	–	–	–	–	–	2	105-60-2	CAPROLACTAM
NT	89.4[a]	NT	NT	+	+	3	2425-06-1	CAPTAFOL
–	–	–	–	A	A	1	133-06-2	CAPTAN
								CAPTAX (see 2-MERCAPTOBENZOTHIAZOLE)
NT	223[a]	NT	NT	+	+	1	563-41-7	CARBAMYL HYDRAZINE.HCl
NT	155[a]	NT	NT	+	+	1	103-03-7	1-CARBAMYL-2-PHENYLHYDRAZINE
–	NT	–	–	NT	NT	1	121-59-5	CARBARSONE
14.1	–	B+	B+	–	–	1	63-25-2	CARBARYL
NT	102[a]	NT	NT	+	+	2	86-74-8	CARBAZOLE
0.765[abe]	127[a]	+	+	+	+	1,3	56-23-5	CARBON TETRACHLORIDE
2.3[af]	NT	+	+	NT	NT	1,3	60391-92-6	CARBOXYMETHYLNITROSOUREA
–	–	–	–	–	–	1	77-65-6	CARBROMAL

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								CARMOISINE (see C.I. FOOD RED 3)
								CAROB SEED GUM (see LOCUST BEAN GUM)
1490[a]	NT	+	B+	NT	NT	1,2	---	CARRAGEENAN, ACID-DEGRADED
–	NT	–	–	NT	NT	1	9000-07-1	CARRAGEENAN, NATIVE[h]
257	NT	+	NT	NT	NT	4,5	120-80-9	CATECHOL
								CCC (see (2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE)
								CDT (see SIMAZINE)
								CELLULOSE CARBOXYMETHYL ETHER, SODIUM (see EDIFAS B)
NT	–	NT	NT	B–	B–	1	474-25-9	CHENODEOXYCHOLIC ACID
								alpha-CHLORALOSE (see ANHYDROGLUCOCHLORAL)
–	5230	–	–	A	+	1	133-90-4	CHLORAMBEN
0.657[a]	0.097[ad]	+	+	+	+	1,4	305-03-3	CHLORAMBUCIL
–	NT	NT	–	NT	NT	1	56-75-7	CHLORAMPHENICOL
NT	–	NT	NT	–	–	1	118-75-2	CHLORANIL
								4-CHLORANILIC (see p-CHLOROANILINE)
–	2.15[a]	–	–	+	+	1,2	57-74-9	CHLORDANE
								CHLORDECONE (see KEPONE)
25.4[a]	141	+	+	+	–	4	115-28-6	CHLORENDIC ACID
								CHLORFENSON (see p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE)
110[a]	86.8[a]	+	+	+	+	3	63449-39-8	CHLORINATED PARAFFINS (C12, 60% CHLORINE)
–	6540	–	E	+	E	3	63449-39-8	CHLORINATED PARAFFINS (C23, 43% CHLORINE)
NT	–	NT	NT	–	–	4	56802-99-4	CHLORINATED TRISODIUM PHOSPHATE
–	NT	B–	B–	NT	NT	1	7782-50-5	CHLORINE
NT	–	NT	NT	NT	–	1	302-22-7	CHLORMADINONE ACETATE
37.6	346	+	NT	–	+	1	101-79-1	4-CHLORO-4′-AMINODIPHENYLETHER
4.85	NT	+	NT	NT	NT	1	37087-94-8	2-CHLORO-5-(3,5-DIMETHYLPIPERIDINOSULPHONYL) BENZOIC ACID
–	–	–	NT	–	–	1	97-00-7	1-CHLORO-2,4-DINITROBENZENE
68.7[a]	73.5[a]	+	+	+	+	4	563-47-3	3-CHLORO-2-METHYLPROPENE, TECHNICAL GRADE (CONTAINING 5% DIMETHYLVINYL CHLORIDE)
–	108[a]	–	NT	+	+	1	88-73-3	1-CHLORO-2-NITROBENZENE
–	430[a]	–	NT	+	+	1	100-00-5	1-CHLORO-4-NITROBENZENE
315	1230	+	–	–	+	1	5131-60-2	4-CHLORO-m-PHENYLENEDIAMINE
197[a]	957[a]	+	+	+	+	1	95-83-0	4-CHLORO-o-PHENYLENEDIAMINE
–	–	–	–	–	–	1	61702-44-1	2-CHLORO-p-PHENYLENEDIAMINE SULFATE
								alpha-CHLORO TOLUENE (see BENZYL CHLORIDE)
–	–	–	–	–	–	1	95-74-9	3-CHLORO-p-TOLUIDINE
–	134[a]	–	–	+	+	1	95-79-4	5-CHLORO-o-TOLUIDINE
–	15.4[af]	–	–	+	+	1	3165-93-3	4-CHLORO-o-TOLUIDINE.HCl
60[a]	NT	+	+	NT	NT	3	75-88-7	2-CHLORO-1,1,1-TRIFLUOROETHANE
7.47[ac]	10.8[c]	+	NT	+	NT	1,3	50892-23-4	[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO] ACETIC ACID
6.49	44.6	+	NT	NT	+	1	---	4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO(N-beta-HYDROXYETHYL)ACETAMIDE
NT	–	NT	NT	–	–	1	107-20-0	CHLOROACETALDEHYDE
–	–	–	–	–	A	1	140-49-8	4′-(CHLOROACETYL)-ACETANILIDE
–	–	A	–	A	A	1	106-47-8	p-CHLOROANILINE
7.62	89.5	+	E	P	–	5	20265-96-7	p-CHLOROANILINE.HCl
247	–	P	–	–	–	3	108-90-7	CHLOROBENZENE
–	43.8[af]	–	–	+	+	1	510-15-6	CHLOROBENZILATE
–	139	–	–	I	P	3	124-48-1	CHLORODIBROMOMETHANE
–	–	–	–	–	–	5	75-45-6	CHLORODIFLUOROMETHANE
–	1810	E	E	I	+	5	75-00-3	CHLOROETHANE
								2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-D-GLUCOPYRANOSE (see CHLOROZOTOCIN)
–	–	–	–	–	–	1	999-81-5	(2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE
26.5[a]	NT	+	+	NT	NT	3	593-70-4	CHLOROFLUOROMETHANE
119[a]	48[a]	+	+	+	+	1,4	67-66-3	CHLOROFORM[h]
5.5	NT	+	NT	NT	NT	1	107-30-2	CHLOROMETHYL METHYL ETHER[g]

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
–	–	–	–	–	–	1	6959-47-3	2-(CHLOROMETHYL)PYRIDINE.HCl
433	161[a]	+	–	+	+	1	6959-48-4	3-(CHLOROMETHYL)PYRIDINE.HCl
								CHLOROMYCETIN (see CHLORAMPHENICOL)
								p-CHLORONITROBENZENE (see 1-CHLORO-4-NITROBENZENE)
NT	–	NT	NT	–	–	1	80-33-1	p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE
86.3	–	+	–	–	–	1,5	150-68-5	3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA
8.78	NT	+	NT	NT	NT	1	10473-70-8	1-(4-CHLOROPHENYL)-1-PHENYL-2-PROPYNYL CARBAMATE
–	NT	–	–	NT	NT	1	2227-13-6	p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE
								1-(p-CHLOROPHENYLSULFONYL)-3-PROPYLUREA (see CHLORPROPAMIDE)
NT	–	I	I	–	–	1	76-06-2	CHLOROPICRIN
NT	12.9	NT	NT	–	+	1	683-50-1	2-CHLOROPROPANAL
								CHLOROPROPENE (see ALLYL CHLORIDE)
NT	5.05	NT	NT	–	+	1	590-21-6	1-CHLOROPROPENE
2080[a]	–	+	+	–	–	1	1897-45-6	CHLOROTHALONIL
								CHLOROWAX 40 (see CHLORINATED PARAFFINS (C23, 43% CHLORINE))
								CHLOROWAX 500c (see CHLORINATED PARAFFINS (C12, 60% CHLORINE))
0.0241[ad]	NT	+	+	NT	NT	1	54749-90-5	CHLOROZOTOCIN
–	–	–	–	–	–	3,4	113-92-8	CHLORPHENIRAMINE MALEATE
–	–	–	–	–	–	1	94-20-2	CHLORPROPAMIDE
								CHLORPROPHAM (see ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE)
								CHLORPYRIFOS (see O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL)PHOSPHOROTHIOATE)
–	–	–	–	–	–	1	12236-46-3	CHOCOLATE BROWN FB
NT	–	NT	NT	–	–	1	4553-89-3	CHOCOLATE BROWN HT
–	NT	–	NT	NT	NT	4	67-48-1	CHOLINE CHLORIDE
–	NT	B–	B–	NT	NT	1	1308-38-9	CHROMIC OXIDE PIGMENT
–	–	B–	B–	–	–	1	1066-30-4	CHROMIUM (III) ACETATE
245	201	+	NT	+	NT	4	117-10-2	CHRYSAZIN
7000	2470[a]	+	–	+	+	2	87-29-6	CINNAMYL ANTHRANILATE
								CIPC (see ISOPROPYL-N-(3-CHLOROPHENYL) CARBAMATE)
1.09[c]	4.17[a]	+	NT	+	NT	3,5	52214-84-3	CIPROFIBRATE
5.28[ac]	NT	+	NT	NT	NT	3	518-75-2	CITRININ
0.5	NT	B+	B+	NT	NT	1	33979-15-6	CLIVORINE
169	NT	+	NT	NT	NT	1	637-07-0	CLOFIBRATE
NT	–	NT	NT	NT	–	1	43054-45-1	CLOMIPHENE CITRATE
–	–	–	–	I	–	1	1420-04-8	CLONITRALID
157[b]	NT	+	NT	NT	NT	3	55600-34-5	CLOPHEN A 30
								CLOPHEN A 60 (see AROCLOR 1260)
								CLOROX (see SODIUM HYPOCHLORITE)
								CMME (see CHLOROMETHYL METHYL ETHER)
								CMNU (see CARBOXYMETHYLNITROSOUREA)
–	NT	–	NT	NT	NT	1	477-30-5	COLCEMID
–	–	–	–	–	–	3	65765-07-3	COMPOUND 50-892
								CONJUGATED EQUINE ESTROGENS (see PREMARIN)
NT	–	NT	NT	–	–	1	137-29-1	COPPER DIMETHYLDITHIOCARBAMATE
NT	–	NT	NT	–	–	1	10380-28-6	COPPER-8-HYDROXYQUINOLINE
–	–	–	–	–	–	1	56-72-4	COUMAPHOS
								COUMARIN (see 1,2-BENZOPYRONE)
470[a]	–	+	+	I	–	1	102-50-1	m-CRESIDINE
76.3[a]	44.7[a]	+	+	+	+	1	120-71-8	p-CRESIDINE
4.2	NT	+	NT	NT	NT	4	123-73-9	CROTONALDEHYDE
								CUMATE (see COPPER DIMETHYLDITHIOCARBAMATE)
5.33[a]	253[a]	+	+	+	+	1	135-20-6	CUPFERRON
–	–	–	–	–	–	1	156-62-7	CYANAMIDE, CALCIUM
								CYANO-(3-PHENOXYPHENYL)METHYL-4-CHLORO-

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								alpha-(1-METHYLETHYL) BENZENE ACETATE (see FENVALERATE)
NT	NT	NT	NT	NT	NT	1	mixture	CYCASIN AND METHYLAZOXYMETHANOL ACETATE[g]
–	587[a]	B–	B–	+	+	1	139-05-9	CYCLAMATE, SODIUM
								2-CYCLO-HEXYL-CARBONYL-1,3,4,6,7,11-b-HEXAHYDRO-2-H-PYRAZINE(2,1-a)ISOQUINOLINE-4-ONE (see PRAZIQUANTEL)
NT	23.6	NT	NT	+	NT	1	12663-46-6	CYCLOCHLOROTINE
–	–	–	–	–	–	5	108-94-1	CYCLOHEXANONE
NT	–	NT	NT	–	–	1	95-33-0	N-CYCLOHEXYL-2-BENZOTHIAZOLE SULFENAMIDE
–	–	–	–	–	–	1	4998-76-9	CYCLOHEXYLAMINE.HCl
–	–	–	–	–	–	1	19834-02-7	CYCLOHEXYLAMINE SULFATE
1.26[aef]	5.78[ad]	+	+	+	+	1,3	50-18-0	CYCLOPHOSPHAMIDE
1.05[ad]	–	+	+	–	–	2	16170-75-5	CYTEMBENA
								CYTOXAN (see CYCLOPHOSPHAMIDE)
								DAAB (see 4,4′-DIAMINOAZOBENZENE)
								DAB (see N,N-DIMETHYL-4-AMINOAZOBENZENE)
								DABA (see 4,4′-DIAMINOBENZANILIDE)
0.71	0.595[ad]	NT	+	+	+	1	4342-03-4	DACARBAZINE
								DACONIL (see CHLOROTHALONIL)
1840[b]	880[a]	–	+	+	+	1	1596-84-5	DAMINOZIDE
								DANTHRON (see CHRYSAZIN)
22.4	–	+	–	–	–	1	80-08-0	DAPSONE
								DARAPRIN (see PYRIMETHAMINE)
								DBCP (see 1,2-DIBROMO-3-CHLOROPROPANE)
								DBM (see DIBROMOMANNITOL)
								DCB (see 3,3′-DICHLOROBENZIDINE)
								DCDD (see 2,7-DICHLORODIBENZO-p-DIOXIN)
NT	–	NT	NT	–	–	1	53-19-0	o,p′-DDD
–	24.9[a]	A	–	+	+	1	72-54-8	p,p′-DDD
–	9.45[a]	–	–	+	+	1,3	72-55-9	p,p′-DDE[g]
57.2[a]	4.55[af]	+	+	+	+	1,3,4	50-29-3	DDT[h]
								DDVP (see DICHLORVOS)
2130[a]	–	P	P	E	–	3	1163-19-5	DECABROMODIPHENYL OXIDE
								DEGRANOL (see MANNITOL NITROGEN MUSTARD)
								DEHYDROACETIC ACID (see 3-ACETYL-6-METHYL-2,4-PYRANDIONE)
								DEN (see N-NITROSODIETHYLAMINE)
								6-F-DEN (see N-NITROSOBIS(2,2,2-TRIFLUOROETHYL) AMINE)
								beta-2′-DEOXY-6-THIOGUANOSINE MONOHYDRATE (see beta-THIOGUANINE DEOXYRIBOSIDE)
								DES (see DIETHYLSTILBESTROL)
–	NT	B–	B–	NT	NT	1	131-01-1	DESERPIDINE
–	NT	–	–	NT	NT	3	9004-54-0	DEXTRAN
182[a]	NT	+	+	NT	NT	2,3	9011-18-1	DEXTRAN SULFATE SODIUM (DS-M-1)
–	NT	–	–	NT	NT	3	9011-18-1	DEXTRAN SULFATE SODIUM (DST-H)
–	NT	–	–	NT	NT	3	9011-18-1	DEXTRAN SULFATE SODIUM (KMDS-H)
								DHAC (see 5,6-DIHYDRO-5-AZACYTIDINE)
19	NT	NT	+	NT	NT	1	---	N-1-DIACETAMIDOFLUORENE
NT	–	NT	NT	–	–	3	3148-73-0	DIACETYL HYDRAZINE
NT	19.4[a]	NT	NT	+	–	1	2303-16-4	DIALLATE
–	–	–	E	A	A	3	131-17-9	DIALLYL PHTHALATE
NT	25.7[a]	NT	NT	+	+	3	5164-11-4	1,1-DIALLYLHYDRAZINE
NT	33.8[a]	NT	NT	+	+	2	---	1,2-DIALLYLHYDRAZINE.2HCl
32.1[a]	NT	+	+	NT	NT	4	16338-97-9	DIALLYLNITROSAMINE[g]
1.71	NT	NT	+	NT	NT	1	720-69-4	4,6-DIAMINO-2-(5-NITRO-2-FURYL)-s-TRIAZINE
72.6[a]	791[a]	+	+	+	+	1	39156-41-7	2,4-DIAMINOANISOLE SULFATE
NT	–	NT	NT	–	–	2	538-41-0	4,4′-DIAMINOAZOBENZENE
NT	–	NT	NT	–	–	2	785-30-8	4,4′-DIAMINOBENZANILIDE
								3,3′-DIAMINOBENZIDINE.4HCl (see 3,3′,4,4′-TETRAAMINOBIPHENYL.4HCl)
								1,5-DIAMINONAPHTHALENE (see

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								1,5-NAPHTHALENEDIAMINE)
1.43[a]	26.7	+	+	–	+	1	95-80-7	2,4-DIAMINOTOLUENE
4.42	201[a]	+	NT	+	+	1	636-23-7	2,4-DIAMINOTOLUENE.2HCl
–	–	–	–	–	–	2	15481-70-6	2,6-DIAMINOTOLUENE.2HCl
–	–	–	–	–	–	1	6369-59-1	2,5-DIAMINOTOLUENE SULFATE
–	–	–	–	–	–	1	333-41-5	DIAZINON
37.6	NT	+	NT	NT	NT	5	---	3-DIAZOTYRAMINE.HCl
NT	5.88	NT	NT	+	NT	1	53-70-3	DIBENZ(a,h)ANTHRACENE
–	–	–	–	–	–	1	262-12-4	DIBENZO-p-DIOXIN
2.48	NT	+	NT	NT	NT	1	4106-66-5	3-DIBENZOFURANAMINE
–	NT	–	–	NT	NT	4	35660-60-7	O,S-DIBENZOYL THIAMINE.HCl
0.106[a]	1.28[a]	+	+	+	+	1	96-12-8	1,2-DIBROMO-3-CHLOROPROPANE
								DIBROMOCHLOROMETHANE (see CHLORODIBROMOMETHANE)
8.37[d]	9.23[ad]	+	NT	+	+	1	10318-26-0	DIBROMODULCITOL
1.1[a]	2.34[af]	+	+	+	+	1,4	106-93-4	1,2-DIBROMOETHANE
24.9[ad]	11.4[ad]	+	+	+	+	1	488-41-5	DIBROMOMANNITOL
–	NT	–	–	NT	NT	3	3296-90-0	DIBROMONEOPENTYL GLYCOL
–	NT	–	–	NT	NT	2	34522-69-5	5,7-DIBROMOQUINOLINE
4.28	NT	NT	+	NT	NT	1	56654-52-5	1,3-DIBUTYL-1-NITROSOUREA
								DIBUTYLNITROSAMINE (see NITROSODIBUTYLAMINE)
–	–	–	I	–	–	1	1067-33-0	DIBUTYLTIN DIACETATE
								DIC (see DACARBAZINE)
								DICHLONE (see 2,3-DICHLORO-1,4-NAPHTHOQUINONE)
								DICHLOREN (see NITROGEN MUSTARD)
								DICHLORICIDE MOTHPROOFER (see STROBANE)
								3,3′-DICHLORO-4,4′-DIAMINODIPHENYLMETHANE (see 4,4′-METHYLENE-BIS(2-CHLOROANILINE))
NT	119	NT	NT	+	NT	2	23950-58-5	3,5-DICHLORO(N-1,1-DIMETHYL-2-PROPYNYL) BENZAMIDE
NT	–	NT	NT	NT	–	1	3883-43-0	2,3-DICHLORO-p-DIOXANE
NT	–	NT	NT	–	–	1	87-56-9	alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID
NT	–	NT	NT	–	–	1	2164-09-2	3,4′-DICHLORO-2-METHYLACRYLANILIDE
								2,2′-DICHLORO-N-METHYLDIETHYLAMINE (see NITROGEN MUSTARD)
NT	–	NT	NT	–	–	1	117-80-6	2,3-DICHLORO-1,4-NAPHTHOQUINONE
NT	–	NT	NT	–	–	1	99-30-9	2,6-DICHLORO-4-NITROANILINE
–	737[a]	–	–	+	+	2	609-20-1	2,6-DICHLORO-p-PHENYLENEDIAMINE
3.34[a]	0.466[a]	+	+	+	+	3	7572-29-4	DICHLOROACETYLENE
–	–	–	–	–	–	3	95-50-1	1,2-DICHLOROBENZENE
644	339[a]	+	–	+	+	4	106-46-7	1,4-DICHLOROBENZENE
								o-DICHLOROBENZENE (see 1,2-DICHLOROBENZENE)
18.3[a]	NT	+	+	NT	NT	1	91-94-1	3,3′-DICHLOROBENZIDINE[g]
								DICHLOROBROMOMETHANE (see BROMODICHLOROMETHANE)
NT	1.52[d]	NT	NT	NT	+	1	110-57-6	trans-1,4-DICHLOROBUTENE-2
–	–	–	–	A	–	1	33857-26-0	2,7-DICHLORODIBENZO-p-DIOXIN
–	–	–	–	–	–	5	75-71-8	DICHLORODIFLUOROMETHANE
–	–	–	A	–	A	1	75-34-3	1,1-DICHLOROETHANE
5.49[a]	61.2[a]	+	+	+	+	1	107-06-2	1,2-DICHLOROETHANE
								DICHLOROMETHANE (see METHYLENE CHLORIDE)
–	–	–	–	–	–	5	120-83-2	2,4-DICHLOROPHENOL
								2-(2,4-DICHLOROPHENOXY)PROPIONIC ACID (see alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID)
NT	–	NT	NT	–	–	1	120-36-5	alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID
NT	–	NT	NT	–	–	1	6965-71-5	alpha-(2,5-DICHLOROPHENOXY)PROPIONIC ACID
NT	–	NT	NT	–	–	1	94-75-7	2,4-DICHLOROPHENOXYACETIC ACID
NT	–	NT	NT	–	–	1	94-80-4	2,4-DICHLOROPHENOXYACETIC ACID, N-BUTYL ESTER
NT	–	NT	NT	–	–	1	25168-26-7	2,4-DICHLOROPHENOXYACETIC ACID, ISOOCTYL ESTER

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
NT	–	NT	NT	–	–	1	94-11-1	2,4-DICHLOROPHENOXYACETIC ACID, ISOPROPYL ESTER
NT	–	NT	NT	–	–	1	330-54-1	3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA
NT	–	NT	NT	–	–	1	97-16-5	2,4-DICHLOROPHENYLBENZENE SULFONATE
–	229[a]	–	E	P	P	4	78-87-5	1,2-DICHLOROPROPANE
								1,3-DICHLOROPROPENE (see TELONE II)
								2-[1-(2,6-DICHLORPHENOXY)-ETHYL]-2-IMIDAZOLINE.HCl (see LOFEXIDINE.HCl)
3.21	61.3[a]	P	E	P	+	1,5	62-73-7	DICHLORVOS
								DICLORAN (see 2,6-DICHLORO-4-NITROANILINE)
–	32.9	–	–	+	–	1	115-32-2	DICOFOL
								DICRYL (see 3,4′-DICHLORO-2-METHYLACRYLANILIDE)
–	–	–	–	–	–	1	1212-29-9	N,N′-DICYCLOHEXYLTHIOUREA
–	–	–	NT	–	–	1	81-21-0	DICYCLOPENTADIENE DIOXIDE
–	0.469[ac]	–	–	+	+	1	60-57-1	DIELDRIN[h]
–	–	–	–	–	–	1	13366-73-9	DIELDRIN, PHOTO-
–	NT	NT	–	NT	NT	1	298-18-0	D,L-DIEPOXYBUTANE
NT	–	NT	NT	NT	–	1	7316-37-2	DIETHYL-beta,gamma-EPOXYPROPYLPHOSPHONATE
								4,4′-(1,2-DIETHYL-1,2-ETHENEDIYL)BIS-PHENOL (see DIETHYLSTILBESTROL)
1.63[c]	NT	+	NT	NT	NT	1	7347-49-1	N,N-DIETHYL-4-(4′-[PYRIDYL-1′-OXIDE]AZO)ANILINE
–	NT	–	–	NT	NT	1	2921-88-2	O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL) PHOSPHOROTHIOATE
8.85[b]	NT	+	NT	NT	NT	1	685-91-6	DIETHYLACETAMIDE
								DIETHYLDITHIOCARBAMATE TRIHYDRATE, SODIUM (see SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE)
1660	NT	+	NT	NT	NT	1	111-46-6	DIETHYLENE GLYCOL
–	NT	–	NT	NT	NT	1	617-84-5	DIETHYLFORMAMIDE
								DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
								N,N-DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
0.114	0.0247[a]	+	–	+	+	1,5	56-53-1	DIETHYLSTILBESTROL
23.8[a]	–	+	+	–	–	1	105-55-5	N,N′-DIETHYLTHIOUREA
NT	571[a]	NT	NT	+	+	1	628-36-4	1,2-DIFORMYLHYDRAZINE
NT	852[a]	NT	NT	+	+	3	21626-89-1	DIFTALONE
2.33[a]	17.9[a]	+	+	+	+	4	101-90-6	DIGLYCIDYL RESORCINOL ETHER, TECHNICAL GRADE
–	NT	–	NT	NT	NT	5	62488-57-7	5,6-DIHYDRO-5-AZACYTIDINE
								(2,3-DIHYDRO-1,5-DIMETHYL-3-OXO-2-PHENYL-1H-PYRAZOL-4-YL)METHYLAMINO METHANESULFONATE MONOHYDRATE (see DIPYRONE)
1.53	NT	NT	+	NT	NT	1	33389-33-2	1,2-DIHYDRO-2-(5-NITRO-2-THIENYL)QUINAZOLIN-4(3H)-ONE
90.6	NT	B+	B+	NT	NT	1	3276-41-3	3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE
								1,2-DIHYDRO-3,6-PYRIDAZINEDIONE (see MALEIC HYDRAZIDE)
143	90[a]	B+	B+	+	+	1	94-58-6	DIHYDROSAFROLE
								1,2-DIHYDROXYBENZENE (see CATECHOL)
–	–	–	–	–	–	1	60-51-5	DIMETHOATE
716	NT	+	NT	NT	NT	1	828-00-2	DIMETHOXANE
–	–	–	–	E	–	5	828-00-2	DIMETHOXANE, COMMERCIAL GRADE
0.721	95.9	+	NT	+	–	1	5803-51-0	2,5-DIMETHOXY-4′-AMINOSTILBENE
–	–	–	–	–	–	1	54150-69-5	2,4-DIMETHOXYANILINE.HCl
742[a]	–	+	+	–	–	1	91-93-0	3,3′-DIMETHOXYBENZIDINE-4,4′-DIISOCYANATE
–	NT	–	NT	NT	NT	1	1146-71-0	5,7-DIMETHOXYCYCLOPENTENE[c]COUMARIN
–	NT	–	NT	NT	NT	1	1150-37-4	5,7-DIMETHOXYCYCLOPENTENONE[2,3-c]COUMARIN
–	NT	–	NT	NT	NT	1	1150-42-1	5,7-DIMETHOXYCYCLOPENTENONE[3,2-c]COUMARIN
1E31	NT	+	NT	NT	NT	5	65176-75-2	5,6-DIMETHOXYSTERIGMATOCYSTIN
3.31	NT	NT	+	NT	NT	1	60-11-7	N,N-DIMETHYL-4-AMINOAZOBENZENE

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								9,10-DIMETHYL-1,2-BENZANTHRACENE (see 7,12-DIMETHYLBENZ(a)ANTHRACENE)
–	NT	–	NT	NT	NT	1	3851-16-9	N,N′-DIMETHYL-N,N′-DINITROSOPHTHALAMIDE
105	–	+	E	–	–	3	868-85-9	DIMETHYL HYDROGEN PHOSPHITE
520	–	P	–	I	–	5	756-79-6	DIMETHYL METHYLPHOSPHONATE
503[a]	–	P	P	–	–	3	597-25-1	DIMETHYL MORPHOLINOPHOSPHORAMIDATE
1.39[c]	NT	NT	+	NT	NT	1	59-35-8	4,6-DIMETHYL-2-(5-NITRO-2-FURYL)PYRIMIDINE
17	NT	NT	+	NT	NT	1	551-92-8	1,2-DIMETHYL-5-NITROIMIDAZOLE
–	–	–	–	–	–	1	120-61-6	DIMETHYL TEREPHTHALATE
								2,2-DIMETHYL-5-(2,5-XYLYLOXY)VALERIC ACID (see GEMFIBROZIL)
60.7[a]	–	+	+	–	–	5	---	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl
–	–	–	–	–	–	5	1095-90-5	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl
22.4	NT	NT	+	NT	NT	1	55738-54-0	trans-2-[(DIMETHYLAMINO)METHYLIMINO]-5-[2-(5-NITRO-2-FURYL)VINYL]-1,3,4-OXADIAZOLE
NT	–	NT	NT	–	–	1	6120-10-1	4-DIMETHYLAMINO-3,5-XYLENOL
NT	–	NT	NT	NT	–	5	108-01-0	2-DIMETHYLAMINOETHANOL
125	–	P	–	–	E	5	121-69-7	N,N-DIMETHYLANILINE
NT	–	NT	NT	–	–	1	75-60-5	DIMETHYLARSINIC ACID
NT	0.084	NT	NT	NT	+	1	57-97-6	7,12-DIMETHYLBENZ(a)ANTHRACENE
								DIMETHYLCARBAMOYL CHLORIDE (see DIMETHYLCARBAMYL CHLORIDE)
NT	5.37[d]	NT	NT	NT	+	1	79-44-7	DIMETHYLCARBAMYL CHLORIDE[g]
NT	–	NT	NT	–	–	1	598-64-1	DIMETHYLDITHIOCARBAMIC ACID, DIMETHYLAMINE
–	NT	–	–	NT	NT	3	1643-20-5	N,N-DIMETHYLDODECYLAMINE-N-OXIDE
NT	2.09[a]	NT	NT	+	+	1	57-14-7	1,1-DIMETHYLHYDRAZINE[g]
NT	0.102[a]	NT	NT	+	+	1	306-37-6	1,2-DIMETHYLHYDRAZINE.2HCl[g]
0.41[c]	NT	NT	+	NT	NT	1	26049-69-4	2-(2,2-DIMETHYLHYDRAZINO)-4-(5-NITRO-2-FURYL) THIAZOLE
0.256[a]	NT	+	+	NT	NT	1	4164-28-7	DIMETHYLNITRAMINE
								DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
								N,N-DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
17.5[a]	14.3[a]	+	+	+	+	4	513-37-1	DIMETHYLVINYL CHLORIDE
NT	–	NT	NT	–	–	1	6119-92-2	DINITRO(1-METHYLHEPTYL)PHENYL CROTONATE
NT	–	NT	NT	B–	B–	1	51-28-5	2,4-DINITROPHENOL
NT	–	NT	NT	NT	–	3	1011-73-0	2,4-DINITROPHENOL, SODIUM
NT	NT	NT	NT	NT	NT	3	55380-34-2	1,4-DINITROSO-2,6-DIMETHYLPIPERAZINE[g]
0.0297[a]	NT	NT	+	NT	NT	1	55557-00-1	DINITROSOHOMOPIPERAZINE
–	NT	–	NT	NT	NT	1	101-25-7	N,N-DINITROSOPENTAMETHYLENETETRAMINE
NT	2.01[a]	NT	NT	+	+	1	140-79-4	DINITROSOPIPERAZINE
–	–	A	A	–	–	1	121-14-2	2,4-DINITROTOLUENE
–	NT	–	NT	NT	NT	5	121-14-2	2,4-DINITROTOLUENE (PURIFIED)
0.574	NT	+	NT	NT	NT	5	606-20-2	2,6-DINITROTOLUENE
8.02	NT	+	NT	NT	NT	5	---	DINITROTOLUENE, TECHNICAL GRADE (2,4 (77%)- and 2,6 (19%)-)
126[af]	594[a]	+	+	+	+	1	123-91-1	1,4-DIOXANE
								p-DIOXANE (see 1,4-DIOXANE)
–	–	–	–	–	–	1	78-34-2	DIOXATHION
								DIOXIN (see 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN)
NT	–	NT	NT	–	–	1	971-15-3	DIPENTAMETHYLENETHIURAM HEXASULFIDE
2.75[a]	NT	+	+	NT	NT	5	13256-06-9	DIPENTYLNITROSAMINE
–	–	E	E	–	–	3,5	147-24-0	DIPHENHYDRAMINE.HCl
NT	–	NT	NT	–	–	1	74-31-7	DIPHENYL-p-PHENYLENEDIAMINE
NT	–	NT	NT	–	–	1	86-29-3	DIPHENYLACETONITRILE
NT	–	NT	NT	–	–	1	102-09-0	DIPHENYLCARBONATE
–	–	–	–	–	–	1,5	57-41-0	5,5-DIPHENYLHYDANTOIN
								DIPHENYLNITROSAMINE (see N-NITROSODIPHENYLAMINE)

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
–	NT	–	NT	NT	NT	1	---	N,N-DIPROPYL-4-(4'-[PYRIDYL-1'-OXIDE]AZO)ANILINE
								DIPROPYLNITROSAMINE (see N-NITROSODIPROPYLAMINE)
–	547[a]	–	–	+	+	3,4	68-89-3	DIPYRONE
								DISODIUM ETHYLENEBISDITHIOCARBAMATE (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
								DISODIUM SULFATE (see SULFATE, SODIUM)
								DISULFIRAM (see TETRAETHYLTHIURAM DISULFIDE)
								DITHANE (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
–	–	–	–	–	A	1	142-46-1	2,5-DITHIOBIUREA
–	NT	NT	–	NT	NT	1	79-40-3	DITHIOOXAMIDE
								DIURON (see 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA)
								DMASA (see DAMINOZIDE)
								DMBA (see 7,12-DIMETHYLBENZ(a)ANTHRACENE)
								DMHP (see DIMETHYL HYDROGEN PHOSPHITE)
								DMMP (see DIMETHYL METHYLPHOSPHONATE)
								DMN (see N-NITROSODIMETHYLAMINE)
								DMT (see DIMETHYL TEREPHTHALATE)
								1,1a,2,2,3,3a,4,5,5,5a,5b,6-DODECACHLOROOCTAHYDRO-1,3,4-METHENO-1H-CYCLOBUTA[cd]PENTALENE (see MIREX)
NT	–	NT	NT	–	–	1	2439-10-3	N-DODECYLGUANIDINE ACETATE
								DODINE (see N-DODECYLGUANIDINE ACETATE)
								DOWICIDE 1 (see o-PHENYLPHENOL)
								DOWICIDE 2S (see 2,4,6-TRICHLOROPHENOL)
								DOWICIDE 7 (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))
								DOWICIDE EC-7 (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))
								DS-M-1 (see DEXTRAN SULFATE SODIUM (DS-M-1))
								DST-H (see DEXTRAN SULFATE SODIUM (DST-H))
								DURAX (see N-CYCLOHEXYL-2-BENZOTHIAZOLE SULFENAMIDE)
								EDB (see 1,2-DIBROMOETHANE)
								EDC (see 1,2-DICHLOROETHANE)
–	–	–	–	–	–	1	9004-59-5	EDIFAS A
–	–	–	–	–	–	1	9004-32-4	EDIFAS B
								EDTA (see EDTA, TRISODIUM SALT TRIHYDRATE)
–	–	–	–	–	–	1	150-38-9	EDTA, TRISODIUM SALT TRIHYDRATE
NT	NT	I	I	I	I	1	316-42-7	EMETINE.2HCl
–	–	–	–	–	–	1	55965-13-4	EMULSIFIER YN
–	–	I	–	I	–	1	115-29-7	ENDOSULFAN
								ENDOXAN (see CYCLOPHOSPHAMIDE)
–	–	–	–	–	–	1	72-20-8	ENDRIN
NT	–	NT	NT	–	–	3	13838-16-9	ENFLURANE
NT	0.151[af]	NT	NT	–	+	1	8015-30-3	ENOVID
NT	–	NT	NT	–	–	1	8015-30-3	ENOVID-E
								ENU (see 1-ETHYL-1-NITROSOUREA)
								EO (see ETHYLENE OXIDE)
–	–	–	–	–	–	3	134-72-5	EPHEDRINE SULPHATE
2.55[a]	–	+	+	NT	–	1,4	106-89-8	EPICHLOROHYDRIN
106	–	+	E	–	–	5	106-88-7	1,2-EPOXYBUTANE
								1,2-EPOXYPROPANE (see 1,2-PROPYLENE OXIDE)
–	NT	–	–	NT	NT	3	6381-77-7	ERYTHORBATE, SODIUM
–	–	–	–	–	–	5	643-22-1	ERYTHROMYCIN STEARATE
								ERYTHROSINE (see FD & C RED NO. 3)
NT	0.282[b]	NT	NT	NT	+	1	50-28-2	ESTRADIOL
								ESTRADIOL-17beta (see ESTRADIOL)
–	0.682[a]	–	–	+	+	1	22966-79-6	ESTRADIOL MUSTARD
NT	51.8	NT	NT	NT	+	3	140-67-0	ESTRAGOLE

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								ETHENZAMIDE (see o-ETHOXYBENZAMIDE)
–	69.3	–	–	–	+	1	536-33-4	ETHIONAMIDE
4.97[c]	NT	+	NT	NT	NT	1	13073-35-3	ETHIONINE
5.24[a]	33.8[af]	+	NT	+	+	2,4	67-21-0	DL-ETHIONINE
NT	513	NT	NT	+	–	4	938-73-8	o-ETHOXYBENZAMIDE
–	NT	–	NT	NT	NT	3,5	91-53-2	ETHOXYQUIN
71.9[a]	260[a]	+	+	+	+	4	140-88-5	ETHYL ACRYLATE
9110	–	+	–	NT	–	1-4	64-17-5	ETHYL ALCOHOL
0.022	NT	+	NT	NT	NT	4	16301-26-1	Z-ETHYL-O,N,N-AZOXYETHANE
0.0189	NT	+	NT	NT	NT	4	57497-29-7	Z-ETHYL-O,N,N-AZOXYMETHANE
1210[a]	NT	+	+	NT	NT	4	100-41-4	ETHYL BENZENE
								ETHYL BROMIDE (see BROMOETHANE)
NT	–	NT	NT	NT	–	1	105-36-2	ETHYL BROMOACETATE
								ETHYL CADMATE (see CADMIUM DIETHYLDITHIOCARBAMATE)
								ETHYL CHLORIDE (see CHLOROETHANE)
								ETHYL-alpha-p-CHLOROPHENOXYISOBUTYRATE (see CLOFIBRATE)
–	NT	–	NT	NT	NT	1	2629-59-6	S-ETHYL-L-CYSTEINE
–	–	–	–	–	A	1	72-56-0	p,p'-ETHYL-DDD
NT	2.49[a]	NT	NT	+	+	1	74920-78-8	N-ETHYL-N-FORMYLHYDRAZINE
–	NT	–	–	NT	NT	2	77-83-8	ETHYL METHYLPHENYLGLYCIDATE
NT	2.84	NT	NT	B+	B+	1	63885-23-4	N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE
0.904[a]	NT	+	+	NT	NT	3	759-73-9	1-ETHYL-1-NITROSOUREA
								N-ETHYL-N-NITROSOUREA (see 1-ETHYL-1-NITROSOUREA)
								1-ETHYL-1-NITROSOURETHAN (see NITROSOETHYLURETHAN)
								ETHYL SELENAC (see SELENIUM DIETHYLDITHIOCARBAMATE)
–	–	A	–	A	–	1	20941-65-5	ETHYL TELLURAC
								ETHYL TUADS (see TETRAETHYLTHIURAM DISULFIDE)
								ETHYL ZIMATE (see ZINC DIETHYLDITHIOCARBAMATE)
								ETHYLENE DIBROMIDE (see 1,2-DIBROMOETHANE)
								ETHYLENE DICHLORIDE (see 1,2-DICHLOROETHANE)
NT	–	NT	NT	NT	–	1	1072-53-3	ETHYLENE GLYCOL
NT	0.283[a]	NT	NT	+	+	1	151-56-4	ETHYLENE IMINE
7.43[af]	39.2[a]	+	+	+	+	2,3,5	75-21-8	ETHYLENE OXIDE
10.8[a]	16.9	+	+	+	–	1	96-45-7	ETHYLENE THIOUREA
NT	–	NT	NT	–	–	1	120-93-4	ETHYLENE UREA
NT	–	NT	NT	–	–	1	142-59-6	ETHYLENEBISDITHIOCARBAMATE, DISODIUM
–	NT	NT	–	NT	NT	1	106-87-6	1-ETHYLENEOXY-3,4-EPOXYCYCLOHEXANE
–	3050[a]	–	–	+	+	2	103-23-1	DI(2-ETHYLHEXYL)ADIPATE
499[a]	825[a]	+	+	+	+	2,5	117-81-7	DI(2-ETHYLHEXYL)PHTHALATE
NT	5.22[a]	NT	NT	+	+	1	18413-14-4	ETHYLHYDRAZINE.HCl
2.91[a]	NT	+	+	NT	NT	1	38434-77-4	ETHYLNITROSOCYANAMIDE
								ETHYLNITROSOUREA (see 1-ETHYL-1-NITROSOUREA)
NT	15.3[a]	NT	NT	NT	+	1	842-00-2	4-ETHYLSULPHONYLNAPHTHALENE-1-SULFONAMIDE
–	–	NT	–	NT	–	1,5	297-76-7	ETHYNODIOL DIACETATE
								ETHYNODIOL DIACETATE/ETHINYL ESTRADIOL [10:1] (see OVULEN)
								ETU (see ETHYLENE THIOUREA)
NT	–	NT	NT	–	NT	1	470-82-6	EUCALYPTOL
–	–	–	–	E	E	3	97-53-0	EUGENOL
								FANFT (see N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] FORMAMIDE)
								FAST GREEN FCF (see FD & C GREEN NO. 3)
–	–	–	–	–	–	1	140-56-7	FENAMINOSULF, FORMULATED
–	–	–	–	A	–	1	55-38-9	FENTHION
–	NT	–	–	NT	NT	3	51630-58-1	FENVALERATE
								FERBAM (see FERRIC DIMETHYLDITHIOCARBAMATE)

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
NT	–	NT	NT	–	–	1	14484-64-1	FERRIC DIMETHYLDITHIOCARBAMATE
								FERRIC NITROSODIMETHYLDITHIOCARBAMATE AND TETRAMETHYLTHIURAM DISULFIDE (see VANGUARD GF)
								FIREMASTER BP-6 (see POLYBROMINATED BIPHENYLS)
								FIREMASTER FF-1 (see POLYBROMINATED BIPHENYL MIXTURE)
–	–	–	–	–	–	3	54143-56-5	FLECAINIDE ACETATE
–	–	–	–	A	–	2	2164-17-2	FLUOMETURON
								FLUORENE-2,7-DIACETIMIDE (see 2,7-BIS-ACETYLAMINOFLUORENE)
1.62	NT	NT	+	NT	NT	1	363-17-7	N-(2-FLUORENYL)-2,2,2-TRIFLUOROACETAMIDE
								FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)
								N-1-FLUORENYLACETAMIDE (see 1-ACETYLAMINOFLUORENE)
								N-2-FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)
								N-4-FLUORENYLACETAMIDE (see 4-ACETYLAMINOFLUORENE)
								N-1-FLUORENYLDIACETAMIDE (see N-1-DIACETAMIDOFLUORENE)
NT	–	NT	NT	B–	–	1,3	7681-49-4	FLUORIDE, SODIUM
NT	1.09[a]	NT	NT	+	+	1	324-93-6	4′-FLUORO-4-AMINODIPHENYL
								N-(4′-FLUORO-4-BIPHENYLYL)ACETAMIDE (see N-4-(4′-FLUOROBIPHENYL)ACETAMIDE)
1.01	NT	+	NT	NT	NT	1	398-32-3	N-4-(4′-FLUOROBIPHENYL)ACETAMIDE
								FLUOROCARBON 31 (see CHLOROFLUOROMETHANE)
								FLUOROCARBON 11 (see TRICHLOROFLUOROMETHANE)
								FLUOROCARBON 113 (see 1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE)
								FLUOROCARBON 12 (see DICHLORODIFLUOROMETHANE)
								FLUOROCARBON 133a (see 2-CHLORO-1,1,1-TRIFLUOROETHANE)
								FLUOROCARBON 22 (see CHLORODIFLUOROMETHANE)
–	NT	–	NT	NT	NT	1	51-21-8	5-FLUOROURACIL
								FNT (see FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZIDE)
								FOLPET (see N-(TRICHLOROMETHYLTHIO) PHTHALIMIDE)
0.798[af]	43.9	+	+	+	–	2-5	50-00-0	FORMALDEHYDE[h]
–	NT	NT	–	NT	NT	1	31873-81-1	FORMIC ACID 2-[4-(2-FURYL)-2-THIAZOLYL] HYDRAZIDE
14.4	NT	NT	+	NT	NT	1	32852-21-4	FORMIC ACID 2-(4-METHYL-2-THIAZOLYL) HYDRAZIDE
3.54[a]	8.85[a]	+	+	NT	+	1	3570-75-0	FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] HYDRAZIDE[g]
								FORMULATED FENAMINOSULF (see FENAMINOSULF, FORMULATED)
–	NT	NT	–	NT	NT	1	2302-84-3	1-FORMYL-3-THIOSEMICARBAZIDE
NT	36[a]	NT	NT	+	+	1	624-84-0	FORMYLHYDRAZINE
								FREON 30 (see METHYLENE CHLORIDE)
–	NT	NT	–	NT	NT	1	2411-74-7	2-FURALDEHYDE SEMICARBAZONE
NT	NT	NT	NT	NT	NT	1	98-01-1	FURFURAL[h]
–	732	E	–	–	P	5	54-31-9	FUROSEMIDE
								2-(2-FURYL)-3-(5-NITRO-2-FURYL)ACRYLAMIDE (see AF-2)
								FURYLFURAMIDE (see AF-2)
–	NT	–	NT	NT	NT	3	23255-69-8	FUSARENON-X

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
–	NT	–	–	NT	NT	4	35449-36-6	GEMCADIOL
–	–	–	–	–	–	2	25812-30-0	GEMFIBROZIL
								GENITE-R99 (see 2,4-DICHLOROPHENYLBENZENE SULFONATE)
NT	57.9[a]	NT	NT	+	+	4	548-62-9	GENTIAN VIOLET
–	–	E	–	–	–	5	mixture	GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE)
–	–	B–	B–	B–	B–	1	12025-19-3	GERMANATE, SODIUM
								GESAMIL (see PROPAZINE)
NT	–	NT	NT	–	–	1	77-06-5	GIBBERELLIC ACID
								GLU-P-1 (see 2-AMINO-6-METHYLDIPYRIDO[1,2-a:3′,2′-d]IMIDAZOLE)
								GLU-P-2 (see 2-AMINODIPYRIDO[1,2-a:3′,2′-d] IMIDAZOLE)
NT	–	NT	NT	–	NT	3	56-86-0	L-GLUTAMIC ACID
								N2-[gamma-L(+)-GLUTAMYL]-4-CARBOXYPHENYLHYDRAZINE (see N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID)
								GLUTAMYL-p-HYDRAZINOBENZOATE (see N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID)
NT	277	NT	NT	+	–	5	---	N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID
NT	–	NT	NT	–	–	2	2757-90-6	beta-N-[gamma-L(+)-GLUTAMYL]-4-HYDROXYMETHYLPHENYLHYDRAZINE
–	NT	–	–	NT	NT	1	96-24-2	GLYCEROL alpha-MONOCHLOROHYDRIN
–	NT	NT	–	NT	NT	1	765-34-4	GLYCIDALDEHYDE
								GLYCOL SULFATE (see ETHYLENE GLYCOL)
NT	–	NT	NT	NT	–	1	3741-38-6	GLYCOL SULFITE
NT	–	NT	NT	–	–	4	71277-79-7	GLYCYRRHIZINATE, DISODIUM
3920[a]	–	+	+	–	–	1	4680-78-8	FD & C GREEN NO. 1
5640	–	B+	B+	–	–	1	5141-20-8	FD & C GREEN NO. 2
–	–	–	–	–	–	1	2353-45-9	FD & C GREEN NO. 3
NT	1660[b]	NT	NT	+	–	1	126-07-8	GRISEOFULVIN[h]
–	–	–	–	–	–	2	9000-30-0	GUAR GUM
								GUINEA GREEN B (see FD & C GREEN NO. 1)
								GUM ACACIA (see GUM ARABIC)
–	–	–	–	–	–	2	9000-01-5	GUM ARABIC
								GUSATHION (see AZINPHOSMETHYL)
								HCB (see HEXACHLOROBENZENE)
5.96E-4	876E-4[a]	–	+	+	+	1	mixture	HCDD MIXTURE
1000	NT	B+	B+	NT	NT	1	517-28-2	HEMATOXYLIN
–	1.09[a]	–	–	+	+	1	76-44-8	HEPTACHLOR
–	NT	–	–	NT	NT	1	1121-92-2	HEPTAMETHYLENEIMINE
–	NT	–	NT	NT	NT	1	1241-27-6	HEPTYLAMINE
								HERCULES-7531 (see 3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA)
								HETEROAUXIN (see INDOLE-3-ACETIC ACID)
1.65[acf]	46.4[a]	+	+	+	+	1,4,5	118-74-1	HEXACHLOROBENZENE[g]
50.5[a]	NT	+	+	NT	NT	1	87-68-3	HEXACHLOROBUTADIENE
NT	25.3	NT	NT	+	NT	3	608-73-1	HEXACHLOROCYCLOHEXANE
11.2	6.62[c]	+	NT	+	NT	1	319-84-6	alpha-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
NT	17.7[a]	NT	NT	+	+	1	319-85-7	beta-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
–	15.4[a]	–	–	+	+	1,5	58-89-9	gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
55.4	319[a]	+	–	+	+	1,5	67-72-1	HEXACHLOROETHANE
–	–	–	–	–	–	1	70-30-4	HEXACHLOROPHENE
NT	–	NT	NT	–	–	1	2163-79-3	3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA
–	–	–	–	–	–	1	100-97-0	HEXAMETHYLENETETRAMINE
10.2	NT	NT	+	NT	NT	1	531-18-0	HEXAMETHYLMELAMINE
–	1950	–	–	+	–	1	628-02-4	HEXANAMIDE
–	–	–	–	E	–	5	136-77-6	4-HEXYLRESORCINOL
								HNT (see 2-HYDRAZINO-4-(5-NITRO-2-FURYL) THIAZOLE)
NT	–	NT	NT	–	–	4	1415-93-6	HUMIC ACIDS, COMMERCIAL GRADE

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
0.194[a]	2.2[a]	+	+	+	+	1,4	302-01-2	HYDRAZINE[g]
39.4[a]	3.35[af]	+	+	+	+	1,2,3,5	10034-93-2	HYDRAZINE SULFATE[g]
1.03	11.3	NT	+	NT	+	1	26049-71-8	2-HYDRAZINO-4-(p-AMINOPHENYL)THIAZOLE
2.83[a]	16.4	NT	+	NT	+	1	26049-68-3	2-HYDRAZINO-4-(5-NITRO-2-FURYL)THIAZOLE
1.97[a]	10.6	NT	+	NT	+	1	26049-70-7	2-HYDRAZINO-4-(p-NITROPHENYL)THIAZOLE
–	NT	NT	–	NT	NT	1	34176-52-8	2-HYDRAZINO-4-PHENYLTHIAZOLE
								p-HYDRAZINOBENZOATE (see p-HYDRAZINOBENZOIC ACID)
NT	–	NT	NT	NT	–	1	619-67-0	p-HYDRAZINOBENZOIC ACID
								p-HYDRAZINOBENZOIC ACID, N2-gamma-GLUTAMYL (see N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID)
NT	380[a]	NT	NT	+	+	5	24589-77-3	p-HYDRAZINOBENZOIC ACID.HCl
3.55[a]	26	+	+	–	+	1	122-66-7	HYDRAZOBENZENE
–	NT	–	NT	NT	NT	4	7647-01-0	HYDROCHLORIC ACID
–	–	–	–	E	–	5	58-93-5	HYDROCHLOROTHIAZIDE
–	NT	–	–	NT	NT	1	50-23-7	HYDROCORTISONE
								HYDROGEN CHLORIDE (see HYDROCHLORIC ACID)
NT	9010	NT	NT	B+	B+	1	7722-84-1	HYDROGEN PEROXIDE
55.8[a]	122	P	P	–	P	5	123-31-9	HYDROQUINONE
NT	–	NT	NT	–	–	1	103-16-2	HYDROQUINONE MONOBENZYL ETHER
								N-HYDROXY-N-ACETYL-2-AMINOFLUORENE (see N-HYDROXY-2-ACETYLAMINOFLUORENE)
–	NT	NT	–	NT	NT	1	4463-22-3	3-HYDROXY-4-ACETYLAMINOBIPHENYL
6.9E-4[a]	6.23	+	+	NT	+	1,3	53-95-2	N-HYDROXY-2-ACETYLAMINOFLUORENE[g]
–	NT	NT	–	NT	NT	1	4363-03-5	3-HYDROXY-4-AMINOBIPHENYL
NT	5530	NT	NT	+	–	5	1083-57-4	3-HYDROXY-p-BUTYROPHENETIDIDE
								2-HYDROXY-1,2-DIPHENYLETHANONE (see BENZOIN)
								HYDROXY-N-2-FLUORENYLACETAMIDE (see N-HYDROXY-2-ACETYLAMINOFLUORENE)
								3-HYDROXY-2-PROPENAL, SODIUM SALT (see MALONALDEHYDE, SODIUM SALT)
								p-HYDROXYACETANILIDE (see ACETAMINOPHEN)
NT	57.8	NT	NT	NT	+	3	51410-44-7	1′-HYDROXYESTRAGOLE
16.7	NT	NT	+	NT	NT	1	5036-03-3	1-(2-HYDROXYETHYL)-3-[(5-NITROFURFURYLIDENE) AMINO]-2-IMIDAZOLIDINONE
0.046[af]	NT	+	+	NT	NT	1,4,5	13743-07-2	1-(2-HYDROXYETHYL)-1-NITROSOUREA
1.87	NT	NT	+	NT	NT	1	33389-36-5	4-(2-HYDROXYETHYLAMINO)-2-(5-NITRO-2-THIENYL) QUINAZOLINE
NT	0.314[a]	NT	NT	+	–	1	109-84-2	2-HYDROXYETHYLHYDRAZINE[h]
								N-(HYDROXYMETHYL)-ACRYLAMIDE (see N-METHYLOLACRYLAMIDE)
–	NT	–	–	NT	NT	1	---	HYDROXYPROPYL DISTARCH GLYCEROL
–	–	–	–	–	–	1-3	148-24-3	8-HYDROXYQUINOLINE
12.1[a]	49.1[a]	+	NT	+	+	1,3	5208-87-7	1′-HYDROXYSAFROLE
								HYPOCHLOROUS ACID, SODIUM SALT (see SODIUM HYPOCHLORITE)
								IBOPAMINE.HCl (see N-METHYLDOPAMINE, O,O′-DIISOBUTYROYL ESTER.HCl)
10.7[d]	23.7[d]	–	+	–	+	1	21416-87-5	ICRF-159
								2-IMIDAZOLIDINONE (see ETHYLENE UREA)
–	–	A	A	–	–	1	3458-22-8	3,3′-IMINOBIS-1-PROPANOL DIMETHANESULFONATE (ESTER).HCl
–	NT	–	–	NT	NT	1	32607-00-4	IMINODIACETIC ACID, MONOSODIUM
								INDIGO CARMINE (see FD & C BLUE NO. 2)
NT	–	NT	NT	–	–	1	87-51-4	INDOLE-3-ACETIC ACID
								INH (see ISONIAZID)
–	NT	–	NT	NT	NT	4	144-48-9	IODOACETAMIDE
–	–	–	–	–	–	1	75-47-8	IODOFORM
								IPC (see ISOPROPYL-N-PHENYL CARBAMATE)
								IPD (see 3,3′-IMINOBIS-1-PROPANOL DIMETHANESULFONATE(ESTER).HCl)
								IQ (see 2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE)

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								IQ.HCl (see 2-AMINO-3-METHYLIMIDAZO[4,5-f] QUINOLINE.HCl)
								ISOASCORBATE (see ERYTHORBATE, SODIUM)
								ISOBENZAN (see TELODRIN)
NT	–	NT	NT	–	–	4	4247-02-3	ISOBUTYL p-HYDROXYBENZOATE
–	NT	–	NT	NT	NT	1	5461-85-8	N-ISOBUTYL-N'-NITRO-N-NITROSOGUANIDINE
								N-ISOBUTYL-N-NITROSOUREA (see N-NITROSO-N-ISOBUTYLUREA)
NT	–	NT	NT	–	–	5	26675-46-7	ISOFLURANE
								ISOLAN (see 1-ISOPROPYL-3-METHYL-s-PYRAZOLYLDIMETHYL CARBAMATE)
120[a]	11.2[af]	+	+	+	+	1-3	54-85-3	ISONIAZID[h]
NT	–	NT	NT	–	–	3	1453-82-3	ISONICOTINAMIDE
NT	–	NT	NT	–	–	1	55-22-1	ISONICOTINIC ACID[h]
								ISONICOTINIC ACID HYDRAZIDE (see ISONIAZID)
NT	27.4	NT	NT	B+	B+	1	149-17-7	ISONICOTINIC ACID VANILLYLIDENEHYDRAZIDE
1210	–	P	–	E	–	3	78-59-1	ISOPHORONE
0.739[d]	5.06[d]	–	+	–	+	1	3778-73-2	ISOPHOSPHAMIDE
NT	–	NT	NT	–	–	1	101-73-5	p-ISOPROPOXYDIPHENYLAMINE
–	–	–	–	–	–	1	101-21-3	ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE[h]
								1-ISOPROPYL-4-(m-METHOXYPHENYL)-7-METHYL-2(1H)-QUINAZOLINONE (see COMPOUND 50-892)
								1-ISOPROPYL-7-METHYL-4-PHENYL-2(IH)-QUINAZOLINONE (see PROQUAZONE)
NT	–	NT	NT	–	–	1	119-38-0	1-ISOPROPYL-3-METHYL-s-PYRAZOLYLDIMETHYL CARBAMATE
NT	–	NT	NT	–	–	1	122-42-9	ISOPROPYL-N-PHENYL CARBAMATE[h]
								4,4'-ISOPROPYLIDENEDIPHENOL (see BISPHENOL A)
NT	–	NT	NT	–	–	1	120-58-1	ISOSAFROLE
–	NT	–	–	NT	NT	3	520-18-3	KAEMPFEROL
–	NT	NT	–	NT	NT	4	12737-87-0	KANECHLOR 400
								KARATHANE (see DINITRO(1-METHYLHEPTYL) PHENYL CROTONATE)
								KARMEX (see 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA)
								KELTHANE (see DICOFOL)
2.96	0.705[a]	–	+	+	+	1	143-50-0	KEPONE
								KMDS-H (see DEXTRAN SULFATE SODIUM (KMDS-H))
								LAAM (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl)
0.141[a]	NT	+	+	NT	NT	1,5	303-34-4	LASIOCARPINE
28.4	–	+	B–	–	–	1,4	301-04-2	LEAD ACETATE
107[a]	472[a]	+	+	+	+	1,4	1335-32-6	LEAD ACETATE, BASIC[h]
–	–	–	–	–	–	1	19010-66-3	LEAD DIMETHYLDITHIOCARBAMATE
								LEAD SUBACETATE (see LEAD ACETATE, BASIC)
								LEDATE (see LEAD DIMETHYLDITHIOCARBAMATE)
NT	55.8	NT	NT	+	–	1	24365-47-7	LEUPEPTIN
								LIGHT GREEN SF YELLOWISH (see FD & C GREEN NO. 2)
								LINDANE (see gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE)
–	–	–	–	–	–	1	434-13-9	LITHOCHOLIC ACID
–	–	–	–	–	–	2	9000-40-2	LOCUST BEAN GUM
–	NT	–	–	NT	NT	3	21498-08-8	LOFEXIDINE.HCl
NT	14.8[a]	NT	NT	+	+	1	21884-44-6	LUTEOSKYRIN
NT	–	NT	NT	–	–	1	8065-91-6	LUTESTRAL
								MACRODANTIN (see 1-[(5-NITROFURFURYLIDENE) AMINO]HYDANTOIN)
								MAGENTA I (see ROSANILINE.HCl)
								p-MAGENTA (see p-ROSANILINE.HCl)
								MAGNESIUM PEMOLINE (see 2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2)
–	–	–	–	–	–	1	1634-78-2	MALAOXON

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
–	–	–	–	–	–	1	121-75-5	MALATHION
								MALATHION-O-ANALOG (see MALAOXON)
–	–	–	–	–	–	1,2	123-33-1	MALEIC HYDRAZIDE
67.7[a]	14.1	+	+	–	+	2,5	24382-04-5	MALONALDEHYDE, SODIUM SALT
								MAM ACETATE AND CYCASIN MIXTURE (see CYCASIN AND METHYLAZOXYMETHANOL ACETATE)
								MANEB (see MANGANESE ETHYLENEBISTHIOCARBAMATE)
157	–	B+	B+	–	–	1	12427-38-2	MANGANESE ETHYLENEBISTHIOCARBAMATE
–	–	–	–	–	–	2	69-65-8	D-MANNITOL
–	NT	–	NT	NT	NT	1	576-68-1	MANNITOL NITROGEN MUSTARD
								MeA-alpha-C (see 2-AMINO-3-METHYL-9H-PYRIDO-[2,3-b]-INDOLE)
								MeIQ (see 2-AMINO-3,4-DIMETHYLIMIDAZO[4,5-f] QUINOLINE)
								MeIQx (see 2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f] QUINOXALINE)
735	–	+	–	–	–	3	108-78-1	MELAMINE
0.0719[ad]	0.137[ad]	+	+	+	+	1	148-82-3	MELPHALAN
–	–	–	–	–	–	1	15356-70-4	DL-MENTHOL
–	NT	NT	–	NT	NT	1	67-98-1	MER-25
157[a]	–	P	P	–	E	1,5	149-30-4	2-MERCAPTOBENZOTHIAZOLE
NT	–	NT	NT	–	–	1	155-04-4	2-MERCAPTOBENZOTHIAZOLE, ZINC
–	NT	–	NT	NT	NT	3	19767-45-4	2-MERCAPTOETHANESULFONATE, SODIUM
–	NT	–	NT	NT	NT	1	50-44-2	6-MERCAPTOPURINE
NT	–	NT	NT	–	–	1	7487-94-7	MERCURIC CHLORIDE
NT	–	NT	NT	–	–	1	115-09-3	MERCURYMETHYLCHLORIDE
NT	–	NT	NT	–	–	1	72-33-3	MESTRANOL
4.46	NT	+	NT	NT	NT	1	57-39-6	METEPA
								DL-METHADONE.HCl (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl)
–	NT	–	–	NT	NT	4	531-06-6	METHAFURYLENE
–	NT	–	–	NT	NT	4	493-78-7	METHAPHENILENE
7.65[a]	NT	+	+	NT	NT	3	135-23-9	METHAPYRILENE.HCl[h]
0.9[a]	NT	+	+	NT	NT	1	60-56-0	METHIMAZOLE
–	NT	–	NT	NT	NT	4	59-51-8	DL-METHIONINE
–	–	–	–	–	–	1	59-05-2	METHOTREXATE[h]
NT	–	NT	NT	–	–	2	80830-39-3	2-METHOXY-4-AMINOAZOBENZENE
NT	60.2	NT	NT	–	+	2	3544-23-8	3-METHOXY-4-AMINOAZOBENZENE
25.7[a]	NT	+	+	NT	NT	1	5834-17-3	2-METHOXY-3-AMINODIBENZOFURAN
								2-METHOXY-3-DIBENZOFURANAMINE (see 2-METHOXY-3-AMINODIBENZOFURAN)
–	–	–	–	–	–	1	72-43-5	METHOXYCHLOR
NT	–	NT	NT	–	–	1	1701-77-5	METHOXYPHENYLACETIC ACID
27.3	NT	+	–	NT	NT	5	298-81-7	8-METHOXYPSORALEN
								METHYL ALLYL CHLORIDE (see 3-CHLORO-2-METHYLPROPENE, TECHNICAL GRADE (CONTAINING 5% DIMETHYLVINYL CHLORIDE))
11.5	NT	+	NT	NT	NT	4	57497-34-4	Z-METHYL-O,N,N-AZOXYETHANE
								Z-METHYL-O,N,N-AZOXYMETHANE (see AZOXYMETHANE)
839[a]	–	+	+	–	–	5	598-55-0	METHYL CARBAMATE
–	NT	–	–	NT	NT	1	6294-89-9	METHYL CARBAZATE
								METHYL CHLOROFORM (see 1,1,1-TRICHLOROETHANE, TECHNICAL GRADE)
9.17[c]	NT	+	NT	NT	NT	2	21340-68-1	METHYL CLOFENAPATE
NT	8.03	NT	NT	B+	B+	1	---	1-METHYL-1,4-DIHYDRO-7-[2-(5-NITROFURYL)VINYL]-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATE, POTASSIUM
3.28[a]	NT	+	NT	NT	NT	4	55-80-1	3'-METHYL-4-DIMETHYLAMINOAZOBENZENE
1.3[bd]	NT	+	NT	NT	NT	1	99-80-9	N-METHYL-N,4-DINITROSOANILINE
								METHYL ETHYL CELLULOSE (see EDIFAS A)

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
NT	0.745[af]	NT	NT	+	+	1,2	758-17-8	N-METHYL-N-FORMYLHYDRAZINE[g]
–	NT	–	NT	NT	NT	2	27323-65-5	METHYL LINOLEATE HYDROPEROXIDE
–	NT	–	NT	NT	NT	2	---	METHYL LINOLEATE, NATIVE
–	–	–	–	–	–	4	80-62-6	METHYL METHACRYLATE
NT	31.8	NT	NT	+	NT	1	66-27-3	METHYL METHANESULFONATE
0.403[a]	NT	+	+	NT	NT	1-5	70-25-7	N-METHYL-N'-NITRO-N-NITROSOGUANIDINE
48.8[a]	1.34[a]	+	+	+	+	1	129-15-7	2-METHYL-1-NITROANTHRAQUINONE
5.34	NT	NT	+	NT	NT	1	21638-36-8	4-METHYL-1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE
0.468[a]	NT	+	+	NT	NT	1	16699-10-8	4-(4-N-METHYL-N-NITROSAMINOSTYRYL)QUINOLINE
3.23[a]	NT	+	+	NT	NT	1	63412-06-6	N-METHYL-N-NITROSOBENZAMIDE
0.633[ad]	NT	+	+	NT	NT	1	---	N-(N-METHYL-N-NITROSOCARBAMOYL)-L-ORNITHINE
20.4	NT	B+	B+	NT	NT	1	14026-03-0	R(-)-2-METHYL-N-NITROSOPIPERIDINE
13.2	NT	B+	B+	NT	NT	1	36702-44-0	S(+)-2-METHYL-N-NITROSOPIPERIDINE
								N-METHYL-N-NITROSOUREA (see N-NITROSO-N-METHYLUREA)
								METHYL ORANGE B (see FENAMINOSULF, FORMULATED)
NT	–	NT	NT	B–	B–	3	21308-79-2	METHYL 12-OXO-trans-10-OCTADECENOATE
–	–	–	–	–	–	1	298-00-0	METHYL PARATHION
								METHYL-PHENYL-NITROSAMINE (see NITROSOMETHYLANILINE)
–	NT	–	–	NT	NT	5	872-50-4	N-METHYL-2-PYRROLIDONE
								METHYL SELENAC (see SELENIUM DIMETHYLDITHIOCARBAMATE)
								METHYL ZIMATE (see ZINC DIMETHYLDITHIOCARBAMATE)
NT	–	NT	NT	–	–	1	443-72-1	(N-6)-METHYLADENINE
NT	–	NT	NT	–	–	1	1867-73-8	(N-6)-METHYLADENOSINE
								METHYLAZOXYMETHANOL ACETATE AND CYCASIN MIXTURE (see CYCASIN AND METHYLAZOXYMETHANOL ACETATE)
								METHYLCHOLANTHRENE (see 3-METHYLCHOLANTHRENE)
0.202[a]	NT	–	+	NT	NT	1,2	56-49-5	3-METHYLCHOLANTHRENE
–	–	–	–	E	–	5	41372-08-1	alpha-METHYLDOPA SESQUIHYDRATE
–	NT	–	–	NT	NT	5	75011-65-3	N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER.HCl
9.09[a]	NT	+	+	NT	NT	1	101-14-4	4,4'-METHYLENE-BIS(2-CHLOROANILINE)[g]
–	66.6	–	NT	–	+	1	64049-29-2	4,4'-METHYLENE-BIS(2-CHLOROANILINE).2HCl
6.91[a]	NT	+	+	NT	NT	1	838-88-0	4,4'-METHYLENE-BIS(2-METHYLANILINE)
598[a]	817[a]	P	+	+	+	3-5	75-09-2	METHYLENE CHLORIDE
16.4[a]	207	+	+	–	+	1	101-61-1	4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE
12.5[a]	22.3[a]	+	+	+	+	3	13552-44-8	4,4'-METHYLENEDIANILINE.2HCl
–	NT	–	NT	NT	NT	1	471-29-4	METHYLGUANIDINE
–	NT	B–	B–	NT	NT	1	578-76-7	7-METHYLGUANINE
NT	4.58[a]	NT	NT	+	+	1	60-34-4	METHYLHYDRAZINE[g]
NT	2.51[a]	NT	NT	+	+	1	302-15-8	METHYLHYDRAZINE SULFATE
								METHYLMERCURIC ACETATE (see MERCURYMETHYLCHLORIDE)
								METHYLMERCURY CHLORIDE (see MERCURYMETHYLCHLORIDE)
0.103	NT	+	NT	NT	NT	5	---	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-BUTANOL
0.182	NT	+	NT	NT	NT	5	64091-91-4	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-(BUTANONE)
NT	18	NT	NT	+	–	1	---	(N-6)-(METHYLNITROSO)ADENINE
NT	15.8[a]	NT	NT	+	+	1	21928-82-5	(N-6)-(METHYLNITROSO)ADENOSINE
0.48	NT	NT	+	NT	NT	3	33868-17-6	METHYLNITROSOCYANAMIDE
–	13.3[a]	–	–	+	+	5	924-42-5	N-METHYLOLACRYLAMIDE
–	NT	–	–	NT	NT	2	91-62-3	6-METHYLQUINOLINE
–	NT	–	–	NT	NT	2	611-32-5	8-METHYLQUINOLINE
NT	–	NT	NT	–	–	5	622-97-9	p-METHYLSTYRENE

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
NT	–	NT	NT	B–	B–	1,3	56-04-2	METHYLTHIOURACIL[g]
–	NT	–	–	NT	NT	1	5800-19-1	METIAPINE
431[a]	347[a]	+	+	+	+	1	443-48-1	METRONIDAZOLE
–	–	–	–	–	–	1	315-18-4	MEXACARBATE
4.87[a]	53[a]	+	+	+	+	1	90-94-8	MICHLER'S KETONE
								MILBAM (see ZINC DIMETHYLDITHIOCARBAMATE)
–	1.1[a]	–	NT	+	+	1	2385-85-5	MIREX
1.46	NT	+	NT	NT	NT	1	39801-14-4	MIREX, PHOTO-
–	–	–	–	–	–	5	59122-46-2	MISOPROSTOL
								MITOMEN (see NITROGEN MUSTARD N-OXIDE)
9.81E-4[ad]	NT	+	+	NT	NT	1	50-07-7	MITOMYCIN-C
								MMS (see METHYL METHANESULFONATE)
								MNNG (see N-METHYL-N'-NITRO-N-NITROSOGUANIDINE)
								MNU (see N-NITROSO-N-METHYLUREA)
								MOCA (see 4,4'-METHYLENE-BIS(2-CHLOROANILINE))
NT	4.48[a]	NT	NT	+	+	3	1068-57-1	MONOACETYL HYDRAZINE
NT	–	NT	NT	–	–	1	79-11-8	MONOCHLOROACETIC ACID
								MONOCHLOROBENZENE (see CHLOROBENZENE)
0.79[a]	NT	+	NT	NT	NT	3	315-22-0	MONOCROTALINE
								MONOMETHYL BENZENE (see TOLUENE)
NT	–	NT	NT	–	NT	3	32221-81-1	DL-MONOSODIUM GLUTAMATE
NT	–	NT	NT	–	NT	3	142-47-2	L-MONOSODIUM GLUTAMATE
								MONOSODIUM IMINODIACETIC ACID (see IMINODIACETIC ACID, MONOSODIUM)
								MONURON (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)
								8-MOP (see 8-METHOXYPSORALEN)
5.03	NT	NT	+	NT	NT	1	58139-48-3	4-MORPHOLINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE
6.33	NT	NT	+	NT	NT	1	3031-51-4	L-5-MORPHOLINOMETHYL-3-[(5-NITROFURFURYLIDENE)AMINO]-2-OXAZOLIDINONE.HCl
								MUCOCHLORIC ACID (see alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID)
–	NT	–	NT	NT	NT	1	55-98-1	MYLERAN
								NABAM (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
138[a]	–	+	+	E	–	5	389-08-2	NALIDIXIC ACID
NT	–	NT	NT	–	–	1	86-86-2	1-NAPHTHALENE ACETAMIDE
NT	–	NT	NT	–	–	1	86-87-3	1-NAPHTHALENE ACETIC ACID
50.8	66.6[a]	–	+	+	+	1	2243-62-1	1,5-NAPHTHALENEDIAMINE
–	–	–	–	–	–	1	1465-25-4	N-(1-NAPHTHYL)ETHYLENEDIAMINE.2HCl
NT	–	NT	NT	–	–	1	93-46-9	sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE
NT	–	NT	NT	–	–	1	86-88-4	1-(1-NAPHTHYL)-2-THIOUREA
61.6	20.5[a]	B–	+	B+	+	1,2	91-59-8	2-NAPHTHYLAMINE[g]
								beta-NAPHTHYLAMINE (see 2-NAPHTHYLAMINE)
NT	–	NT	NT	–	–	2	81-16-3	2-NAPHTHYLAMINO,1-SULFONIC ACID
								NAS (see 2-NAPHTHYLAMINO,1-SULFONIC ACID)
–	NT	–	–	NT	NT	5	88385-81-3	NEOSUGAR
								NEW COCCINE (see SX PURPLE)
								NFTA (see N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] ACETAMIDE)
								NHEU (see 1-(2-HYDROXYETHYL)-1-NITROSOUREA)
–	NT	–	–	NT	NT	1	7440-02-0	NICKEL
NT	–	NT	NT	–	–	1	373-02-4	NICKEL (II) ACETATE
NT	–	NT	NT	–	–	1	13927-77-0	NICKEL DIBUTYLDITHIOCARBAMATE
								NICLOSAMIDE (see CLONITRALID)
NT	–	NT	NT	–	–	3	98-92-0	NICOTINAMIDE
–	NT	–	–	NT	NT	1	54-11-5	NICOTINE
NT	–	NT	NT	–	–	2	636-79-3	NICOTINE.HCl
NT	–	NT	NT	–	–	2	59-67-6	NICOTINIC ACID
NT	145[a]	NT	NT	+	+	1	553-53-7	NICOTINIC ACID HYDRAZIDE
–	NT	–	–	NT	NT	1	---	NIGROSINE

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
NT	–	NT	NT	B–	B–	1	12034-09-2	NIOBATE, SODIUM
131	758	–	+	+	–	1	139-94-6	NITHIAZIDE
–	NT	–	–	NT	NT	1,2	7631-99-4	NITRATE, SODIUM
NT	–	NT	NT	NT	–	1	10102-43-9	NITRIC OXIDE
1450[a]	1470[a]	+	+	+	+	1	139-13-9	NITRILOTRIACETIC ACID
224[a]	–	+	+	–	–	1	18662-53-8	NITRILOTRIACETIC ACID, TRISODIUM SALT, MONOHYDRATE
124[a]	–	+	+	–	–	1,2,3,5	7632-00-0	NITRITE, SODIUM[h]
–	2270	–	–	+	–	1	1777-84-0	3-NITRO-p-ACETOPHENETIDE
28.1[a]	3720	+	+	–	+	1	99-59-2	5-NITRO-o-ANISIDINE
4.64[ac]	22.4	E	+	–	+	1,5	59-87-0	5-NITRO-2-FURALDEHYDE SEMICARBAZONE
–	NT	NT	–	NT	NT	1	772-43-0	5-NITRO-2-FURAMIDOXIME
–	NT	NT	–	NT	NT	1	92-55-7	5-NITRO-2-FURANMETHANEDIOL DIACETATE
11.9[a]	20.3[ac]	+	+	+	+	1	75198-31-1	3-(5-NITRO-2-FURYL)-IMIDAZO(1,2-alpha)PYRIDINE
8.61	NT	NT	+	NT	NT	1	2122-86-3	5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE-2-OL
59.6[b]	NT	NT	+	NT	NT	1	36133-88-7	N-([3-(5-NITRO-2-FURYL)-1,2,4-OXADIAZOLE-5-YL]-METHYL)ACETAMIDE
8.84	6.74	NT	+	NT	+	1	2578-75-8	N-[5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOL-2-YL] ACETAMIDE
7.68	NT	NT	+	NT	NT	2	53757-28-1	4-(5-NITRO-2-FURYL)THIAZOLE
10.5[a]	NT	NT	+	NT	NT	1	531-82-8	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE[g]
1.31[af]	7.72[af]	+	+	+	+	1-4	24554-26-5	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE[g]
14.1	NT	NT	+	NT	NT	1	51325-35-0	N,N'-[6-(5-NITRO-2-FURYL)-s-TRIAZINE-2,4-DIYL] BISACETAMIDE
8.66	0.346	B+	B+	B+	B+	1	4812-22-0	3-NITRO-3-HEXENE
–	–	E	–	–	–	1,5	121-19-7	3-NITRO-4-HYDROXYPHENYLARSONIC ACID
–	614	–	–	–	+	1	5307-14-2	2-NITRO-p-PHENYLENEDIAMINE
–	–	–	–	–	–	1	99-56-9	4-NITRO-o-PHENYLENEDIAMINE
–	242[a]	–	–	+	+	1	99-55-8	5-NITRO-o-TOLUIDINE
5.98[a]	45.3	+	+	–	+	1	602-87-9	5-NITROACENAPHTHENE[h]
–	–	–	–	–	–	1	619-17-0	4-NITROANTHRANILIC ACID
–	354[a]	–	–	+	+	1	94-52-0	6-NITROBENZIMIDAZOLE
420	64.2[a]	I	+	+	+	1	1836-75-5	NITROFEN
								NITROFURANTOIN (see 1-[(5-NITROFURFURYLIDENE) AMINO]HYDANTOIN)
								NITROFURAZONE (see 5-NITRO-2-FURALDEHYDE SEMICARBAZONE)
698	866	P	–	–	+	1,3,5	67-20-9	1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN
5.26	NT	NT	+	NT	NT	1	555-84-0	1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE
0.0114[d]	NT	+	NT	NT	NT	1	51-75-2	NITROGEN MUSTARD
0.764[d]	NT	+	NT	NT	NT	1	126-85-2	NITROGEN MUSTARD N-OXIDE
								NITROGEN OXIDE (see NITROUS OXIDE)
–	–	–	–	–	–	1	86-57-7	1-NITRONAPHTHALENE
								D-(-)-threo-1-(p-NITROPHENYL)-2-DICHLOROACETAMIDO-1,3-PROPANEDIOL (see CHLORAMPHENICOL)
–	NT	–	–	NT	NT	3,5	108-03-2	1-NITROPROPANE
–	NT	–	–	NT	NT	1	79-46-9	2-NITROPROPANE
–	–	A	–	–	–	1	504-88-1	3-NITROPROPIONIC ACID
–	NT	–	–	NT	NT	2	613-50-3	6-NITROQUINOLINE
9.55[a]	NT	+	+	NT	NT	2	607-35-2	8-NITROQUINOLINE
0.364	NT	+	NT	NT	NT	1	38777-13-8	NITROSO-BAYGON
0.707[a]	NT	+	+	NT	NT	2	83335-32-4	N-NITROSO-BIS-(4,4,4-TRIFLUORO-N-BUTYL)AMINE
								N-NITROSO-3,6-DIHYDROOXAZINE-1,2 (see 3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE)
–	NT	–	–	NT	NT	3	62641-67-2	1-NITROSO-5,6-DIHYDROTHYMINE
0.0932[a]	NT	+	+	NT	NT	1	16813-36-8	1-NITROSO-5,6-DIHYDROURACIL
0.0535	NT	NT	+	NT	NT	3	89911-79-5	N-NITROSO-2,3-DIHYDROXYPROPYL-2-HYDROXYPROPYLAMINE[g]
0.0352	NT	NT	+	NT	NT	3	92177-50-9	NITROSO-2,3-DIHYDROXYPROPYL-2-OXOPROPYLAMINE[g]
5.98	NT	NT	+	NT	NT	3	89911-78-4	N-NITROSO-2,3-DIHYDROXYPROPYLETHANOLAMINE[h]

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
9.66	NT	NT	+	NT	NT	2	61034-40-0	1-NITROSO-3,5-DIMETHYL-4-BENZOYLPIPERAZINE
NT	NT	NT	NT	NT	NT	1	1456-28-6	NITROSO-2,6-DIMETHYLMORPHOLINE[g]
0.15[a]	NT	+	+	NT	NT	4	---	1-NITROSO-1-HYDROXYETHYL-3-CHLOROETHYLUREA N-NITROSO-2-HYDROXYETHYLUREA (see 1-(2-HYDROXYETHYL)-1-NITROSOUREA)
0.861[a]	NT	+	+	NT	NT	4	---	1-NITROSO-1-(2-HYDROXYPROPYL)-3-CHLOROETHYLUREA
1.02	NT	NT	+	NT	NT	3	75896-33-2	N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMINE
7.65	NT	B+	B+	NT	NT	3	56222-35-6	N-NITROSO-3-HYDROXYPYRROLIDINE
4.73	NT	NT	+	NT	NT	3	760-60-1	N-NITROSO-N-ISOBUTYLUREA
0.487[a]	NT	+	+	NT	NT	2,3	55090-44-3	N-NITROSO-N-METHYL-N-DODECYLAMINE
0.255	NT	+	NT	NT	NT	3	937-25-7	N-NITROSO-N-METHYL-4-FLUOROANILINE
–	NT	–	NT	NT	NT	3	943-41-9	N-NITROSO-N-METHYL-4-NITROANILINE
0.00788[a]	NT	+	NT	NT	NT	1	13256-11-6	NITROSO-N-METHYL-N-(2-PHENYL)ETHYLAMINE
1.65[c]	NT	+	NT	NT	NT	2	75881-20-8	N-NITROSO-N-METHYL-N-TETRADECYLAMINE
1.26	NT	+	NT	NT	NT	2	75881-22-0	N-NITROSO-N-METHYLDECYLAMINE
NT	NT	NT	NT	NT	NT	4	79624-33-2	NITROSO-5-METHYLOXAZOLIDONE[g]
NT	NT	NT	NT	NT	NT	1	684-93-5	N-NITROSO-N-METHYLUREA[g]
NT	NT	NT	NT	NT	NT	1	615-53-2	N-NITROSO-N-METHYLURETHAN[g]
NT	NT	NT	NT	NT	NT	3,4	39884-52-1	N-NITROSO-1,3-OXAZOLIDINE[g]
0.262[ac]	NT	+	NT	NT	NT	5	38347-74-9	3-NITROSO-2-OXAZOLIDINONE
1.8	NT	NT	+	NT	NT	3	92177-49-6	NITROSO-2-OXOPROPYLETHANOLAMINE[g]
0.166[d]	NT	+	NT	NT	NT	3	15973-99-6	DI(N-NITROSO)-PERHYDROPYRIMIDINE
0.0374[a]	NT	NT	+	NT	NT	1	55556-92-8	NITROSO-1,2,3,6-TETRAHYDROPYRIDINE
2.52	NT	+	NT	NT	NT	3	82018-90-4	N-NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLAMINE
3.31[d]	NT	+	NT	NT	NT	1	29929-77-9	N-NITROSO-2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE POLYMER
0.151	NT	NT	+	NT	NT	3	75881-18-4	1-NITROSO-3,4,5-TRIMETHYLPIPERAZINE[g]
0.825	NT	NT	+	NT	NT	3	88208-16-6	N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE
0.877	NT	NT	+	NT	NT	3	91308-70-2	N-NITROSOALLYL-2-HYDROXYPROPYLAMINE
0.335	NT	NT	+	NT	NT	3	91308-71-3	N-NITROSOALLYL-2-OXOPROPYLAMINE[g]
0.491	NT	NT	+	NT	NT	3	91308-69-9	N-NITROSOALLYLETHANOLAMINE
1.01	NT	NT	+	NT	NT	2	---	NITROSOAMYLURETHAN
11[a]	NT	+	+	NT	NT	1	1133-64-8	NITROSOANABASINE
NT	NT	NT	NT	NT	NT	3	15216-10-1	N-NITROSOAZETIDINE[g]
1.13	NT	B+	B+	NT	NT	1	51542-33-7	N-NITROSOBENZTHIAZURON
0.813[a]	NT	+	+	NT	NT	1,3	53609-64-6	N-NITROSOBIS(2-HYDROXYPROPYL)AMINE
0.232[a]	NT	+	+	NT	NT	2,3	60599-38-4	N-NITROSOBIS(2-OXOPROPYL)AMINE
–	NT	–	–	NT	NT	1	625-89-8	N-NITROSOBIS(2,2,2-TRIFLUOROETHYL)AMINE
NT	–	NT	NT	–	–	1	51715-17-4	NITROSOCHLORDIAZEPOXIDE
–	NT	–	–	NT	NT	3	73785-40-7	N-NITROSOCIMETIDINE
0.691	1.09	+	NT	+	NT	1,3	924-16-3	NITROSODIBUTYLAMINE
1.9[af]	NT	+	+	NT	NT	2,3,5	1116-54-7	N-NITROSODIETHANOLAMINE
0.00787[af]	NT	+	+	NT	NT	1,3,5	55-18-5	N-NITROSODIETHYLAMINE[g]
0.0587[af]	0.153[a]	+	+	+	+	1,2,3,5	62-75-9	N-NITROSODIMETHYLAMINE
116[a]	–	+	+	–	–	1	86-30-6	N-NITROSODIPHENYLAMINE
201	340	+	–	+	–	1	156-10-5	p-NITROSODIPHENYLAMINE
0.186	NT	NT	+	NT	NT	3	621-64-7	N-NITROSODIPROPYLAMINE
–	NT	NT	–	NT	NT	5	114282-83-6	N-NITROSODITHIAZINE
10.9[a]	NT	+	+	NT	NT	3	40580-89-0	NITROSODODECAMETHYLENEIMINE
95.2	NT	+	NT	NT	NT	1	17608-59-2	N-NITROSOEPHEDRINE
								NITROSOETHANECARBAMONITRILE (see ETHYLNITROSOCYANAMIDE)
0.0503	NT	+	–	NT	NT	3,5	10595-95-6	NITROSOETHYLMETHYLAMINE
0.248	NT	NT	+	NT	NT	2	614-95-9	NITROSOETHYLURETHAN
–	NT	–	NT	NT	NT	5	55557-02-3	N-NITROSOGUVACOLINE
0.0292[a]	NT	+	NT	NT	NT	1	20917-49-1	NITROSOHEPTAMETHYLENEIMINE
NT	0.313[a]	NT	NT	+	+	3	932-83-2	N-NITROSOHEXAMETHYLENEIMINE
43.8[a]	NT	+	+	NT	NT	1	42579-28-2	1-NITROSOHYDANTOIN
–	NT	–	–	NT	NT	1	30310-80-6	NITROSOHYDROXYPROLINE
–	NT	–	–	NT	NT	1	25081-31-6	NITROSOIMINODIACETIC ACID

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
0.646	NT	NT	+	NT	NT	3	86451-37-8	N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE[g]
								NITROSOMETHYL-N-DODECYLAMINE (see N-NITROSO-N-METHYL-N-DODECYLAMINE)
1.29	NT	+	NT	NT	NT	5	26921-68-6	N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE
1.09[a]	NT	+	+	NT	NT	5	70415-59-7	N-NITROSOMETHYL-(3-HYDROXYPROPYL)AMINE
0.0442[a]	NT	+	+	NT	NT	3	75411-83-5	N-NITROSOMETHYL-2-HYDROXYPROPYLAMINE
3.47[a]	NT	+	+	NT	NT	5	---	N-NITROSOMETHYL-(2-TOSYLOXYETHYL)AMINE
0.214	NT	NT	+	NT	NT	1	16219-98-0	2-NITROSOMETHYLAMINOPYRIDINE
–	NT	NT	–	NT	NT	1	69658-91-9	3-NITROSOMETHYLAMINOPYRIDINE
–	NT	NT	–	NT	NT	1	16219-99-1	4-NITROSOMETHYLAMINOPYRIDINE
0.0343[af]	NT	+	+	NT	NT	1,3	614-00-6	NITROSOMETHYLANILINE
								N-NITROSOMETHYLETHYLAMINE (see NITROSOETHYLMETHYLAMINE)
NT	–	NT	NT	–	–	1	55557-03-4	NITROSOMETHYLPHENIDATE
2.37	NT	+	NT	NT	NT	1	68107-26-6	NITROSOMETHYLUNDECYLAMINE
								NITROSOMETHYLUREA (see N-NITROSO-N-METHYLUREA)
								NITROSOMORPHOLINE (see N-NITROSOMORPHOLINE)
0.127[a]	NT	NT	+	NT	NT	3,5	59-89-2	N-NITROSOMORPHOLINE[g]
NT	NT	NT	NT	NT	NT	3	16543-55-8	N'-NITROSONORNICOTINE[g]
0.573[a]	NT	+	+	NT	NT	3	78246-24-9	N'-NITROSONORNICOTINE-1-N-OXIDE[h]
								NITROSOOXAZOLIDONE (see N-NITROSO-1,3-OXAZOLIDINE)
–	NT	–	–	NT	NT	1	4515-18-8	NITROSOPIPECOLIC ACID
								NITROSOPIPERAZINE (see N-NITROSOPIPERAZINE)
								1-NITROSOPIPERAZINE (see N-NITROSOPIPERAZINE)
5.51[ab]	NT	+	+	NT	NT	1	5632-47-3	N-NITROSOPIPERAZINE
1.57	1.3	B+	B+	+	NT	1,3	100-75-4	N-NITROSOPIPERIDINE[g]
–	NT	–	–	NT	NT	1	7519-36-0	NITROSOPROLINE
								NITROSOPYRROLIDINE (see N-NITROSOPYRROLIDINE)
0.409[ac]	0.679	+	+	+	NT	1,2,4,5	930-55-2	N-NITROSOPYRROLIDINE[g]
0.483	NT	NT	+	NT	NT	5	81795-07-5	N-NITROSOTHIALDINE
4.15[a]	NT	+	+	NT	NT	1	26541-51-5	N-NITROSOTHIOMORPHOLINE
50.7	NT	+	NT	NT	NT	2	611-23-4	o-NITROSOTOLUENE
								beta-NITROSTYRENE AND STYRENE MIXTURE (see STYRENE AND beta-NITROSTYRENE MIXTURE)
NT	–	NT	NT	–	–	4	10024-97-2	NITROUS OXIDE
NT	–	NT	NT	–	–	1	68-23-5	NORETHYNODREL
								NORETHYNODREL/MESTRANOL [25:1] (see ENOVID-E)
								NORETHYNODREL/MESTRANOL [66:1] (see ENOVID)
–	NT	–	NT	NT	NT	1	244-63-3	NORHARMAN
1.94	1.34[b]	B+	B+	NT	+	1,2	8015-12-1	NORLESTRIN[h]
–	–	B–	B–	B–	B–	1	---	NOVADELOX
0.0579[a]	3.53[a]	+	+	+	+	1,4,5	303-47-9	OCHRATOXIN A
–	NT	–	–	NT	NT	4	29082-74-4	OCTACHLOROSTYRENE
								DI-sec-OCTYL PHTHALATE (see DI(2-ETHYLHEXYL) PHTHALATE)
								17beta-OESTRADIOL (see ESTRADIOL)
–	NT	–	–	NT	NT	4	143-19-1	OLEATE, SODIUM
–	–	–	–	–	–	4	73590-58-6	OMEPRAZOLE
1710	–	–	+	–	–	5	6373-74-6	C.I. ACID ORANGE 3
–	–	–	–	–	–	5	1936-15-8	C.I. ACID ORANGE 10
								ORTHOXENOL (see o-PHENYLPHENOL)
								OTOS (see N-OXYDIETHYLENE THIOCARBAMYL-N-OXYDIETHYLENE SULFENAMIDE)
								OVEX (see p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE)
NT	–	NT	NT	–	–	1	8056-92-6	OVULEN
								OVULEN-50 (see ETHYNODIOL DIACETATE)
–	–	–	–	–	–	4	23135-22-0	OXAMYL
6.17	NT	NT	+	NT	NT	1	3096-50-2	N-(9-OXO-2-FLUORENYL)ACETAMIDE
–	NT	–	NT	NT	NT	1	30418-53-2	1'-OXOSAFROLE

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
–	–	–	–	–	–	1	6452-73-9	OXPRENOLOL.HCl
6.65[a]	19.7[a]	+	+	+	+	2	101-80-4	4,4′-OXYDIANILINE
85.5[a]	NT	+	+	NT	NT	4	13752-51-7	N-OXYDIETHYLENE THIOCARBAMYL-N-OXYDIETHYLENE SULFENAMIDE
NT	–	NT	NT	–	–	1	102-77-2	N-OXYDIETHYLENEBENZOTHIAZOLE-2-SULFENAMIDE
–	–	E	E	–	–	4	2058-46-0	OXYTETRACYCLINE.HCl
								PARACETAMOL (see ACETAMINOPHEN)
–	–	A	A	–	–	1	56-38-2	PARATHION
								PARAXENOL (see p-PHENYLPHENOL)
–	NT	NT	–	NT	NT	1	149-29-1	PATULIN
								PCBs (see AROCLOR 1254)
								PCBs (see AROCLOR 1260)
								PCBs (see KANECHLOR 400)
								PCNB (see PENTACHLORONITROBENZENE)
								PCP (see 2,3,4,5,6-PENTACHLOROPHENOL)
–	–	–	–	–	–	5	132-98-9	PENICILLIN VK
								PENTA (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))
–	39.8[a]	A	–	+	+	3	76-01-7	PENTACHLOROETHANE
–	71.1	–	–	+	–	1,4	82-68-8	PENTACHLORONITROBENZENE
NT	–	NT	NT	NT	–	3	87-86-5	2,3,4,5,6-PENTACHLOROPHENOL
–	17.5[a]	–	–	+	+	1,5	87-86-5	2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7)
NT	10.5[a]	NT	NT	+	P	5	87-86-5	2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE
–	–	E	E	–	–	5	78-11-5	PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE
								PENTALIN (see PENTACHLOROETHANE)
NT	3.12[a]	NT	NT	+	+	5	57590-20-2	PENTANAL METHYLFORMYLHYDRAZONE
–	NT	–	NT	NT	NT	1	13010-10-1	N-PENTYL-N′-NITRO-N-NITROSOGUANIDINE
NT	5.87	NT	NT	–	+	1	1119-68-2	n-PENTYLHYDRAZINE.HCl
NT	–	NT	NT	–	NT	1	8006-90-4	PEPPERMINT OIL
								PERCHLOROETHYLENE (see TETRACHLOROETHYLENE)
								PERTHANE (see p,p′-ETHYL-DDD)
0.662[a]	NT	+	+	NT	NT	1	60102-37-6	PETASITENINE
								PETN, NF (see PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE)
741[a]	1100[af]	+	+	+	+	1-3	62-44-2	PHENACETIN
								PHENACETIN, ASPIRIN, AND CAFFEINE (see ASPIRIN, PHENACETIN, AND CAFFEINE)
1230	NT	+	NT	NT	NT	1	60-80-0	PHENAZONE
303[a]	71.1	+	+	–	+	1	136-40-3	PHENAZOPYRIDINE.HCl
0.523	0.211[a]	–	+	+	+	1	3546-10-9	PHENESTERIN
–	–	–	–	–	–	1	834-28-6	PHENFORMIN.HCl
–	4.18[a]	–	–	+	+	1-5	50-06-6	PHENOBARBITAL[h]
74.3[a]	34.6[a]	+	+	+	+	1,4	57-30-7	PHENOBARBITAL, SODIUM
								PHENOBARBITONE (see PHENOBARBITAL)
								PHENOBARBITONE, SODIUM (see PHENOBARBITAL, SODIUM)
–	–	–	–	–	–	2	108-95-2	PHENOL
NT	–	NT	NT	–	–	1	92-84-2	PHENOTHIAZINE
0.71[ad]	4.95[ad]	+	+	+	+	1	63-92-3	PHENOXYBENZAMINE.HCl
2.31	NT	B+	B+	NT	NT	1	7227-91-0	1-PHENYL-3,3-DIMETHYLTRIAZENE
NT	–	NT	NT	–	–	1	103-72-0	PHENYL ISOTHIOCYANATE
–	–	–	–	–	–	1	89-25-8	1-PHENYL-3-METHYL-5-PYRAZOLONE
–	–	–	–	–	E	1,2,5	135-88-6	PHENYL-beta-NAPHTHYLAMINE[h]
								N-PHENYL-2-NAPHTHYLAMINE (see PHENYL-beta-NAPHTHYLAMINE)
–	–	–	–	–	–	1	2198-59-6	N-PHENYL-p-PHENYLENEDIAMINE.HCl
–	–	–	–	–	–	1	103-85-5	1-PHENYL-2-THIOUREA
								4′-PHENYLACETANILIDE (see 4-ACETYLAMINOBIPHENYL)
17.7[a]	–	+	+	–	–	1,2	842-07-9	1-PHENYLAZO-2-NAPHTHOL

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
–	NT	–	–	NT	NT	5	50-33-9	PHENYLBUTAZONE
NT	–	NT	NT	–	–	5	108-45-2	m-PHENYLENEDIAMINE
–	NT	–	–	NT	NT	3	106-50-3	p-PHENYLENEDIAMINE
–	–	–	NT	–	–	1	541-69-5	m-PHENYLENEDIAMINE.2HCl
248	611[a]	+	NT	+	+	1	615-28-1	o-PHENYLENEDIAMINE.2HCl
–	–	–	–	–	–	1	624-18-0	p-PHENYLENEDIAMINE.2HCl
–	–	–	–	–	–	4	61-76-7	PHENYLEPHRINE.HCl
								PHENYLETHYLBARBITURIC ACID (see PHENOBARBITAL)
NT	14.6	NT	NT	–	+	1	156-51-4	PHENYLETHYLHYDRAZINE SULFATE
29.1[a]	NT	+	+	NT	NT	3	122-60-1	PHENYLGLYCIDYL ETHER
NT	–	NT	NT	NT	–	1	100-63-0	PHENYLHYDRAZINE
NT	70.6[a]	NT	NT	+	+	1	59-88-1	PHENYLHYDRAZINE.HCl
NT	–	NT	NT	–	–	3	66-05-7	beta-PHENYLISOPROPYLHYDRAZINE.HCl
NT	–	NT	NT	–	–	1	62-38-4	PHENYLMERCURIC ACETATE
195[af]	–	+	+	–	–	1,3,4	132-27-4	o-PHENYLPHENATE, SODIUM
232	–	+	NT	–	–	1,3	90-43-7	o-PHENYLPHENOL
NT	–	NT	NT	–	–	1	92-69-3	p-PHENYLPHENOL
								PHENYTOIN (see 5,5-DIPHENYLHYDANTOIN)
NT	2.21[d]	NT	NT	–	+	1	17673-25-5	PHORBOL
NT	–	I	I	–	–	1	13171-21-6	PHOSPHAMIDON
–	NT	–	–	NT	NT	1	---	PHOSPHATED DISTARCH PHOSPHATE
–	NT	–	–	NT	NT	4	7803-51-2	PHOSPHINE
								PHOTODIELDRIN (see DIELDRIN, PHOTO-)
								PHOTOMIREX (see MIREX, PHOTO-)
–	–	–	–	–	–	1	88-96-0	PHTHALAMIDE
–	–	–	–	–	–	1	85-44-9	PHTHALIC ANHYDRIDE
								PHTIVAZID (see ISONICOTINIC ACID VANILLYLIDENEHYDRAZIDE)
–	–	–	A	–	–	1	1918-02-1	PICLORAM
NT	–	NT	NT	–	–	3	56393-22-7	PILDRALAZINE
–	NT	–	–	NT	NT	1	92-13-7	PILOCARPINE
–	NT	–	–	NT	NT	1	7681-93-8	PIMARICIN
								PIP (see N-NITROSOPIPERIDINE)
–	NT	–	–	NT	NT	1	110-85-0	PIPERAZINE
–	NT	–	–	NT	NT	1	110-89-4	PIPERIDINE
–	–	–	–	–	–	1,4	51-03-6	PIPERONYL BUTOXIDE
NT	–	NT	NT	–	–	1	51-03-6	PIPERONYL BUTOXIDE IN SOLVENT
–	62.2	–	–	+	–	1	120-62-7	PIPERONYL SULFOXIDE
154[a]	–	+	+	–	–	1	1955-45-9	PIVALOLACTONE
								PLANOFIX (see 1-NAPHTHALENE ACETIC ACID)
0.148[a]	0.381[a]	+	+	+	+	3	67774-32-7	POLYBROMINATED BIPHENYL MIXTURE
–	NT	NT	–	NT	NT	1	59536-65-1	POLYBROMINATED BIPHENYLS
								POLYCHLORINATED BIPHENYLS (see AROCLOR 1254)
								POLYCHLORINATED BIPHENYLS (see AROCLOR 1260)
								POLYCHLORINATED BIPHENYLS (see KANECHLOR 400)
–	–	NT	–	NT	–	1	---	POLYVINYLPYRIDINE-N-OXIDE
								PONCEAU 3R (see FD & C RED NO. 1)
								PONCEAU 4R (see SX PURPLE)
								PONCEAU MX (see D & C RED NO. 5)
								PONCEAU SX (see FD & C RED NO. 4)
								POTASSIUM BROMATE (see BROMATE, POTASSIUM)
–	NT	–	NT	NT	NT	4	7447-40-7	POTASSIUM CHLORIDE
								POTASSIUM METABISULFITE (see SULFITE, POTASSIUM METABI-)
–	NT	–	–	NT	NT	2	55268-74-1	PRAZIQUANTEL[h]
19.2	NT	NT	+	NT	NT	4	29069-24-7	PREDNIMUSTINE
–	NT	NT	–	NT	NT	4	50-24-8	PREDNISOLONE
–	NT	–	–	NT	NT	1	---	PREMARIN
NT	–	NT	NT	–	–	3	40778-40-3	PRIMIDOLOL.HCl
4.01[d]	NT	+	NT	NT	NT	1	671-16-9	PROCARBAZINE
0.284[ad]	0.194[ad]	+	+	+	+	1	366-70-1	PROCARBAZINE.HCl[g]

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
NT	NT	I	I	I	I	1	952-23-8	PROFLAVINE.HCl HEMIHYDRATE
NT	–	NT	NT	–	–	1	54-80-8	PRONETHALOL
NT	–	NT	NT	–	–	1	51-02-5	PRONETHALOL.HCl
3.64[a]	NT	+	+	NT	NT	1	1120-71-4	PROPANE SULTONE
NT	–	NT	NT	–	–	1	139-40-2	PROPAZINE
								2-PROPENAMIDE (see ACRYLAMIDE)
								p-PROPENYLANISOLE (see ANETHOLE)
1.34[a]	1.16[a]	NT	+	+	+	1,2	57-57-8	beta-PROPIOLACTONE
–	–	–	–	–	–	3	318-98-9	PROPRANOLOL.HCl
NT	–	NT	NT	–	–	1	1114-71-2	PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE
NT	8.74[a]	NT	NT	+	+	1	77337-54-3	N-N'-PROPYL-N-FORMYLHYDRAZINE
–	–	–	–	–	–	2,5	121-79-9	PROPYL GALLATE
NT	–	NT	NT	–	–	1	83-59-0	N-PROPYL ISOME
0.919[a]	NT	+	NT	NT	NT	1	13010-07-6	N-PROPYL-N'-NITRO-N-NITROSOGUANIDINE
–	–	–	–	–	–	3,5	115-07-1	PROPYLENE
								PROPYLENE DICHLORIDE (see 1,2-DICHLOROPROPANE)
–	NT	–	–	NT	NT	1	57-55-6	PROPYLENE GLYCOL
35.1[af]	732[a]	+	+	+	+	2,3,5	75-56-9	1,2-PROPYLENE OXIDE
NT	41.4[a]	NT	NT	+	+	1	56795-66-5	PROPYLHYDRAZINE.HCl
								DI-N-PROPYLNITROSAMINE (see N-NITROSODIPROPYLAMINE)
10.3[a]	409	+	+	B+	B+	1	51-52-5	PROPYLTHIOURACIL
NT	–	NT	NT	–	–	3	22760-18-5	PROQUAZONE
–	NT	–	NT	NT	NT	1	1508-45-8	PRORESID
24500	NT	B+	B+	NT	NT	1	2611-82-7	SX PURPLE
								PYRAZAPON (see RIPAZEPAM)
–	–	–	–	–	I	1	98-96-4	PYRAZINAMIDE
								3-PYRIDOYL HYDRAZINE (see NICOTINIC ACID HYDRAZIDE)
175[a]	NT	+	+	NT	NT	3	59-33-6	PYRILAMINE MALEATE
–	–	–	–	I	–	1	58-14-0	PYRIMETHAMINE
5.12[a]	–	+	+	–	–	1,3	117-39-5	QUERCETIN
–	NT	–	–	NT	NT	1-3	6151-25-3	QUERCETIN DIHYDRATE[h]
–	–	–	–	–	–	1,2	---	QUILLAIA EXTRACT
								8-QUINOLINOL (see 8-HYDROXYQUINOLINE)
106	–	–	+	–	–	1	105-11-3	p-QUINONE DIOXIME
								QUINTOZENE (see PENTACHLORONITROBENZENE)
								C.I. BASIC RED 9.HCl (see p-ROSANILINE.HCl)
–	–	–	–	–	–	1,2	3567-69-9	C.I. FOOD RED 3
233[a]	659[a]	+	+	+	+	1,3	3761-53-3	D & C RED NO. 5
104	–	+	A	–	–	1,2	5160-02-1	D & C RED NO. 9
–	NT	–	–	NT	NT	1	1248-18-6	D & C RED NO. 10
225[af]	NT	+	+	NT	NT	1	3564-09-8	FD & C RED NO. 1
632[a]	NT	B+	B+	NT	NT	1	915-67-3	FD & C RED NO. 2
–	–	–	–	–	–	1,5	16423-68-0	FD & C RED NO. 3
6130[a]	–	B+	B+	B–	B–	1	4548-53-2	FD & C RED NO. 4[h]
–	–	–	–	E	I	3	2871-01-4	HC RED NO. 3
								REDAX (see N-NITROSODIPHENYLAMINE)
								RENARDINE (see SENKIRKINE)
0.306	3.58[a]	+	–	+	+	1	50-55-5	RESERPINE
–	NT	–	–	NT	NT	1	302-79-4	RETINOIC ACID
–	NT	–	–	NT	NT	4,5	127-47-9	RETINOL ACETATE
–	NT	–	NT	NT	NT	5	79-81-2	RETINOL PALMITATE
–	33.6	–	–	–	+	1	13292-46-1	RIFAMPICIN
–	67.8[a]	–	–	+	+	3	26308-28-1	RIPAZEPAM
–	NT	–	–	NT	NT	1,2	632-99-5	ROSANILINE.HCl[h]
21.2[a]	28.8[a]	+	+	+	+	1-3	569-61-9	p-ROSANILINE.HCl[h]
								ROTAX (see 2-MERCAPTOBENZOTHIAZOLE)
–	–	E	–	–	–	1,5	83-79-4	ROTENONE
								ROXARSONE (see 3-NITRO-4-HYDROXYPHENYLARSONIC ACID)
								RUTIN (see RUTIN TRIHYDRATE)

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
–	NT	–	–	NT	NT	3	12768-44-4	RUTIN SULFATE
–	NT	–	–	NT	NT	1,2	153-18-4	RUTIN TRIHYDRATE[h]
NT	–	NT	NT	–	–	1	81-07-2	SACCHARIN
1110[af]	–	+	–	–	–	1-4	128-44-9	SACCHARIN, SODIUM
340[a]	27[a]	+	B+	+	+	1-3	94-59-7	SAFROLE
36.3[a]	NT	NT	+	NT	NT	3,5	18559-94-9	SALBUTAMOL
								SANAMYCIN (see ACTINOMYCIN C)
								L-SARCOLYSIN (see MELPHALAN)
								SDDC (see SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE)
NT	–	NT	NT	NT	–	1	7782-49-2	SELENIUM
NT	1.49	NT	NT	+	–	1	5456-28-0	SELENIUM DIETHYLDITHIOCARBAMATE
NT	–	NT	NT	–	–	1	144-34-3	SELENIUM DIMETHYLDITHIOCARBAMATE
6.14[a]	46.8	+	+	–	+	1	7446-34-6	SELENIUM SULFIDE
1.7[d]	NT	+	NT	NT	NT	1	2318-18-5	SENKIRKINE
								SEVIN (see CARBARYL)
NT	–	NT	NT	–	–	1	122-34-9	SIMAZINE
								SODIUM ARSENITE (see ARSENITE, SODIUM)
								SODIUM AZIDE (see AZIDE, SODIUM)
								SODIUM BENZOATE (see BENZOATE, SODIUM)
NT	–	NT	NT	–	–	1	6385-58-6	SODIUM BITHIONOLATE
–	–	–	NT	–	–	4	7647-14-5	SODIUM CHLORIDE
–	–	–	–	–	–	4	7758-19-2	SODIUM CHLORITE
								SODIUM CYCLAMATE (see CYCLAMATE, SODIUM)
–	–	–	–	–	–	1	148-18-5	SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE
								SODIUM FLUORIDE (see FLUORIDE, SODIUM)
–	–	–	–	–	–	4	7681-52-9	SODIUM HYPOCHLORITE
								SODIUM NIOBATE (see NIOBATE, SODIUM)
								SODIUM NITRATE (see NITRATE, SODIUM)
								SODIUM NITRITE (see NITRITE, SODIUM)
								SODIUM SULFATE (see SULFATE, SODIUM)
								SODIUM TETRAFLUOROBORATE (see TETRAFLUOROBORATE, SODIUM)
								SODIUM TUNGSTATE (see TUNGSTATE, SODIUM)
–	–	–	–	–	–	1	110-44-1	SORBIC ACID
–	–	–	–	–	–	3	959-24-0	SOTALOL.HCl
–	NT	–	–	NT	NT	1	8002-43-5	SOYBEAN LECITHIN
								SQ 18506 (see trans-5-AMINO-3[2-(5-NITRO-2-FURYL) VINYL-1,2,4-OXADIAZOLE)
								STANNOUS CHLORIDE (see TIN (II) CHLORIDE)
–	NT	–	–	NT	NT	1	9045-28-7	STARCH ACETATE
0.0825[af]	0.689[a]	+	B+	NT	+	1,2	10048-13-2	STERIGMATOCYSTIN
								STRAWBERRY ALDEHYDE (see ETHYL METHYLPHENYLGLYCIDATE)
0.776[ad]	0.193[ad]	+	+	+	+	1	18883-66-4	STREPTOZOTOCIN
NT	0.644[a]	NT	NT	+	–	1	8001-50-1	STROBANE
23.3	–	–	+	A	–	1,5	100-42-5	STYRENE
–	–	–	–	–	–	1	mixture	STYRENE AND beta-NITROSTYRENE MIXTURE
30.7[a]	90[a]	+	+	+	+	3-5	96-09-3	STYRENE OXIDE
								SUCCINIC ACID 2,2-DIMETHYLHYDRAZIDE (see DAMINOZIDE)
NT	–	NT	NT	NT	–	1	57-50-1	SUCROSE
								SULFADS (see DIPENTAMETHYLENETHIURAM HEXASULFIDE)
17.2[a]	27.3[a]	+	+	+	+	1	95-06-7	SULFALLATE
NT	–	NT	NT	NT	–	1	7757-82-6	SULFATE, SODIUM
–	–	–	–	–	–	1	127-69-5	SULFISOXAZOLE
NT	–	NT	NT	–	–	1	4429-42-9	SULFITE, POTASSIUM METABI-
–	–	–	–	–	–	1	77-79-2	3-SULFOLENE
55.6[b]	NT	NT	+	NT	NT	1	77-46-3	4,4′-SULFONYLBISACETANILIDE
								SULPYRIN (see DIPYRONE)
								SUNSET YELLOW FCF (see FD & C YELLOW NO. 6)
1.91[d]	NT	+	NT	NT	NT	1	22571-95-5	SYMPHYTINE

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								2,4,5-T (see 2,4,5-TRICHLOROPHENOXYACETIC ACID)
–	NT	–	–	NT	NT	1	569-57-3	TACE
–	–	–	–	–	–	2	39300-88-4	TARA GUM
								TARTRAZINE (see FD & C YELLOW NO. 5)
								TBP (see 2,2-THIOBIS(4,6-DICHLOROPHENOL))
								TCDD (see 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN)
								TCE (see TRICHLOROETHYLENE)
								TCE (see TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN))
								TDE (see p,p'-DDD)
NT	–	NT	NT	–	–	1	297-78-9	TELODRIN
33.2[a]	36.3	+	P	I	+	3	542-75-6	TELONE II
								TELVAR (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)
								TEMIK (see ALDICARB)
410	NT	NT	+	NT	NT	3	23031-25-6	TERBUTALINE
								2,3,4,6-TETRA-O-ACETYL-1-THIO-1-beta-D-GLUCOPYRANOSATO-S) (TRIETHYLPHOSPHINE) GOLD (see AURANOFIN)
395	288	+	NT	+	–	1	7411-49-6	3,3',4,4'-TETRAAMINOBIPHENYL.4HCl
								TETRACHLORO-p-BENZOQUINONE (see CHLORANIL)
–	–	–	–	–	–	1	2438-88-2	2,3,5,6-TETRACHLORO-4-NITROANISOLE
–	–	–	–	NT	–	1	15721-02-5	2,2',5,5'-TETRACHLOROBENZIDINE
6.67E-6[af]	8.68E-5[a]	+	+	+	+	1	1746-01-6	2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN
NT	–	NT	NT	–	–	1	116-29-0	2,4,5,4'-TETRACHLORODIPHENYL SULFONE
–	175[a]	–	–	+	+	3	630-20-6	1,1,1,2-TETRACHLOROETHANE
–	35.4[a]	–	–	+	+	1	79-34-5	1,1,2,2-TETRACHLOROETHANE
90.8[a]	75.6[a]	+	P	+	+	1,3	127-18-4	TETRACHLOROETHYLENE
–	228	–	A	+	A	1,4	961-11-5	TETRACHLORVINPHOS
–	–	–	–	–	–	5	64-75-5	TETRACYCLINE.HCl
–	–	–	–	–	–	1	97-77-8	TETRAETHYLTHIURAM DISULFIDE
								TETRAFIDON (see 2,4,5,4'-TETRACHLORODIPHENYL SULFONE)
–	86.3	–	NT	+	–	1	63886-77-1	TETRAFLUORO-m-PHENYLENEDIAMINE.2HCl
NT	NT	NT	NT	NT	NT	2	13755-29-8	TETRAFLUOROBORATE, SODIUM[h]
24.3	NT	B+	B+	NT	NT	1	40548-68-3	TETRAHYDRO-2-NITROSO-2H-1,2-OXAZINE
–	NT	–	NT	NT	NT	5	18771-50-1	3,4,5,6-TETRAHYDROURIDINE
–	–	–	–	–	–	4	124-64-1	TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM CHLORIDE
–	–	–	–	–	–	4	55566-30-8	TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM SULFATE
								2,2,9,9-TETRAMETHYL-1,10-DECANEDIOL (see GEMCADIOL)
–	–	–	–	–	–	1,3	137-26-8	TETRAMETHYLTHIURAM DISULFIDE
								TETRAMETHYLTHIURAM DISULFIDE AND FERRIC NITROSODIMETHYLDITHIOCARBAMATE (see VANGUARD GF)
NT	–	NT	NT	–	–	1	97-74-5	TETRAMETHYLTHIURAM MONOSULFIDE
								TETRASUL (see p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE)
								beta-TGdR (see beta-THIOGUANINE DEOXYRIBOSIDE)
–	NT	–	–	NT	NT	4	91-79-2	THENYLDIAMINE
–	NT	–	–	NT	NT	4	148-79-8	THIABENDAZOLE
								2-(4-THIAZOLYL)-BENZIMAZOLE (see THIABENDAZOLE)
0.122[ad]	0.21[ad]	+	+	+	+	1	52-24-4	THIO-TEPA
11.5	5.36[a]	+	NT	+	+	1,5	62-55-5	THIOACETAMIDE
NT	–	NT	NT	–	–	1	97-18-7	2,2-THIOBIS(4,6-DICHLOROPHENOL)
								THIOCARBAMYLHYDRAZINE (see THIOSEMICARBAZIDE)
								THIODAN (see ENDOSULFAN)
5.52[a]	32.7[a]	+	+	+	+	1	139-65-1	4,4'-THIODIANILINE
2.1[d]	NT	A	+	I	I	1	64039-27-6	beta-THIOGUANINE DEOXYRIBOSIDE

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
–	–	NT	–	–	–	1,3	79-19-6	THIOSEMICARBAZIDE
NT	48.6[a]	NT	NT	+	+	1	141-90-2	THIOURACIL
93.5[a]	–	+	–	NT	–	1	62-56-6	THIOUREA
								THIRAM (see TETRAMETHYLTHIURAM DISULFIDE)
								THPC (see TETRAKIS(HYDROXYMETHYL) PHOSPHONIUM CHLORIDE)
								THPS (see TETRAKIS(HYDROXYMETHYL) PHOSPHONIUM SULFATE)
								TIBRIC ACID (see 2-CHLORO-5-(3,5-DIMETHYLPIPERIDINOSULPHONYL)BENZOIC ACID)
–	–	–	–	–	–	4	55567-81-2	TILIDINE FUMARATE
								TILLAM-6-E (see PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE)
–	–	–	–	–	–	1,2	7772-99-8	TIN (II) CHLORIDE
–	–	–	–	–	–	1	13463-67-7	TITANIUM DIOXIDE
NT	–	NT	NT	–	–	1	14481-26-6	TITANIUM OXALATE, POTASSIUM
								TMTD (see TETRAMETHYLTHIURAM DISULFIDE)
–	NT	–	NT	NT	NT	5	10191-41-0	DL-alpha-TOCOPHEROL
–	NT	–	–	NT	NT	3	58-95-7	DL-alpha-TOCOPHERYL ACETATE
–	–	–	–	–	–	1	1156-19-0	TOLAZAMIDE
–	–	–	–	–	–	1	64-77-7	TOLBUTAMIDE
578[a]	NT	+	+	NT	NT	3,4	108-88-3	TOLUENE
25.4[a]	181	+	+	–	+	4	26471-62-5	TOLUENE DIISOCYANATE, COMMERCIAL GRADE (2,4 (80%)- AND 2,6 (20%)-)
								2,4-TOLUENEDIAMINE.2HCl (see 2,4-DIAMINOTOLUENE.2HCl)
								2,6-TOLUENEDIAMINE.2HCl (see 2,6-DIAMINOTOLUENE.2HCl)
								2,5-TOLUENEDIAMINE SULFATE (see 2,5-DIAMINOTOLUENE SULFATE)
3960	NT	B+	B+	NT	NT	1	88-19-7	o-TOLUENESULFONAMIDE
–	1440[b]	–	NT	+	–	1	638-03-9	m-TOLUIDINE.HCl
23.3[a]	646[a]	+	+	+	+	1,2	636-21-5	o-TOLUIDINE.HCl
–	49.1[a]	–	NT	+	+	1	540-23-8	p-TOLUIDINE.HCl
–	206	–	–	+	–	1	622-51-5	p-TOLYLUREA
–	4.08[a]	A	A	+	+	1	8001-35-2	TOXAPHENE
0.00504[d]	NT	+	NT	NT	NT	1	68-76-8	TRENIMON
469[a]	–	P	+	–	–	5	75-25-2	TRIBROMOMETHANE
NT	–	NT	NT	–	–	1	6379-46-0	1,2,3-TRICHLORO-4,6-DINITROBENZENE
–	NT	–	–	NT	NT	5	76-13-1	1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE
–	259	–	NT	+	–	1	634-93-5	2,4,6-TRICHLOROANILINE
–	47.6[a]	–	–	+	+	1	79-00-5	1,1,2-TRICHLOROETHANE
–	–	I	I	I	I	1,5	71-55-6	1,1,1-TRICHLOROETHANE, TECHNICAL GRADE
557[a]	421[af]	+	–	+	+	1,3,4	79-01-6	TRICHLOROETHYLENE[h]
–	294[a]	I	I	+	+	5	79-01-6	TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)
–	–	I	I	–	–	1,5	75-69-4	TRICHLOROFLUOROMETHANE
NT	–	NT	NT	–	–	1	133-07-3	N-(TRICHLOROMETHYLTHIO)PHTHALIMIDE
405	856[a]	+	–	+	+	1	88-06-2	2,4,6-TRICHLOROPHENOL
NT	–	NT	NT	–	–	1	93-72-1	2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID
–	–	–	–	–	–	1	93-76-5	2,4,5-TRICHLOROPHENOXYACETIC ACID
–	100[a]	–	–	+	+	1,4	102-71-6	TRIETHANOLAMINE
–	NT	–	NT	NT	NT	1	112-27-6	TRIETHYLENE GLYCOL
6.79	9.98	NT	+	NT	+	1	42011-48-3	2,2,2-TRIFLUORO-N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE
–	330	–	–	–	+	1	1582-09-8	TRIFLURALIN, TECHNICAL GRADE
								TRIIODOMETHANE (see IODOFORM)
20.4[a]	6.13	+	+	–	+	1	137-17-7	2,4,5-TRIMETHYLANILINE
98.5[b]	40[a]	+	NT	+	+	1	21436-97-5	2,4,5-TRIMETHYLANILINE.HCl
5.17	19.3[a]	+	NT	+	+	1	6334-11-8	2,4,6-TRIMETHYLANILINE.HCl
–	335	A	–	–	+	1	512-56-1	TRIMETHYLPHOSPHATE
25.8	–	–	+	–	–	1	2489-77-2	TRIMETHYLTHIOUREA

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
NT	–	NT	NT	–	–	1	900-95-8	TRIPHENYLTIN ACETATE
–	–	–	–	–	–	1	76-87-9	TRIPHENYLTIN HYDROXIDE
								TRIS (see TRIS(2,3-DIBROMOPROPYL)PHOSPHATE)
NT	3.44[d]	NT	NT	NT	+	1	38571-73-2	TRIS-1,2,3-(CHLOROMETHOXY)PROPANE
1.57[a]	80.1[a]	+	+	+	+	1,3	126-72-7	TRIS(2,3-DIBROMOPROPYL)PHOSPHATE
–	2560	E	–	–	P	3	78-42-2	TRIS(2-ETHYLHEXYL)PHOSPHATE
								TRISODIUM ETHYLENEDIAMINETETRAACETATE TRIHYDRATE (see EDTA, TRISODIUM SALT TRIHYDRATE)
								TRP-P-1 ACETATE (see 3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE)
								TRP-P-2 ACETATE (see 3-AMINO-1-METHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE)
–	NT	–	NT	NT	NT	3	54-12-6	DL-TRYPTOPHAN
–	–	–	–	–	–	1-3	73-22-3	L-TRYPTOPHAN
								TUBATOXIN (see ROTENONE)
–	NT	–	–	NT	NT	1	13472-45-2	TUNGSTATE, SODIUM
								TYLENOL (see ACETAMINOPHEN)
								UDMH (see 1,1-DIMETHYLHYDRAZINE)
								UNADS (see TETRAMETHYLTHIURAM MONOSULFIDE)
–	–	–	–	–	–	1	57-13-6	UREA
41.3	12.5[a]	B+	B+	+	+	1	51-79-6	URETHANE[g]
								VALORON (see TILIDINE FUMARATE)
NT	–	NT	NT	–	–	1	27774-13-6	VANADYL SULFATE
								VANCIDE BL (see 2,2-THIOBIS(4,6-DICHLOROPHENOL))
								VANCIDE BN (see SODIUM BITHIONOLATE)
								VANCIDE PB (see 1,2,3-TRICHLORO-4,6-DINITROBENZENE)
NT	–	NT	NT	–	–	1	mixture	VANGUARD GF
								VANGUARD N (see NICKEL DIBUTYLDITHIOCARBAMATE)
								VAPONA (see DICHLORVOS)
–	NT	–	NT	NT	NT	1	865-21-4	VINBLASTINE
132[a]	NT	+	+	NT	NT	3	108-05-4	VINYL ACETATE
17.9[a]	NT	+	+	NT	NT	1	593-60-2	VINYL BROMIDE
3.69[af]	10.6[a]	+	+	+	+	1-5	75-01-4	VINYL CHLORIDE[g]
NT	94.4	I	I	I	+	4	100-40-3	4-VINYLCYCLOHEXENE
–	22[a]	–	–	+	+	1-4	75-35-4	VINYLIDENE CHLORIDE
418[a]	–	–	+	–	–	1,3	1694-09-3	FD & C VIOLET NO. 1
								VITAMIN A ACID (see RETINOIC ACID)
								VITAMIN A, ACETATE (see RETINOL ACETATE)
								VITAMIN A, PALMITATE (see RETINOL PALMITATE)
								VITAMIN C (see L-ASCORBIC ACID)
								VITAMIN C, SODIUM (see L-ASCORBATE, SODIUM)
								VITAMIN D2 (see CALCIFEROL)
								VITAMIN E (see DL-alpha-TOCOPHERYL)
								VITAMIN E ACETATE (see DL-alpha-TOCOPHERYL ACETATE)
–	–	–	–	–	–	4	1330-20-7	XYLENE MIXTURE (60% m-XYLENE, 9% o-XYLENE, 14% p-XYLENE, 17% ETHYLBENZENE)
524[a]	NT	+	+	NT	NT	4	mixture	XYLENE MIXTURE (m-XYLENE, o-XYLENE, p-XYLENE)
–	12.4	–	NT	–	+	1	21436-96-4	2,4-XYLIDINE.HCl
152	552[a]	+	NT	+	+	1	51786-53-9	2,5-XYLIDINE.HCl
380	1020	+	–	–	+	2	2832-40-8	C.I. DISPERSE YELLOW 3
–	–	–	–	–	–	1	6358-85-6	C.I. PIGMENT YELLOW 12
–	–	B–	B–	B–	B–	1	5979-28-2	C.I. PIGMENT YELLOW 16
–	–	B–	B–	B–	B–	1	5567-15-7	C.I. PIGMENT YELLOW 83
								C.I. SOLVENT YELLOW 14 (see 1-PHENYLAZO-2-NAPHTHOL)
–	10900	–	–	+	–	1	128-66-5	C.I. VAT YELLOW 4
								DIARYLANILIDE YELLOW (see C.I. PIGMENT

TD_{50} (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								YELLOW 12)
–	–	–	–	–	–	1,5	1934-21-0	FD & C YELLOW NO. 5
–	–	–	–	–	–	1,2	2783-94-0	FD & C YELLOW NO. 6
–	22[a]	–	–	+	+	2	17924-92-4	ZEARALENONE
								ZECTRAN (see MEXACARBATE)
								ZETAX (see 2-MERCAPTOBENZOTHIAZOLE, ZINC)
NT	–	NT	NT	–	–	1	136-23-2	ZINC DIBUTYLDITHIOCARBAMATE
NT	–	NT	NT	–	–	1	14324-55-1	ZINC DIETHYLDITHIOCARBAMATE
25.8[a]	–	+	B+	–	E	1,3	137-30-4	ZINC DIMETHYLDITHIOCARBAMATE
255	–	B+	B+	–	–	1	12122-67-7	ZINC ETHYLENEBISTHIOCARBAMATE
								ZINEB (see ZINC ETHYLENEBISTHIOCARBAMATE)
								ZIRAM (see ZINC DIMETHYLDITHIOCARBAMATE)
NT	–	NT	NT	B–	B–	1	14644-61-2	ZIRCONIUM (IV) SULFATE